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ABSTRACT 
Background 
The goal of effective prescribing with the aim of improving the quality of prescribing in 
primary care is both a clinical and economic challenge. There are wide variations in 
prescribing in primary care that cannot be fully accounted for by demographic patterns. 
Over the years, numerous educational and policy initiatives on improving primary care 
prescribing in the NHS have been developed and implemented. However, in order to 
achieve both clinical and cost effectiveness, a wider perspective must be adopted. Focusing 
solely on the reduction of purchasing costs of drugs is not only ineffective, but may result in 
increased expenditure in the longer term due to the cost of treating hidden adverse 
complications. 
Aims 
This study aimed to investigate the effect of incorporating adverse drug reactions m 
economic analyses of drug therapies. Subsequently, the impact of this information on 
prescribing in primary care is explored. 
Literature Review 
The literature related to the clinical and economic burden of adverse drug reactions was 
reviewed. Adverse drug reactions have been shown to incur substantial clinical and 
economic burdens to health care systems. Although different drugs have different adverse 
events profile, no drugs are free of adverse drug reactions and all result in additional costs. 
The economic consequences associated with adverse drug reactions have often been 
neglected. 
Evidence about the impact of economic information on primary care decision making is 
sparse. Several surveys have attempted to investigate the use and the role of economic 
evidence in primary care practice, but these studies are limited by their methodology. 
2 
However, the findings of these studies are in general agreement that there is an awareness 
and interest in economic information among general practitioners, but there is no indication 
of successful implementation in changing day-to-day practice. Several barriers to 
implementation of economic evidence have been identified. 
Methods 
In order to achieve the aims of the study, three main studies were conducted. In the first 
study, an economic analysis was conducted to estimate the comparative costs of a large UK 
population (N = 98 887) given nonsteroidal anti-inflammatory drug (NSAID) therapy alone 
and in combination of gastrointestinal (GI) protective agents including concomitant 
prescriptions of H2 blockers, omeprazole and misoprostol. The study population was 
divided into four groups: NSAID only sub-cohort (N = 49 212), NSAID and co-prescribed 
H2 blockers/omeprazole sub-cohort (N = 2 113), NSAID and co-prescribed misoprostol 
sub-cohort (N = 212) and the general population comparator cohort (N = 47 350). Direct 
healthcare costs associated with each individual were calculated at days, six months and 12 
months. In addition to the total costs, the sex and age-specific costs, and the relative cost of 
high and low risk groups associated with NSAID therapy alone and in combination with GI 
protective agents were also calculated. 
The second study was a pharmacoeconomic analysis, using data from the literature and 
local expert opinion, of three commonly prescribed classes of drugs in primary care -
NSAIDs, selective serotonin reuptake inhibitors (SSRis) and angiotensin converting 
enzyme (ACE) inhibitors for the treatment of rheumatoid arthritis, depression and 
hypertension respectively. The total cost of drug therapy, taking into account the cost of the 
drugs and the cost of treating possible associated drug-induced adverse drug reactions 
(ADRs)- termed the 'shadow cost' were calculated. 
Finally, the results from the pharmacoeconomic analysis were disseminated to GPs in a 
local Health Board to explore the impact on influencing primary care prescribing. The 
prescribing trend over a six-month period was analysed using routine data from Prescription 
Cost Analysis for Scotland. A postal and email survey and qualitative interviews were also 
undertaken to help better understanding of these findings. 
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Results 
The results from both economic analyses showed clearly that drug associated adverse 
clinical events may add substantially to the cost of drug therapy. 
In the first study using the population database, almost all event rates and costs showed 
significant differences between any two groups. Over a period of 12 months, the 
incremental cost of the NSAID-only group was £253 compared to the general population; 
similarly, the incremental cost of the NSAID and misoprostol group, and NSAID and 
H2/omeprazole, over the NSAID group was £417 and £543 respectively. The costs of 
prescriptions and cardiovascular (CV) admissions constituted the bulk of the total costs in 
all groups. Surprisingly, GI endoscopies only accounted for 8% of the incremental costs. 
Sensitivity analysis showed that the conclusions were robust and that differences in costs 
was not due to differences in sex, age, or previous history of hospital admissions. 
In the second study eight NSAIDs, four SSRis and seven ACE inhibitors were evaluated. 
The economic impact of drug-induced ADRs was particularly apparent among NSAIDs, 
when the shadow cost (cost of managing adverse events) accounted for 12% (ketoprofen) to 
59% (diclofenac sodium) of the total cost of therapy. In some cases, drugs that may be 
more costly to purchase in the first place, resulted in savings in the long term. This was 
observed among NSAIDs such as naproxen, ketoprofen and indomethacin, and ACE 
inhibitors such as trandolapril. 
The findings of the pharmacoeconomic analyses were presented to 12 GPs within a local 
healthcare co-operative (LHCC). Prescribing volume of NSAIDs, SSRis and ACE 
inhibitors were monitored and comparisons were made between the three months pre- and 
post-dissemination. General practitioners in the same LHCC but who did not participate in 
the study acted as controls and did not receive any interventions. No change in prescribing 
trends of the three classes of drugs was observed. The subsequent postal and email survey 
confirmed the general lack of use of economic information. Qualitative interviews have 
revealed that GPs do not believe that such information should be considered at a practice 
level. 
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Conclusions 
Economic analyses based on various data sources have shown that the total cost of drug 
therapies are often much higher than the purchasing cost alone. There is much value in 
taking into account the clinical and economic impact of drug-induced ADRs when 
conducting pharmacoeconomic evaluations. However, this is often restricted by the 
availability of some of the data that are required to complete the economic model. The 
necessary data do exist, but linked clinical data for this type of analysis are not readily 
available for research purposes. 
General practitioners were generally supportive of econormc evaluations and the 
exploratory study on disseminating pharmacoeconomic information. However, the 
dissemination exercise had failed to demonstrate a positive relationship. In addition to the 
barriers highlighted in the literature, it was found that GPs do not feel that there is a role for 
the implementation of economic information in primary care. 
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1 INTRODUCTION 
INTRODUCTION 
1.1 BACKGROUND TO miS STUDY 
National Health Service (NHS) expenditure is rising constantly, and today, the concept of 
scarce healthcare resources is widely accepted by all. Although administrative inefficiency, 
managerial paralysis, more experimental technical advances and the ageing population have 
frequently been blamed for this, there are many other interacting factors contributing to 
escalating healthcare costs. 
The expenditure on drug treatment has increased by approximately five-fold over the past 
30 years and currently forms about 12% of all NHS expenditure 1. In the last decade, the 
rate of increase averaged almost 9% annually 2, well above inflation, faster than any other 
sector in the NHS (Figure 1). The reason for this trend may be explained, in part, by the 
rise in unit cost per prescription and volumes per capita. The introduction of new 
therapeutic interventions by the pharmaceutical industry has led to significant increases in 
drug expenditure within the NHS. More and more effective drugs are becoming available 
to provide better treatment or deal with conditions which until recently could not be treated 
at all. It has been estimated that 55% of the increased expenditure is due to new products 
replacing existing agents and 30% due to an increase in number of medicines consumed by 
. 3 patients . 
The government has committed itself to 'a primary care based NHS'. Over the years, the 
government has introduced strategies (reviewed in Appendix I) in attempts to contain the 
costs in prescribing. Various approaches to cost containment have been introduced and 
adopted throughout the years, ranging from the "stick" approach (e.g. restricted list) to the 
"carrot approach" (e.g. incentives with a prescribing message on them). However, there is 
often a lack of rigorous evidence because interventions were implemented as part of a 
strategic decision rather than on a formally evaluated basis. In addition, most of these 
methods appear only to have short-term benefits. Cost containment strategies could only 
generate a finite amount of savings, which would reach a plateau in the long term. In order 
to achieve cost effectiveness in healthcare, a wider perspective needs to be adopted. 
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At the time of the work for this thesis, general practice is the core of primary care, and the 
majority of primary care is delivered by general practice-based teams. The prominent role 
of general practice in primary care has been strengthened since the 1991 reforms, which 
have given purchasing responsibilities to general practitioners (GPs). It has given GPs 
budgets to purchase hospital care as well as contracting them to provide both clinical and 
preventive primary care for their registered patients. It has allowed them to keep savings 
made from economies in prescribing for use in providing other services. It has shifted NHS 
resources from secondary to primary care, and it has achieved a subtle but undeniable 
increase in the influence of GPs over their colleagues in hospital practice. 
General practitioners occupy a prominent role in the rationing process within the NHS, but 
decision making has become increasingly complex. The constant rise in cost and demand 
for healthcare has led to the need for optimum use of limited resources in the face of 
continuous and increasing demand. More recently, economic considerations, especially 
cost effectiveness, have become an integral part of clinical decision making, and may be 
essential to the survival of the NHS. 
1.2 PRIMARY CARE 
General practitioners are often described as "gate-keepers" as general practice is the first 
port of call for all patients. The most frequent contact with the health service, for most 
people, is through their GPs in primary care, where drug therapy is the most common 
therapeutic approach adopted for treatment. In Scotland, 3066 consultations per 1000 
practice population were recorded in the year 1999 (based on data from 51 practices) 4 . It is 
believed that up to 70% of GP consultations result in a prescription, either as a one-off 
treatment or as part of long-term management of chronic illness 5. 
In spite of a fairly steady population growth, the total quantity of drugs issued and their 
costs rise year after year. A total of 60.9 million NHS prescriptions - equivalent to 11.3 
prescriptions per head - were dispensed in 1999/2000 in Scotland 4, representing a 3.6% 
increase from the previous year, at a cost of £713 million. A combination of factors is 
responsible for the rise in prescribing expenditure every year. This includes the 3% to 4% 
annual increase in the number of prescriptions issued, the changes in the price of drugs, the 
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introduction of new and often more expensive drugs, and changes in prescribing practice. 
The average net ingredient cost per prescription dispensed in Scotland over the past 15 
years has risen from £3.94 in 1985 to £10.11 in 2000 (compared with an increase to £6.46 if 
price inflation alone was taken into account). The substantial increases in the volume and 
cost of prescriptions over the past seven years are shown in Figure 2. 
The quality of prescribing has a direct impact on the quality of patient care and total NHS 
expenditure. Although many GPs are generally efficient in their role, inappropriate 
prescribing does occur in general practice 6. The Accounts Commission Report published 
in September 1999 2 highlighted current attempts at improving the quality and cost 
effectiveness of prescribing, which it claimed would lead to annual savings in the region of 
£26 million in Scotland if half of these improvements were achieved. These include: 
• Generic prescribing 
The prescribing of generic drugs has continued to rise from around 40% in 1992/1993 
to almost 67% in 1998/1999. Although this increase was already 3.5% higher than 
previous year, there was still significant variation among Health Boards, ranging from 
50% in Shetland to 74% in the Lothian area 7. Substantial savings have been generated 
through increased generic substitution, especially in the mid 1990s. However, the 
House of Commons Select Committee on Health recently reported on the increase in the 
price of generic drugs, and as much as 500% increase has been observed, possibly 
related to the shortage of some generic drugs 8 . 
• Substitution of therapeutically similar drugs 
Where efficacy and safety are not compromised, cheaper alternatives should be 
considered. However, well-conducted pharmacoeconomic evidence, assessing all 
aspects of cost implications, is essential to assist such prescribing decisions. 
• A void premium priced preparations 
Preparations such as slow release or effervescent preparations which are more 
expensive than the basic formulations should be avoided. They do not offer 
pharmacological advantages to the majority of the patients for whom they are 
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prescribed and should be reserved for a more highly selected patient group who would 
benefit the most. 
• Reduce prescribing of drugs of limited clinical value 
Since 1999, a category of drugs considered by the Joint Formulary Committee to be 
"less suitable for prescribing" has been included in the British National Formulary 
(BNF)9• These are drugs that are not normally considered as a first choice for 
treatment, although their use may be justifiable in certain patient groups and specific 
combinations of disease states (co-morbidity). The main drugs in this group included 
combination analgesics, peripheral vasodilators and compound bronchodilators. Social 
audit has estimated that over £100 million is spent on preparations that the BNF deems 
less suitable 9• This has provided an indication of the level of potentially inappropriate 
prescribing. 
• Reduce the use of over-prescribed drugs 
Antibacterials, hypnotics and anxiolytics are all classes of drugs recognised as having 
been over-prescribed. In addition to cost implications, over-prescribing has an adverse 
clinical impact. For instance, the over-prescribing of antibacterial agents may hasten 
development of resistance by micro-organisms. This has become a growing concern 
nationally and internationally. In the case of antibacterials indicated for lower 
respiratory tract disorder, a recent Scottish Intercollegiate Guideline Network (SIGN) 
guideline 10 has suggested that a 40% reduction in prescribing would generate over 
£1 million savings for the NHS in Scotland. The estimated figure did not take into 
account of savings that may be made from reduced GP consultations and reduced 
management of adverse drug reactions. 
• Improved management of repeat prescribing systems 
Repeat prescribing has long been target for improvement. Unnecessary treatment 
should be avoided and reduce the risk of side effects and adverse effects from drug 
interactions. 
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General practitioners generally agree with the principles of rational prescribing, however, 
they also recognise that there are circumstances when rational prescribing is impractical. 
Instead of being an outcome of the consultation, a prescription may be viewed as a 
problem-solving tool that could be used to manage a variety of patient situations. There 
may be instances when prescriptions may be used as a means to cope with a busy workload, 
to manage a distressing patient situation or to maintain a doctor-patient relationship. 
In primary care, the Primary Care Trusts (PCTs) have budgets to manage, and GPs are the 
individuals responsible for prescribing decisions. The process of drug selection and usage 
is complex. In addition to making choices based on efficacy and safety, GPs have to 
account for related cost issues. They are expected to work within resource constraints, 
make optimum use of available resources and recognise the effect their decisions may have 
on the resources and choices available to others. 
There is a general acceptance among GPs that costs should be accounted for when 
prescribing, and prescribing costs could be reduced without affecting care. However, there 
is a lack of awareness and a poor perception of the cost of drug therapies among some GPs 
- the cost of cheap drugs is often over-estimated, while expensive ones, underestimated 11 . 
Therefore, it is important that GPs understand both the evidence for new interventions and 
the potential for cost containment. A report from the King's Fund 12 has called for more 
responsibility from health professionals for deciding how money should be spent. It is 
believed that promoting cost awareness may influence GPs' prescribing decisions 13. 
1.3 THE ROLE OF ECONOMIC EVALUATIONS IN HEALTHCARE 
1.3.1 Economic Evaluations 
Traditionally, when considering cost issues in the NHS, the purchasing cost of new drugs 
was simply compared to existing alternatives. The present healthcare culture demands 
proper consideration of the economic aspects of drug therapies. Health economics is now a 
common term in public policy documents, scientific literature and even the lay press. 
'Value for money' is becoming a major concern for health policy makers, and economic 
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evaluations have become an important tool in assisting clinical decision-making. Economic 
evaluation is also an accepted tool for the appraisal of healthcare programmes, and there is a 
growing volume of economic analyses of healthcare worldwide. 
An economic evaluation in healthcare has been defined as "a comparative analysis of 
alternative courses of action in terms of both their costs and consequences" 14. Economic 
analyses are comparative analyses and are applied to explicit alternatives. Whatever the 
alternatives, all the direct (associated with resource use) and indirect (associated with loss 
of production to society) costs related to all aspects of managing the disease should be 
considered. These should then be weighed against the benefits, in terms of improvement on 
the length or quality of life. 
Depending on the perspective of the study and the question posed, different types of 
economic evaluations can be adopted: 
• Cost-consequence analyses - when effectiveness is measured in different disease-
specific measures, generally used to describe costs and outcomes. For instance, 
cost-consequence analysis may be used to determine whether a primary care 
dermatology liaison nurse should be introduced into a health authority 15. 
• Cost-minimisation analyses- generally used to compare treatments within the same 
disease when the effectiveness of comparators are equal. For instance, the treatment 
of deep vein thrombosis by in-hospital treatment with unfractionated heparin may 
be compared to at-home therapy with low molecular weight heparin. Data from a 
clinical trial has demonstrated that the group sent home to self-inject with low 
molecular weight heparin would experience similar rates of bleeding or deep vein 
thrombosis recurrence as those kept in hospital. Since the clinical outcomes have 
been proven to be equivalent in the two groups, analysis may be limited to 
analysing only the costs 16. 
• Cost-effectiveness analyses - when the outcomes or consequences of different 
interventions vary but can be measured in identical natural units, then inputs are 
costed. Interventions are compared in terms of cost per unit of consequence. 
Therefore, the intervention associated with the minimum cost per unit outcome, or 
the maximum outcome per unit cost would be the most cost effective option. For 
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instance, the prescribing of antibiotic prophylaxis may be compared with no routine 
prophylaxis in women undergoing caesarean section 17. The cost per adverse 
outcome averted was calculated and compared between the two groups. 
• Cost-utility analyses - when effectiveness is measured as combined survival and 
quality of life (quality-adjusted-life years); generally used to compare treatments for 
different diseases. For instance, cost-utility analysis may be used to determine 
whether resources should be allocated to the treatment of established osteoporosis to 
prevent fractures, considering other uses for the equivalent resources 18 . 
• Cost-benefit analyses - when both the inputs and outcomes or consequences of the 
comparative interventions are expressed as monetary benefit (such as willingness-
to-pay); generally used to compare investments in the health care sector with 
investments in other sectors. For instance, this may be used to determine the 
willingness to pay for carrier screening for a congenital deafness gene from the 
perspective of pregnant women 19• 
All methods of economic evaluation value both inputs and outcomes or consequences and 
follow the same three steps relating to both inputs and outcomes: (1) identification, (2) 
measurement and (3) valuation. There are potential difficulties in conducting all three 
phases of the evaluation. Identification may be difficult as some health care interventions 
have hidden or unknown costs and consequences. For instance, when evaluating drug 
therapies, in addition to the acquisition cost, cost associated with administration and 
management of associated side effects (termed 'iatrogenic costs' or 'shadow 
costs') 20•21 should be taken into account. This may include costs incurred by extra GP 
consultations, drug changes, additional prescriptions, investigations, laboratory 
investigations, outpatient referrals and possibly hospital admissions. The costs of managing 
adverse drug reactions (ADRs) are substantial, and will be discussed in a later section. 
Measurement of outcomes is not always straight forward as there are costs and 
consequences that cannot be measured in appropriate physical units due to intangible 
outcomes such as the reduction of pain. Valuing inputs and consequences is the most 
difficult aspect of conducting an economic evaluation and the most difficult for health care 
professionals to interpret, as in reality the only readily available measures of value, prices, 
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exist only where there are true markets, and these cover only a minority of health inputs and 
consequences. 
This thesis focuses on the economic analyses of the 'iatrogenic costs' or the 'shadow costs' 
associated with drug treatments - non-steroidal anti-inflammatory drugs (NSAIDs), 
selective reuptake serotonin inhibitors (SSRis) and angiotensin converting enzyme (ACE) 
inhibitors for the management of rheumatoid arthritis (RA), depression and hypertension, 
respectively. These drugs, each within their own pharmacological family share the same 
mechanism of action and have been demonstrated in clinical trials to have equal efficacy. 
1.3.2 Perspective Worldwide 
In response to recognising the role of economic evidence in clinical decision making, many 
countries have made it mandatory by law to include proof of cost effectiveness when 
applying for licensing of new drugs. Some, such as the UK, have chosen to set up 
specialised groups to assess current and new therapies, with economic analysis an integral 
part of such assessment. 
Australia was the first country to make submission of proof of cost effectiveness an official 
requirement before pharmaceuticals can be reimbursed for the Australian Pharmaceutical 
Benefits Scheme in 1993 22. This policy was enacted at the time when drug prices and the 
annual increase in the Australian drugs bill were below the developed world average. In 
November 1994, Canada was the next to follow suit. The Canadian Co-ordinating Office 
for Health Technology Assessment (CCOHTA) issued a set of national guidelines for 
economic evaluations of drugs 23 . Since September 1995 applications to Ontario's 
provincial drugs reimbursement formulary would be considered incomplete if they do not 
include economic analysis of the drug in question. In 1997, the World Health Organisation 
(WHO) produced a draft working party document arguing that "sharper questions must be 
asked about final impact of new products before any decision is taken on investing public 
funds in their use" 24. To date, countries including New Zealand, Finland, Norway and the 
Netherlands have made the submission of proof of cost effectiveness a mandatory 
requirement for all new drugs, introducing a 'fourth hurdle' to the three existing assessment 
criteria for new therapies- efficacy, safety and effectiveness. 
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The National Institute for Clinical Excellence (NICE) 
Although the Department of Health has been promoting cost-effective initiatives in the 
pharmaceutical field, this has not yet extended to licensing. Over 95% of the drugs on the 
UK market are authorised by the licensing authority, acting through the Medicines Control 
Agency (MCA). A small number are now licensed throughout the EC via a centralised 
procedure, regulated by the European Agency for the Evaluation of Medicinal Products 
(EMEA). Prior to authorisation, the EMEA or MCA assess the safety, efficacy and quality 
of a drug. New drugs must be shown to be at least as safe as existing therapies, and also 
show comparable efficacy. If no suitable comparator exists, then efficacy must be shown to 
be superior to placebo. While the regulators consider the overall clinical benefit, they do 
not consider the cost effectiveness of the drug. 
In April 1999, the National Institute for Clinical Excellence (NICE) was set up in the UK to 
evaluate clinical and cost effectiveness of new and existing pharmaceuticals and health 
technologies, and to prepare guidance on how they should be used appropriately by the 
English and Welsh NHS. The role of the institute is to promote the use of cost-effective 
treatments, while ensuring that the availability of these treatments does not vary by 
geographical distribution or postcode. Existing and new evidence contained in the 
manufacturers' submissions for drugs and technologies are reviewed before 
recommendations are disseminated to health professionals. 
The first NICE recommendation to the NHS was issued in 1999, against the prescription of 
zanamivir for the treatment of influenza virus infection 25. Although zanamivir was 
approved by the MCA for its indication, NICE cited evidence which showed only modest 
benefit in otherwise healthy individuals with influenza and at a significant cost. In addition, 
NICE decided that insufficient evidence was available for recommendations on the use of 
zanamivir in high-risk patient groups. 
Although NICE has not formed a complete barrier to the reimbursement of new drugs, since 
the beginning of 2002 26, health authorities are obliged to fund treatments based on their 
recommendations. Some of the recommendations have been controversial and health 
authorities have shown reluctance in allocating additional resources to implement the 
guidance 27 . 
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Health Technology Board for Scotland CHTBS) 
The Health Technology Board for Scotland (HTBS) was set up in November 1999. The 
objective of the board was to act as a national resource of information and independent 
advice on clinical and cost effectiveness on new and existing health technologies to 
decision makers in local Drugs and Therapeutics Committees (DTC), Health Boards, NHS 
Trusts, and the Scottish Executive Health Department. The Health Technology Board for 
Scotland was designed to undertake assessment on health technologies that have not been 
reviewed by NICE and provide advice and guidance on NICE technology appraisal in the 
Scottish context. 
To date, the HTBS has completed 14 health technology assessments and made over 20 
comments on NICE guidance. However, its approach to health technology assessment and 
its efficiency in producing comments and guidance have been heavily criticised. The 
Health Technology Board for Scotland has adopted an open and consultative process to 
assessing new health technologies in attempt to reflect voices of individual healthcare 
sectors within the NHS in Scotland. Specialised experts in appropriate areas of expertise 
have been invited to review HTBS assessment reports. However, these experts are often 
not representative of general clinical practice. There have also been doubts about the 
practical applications of the HTBS comments that are issued generally six to ten weeks after 
the NICE guidance documents are published. 
In October 2002, the HTBS merged with the Clinical Standards Board for Scotland and the 
Scottish Health Advisory Service to create the Quality and Standards Board for Health in 
Scotland. It is believed that the objectives and functions of the HTBS would remain similar 
to those when it was founded in 1999. 
SUMMARY 
The expenditure on drugs in primary care will continue to nse. In response to this, 
literature on prescribing management is growing and budgetary reforms are introduced. 
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The establishment of NICE and HTBS in the UK have highlighted the importance of 
economic evaluations at national policy level. However, their impact on clinical practice 
and health costs has been difficult to measure. In addition, the optimum strategy for the 
design and effective dissemination of these economic materials is still unclear. 
1.4 STRUCTURE OF THE THESIS 
This thesis reports on two closely related areas of research. Firstly, it describes the 
economic burden of ADRs; then it describes the impact of economic information on 
decision making in primary care. These distinct themes are reported in such order 
throughout the thesis. 
In order to explore the clinical and economic burden of ADRs in different classes of drugs, 
this thesis used three different classes of drugs as examples - NSAIDs, SSRis and ACE 
inhibitors in the management of RA, depression and hypertension, respectively. Due to the 
limited financial scope of the PhD, two different types of ADR data had to be used. Firstly, 
this thesis reports on a large-scale population study, which estimated the substantial costs 
resulting from drug-associated adverse events while on NSAIDs. This is followed by three 
meta-analysis-based economic analyses of NSAIDs, SSRis and ACE inhibitors. It is worth 
noting that the cyclo-oxygenase II inhibitors that selectively target specific inflammatory 
receptors are not included in these analyses due to the different mechanism of action from 
the "traditional" NSAIDs. 
The impact of economic information on decision making in primary care was explored in a 
dissemination exercise and a postal survey, and are reported in subsequent chapters of this 
thesis. On reviewing the results, an additional qualitative study was introduced to explore 
in-depth, the implications of the findings of the dissemination exercise and the postal 
survey. 
To avoid excessive fragmentation of the text in the chapters, all the tables and figures have 
been located at the end of the thesis. 
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2 AIMS AND OBJECTIVES 
AIMS AND OBJECTIVES 
2.1 STUDY AIMS 
An initial literature review showed that despite the growing literature on econonnc 
evaluations on healthcare, there is limited evidence on the role of economic information on 
medical decision-making, in particular, relating to prescribing issues. This study was 
planned to examine the role of pharmacoeconomic information in primary care prescribing. 
In doing this, two broad aims were developed: 
• the first aim was to investigate the effect of incorporating adverse drug reactions in 
economic evaluations of drug therapies; 
• the second aim was to investigate the impact of this information on prescribing in 
pnmary care. 
2.2 STUDY OBJECTIVES 
This study had seven objectives, which were developed from the study aims. The first five 
objectives relate to the first aim while the remaining two objectives address the second aim 
of the study. The study objectives were: 
1. to evaluate the cost associated with the use of NSAID therapy in a Scottish population 
based on epidemiological data from a population database; 
2. to evaluate the cost associated with NSAID therapies in the treatment of rheumatoid 
arthritis, based on data reported in clinical trials and expert opinion; 
3. to evaluate the cost associated with SSRI therapies in the treatment of depression, based 
on data reported in clinical trials and expert opinion; 
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4. to evaluate the cost associated with ACE inhibitor therapies in the treatment of 
hypertension, based on data reported in clinical trials and expert opinion; 
5. to examine the use of data from a population database compared to randomised 
controlled trials; 
6. to investigate the effect of disseminating economic information on pnmary care 
prescribing; 
7. to examine the role of economic information on primary care prescribing from the 
perspective of GPs. 
2.3 STUDY HYPOTHESES 
A limited set of hypotheses was developed from the above objectives. These have been 
expressed as experimental hypotheses. The first three hypotheses address the first aim of 
the study while the remaining two objectives focus on the second aim of the study. The 
study hypotheses were: 
1. some drugs of the same pharmacological family have been shown to have equal 
efficacy, however, these drugs may have different adverse drug reaction profiles; 
2. the cost associated with treating adverse drug reactions is substantial; 
3. drugs that are the cheapest to purchase are not necessarily the most cost effective to use; 
4. targeted dissemination of pharmacoeconomic information can be used to help influence 
primary care prescribing; 
5. general practitioners believe that economic information has a role in medical decision 
making. 
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3 ECONOMIC EVALUATION AND 
MEDICAL DECISION MAKING: A 
CRITICAL LITERATURE REVIEW 
ECONOMIC EVALUATION AND MEDICAL DECISION 
MAKING: A CRITICAL LITERATURE REVIEW 
3.1 INTRODUCTION 
This literature review is split into two main sections according to the aims - the inclusion of 
ADRs in economic evaluation of drug therapies (Section 3.2), and the impact of economic 
information on decision making in primary care (Section 3.3). 
The review in Section 3.2 has been designed to address the following questions: 
• What is the incidence of ADRs? 
• What are the clinical and economic consequences associated with ADRs? 
The first section first looks at the broad issue, and then specific sections are given to the 
three classes of drugs focused by this thesis - NSAIDs, SSRis and ACE inhibitors. 
The published evidence on the incidence of ADR-related morbidity and mortality is 
reviewed. Section 3.2.1 discusses and evaluates the various sources of ADR data. Section 
3.2.2 assesses the ADR incidence reported by studies of spontaneous reporting systems, the 
ADR incidence in hospital patients, including ADR-related hospitalisations, inpatient ADR 
incidents and ADR-related death found in studies of hospital patients and the ADR 
incidence in primary care. The clinical and economic consequences associated with ADRs 
are discussed in Section 3.2.3. 
The next section (Section 3.3) discusses the findings of the studies that investigated the 
impact of economic information on medical decision making in primary care. The extent of 
knowledge (Section 3.3.1) and use (Section 3.3.2) of health economics in primary care 
decision makers, in particular among GPs are reviewed. In addition, the source of such 
information is examined (Section 3.3.3). Finally, the barriers to implementing economic 
information in primary care are discussed (Section 3.3.4). 
The extensive literature review conducted on ADRs associated with NSAIDs, SSRis and 
ACE inhibitors is described in the methods section (Section 4.3.1) and the results section 
(Section 5.3). 
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3.2 THE INCLUSION OF ADVERSE DRUG REACTIONS IN ECONOMIC 
EVALUATIONS 
All drugs undergo a lengthy process of evaluation on efficacy, safety, effectiveness and cost 
effectiveness prior to licensing. Even when used according to its indication and at 
recommended daily doses, no drugs are entirely safe and without a toxicity profile. Optimal 
drug use is dependent upon the risk-benefit balance. Adverse drug reactions (ADRs) refer 
to adverse effects resulting from appropriate use of medicine, rather than due to medical 
error. The World Health Organisation has defined ADR as: "a response to a drug that is 
noxious and unintended and occurs at doses normally used in man for the prophylaxis, 
diagnosis or therapy of disease, or for modification of physiological function" 28 • In the 
UK, the Committee of Safety of Medicine (CSM)/Medicines Control Agency (MCA) 
defines an ADR as: an unwanted or harmful reaction experienced following the 
administration of a drug or combination of drugs under normal conditions of use and 
suspected to be related to the drug" 29 . This thesis refers to ADRs based on these 
definitions and does not include events that resulted from inappropriate use of drugs, non-
compliance and medical negligence. 
Adverse drug reactions are generally mild (e.g. mild sedation from antihistamines); 
although rare, serious ADRs (e.g. haemorrhage from anticoagulation therapy) may lead to 
hospitalisation and occasionally death. Therefore, ADRs are a serious issue and 
management of these events may be associated with a substantial health and economic 
impact to the health service and to society. This is discussed in later sections of this 
chapter. 
3.2.1 Source of Adverse Drug Reaction Data 
Drug safety takes an equally important role alongside drug efficacy in pre-marketing drug 
development. Similarly, ADRs are monitored post-marketing alongside the effectiveness of 
drug therapies. All developed countries have some form of spontaneous reporting scheme 
to monitor adverse drug reactions continuously since the thalidomide disaster in 1961. In 
the UK, the Yell ow Card Scheme has been set up to encourage reporting of suspected 
ADRs by healthcare professionals such as doctors, dentists, coroners, pharmacists and the 
pharmaceutical industry. This scheme was later extended to include reporting by nurses, 
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midwives and health visitors in 2002, and a pilot patient reporting scheme was introduced 
in 2003. 
An alternative to the Yell ow Card Scheme is prescription event monitoring (PEM) 
undertaken by the Drug Safety Research Unit (DSRU) at Southampton 30. The DSRU 
focuses on a limited number of drugs (10 to 12) at any one time. The Prescription Pricing 
Authority (PP A) in England receives records of all dispensed prescriptions in England and 
forwards all the records of prescriptions for the drugs of interest to the DSRU. A 'green 
form' is then sent to the prescribing GP enquiring details of any ADRs in the patients who 
were prescribed the drugs of interest. Unlike the Yell ow Card Scheme, both the numerator 
(returned 'green forms') and denominator in the ADR incidence rate calculation (number of 
dispensed drugs of interest) are known and overall, the PEM scheme is less limited by 
under-reporting. 
Despite not being designed with the objective of monitoring ADR, there are several 
epidemiological databases that contain data that may be potentially used for researching in 
ADRs. 
One of the most extensive database of this kind is the General Practice Research Database 
(GPRD) which contains both prescribing and diagnostic data 31 . The GPRD currently 
receives data from approximately 525 practices (3.4 million patients, over 30 million years 
of prescribing histories), recording every prescription and all significant morbidity. This 
database can be analysed to provide information on patients with selected diseases 
prescribed specific drugs. Although diagnoses are based solely on clinical judgement, the 
data have been found to be reliable and accurate when compared to other sources (e.g. 
consultants' letters, hospital discharge letters, or questionnaire surveys with GPs). 
Mediplus is a second dynamic pnmary care database, most commonly used by the 
pharmaceutical industry 32. It contains extensive data on patient demographics, morbidity, 
prescribing and mortality. Over 148 practices serving approximately 1.8 million patients 
participate in this data collection system. Although under-represented in Scotland, the data 
are believed to be representative of the UK as a whole. The data has been captured- during 
primary care consultation and from other information received in the practice -
systematically, encoded and stored electronically in formatted records and updated monthly. 
The main data set contains details of patients, prescriptions, diagnoses, symptoms, 
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observations and tests in primary care, secondary referrals and main outcome of referral. 
Linkage between diagnosis and prescriptions is possible, but inappropriate linkage may 
cause problems with interpretation of data. The major limitation to Mediplus however, is 
the cost of accessing the database. Mediplus is a privately owned database and subscription 
to the database may cost as much as £25 000 per year. Therefore, Mediplus is primarily 
used by the pharmaceutical companies for marketing purposes. 
In Scotland, the development of the General Practice Administration System for Scotland 
(GPASS) 33 and Continuous Morbidity Recording (CMR) 34 in recent years has shown 
positive signals in producing a comprehensive database for primary care research. Over 
80% of all practices in Scotland participate in a national Scottish computer system for 
general practice - GPASS, which was set up primarily to collect data for administrative 
functions. Data from individual practices such as patient registration, repeat prescriptions, 
call and recall, health promotion and immunisation have been captured via Electronic 
Questionnaires (EQ). Reports on the practice data can be generated, in particular, on areas 
of health promotion, chronic disease management and patient summaries, which has been 
extremely useful to GPs. Based on the original EQ, the GPASS Data Evaluation Project 
(GDEP) has redeveloped the data capture system to collect anonymous data at patient level 
from over 400 practices (approximately 2.8 million patients). The GPASS Data Evaluation 
Project has created an extensive primary care database, where relevant patient data can be 
extracted, interpreted and compared regionally and nationally, with the aid of software 
utilities such as Prescribing Analysis Tools 35, Practice Report Utility 36, among others. 
Feedback on individual practice, regional and national data has been distributed bi-
annually. 
Continuous Morbidity Recording is a three-way collaboration between the Information and 
Statistics Division (lSD), Department of General Practice at the University of Aberdeen and 
the Scottish Centre for Infection and Environmental Health (SCIEH), which began as a pilot 
project in 1992. The project has now evolved into an invaluable national source of primary 
care morbidity data from over 60 practices throughout Scotland 34, and participating 
practices cover all but two health board areas - Orkney and the Western Isles. 
Continuous Morbidity Recording is generating a database of active morbidity and GP 
workload. Morbidity information is collected on a continuing basis from all face-to-face 
consultations between patients and GPs. Based on the development of the EQ, the CMR 
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project has been developed to collect and analyse additional data from the daily work of 
general practice: the patients, symptoms, disease, consulting and prescribing behaviour and 
geographical and socio-economic patterns, including deprivation. Details of each doctor-
patient contact - at surgeries, home visits or clinics - has been recorded. However, no data 
are collected about prescribing, direct data entry (health promotion and administration) or 
nurse-led clinic activities. CMR data provide insight into demand for GP services and can 
be extrapolated to provide estimates of workload at national level. However, due to the 
small number of participating practices at present, the patient population covered is not 
representative of Scotland as a whole in terms of age, geography and deprivation. 
3.2.2 The Incidence of Adverse Drug Reactions 
Spontaneous Reporting 
Since 1964, when the scheme was set up, over 400 000 suspected ADRs have been 
reported. In the year 2000 alone, over 33 000 reports were submitted to the Yellow Card 
Scheme, most were associated with the Meningitis C vaccine 37 . Despite some success in 
identifying ADRs such as remoxipride and aplastic anaemia, the main limitation of under-
reporting remain. A large retrospective review of case notes has revealed that only 2% to 
4% of all ADRs 38 are reported through spontaneous reporting. Similarly, it has been 
reported that only 10% of serious ADRs are reported through spontaneous reporting 39 . 
In 2002, 1369 suspected ADRs were reported to the CSM in Scotland 40. Assuming that 
due to under-reporting only 2% to 4% of all ADRs are reported 38, the expected number of 
ADRs is approximately 34 225 to 68 450. In the same year, approximately 66.2 million 
prescription items were dispensed in Scotland (equivalent to 12.4 prescriptions per patient 
on GPs' list) 41 , giving an ADR incidence rate of approximately 0.05% to 0.10% of all 
prescriptions. However, the severity of the ADRs and the proportion of patients who seek 
or require medical treatment are unclear. 
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Incidence of ADR in Hospital Patients 
Although data from spontaneous reporting schemes gives an indication of the incidence of 
ADRs, the risk, management and cost of ADRs associated cannot be determined. In order 
to examine these issues, specifically designed studies need to be undertaken. The risk, 
management and cost of ADRs are not widely investigated. Studies that have attempted to 
investigate the incidence of ADRs in the medical literature, have focused primarily on 
serious events that led to hospitalisation or ADRs that occurred in patients whilst in 
hospital. 
An early systematic review (1993) 42 of drug-related hospital admissions (defined as 
admissions resulting from a patient's non-compliant or unintentionally inappropriate drug 
use), examined the findings of 36 studies published between 1966 and 1989. The 
prevalence of the pooled admissions resulting from ADRs was 5.1% (95% CI 4.4% to 
5.8%). Of these ADR admissions, 71.5% were classed as "side effects", 16.5% "excessive 
effects", 11.3% hypersensitivity reactions and 0.4% idiosyncratic; 5% of admissions due to 
ADR resulted in mortality. 
In a meta-analysis of 39 prospective studies published from 1966 to 1996 from US 
hospitals 43 , serious ADRs were defined as those requiring hospitalisation, were 
permanently disabling or resulted in death. The incidence of serious ADRs that led to 
hospitalisation (4.7%; 95% CI 3.1% to 6.2%) was combined with the incidence of ADR 
whilst in hospital (2.1 %; 95% CI 1.9% to 2.3%) to determine the overall incidence of 
serious ADRs in hospital patients (6.7%; 95% CI 5.2% to 8.2%). Fatal ADRs were 
estimated in 0.32% of all hospitalisations. A similar overall ADR incidence (6.7%; 95% CI 
6.6% to 6.8%) was estimated in a more recent systematic review and meta-analysis of data 
from 69 studies conducted worldwide published between 1966 and 1999 44 (US studies = 
21, European studies excluding UK and Ireland = 21 and studies based in the UK and 
Ireland = 7). However, when the analysis was stratified by geographical setting, it was 
found that ADR incidence based on data from the UK (7.5%; 95% CI 7.2% to 7.8%) and 
Europe (14.1 %; 95% CI 13.8% to 14.3%) were significantly higher those reported from 
North American studies (4.6%; 95% CI 4.5% to 4.7%). 
Beijer and de Blaey (2002) 45 conducted a systematic review on the rate of ADR-related 
hospitalisation. Sixty-eight studies from the US (n = 25), Europe (n = 19) and Australia (n 
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= 15) were included in the review. Adverse drug reactions were defined according to the 
WHO definition. The studies reviewed varied considerably in sample size (ranging from 41 
to 24 000) and observed ADR-related hospitalisation (ranging from 0.2% to 41.3%). 
Aggregated ADR incidence rates calculated from two different methods were presented: (1) 
a proportion calculated by the number of total ADR-related hospitalisations across all 
studies divided by the total number of hospitalisations across all studies (4.9%; 95%CI 
4.8% to 5.0%); (2) an average of the proportions of ADR-related hospitalisation as 
published in individual studies (12.5%; 95%CI 9.9% to 15.1 %). 
Although no formal analysis of heterogeneity was undertaken, it is apparent that much 
inconsistency exists between the individual studies included in the reviews. However, the 
estimated overall incidence of ADR in hospital patients was relatively consistent among the 
systematic reviews, with overlapping confidence intervals. Therefore, it is reasonable to 
suggest that the incidence of ADRs in hospital patients fall within the range of 4.4% to 
15.1%. 
Incidence of ADR in Primary Care 
To date, no systematic review has been conducted to evaluate the incidence of ADRs in 
general practice and little is known. However, the lack of data reflects on the difficulty in 
conducting research in this area. The largest survey of ADRs (based on the WHO 
definition) in general practice in the UK was conducted by Lumley CE et al (1986) 46, when 
data were collected from 24 training practices in a health region (former South West 
Thames) in England, over a period of four weeks (n = 100). Of 36 470 consultations 
evaluated, 1.7% reported ADRs (n = 638 consultations). In approximately half of these 
cases (0.8%), the ADR was the cause of the GP consultation. However, only 1.6% of 
ADRs reported (arising in 0.027% of consultations) were judged to be senous. 
Cardiovascular drugs and diuretics were the most frequently involved drugs (23%), while 
gastrointestinal (GI) disturbance was the most frequently observed ADR (13%). 
The most recent study was conducted by Lacoste-Roussillon C et al (2001) 47 . A 
prospective study of the incidence of serious ADRs (based on the WHO definition) in 254 
GPs was conducted in France. During a five-day period, 13 validated serious ADRs (two 
were fatal) were observed, representing an "incidence density" of 10.2 (95% CI 5.4 to 17.5) 
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per 1000 days of practice. If this was extrapolated to the 60 000 active GPs in France, it 
could be estimated that 123 000 (95% CI 65 400 to 210 000) serious ADRs are seen each 
year by GPs in France. In this study, antineoplastic and anticoagulant agents were the most 
frequently involved drugs (seven cases), while blood dyscrasia and bleeding were the most 
frequently observed ADRs. 
This thesis focuses on three different classes - NSAIDs, SSRis and ACE inhibitors - of 
drugs with different mechanisms of action for their intended effects. These drugs are 
associated with different ADR profiles, which are discussed below. 
Non-steroidal Anti-inflammatory Drugs 
Non-steroidal anti-inflammatory drug therapy is the dominant treatment in arthritis and 
musculoskeletal conditions. The use of these drugs is extensive. In the UK alone, over 20 
million prescriptions are made for NSAIDs annually, accounting for approximately 5% of 
all the NHS prescriptions 48 . 
These drugs are extremely effective in appropriately maintained dosages. Currently, there is 
no established method to predict which NSAID will be the most effective for an individual 
patient, but minor differences in efficacy have been found. Statistically, all NSAIDs are 
similar in potency despite consistent but unexplained inter-patient variability in both 
efficacy and adverse drug reactions profiles. However, attention has been increasingly 
focused upon inherent safety problems, and the size of the problem associated with NSAID-
induced adverse drug reactions is highly significant. In 1986, the CSM reported that 25% 
of all the 'yellow card' reports received in the UK are NSAIDs-related 49. The most 
frequent, as well as the most severe adverse drug reactions, are located in the GI tract, other 
adverse events are related to the central nervous system (CNS), the kidneys, the liver, the 
blood and the mucocutaneous system 50•51 • There is emerging evidence of substantial 
differences in toxicity between in NSAIDs 52. 
A number of studies have been dedicated to NSAID-induced GI toxicity. Gastropathy 
induced by the treatment with these drugs is undoubtedly the most common adverse 
reaction related to the regular use of NSAIDs 53-56 . 
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Mild GI complications are common, such as dyspepsia, diarrhoea, constipation and gastric 
mucosal damage (with endoscopic evidence of gastritis). It has been suggested that 5 to 
50% of the patients on NSAID therapy would experience dyspepsia 57•58 . 
Serious and often life-threatening events have also been reported such as peptic ulcer 
disease and upper GI bleeding 59• The incidence of peptic ulcers (gastric and duodenal) 
range from 10 to 40% of patients who are on NSAID therapy 60. Clinically important peptic 
ulcer caused by NSAIDs can occur in mucosa inflamed because of infection with 
Helicobactor pylori or in histologically normal mucosa. A study carried out in 1992, 
evaluated GI damage in 713 post mortems conducted on a random series of hospital 
patients, of whom 249 had taken NSAIDs. Peptic ulcer was found in 20% of the NSAID 
users compared with 12% in non-NSAID users 61 . In addition to an association with gastric 
ulceration, NSAIDs are also believed to inhibit epithelial regeneration at the edge of gastric 
ulcers, thereby delaying ulcer healing 62. 
In 1983, Venning published a series of articles in the British Medical Journal on the 
"identification of adverse reactions to new drugs" 63 . He suggested that the fatal reports 
related to NSAID-induced GI bleeding indicated that it was the third most important drug-
induced cause of death between 1964 and 1980. Independent studies have indicated that the 
relative risk of ulcer complications for NSAID users is approximately four times higher 
than non-users 64•65 • Estimates show that 0.7% to 1% of regular NSAID users are 
hospitalised as a result of upper GI bleeds 66. 
Co-prescribing GI protective drugs such as antacids, H2 blockers, misoprostol and proton 
pump inhibitors are common procedures in treating mild GI adverse drug reactions due to 
NSAIDs. However, in cases when the symptoms are severe, further investigations such as 
endoscopy or gastric biopsy and hospitalisation may be required. These procedures make a 
significant contribution to the cost of NSAID therapy. 
Renal dysfunction is a recognised complication of oral NSAIDs. These drugs may induce 
fluid and electrolyte disorders and both acute and chronic renal failure 67 . The most 
common renal adverse effect is haemodynamically mediated, resulting in depression of 
renal function, which is usually completely reversible within 24 to 72 hours following 
discontinuation of the drug. Interstitial nephritis is an extremely rare and idiosyncratic 
event which has been described with many NSAIDs 52•68 . 
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It has been estimated that approximately 5 to 18% of outpatients receiving NSAIDs have 
renal impairment and the impact on the kidney is the greatest among these patients (usually 
the elderly) who depend on the synthesis of vasodilatory prostaglandin to maintain renal 
homeostasis. There is increasing awareness of the difference in the extent of renal damage 
induced by individual NSAIDs 60• It is believed that drugs with high renal clearance of 
active metabolites, such as indomethacin and naproxen, are more toxic to the kidneys 69 . 
Isolated cases of hepatic damage have been noted with almost all NSAIDs in clinical use. 
The severity of liver disease has varied from mild asymptomatic elevation of one or more 
hepatic enzymes to severe hepatocellular injury resulting in death, but these events are 
generally uncommon. Case reports suggest that NSAIDs may be associated with liver 
disease, but it appears that the risk is very small 70. It is believed that greater risk is 
observed in RA patients and in those who were concomitantly exposed to other potentially 
hepatotoxic drugs. One study estimated the incidence rate of acute liver injury induced by 
regular use of NSAIDs to be one per 100 000 prescriptions (equivalent to four per 100 000 
users) 71 . These events are generally mild and are usually reversible with reduction in 
dosage or discontinuation of the drug. 
Second to GI toxicity, skin reactions due to NSAIDs are common. Although these reactions 
(including pruritis and non-specific rashes) are relatively mild in nature, fatal reactions, 
including erythema multiforme, have been reported. Most cases of dermatological 
reactions improve when the NSAID is discontinued. Generally, no treatment is required but 
antihistamines are sometimes prescribed to alleviate itching. It was suggested that drugs 
with long half-lives, such as piroxicam, are more commonly associated with adverse 
cutaneous reactions 72. 
All NSAIDs have been implicated in adverse events in the CNS, and up to 10% of the 
regular NSAID users suffer a variety of these symptoms. These include severe headache, 
dizziness, trouble with thinking, tinnitus and blurred vision. Headache is the most common 
NSAID-induced CNS side-effect, particularly with patients taking indomethacin 73 . 
Tinnitus is reported rarely, commonly observed in subjects with high doses of salicylates, 
e.g. Aspirin, who also experience a reversible sensorineural hearing deficit of up to 30 - 40 
decibels across all frequencies. More severe side-effects such as aseptic meningitis, 
psychosis and cognitive dysfunction have been documented. However, these cases are 
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extremely rare and have not been reported in the clinical trials or post-marketing studies 
consulted in this study 74 . 
Haematological disorders include aplastic anaemia, agranulocytosis, thrombocytopenia and 
haemolytic anaemia 75 • Agranulocytosis tends to develop primarily in younger patients, 
often after a few days or weeks of NSAID therapy, but is usually reversible on 
discontinuation. Phenylbutazone-induced aplastic anaemia was listed as one of the 18 most 
important adverse reactions by Venning (1983) 63 . This adverse effect occurs more 
frequently in the elderly and is more likely to prove fatal. Recent studies suggest that 
indomethacin and diclofenac may cause more haematological toxicity than other 
NSAIDs 55 . 
In addition to the above mentioned NSAID-induced drug reactions discussed, other side-
events have also been observed with NSAID therapy. These include a variety of disorders 
such as pulmonary toxicity (commonly observed as bronchospasm), cardiovascular (CV) 
oedema, enhanced mean arterial blood pressure of hypertensive patients, lethargy, 
palpitations, amongst others. However, these events are extremely infrequent and have 
mostly been reported only in individual case reports 76 . Therefore, these secondary events 
are believed to make little or no contribution towards the economic consequences of 
NSAID therapy and have not been included in this evaluation. 
Selective Serotonin Reuptake Inhibitors 
The group of SSRis including fluoxetine, fluvoxamine, paroxetine and sertraline is one of 
the most common classes of drugs used in the treatment of depression. Although similar in 
efficacy to the traditional tricyclic anticholinergics (TCAs), overall, these drugs have been 
shown to have a superior safety profile, free from anticholinergic, CNS and CV effects 77• 
However, no drugs are free of ADRs and events such as nausea, diarrhoea, insomnia, 
nervousness, agitation and anxiety have been observed with SSRis 78-80• Selective serotonin 
reuptake inhibitors act by inhibition of serotonin reuptake, resulting in increasing amounts 
of plasma neurotransmitter being available to interact with the receptors. Therefore, most 
of the adverse events associated with SSRis are dose related and can be attributed to 
serotonergic effects. The typical ADRs associated with SSRis include GI effects, CNS 
effects and sexual dysfunction. 
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Compared with the use of NSAIDs, SSRis are associated with a less substantial ADR 
profile. Gastrointestinal disturbance are the most frequently reported ADR among patients 
on SSRis 81 . Clinical trials have reported GI events such as nausea, vomiting, dyspepsia, 
abdominal pain, diarrhoea and constipation ranging from 6% to 37%. During the first two 
years of marketing, gastrointestinal ADRs have been reported between 21.1% (paroxetine) 
and 38.8% (fluoxetine) of patients in the UK 78 • In a meta-analysis of SSRis for major 
depression 79, gastrointestinal ADRs such as nausea and diarrhoea were shown to be more 
commonly reported - 10.3% (95% CI 7.3% to 13.3%) and 9% (95% CI 4% to 14%), 
respectively more than those on TCAs. However, when compared with TCAs, a lower rate 
of constipation was reported (11 %; 95% CI 8% to 14%, less than that observed with TCAs). 
Between 11% and 26% of patients have reported ADRs to the central nervous system 
(CNS) including insomnia, somnolence, tremor, dizziness and headache. Other ADRs such 
as dry mouth and sweating have been observed in 9% to 30%. 
Sexual dysfunction is a common characteristic of depression itself, as well as an adverse 
reaction to antidepression therapy. Therefore, the true incidence of sexual dysfunction 
attributable to SSRI use is difficult to measure. Studies have reported incidences ranging 
from 13.5% to 22% based on checklists and spontaneous reporting, respectively. However, 
systematic enquiry has reported much higher rates of 54% to 65% 82. 
Weight gain or weight loss have been reported in approximately 4% of patients on SSRis. 
In particular, the weight loss observed with the early short-term clinical trials with 
fluoxetine have prompted further investigations into fluoxetine as a potential weight loss 
agent 83 . Although some SSRis are associated with weight loss at the onset of therapy, 
weight is often regained after six months and can be followed by additional weight gain 
with long-term use. Therefore, weight gain has subsequently been shown to be a common 
ADR of long-term SSRI therapy. Mean weight gains of 6.75 Kg to as much as 10.8 Kg 
have been observed with sertraline and paroxetine respectively, over a period of six to 12 
months in uncontrolled studies 84•85 . 
Cardiovascular ADRs are uncommon. Symptoms such as palpitation and hypotension, 
including postural hypotension and tachycardia have been reported in a small proportion of 
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patients on SSRis. Collectively, CV events have been reported in 2.6% to 4.1% of patients 
on SSRis 78 • 
Angiotensin Converting Enzyme Inhibitors 
ACE inhibitors are widely prescribed as a first line therapy in the management of essential 
hypertension, particularly in patients with concomitant diabetes, renal disease and 
congestive heart failure. Their efficacy in reducing both mortality and morbidity 
associated with hypertension has been shown in many randomised controlled trials. 
However, in treatment of hypertension, patients often receive sub-optimal treatment due to 
poor compliance, intermittent or switched prescriptions. Termination of use disrupts the 
consistency of treatment. Hypertension is asymptomatic; therefore, patients who are treated 
with an antihypertensive agent that causes adverse events may perceive a lower quality of 
life, although blood pressure is controlled. This contributes substantially to patient non-
compliance. Non-compliance, in tum results in rebound hypertension and potentially 
serious CV and renal complications. 
Adverse drug reactions (ADRs) may be one reason for changing or stopping drug use, but 
the proportion of hypertensive patients who change or discontinue treatment because of 
ADRs is difficult to estimate. A recent pharmacoepidemiology study in Italy showed that 
physicians (N = 1255) considered the main reason for discontinuation and switching to be 
inadequate blood pressure control (51.2% of patients) and adverse drug events (34.5%) 86 • 
However, completed questionnaires from 4612 patients in the same study considered 
ADRs as the major reason for switching (53.3%) followed by inadequate blood pressure 
control (34.1 %). 
Angiotensin converting enzyme inhibitors are generally well tolerated. The most frequently 
reported adverse effects include headache, cough, dizziness, fatigue and diarrhoea. Adverse 
events vary among individual drugs within the class. Common side effects include rash 
(often alleviated with reduced dose), hypotension (first dose, common among elderly) and 
cough (non-productive, nocturnal and hacking- up to 5% to 15%) 87 . Cough is believed to 
be a class effect of the ACE inhibitors, occurring in about 25% of patients. The cough is 
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characterised as dry, non productive, and persistent, and may be disturbing enough to 
prompt discontinuation of therapy. 
Angioedema, often presenting as swelling of the face and neck has also been reported, but 
in less than 1% of all patients. Although rare, it is potentially life threatening. Leukopenia 
also occurs rarely, mostly in patients with specific risk factors- severe renal dysfunction or 
vascular disease 88 • Renal failure is also uncommon, but may occur in patients with 
bilateral renal artery stenosis or disease associated with high renin activity such as pre-
existing congestive heart failure. Uraemia is often observed in those who lack careful renal 
function monitoring for example in vulnerable patients 88 . 
3.2.3 Clinical and Economic Consequences of Adverse Drug Reactions 
The impact of ADRs on healthcare is difficult to estimate. There is a lack of real patient 
data; therefore, only extrapolation is possible. By extrapolating the study findings, Lazarou 
J et al (1998) 43 estimated that over 2.2 million hospitalised patients had serious ADRs and 
106 000 had fatal ADRs in the US, making these reactions between the fourth and sixth 
leading cause of death in 1994. However, this study has been criticised for bias resulting 
from heterogeneity between the aggregated data and it is believed that the estimated 
mortality has been much inflated 89. 
The direct and indirect costs are difficult to estimate, as data on the consequences, in 
particular on healthcare resource use of most ADRs are very limited. The costs of incidents 
where ADRs are probable causes of death or hospital admissions may be identified and 
measured. Costs may also be estimated based on the description of the nature of ADRs, 
which gives indication about the severity of the event. However, it is extremely difficult to 
measure, for example, the medical expenditure or number of days lost from work due to all 
kinds of ADRs. 
The lengths of stay, and subsequently the cost of hospitalisation associated with ADRs have 
been shown to be substantial 90•91 . In a matched case-control study, Classen et al (1997) 91 
matched 1580 patients with one hospital-acquired ADR with 20 197 controls and reported 
an ADR incident rate of 2.4% during the three-year study period. These events were 
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associated with an increased length of stay of 1.91 days and an additional cost of US$2262. 
Similarly, Bates et al (1997) 90 reported an ADR incidence rate of 4.6% in a cohort of 4108 
admissions over a six-month period. The additional length of stay and costs associated with 
ADRs and preventable ADRs were 2.2 days and US$3244, and 4.6 days and US$5857, 
respectively. 
Hospital admissions associated with ADRs are only one aspect of drug related morbidity. 
A larger proportion of ADRs may never result in hospitalisations, but these events may still 
lead to substantial health and economic impact in the form of regular visits to GPs, co-
prescribing and the use of other social services. 
Non-steroidal Anti-inflammatory Drugs 
Non-steroidal anti-inflammatory drug therapy is costly. The costs of treating adverse 
effects add a considerable expense to the cost of the therapy. Adverse drug reactions in 
NSAID-therapy add considerable burden to the NHS. 
Blower et al (1997) 92 attempted to measure the burden of NSAID-related ADRs in the UK 
in a retrospective analysis of all emergency admissions for upper GI disease, as well as an 
analysis of the records of all community deaths attributed to upper GI diagnoses, compared 
with matched controls. The results showed that NSAID users were more likely to require a 
blood transfusion, a higher volume of transfused blood and to be hospitalised longer than 
those who are not on NSAIDs. Similar findings were reported by Hawkey et al (1997) 93 
when 500 patients, aged over 60 years admitted to hospital with peptic ulcer bleeding over a 
five-year period were interviewed. In addition, prescribing in 103 practices was also 
examined. This study reported an average admission rate for bleeding peptic ulcer of 15 per 
1000 000 per year. In addition, the authors concluded that the findings were equivalent to 
one episode of ulcer bleeding in the elderly per 2823 (95% CI 2095 to 8116) prescriptions. 
In another cohort study of patients over 50 years, based on population data from Tayside 94, 
2% of NSAID takers were admitted with GI events compared to 1.4% of non NSAID 
takers, suggesting that about 0.2% of the over 50s population may be admitted in any one 
year because of NSAID-related GI events. 
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In an attempt to address the GI problems associated with NSAID use, the co-prescription of 
gastroprotective agents such as H2-receptor antagonists, proton pump inhibitors and 
misoprostol has become common practice. Among these drugs, misoprostol has been found 
in clinical trials to reduce the incidence of gastric and duodenal ulcers in patients requiring 
continuous NSAID therapy. H2 blockers seem to reduce complications of gastric and 
duodenal ulcers. In Scotland, Omeprazole was the most costly and the ninth most 
commonly prescribed drug in the year 2000, at £37 699 000 for over one million 
prescriptions, lansoprazole was the third most costly at £14 858 000 and ranitidine was the 
sixth most costly drug at £12 252 000 95 . 
In another study, Moore and Phillips (1999) 96estimated the annual burden of NSAID-
related GI ADRs from the perspective of the NHS by conducting a simulation study based 
on three patterns of NSAID co-prescribing. When the costs for NSAIDs and 
gastroprotective agents (omeprazole and ranitidine) were included, the cost per patient 
prescribed an NSAID for an average co-prescription estimate amounted to £40 per year, and 
to £215 million when the results were extrapolated to the whole of the UK. In addition, the 
total costs per patient with an NSAID-related bleed were estimated to be £2198, equivalent 
to an annual cost of £35.5 million in the UK. 
Several studies on the real cost of NSAID therapy have been documented. These 
evaluations not only take into account the cost of the drug but also the cost of treating other 
factors such as associated GI complications (the 'shadow' cost) 20•21 . De Pouvourville 
(1992) 20 suggested in his study that the cost of NSAID therapy may be increased by 2.1 to 
3.6 fold when the shadow cost of treating GI complications has been taken into account. 
The economic consequences of the unwanted secondary effects of NSAID therapy can be 
demonstrated by a simple shadow cost model. The cheapest drug may not be the least 
expensive in the end. 
Selective Serotonin Reuptake Inhibitors 
The high costs associated the treatment of depression have increased interest in 
pharmacoeconomic evaluations of drug treatment, particularly in the 1990s, as the use of 
SSRis expanded substantially. Many observational studies have been carried out to 
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compare differences between SSRis and TCAs 97-99 • These studies attempted to estimate the 
costs to the healthcare system based on outcomes such as treatment duration and drug 
switching. Although SSRis are generally associated with higher acquisition costs than 
TCAs, the total healthcare costs are decreased, by the reduction in acquisition costs 
associated with the use of SSRis. 
Results from short-term studies comparing SSRis and TCAs suggested that SSRis are either 
more cost effective, or that there is no difference in costs. A prospective, randomized 
trial 97 comparing clinical outcomes and treatment costs for patients who were initially 
prescribed an SSRI or TCA, showed that the higher cost of fluoxetine therapy was balanced 
by fewer outpatient and inpatient costs. Patients who were prescribed fluoxetine reported 
fewer ADRs and lower rates of medication switching and were more likely to reach 
adequate dosing levels in patients who were prescribed TCAs. The total costs for care over 
six months were equal in both groups. 
Longer term studies, mainly lifetime simulation models, focused more on the impact of 
maintenance antidepressant therapy and showed more mixed results, but still favoured 
SSRis over TCAs. The cost effectiveness of treatments was mainly determined by the costs 
associated with reduction in relapse rates, and the assumption of lower treatment 
discontinuation rates 100. However, comparative studies of individual SSRis, focusing on 
the costs associated with adverse drug events, have not been identified. The cost of treating 
some of these adverse effects has been cited as a major contributor to the overall costs of 
drug therapy 101 . Adverse effects leading to discontinuation of medication may, in fact, be 
associated with discomfort and loss of productivity and other indirect costs attributable to 
treatment failure. 
Angiotensin Converting Enzyme Inhibitors 
In the US, the total cost of hypertension treatment in 1998 was estimated at $23.3 billion, 
$7.5 billion of which was the pharmaceutical cost 102. In Sweden, the total annual cost of 
treating hypertension in 1992 was approximately 1.6 billion Swedish Crowns (£160m) 103. 
Unlike the case of NSAIDs , the literature for cost effectiveness studies on ACE inhibitors 
in the treatment for hypertension is sparse. Some cost of illness studies have reported on 
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the economic burden of hypertension to the healthcare system and society as a whole, but 
few examined the cost effectiveness of drug therapies for the treatment of hypertension. 
Only a few studies attempted to evaluate the cost of individual ACE inhibitors for the 
treatment of hypertension. These studies compared selected ACE inhibitors with drugs 
from different classes of antihypertensive agents 104-106, Angiotensin I receptor blockers 107• 
Others examined the economic and clinical consequences in specific patient groups, in 
particular, those with type 2 diabetes 108• The cost implications of drug switching have also 
been evaluated 109-111 . 
However, the measure of effectiveness, the cost variables included, and the characteristics 
of the patient population varied considerably across the studies. This lack of conformity 
has made it difficult, "if not impossible", to compare the findings and make conclusions 
about the relative cost effectiveness of different antihypertensive therapies. 
SUMMARY 
The importance of ADRs is often underestimated. These events are common and in 
extreme cases, may lead to mortality; while at the opposite end of the scale, these events 
may incur unnecessary expenses to the NHS. Although the incidence of ADRs and their 
subsequent impact on costs have been investigated in studies based primarily in hospitals in 
the US, the implications are clear from the published results that ADRs constitute a 
widespread problem that causes adverse clinical events and substantial increases in costs. 
Therefore, a full economic analysis of drug use must take into account not only the cost of 
the drug but also the cost of any potential ADR induced by the use of this drug. Despite the 
wealth of literature on the effect of ADR on an increase length of stay, and with additional 
hospital admissions, the costs associated with these events in primary care are unknown. 
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3.3 THE IMPACT OF ECONOMIC INFORMATION ON MEDICAL DECISION 
MAKING: A PRIMARY CARE PERSPECTIVE 
A literature review on the impact of pharmacoeconomic information in influencing primary 
care prescribing was initially intended. A literature search for studies investigating the 
influence of economic information in influencing prescribing decisions was conducted. 
However, extensive trawling of the literature has revealed no studies fulfilling the search 
criteria. Therefore, a critical review of the impact of economic information, not specific to 
primary care prescribing, but in overall medical decision making in primary care, was 
conducted. This review focused on studies that aimed to examine decision makers' 
perspective on the usefulness, the value and their awareness of economic information; their 
perceptions about barriers to implementing such information were also examined. 
The search strategies (Appendix II) included searching all major electronic databases, the 
Internet, hand searching of references from relevant literature, author citation search using 
the Web of Science Database and consultation with other researchers, in the attempt to 
capture both the mainstream and grey literature in the area. Only articles published in 
English were retrieved. All the studies meeting the following criteria were included: (1) 
study participants included medical decision makers in a primary care setting and (2) the 
aim focused on economic, not cost information. 
Despite the volume of research on health economic issues, few published studies 
concerning the impact of economic information in primary care medical decision making 
were identified. These studies all focused on primary care decision makers' understanding 
and perspectives in the role of economic information in medical decision making; therefore, 
consisted solely of qualitative research such as surveys and focus groups (Table 1). The 
perspectives of a heterogeneous mix of medical decision makers in different countries were 
explored including clinicians (primary and secondary care), prescribing advisers, managers 
and purchasers, both in government and health authorities. Although data relating to 
primary care decision makers cannot be extracted in isolation, these studies were also 
included in this review. 
The literature has identified and highlighted several influencing factors surrounding the role 
of economic information in primary care medical decision making. The main findings of 
these studies are generally in agreement, that there is recognition of the importance of 
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economic information in decision making, but the current evidence available is not being 
used sufficiently, due to various barriers relating to relevance and bias. 
All the studies identified in the literature search are summarised in Table 1. 
3.3.1 Knowledge in Economic Information 
There have been some attempts in the literature to assess the level of knowledge in health 
economics among decision makers through measuring formal training in health economics 
and use of direct questions regarding self-perception of knowledge. A postal survey (n = 
446) conducted in 1997 112 reported that health economics training primarily consisted of a 
short course, was modest (37% overall), among prescribing advisers (40%), pharmacists 
(17%) and directors of public health (86% ). The high proportion observed among 
directors of public health may be explained by the fact that knowledge about health 
economics was needed as part of their qualifying examinations. Similar results were 
observed in the European Network on Methodology and Application of Economic 
Evaluation Techniques (EUROMET) project when decision makers (n = 1022) over nine 
European countries (including the UK) were surveyed by postal questionnaire, semi-
structured interviews, or through focus groups113 • The study reported, "on average, those 
who had participated in health economic courses amount to a third", with Norway 
reported to have the highest training rate of 50%. 
The overall lack of training has been reflected in the lack of understanding about economic 
evaluation techniques. Duthie et al (1999) 114 presented decision makers with different 
health economic outcome statements on randomly ordered shuffle cards in a focus group 
study to determine what decision makers view as relevant to their decision making. It was 
found that a high proportion of the statements relating to traditional health economic 
outcomes such as incremental ratios, quality adjusted life years and willingness-to pay were 
not understood, or were viewed as irrelevant. Similar conclusions were drawn from the 
EUROMET study113, where the majority of the participants were reported to have poor 
knowledge of cost benefit, cost effectiveness or cost utility analysis. In a recent focus 
group study, decision makers from two health authorities (n = 12) were presented with 
abstracts retrieved from the NHS Economic Evaluation Database (NHS EED) 115 for 
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discussion. The authors reported that some of the participants experienced difficulties with 
the economic terminology used in the literature. 
3.3.2 The Use of Economic Information 
Secondary to evidence of clinical effectiveness, there is a general agreement among 
decision makers that economic information is an important factor to be taken into account 
in medical decision making, in particular, when making decisions on adopting new 
treatments 113•116• However, studies have generally reported modest use (approximately one 
third of surveyed participants) of economic information in decision making 113•117. Contrary 
to these findings, although no numerical data were presented, it is believed that the focus 
group study conducted by Hoffmann et al (2002) 115 indicated a higher level of use, stating 
that "most of the participants" had used economic information previously. 
3.3.3 Source of Economic Information 
Peer-reviewed clinical journals have been reported to be the most important source of 
economic information for decision makers 112•113 • The EUROMET study reported that 
decision makers in the UK viewed secondary sources (e.g. Bandolier 118, effective 
healthcare bulletins 119, drug and therapeutic bulletins 120) as the most important source of 
information. Opinions of colleagues have also been perceived by prescribing advisers and 
pharmacists to be reliable sources of information112. 
3.3.4 Barriers to the Use of Economic Evaluation 
All the studies included in this review investigated barriers to the use of economic 
evaluation to some extent. Despite the different settings of the studies, with regards to the 
country in which the studies were undertaken and the type of decision makers consulted, 
there was a certain pattern to the barriers identified. 
Organisational barriers such as the rigidity of the structure of the healthcare system and 
difficulty in reallocating resources have been highlighted as the major factor associated with 
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the limited use of economic information in decision making 112-114. This is not unique to the 
UK as similar conclusions were drawn from the EUROMET study 113 , where "difficulty in 
moving resources from one sector (budget) to another" has been ranked as the main barrier 
to the use of economic studies in decision making. Because of this, decision makers felt 
that there is limited scope in using economic studies in their everyday practice, and that 
findings from economic studies are of little relevance to their everyday practice. This was 
echoed by decision makers in the study conducted by Duthie et al 114. All the participants 
in the study indicated that financial savings reported in economic studies were only of 
interest if the savings were "realisable" and resources could be "physically reduced". 
Another major barrier discussed was the perceived lack of credibility of economic studies. 
This was described by 26% of participants in the survey by Ross et al (1995) 117. Similarly, 
"studies open to bias because of large number of assumptions" was the second most 
common barrier reported, described by 56% of decision makers in the Drummond 
survey 112. 
In addition, an equal proportion of participants (26%) raised concerns regarding health 
economics 'jargon' used in the survey by Ross et al (1995) 117 . It was felt that academic 
researchers seem to put more emphasis on the rigour of their methods than on 
communicating the principles involved to decision making. Similar concerns were raised 
by Duthie et al 114, describing a general mistrust in statements containing health economic 
jargons and later, by Hoffmann et al 113, who reported that "sponsorship of studies (e.g. by 
the industry) biases the results" and "economic studies make too many assumptions" as the 
second and fifth most referred barriers by decision makers. 
Decision makers also felt that economic analysis often adopts a long-term perspective. The 
time horizon adopted in economic studies has often been viewed as impractical and reduces 
the value of the economic studies 116. For instance, studies that identified benefits over five 
to 10 years in exchange for increase spending now; if this were the case, there is a danger of 
overspending at present. It was felt that faced with pressures to operate within given 
budgets would mean that investment in a policy for long-term savings may often be 
impossible. 
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SUMMARY 
Overall, the findings of the studies included in this review are in general agreement with 
each other. Primary care decision makers such as GPs, medical prescribing advisors and 
pharmaceutical prescribing advisors generally have a positive interest towards economic 
information and agreed that economics should be an integral part of medical decision 
making. However, the knowledge and understanding of health economic principles among 
decision makers is limited and the extent of actual use of such information in decision 
making remains unclear. Two key barriers to implementing results of economic studies 
have been identified: one practical barrier - the difficulty in reallocating resources, and 
another barrier associated with methodological issues in conducting economic studies. 
The impact of any intervention on decision makers' perspectives and behaviour is 
extremely difficult to measure and the current studies have their own limitations. Several 
methodologies have been adopted to attempt to measure the level of knowledge of 
economic issues among primary care decision makers, ranging from examining the level of 
training in economic issues to presenting and discussing economic studies at face-to-face 
meetings. In two separate studies, statements relating to economic principles 114 and 
abstracts of economic studies 113 have been presented to decision makers. Although this 
gave some indication of the decision makers' understanding on particular health economic 
issues, their wider understanding of health economics was not explored. 
Due to the nature of the research area, these studies have been primarily surveys and 
qualitative interviews, where responses cannot be validated. Often, in studies of this nature, 
participants' responses may be more representative of how they believe they should respond 
instead of what they actually think or practise. This would have particular influence on the 
measure of use of economic information in practice and is likely to over-estimate the actual 
use of economic information. In addition, the "use" of economic information has not been 
defined. It is unknown what exactly was meant when respondents claimed to have "used 
economic information". 
Several barriers to implementing economic information have been identified. However, 
how real these barriers are is not clear, since there has been no evidence of any attempts by 
primary care decision makers to actually use an economic evaluation to influence their 
practice. Methodological issues such as the perspectives adopted, assumptions made in the 
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economic studies and funding sources have been mentioned in all the studies as one of the 
barriers to implementing economic information. Over the years, several checklists have 
been developed to tackle these issues specifically, for the purpose of critical appraisal of 
economic studies , based on the 1 0-point checklist developed by Drummond M et al 121 • 
However, this seems to have had little effect on improving the credibility of economic 
studies among these decision makers. 
Finally, in addition to the reasons discussed above, these studies are also highly susceptible 
to selection bias. In general, survey respondents and those who consent to participating in 
interviews are more likely to have particular interest and knowledge in the area. Those who 
declined to participate may be likely to be representative of those for whom economic 
information has the least impact. 
Therefore, findings of the impact studies are difficult to interpret and should be treated with 
caution and firm conclusions cannot be drawn. The study population of these studies are 
generally small, but this probably reflects the difficulty in conducting research and 
collecting data in this area. Despite the variations in study methodology and study 
population, it is clear that the themes generated from the individual studies do tend to 
support each other. 
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4 STUDY DESIGN AND METHODS 
STUDY DESIGN AND METHODS 
4.1 INTRODUCTION 
This thesis set out to explore the inclusion of ADR data in phannacoeconomic evaluations. 
Through discussions with local medical prescribing advisors, three therapeutic areas of 
interest were selected: NSAIDs for the management of rheumatoid arthritis, SSRis for the 
management of depression and ACE inhibitors for the management of hypertension. 
An initial phannacoeconomic study on NSAID therapy (described in Section 4.2), using 
data from a large record linkage database from Tayside (Scotland) was conducted. Ideally, 
a similar methodology would be adopted for the other two classes of drugs, however, it was 
beyond the financial scope of this PhD to purchase the additional data required. Therefore, 
an alternative data source, based on published randomised controlled trials, was used 
(Section 4.3). 
The second aim of this thesis was to explore the impact of economic information on 
primary care prescribing. Since there is an absence of literature in this area, no validated 
tools have been developed. Therefore, three strategies (Section 4.4), based on lessons learnt 
from studies examining the impact of economic information in other areas of medical 
decision making were adopted. 
4.2 POPULATION-BASED PHARMACOECONOMIC ANALYSIS: AN 
EXAMPLE WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
(NSAIDs) 
This evaluation is based on clinical data supplied by the record linkage database of MEMO 
in Tayside (population = 427 786; 1995). This record linkage system contains extensive 
clinical information from 1 January 1989 on all the people who were registered with a GP 
and residing in the Tayside Health Board area. Every person is allocated a "CHI 
(Community Health Index) number" for effective clinical data records linkage. The CHI 
number start date is either 1 January 1989 (the MEMO start date) or the date on which a 
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person is subsequently registered with a local GP. This unique patient identifier was 
recoded into an anonymised sequential number to maintain patient confidentiality. 
This linked data set includes details of all dispensed prescriptions within the community 
and demographic data. Diagnostic data based on International Classification of Disease 
(lCD 9) and operations based on the Office of Population Censuses and Surveys (OPCS) 
codes on all the patients who have been admitted to Tayside hospitals, each episode of 
hospital care generating a form- the Scottish Morbidity Record 1 (SMR 1). 
4.2.1 Study Cohort 
All the appropriate population data available at the point of study were incorporated into the 
economic model which covers the recorded data between 1 January 1989 and 31 December 
1993. 
Individuals less than 50 years old on 1 January 1989 were excluded from the study. 
Patients' data for six months prior to (recent history) and 12 months after the index date, i.e. 
the start date of the follow-up period were used. Therefore, those who had died before 30 
June 1990, those who have an index date after 31 December 1992 and those who died at 
any time during the 12 months of follow-up were excluded from the study. However deaths 
in the year after the end of the study period were linked to an individual's record (Figure 3). 
The cohort of patients who received an NSAID prescription during the study period was 
classed as the 'NSAID' cohort (Figure 4). The indications for NSAID prescriptions are not 
recorded routinely in this database, however, it is believed that this sub-population mimics 
NSAID use in the widest sense. A further cohort who met the selection criteria but did not 
receive any NSAID prescriptions during the study period were categorised as the 
COMPARATOR cohort. These were unselected, comprising the total population of 
relevant individuals in Tayside. This group provided a comparable population of Tayside 
patients for whom there was no prescribed use of NSAIDs throughout the study period. 
This group provided background rates of events in a local population not on NSAIDs. 
Demographic details for all patients were recorded including their age at the start of the 
study, date of birth, sex, date of death (if after the study period) and postcode. Index dates 
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for all individuals on NSAIDs were created as the date of the first NSAID prescription 
dispensed after 1 July 1989 - to ensure at least six months of previous dispensing history 
prior to this index date being available. Since the individuals in the comparator cohort 
would not have received a NSAID prescription throughout the entire course of the study 
period, index dates from the NSAID cohort were used to generate index dates for the 
comparators. The index dates, in a sequential file of NSAIDs ordered by CHI numbers, 
were randomised and allocated to the individuals in the comparator file. 
The 'NSAID' cohort was further divided into three sub-cohorts based on the records of 
concomitant prescriptions. These were defined as the prescribing within three days of the 
index date, of H2 blockers or omeprazole which generated the 'NSAID and H2/0meprazole' 
sub-cohort, or of misoprostol which generated the 'NSAID and Misoprostol' sub-cohort. 
The remaining patients formed the 'NSAID Only' sub-cohort. Details of these drugs such as 
the dispensed date, the exact type and dose of the formulations and the amount of drugs 
dispensed were recorded. 
This evaluation compared the economic consequences of the three NSAID sub-cohorts and 
the comparator cohort at 45 days, six months and 12 months following the index date, to 
determine the effects of initial prophylactic concomitant prescribing of misoprostol on later 
events, compared with concomitant prescribing of H2 blockers or omeprazole, and with no 
concomitant prescribing. Data on six months of previous medical history up to the index 
date were consulted to allow any potential confounding factors to be investigated. Details 
of recorded clinical events included hospitalisations, GI endoscopies, additional co-
prescriptions dispensed, and changes in prescriptions at 45 days from the index date, from 
45 days to six months and from six months to 12 months. Dispensed prescriptions for the 
drugs of interest and clinical events (hospital admissions) recorded during these periods 
were available for future investigations of possible cause and effect relationships. 
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4.2.2 Clinical Events 
These data included records of diagnoses and hospital admissions coded with a 
gastrointestinal, cardiovascular, rheumatoid and osteoarthritis-diagnosis (ICD/OPCS codes 
- Appendix Ill) during each episode of hospital care per patient. For the purpose of 
effective modelling, it was assumed that each episode of care represents one hospital 
admission. Although this may over-estimate the admission rate and subsequently the 
hospitalisation costs for the proportion of patients who received more than one episode of 
care during individual hospital admissions, this assumption will be tested extensively in a 
sensitivity analysis. 
The lengths of stay (LOS) of these admissions were calculated (discharge date minus 
admission date plus one day). However, it was believed that there would be a small 
proportion of patients who may remain in hospital for a long period of time which would 
exceed the follow-up period, such as those admitted to geriatric units. These patients' LOS 
would be censored to the length or to the end of the follow-up period (i.e. the maximum 
LOS in the three time periods would be 45 days, 183 days and 365 days respectively). 
Admissions recorded in the six months prior to the index date were defined as a 'prior 
history of admission'. Admissions within 45 days following the index date, from 45 days to 
six months and from six months to 12 months were defined as 'events'. 
Diagnostic and admission details, in the form of ICD-9 and OPCS codes respectively, of the 
longest hospital event during each follow-up period were used to indicate possible adverse 
events associated with the various drug therapies. It was believed that only a small 
proportion of patients would have more than one hospital admission over the 12 months of 
the study period. Therefore, the admission with the longest LOS, which represented the 
most significant cost contribution, would provide a fair indication of the type (GI, CV, 
rheumatoid or osteoarthritis admissions) and specialty (such as medical, orthopaedics or 
general surgery) of the other admissions if a patient had more than one admission. All other 
additional admissions were recorded as counts, i.e. the number of additional admissions and 
the LOS for all other admissions was also calculated as one aggregated total. The LOS for 
the longest admission was recorded separately from other admissions. 
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Details of GI endoscopies carried out were recorded for the whole study population. These 
were recorded as counts, i.e. the number of GI endoscopies performed. Endoscopies during 
the six months prior to the index dates were defined as 'previous endoscopies'. Those 
recorded after the index dates were grouped appropriately to the three time periods 
according to the date of endoscopy following the index date. 
The drug prescriptions in this data set were based on records of the prescription items which 
were dispensed. One prescription may cover several items consisting of different drug 
classes. These items were recorded individually in the data set. 
The inception drugs (NSAIDs, H2 blockers, omeprazole and misoprostol) which were 
recorded as concomitant prescriptions comprised the basic drug therapies. These were 
identified and recorded in detail, including the type and dose of the formulations and the 
amount dispensed. 
In an attempt to account for all the prescription items dispensed during the three study 
periods, all dispensed items were identified and recorded as counts, i.e. the number of 
prescription items dispensed, with the exception of the first and the last items in any period 
which were recorded in full. This was done to detect changes in drugs the patients were 
being prescribed. If the first drug recorded differed from the last in any period, then at least 
one switch was assumed to have taken place (Figure 5). This would also suggest at least 
one visit to the GP during which the change was made. Records of dispensed items were 
divided into three categories: NSAIDs, ulcer-healing drugs and all other drugs. 
The above data were linked together by the CID number to provide the raw data for this 
economic evaluation. Thus, in addition to the demographic details, the linked data set 
contains all the dispensed prescription item details, records of endoscopies and hospital 
admissions, and diagnoses for the longest admission of every patient, where appropriate. 
All the recorded data from the three follow-up periods were aggregated to create 
appropriate linked data for the three time spans: from the index date to 45 days, from index 
date to six months and from index date to 12 months. The total costs associated with the 
three treatment therapies and the comparator group were calculated separately for the three 
study periods. 
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The analysis for all treatment groups was split by sex, and into three age groups, for 
effective modelling and to allow determination of sex- and age-specific costs. Independent 
analyses were carried out for males and females, and for patients aged 50 to 59 years, 60 to 
7 4 years and 7 5 years and over. 
4.2.3 Cost Estimates 
Based on the assumption that all co-prescriptions were prescribed for events associated with 
the initial NSAID prescribed, all the drugs were recorded and costed as a clinical event of 
interest. 
The drug costs used in the models were supplied by the Prescriptions Pricing Division 
(PPD) in place of the commonly used British National Formulary, due to the large number 
of different formulations covered by the population (approximately 12 000). However, the 
drug prices listed in the two sources appear to be similar. The actual amount dispensed to 
the patients was calculated exactly. In addition, the dispensing and container fee (£0.80) for 
each item which is charged by pharmacists to the NHS for each dispensed item was 
incorporated in the model. The reference sources for all the unit costs used in the 
calculations are shown in Appendix IV. 
The inception drugs were decoded, identified and costed to generate the basic inception 
drug therapy costs for each patient. 
The costs for the first and last dispensed additional prescription items recorded during each 
of the study periods were also calculated in a similar manner. For all the other prescriptions 
(if any), only the number of items dispensed was available. Therefore, an average cost of 
the first and last dispensed items recorded during each of the study periods was calculated 
to give an average dispensed prescription item cost which is unique to each individual 
patient for each study period. The sum of the total costs for drug therapy over one year for 
each patient was finally calculated by aggregating the inception drug cost, the cost of the 
first and last prescriptions dispensed and the average cost of all other additional items 
dispensed during each of the study periods. 
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It had to be assumed that all the GI endoscopies carried out were day cases since details 
defining inpatient or day case endoscopies were not available. The cost of all the 
endoscopic procedures was calculated by multiplying the number of recorded endoscopies 
per person during the follow-up period by a weighted cost of day case GI endoscopy in 
Tayside (£208.33). This cost is an average of the various costs of GI endoscopic 
examinations in all the hospitals in Tayside listed in the Scottish Health Service Costs 
1994/5122 weighted for the number of examinations undertaken in these individual hospitals. 
The costs associated with four different types of admission - GI, CV, rheumatoid and 
osteoarthritis admissions- were not the same and were calculated independently. The cost 
of hospital admissions is dictated by the specialty group (of the longest admission) and the 
LOS. A weighted average inpatient cost for each specialty per day was calculated 
(weighted for the number of admissions recorded in these Tayside hospitals). For each 
individual patient the appropriate weighted cost is then multiplied by the total number of 
days in hospital to give the cost of each type of admission. 
For the purpose of modelling, it was assumed that each hospital admission was attached to 
two GP consultations - one prior to admission, one after - and one outpatient consultation 
following discharge. The sum of these individual costs was added to the cost of the longest 
hospital admission. Patients with more than one admission had similar costs added to give 
the total cost of hospitalised events per patient (Figure 6a and 6b ). 
The total cost of therapy and their 95% confidence intervals (CI) associated with the 
comparator cohort and the three sub-cohorts was calculated. 
Sex and age-specific analyses were performed across the four groups and univariate 
comparisons (F test) between males and females and between the three age groups were 
carried out. These costs were aggregated for all individuals in each treatment group. Since 
some individuals incurred much greater costs than others, an average cost for each member 
of the individual group was also calculated. 
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4.2.4 Sensitivity Analysis 
Extensive sensitivity analysis was performed on all obvious confounding variables 
including co-morbidities and mortalities. Patients in the study group who were aspirin 
takers, who had any prior hospital admissions, prior endoscopies, or prior NSAID 
prescriptions, were removed from the dataset for re-analysis. These exclusions were dealt 
with singly and in combination. This is equivalent to the restrictive cohort technique 
adopted to address confounding factors 123. In addition, the cost data that were used in the 
model, including the cost of GP consultations and GI endoscopies, were also tested in the 
sensitivity analysis. 
4.3 MODEL-BASED PHARMACOECONOMIC ANALYSIS: EXAMPLES 
WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs), 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRis) AND 
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS 
Three pharmacoeconomic analyses were conducted on three of the most widely prescribed 
classes of drugs in primary care - NSAIDs for the treatment of rheumatoid arthritis, SSRis 
for the treatment of depression and ACE inhibitors for the treatment of hypertension. The 
direct costs associated with the use of all three classes of drug therapies were calculated. 
The economic models were based on the key assumption that drugs within each class of 
drugs were equally effective and the main difference between these drugs was their side 
effect profile, which dominates patients' preferences and the cost of therapy. The clinical 
outcomes investigated were all associated ADRs, and the total costs of drug therapy were 
calculated as 'economic outcomes'. Similar methodologies have previously been adopted 
in the evaluation of NSAIDs 20•21 •124• The models adopted the perspective of the NHS. 
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4.3.1 Data Collection 
Identical methodologies were adopted for all three pharmacoeconomic evaluations. An 
extensive literature search was carried out on each individual drug using :MEDLINE 
(1966 to present), BIDS embase (1980 to present) and the Cochrane Trials Register. 
Search filters published by the SIGN guidelines for randomised controlled trials were 
combined with keywords on individual drugs and treatment indications (Appendix ll). 
The main searches were restricted to references to randomised controlled trials 
published in English. Randomised controlled trials of the following comparisons were 
selected: 
• Comparing any of the individual NSAIDs with active or placebo control in the 
treatment of uncomplicated rheumatoid or osteoarthritis in adults. 
• Comparing any of the individual SSRis with active or placebo control m the 
treatment of uncomplicated major depression in adults. 
• Comparing any of the individual ACE inhibitors with active or placebo control in 
the treatment of uncomplicated hypertension in adults. 
Only double-blind randomised-controlled trials of individual drugs of interest were 
selected for the meta-analysis. In addition, the trials had to meet the following inclusion 
criteria: 
• Sample size greater than 20 patients - on the basis that this excludes most pre-phase 
III trials. 
• Study duration of at least two weeks -excludes most pre-phase III trials. 
• Control group included. 
• Reported numerical data on the number of ADRs recorded. 
The quality of the selected clinical trials were assessed using the five-point Jadad 
score 125• Points were awarded for the description and the appropriateness of 
randomisation and blinding. For instance, studies that were described as 'randomised 
and double-blinded' would be awarded two points. If the method of randomisation and 
blinding were described and believed to be appropriate, an additional two points may be 
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awarded. However, if the method of randomisation and blinding were inappropriate, 
negative points should be awarded to the trial. In order to gain the maximum score of 
five, data (number of patients and reasons) on withdrawal and drop-outs have also to be 
presented. 
4.3.2 Adverse Drug Reactions Data 
All the adverse drug reactions data reported in the included trials were collected. Meta-
analyses were performed for each individual drug, pooling together all the available side 
effects data on each individual symptom or event. Average incidence rates, weighted 
by the sample size of the studies, were calculated for each side effect reported for each 
individual drug. The 95% confidence interval was also calculated, based on the 
equation which is normally used to calculated 95% confidence intervals for count 
tables: 
!.. ± 1.96~ r(n- r) 
n n 
(where r = sum of ADRs reported; n = sum of patients in all the trials) 
4.3.3 Management of Adverse Drug Reactions 
A list of possible treatment-induced side effects was constructed from the clinical trials. 
Treatment strategies for each side effect were derived from both the literature and 
expert opinions. All general practitioners in one of the local healthcare co-operatives 
(LHCCs) in the Dumfries and Galloway area were invited to participate in providing 
expert opinion on the management of drug-induced ADRs. Consent to contacting and 
inviting GPs in this LHCC was given by the LHCC manager, and the author presented 
the aims, objectives and methodology of the study at a monthly LHCC meeting prior to 
recruiting GPs. A letter was sent to all the GPs by post (Appendix V), and followed-up 
with a telephone call. During the period between December 2000 and June 2001, face-
to-face, semi-structured interviews were carried out with those who agreed to take part, 
to determine how these symptoms are generally managed. General practitioners were 
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asked a series of questions relating to how they would treat the ADR reported in the 
clinical trials. Each ADR was considered independently. The interviews were based on 
a clinical scenario that resembles an average patient on NSAIDs, SSRis or ACE 
inhibitors. Initially, GPs were asked if they considered the symptom to be drug-related, 
and if so, what investigations and treatment they would recommend, and for what 
proportion of the patients. A final consensus on how individual adverse events would 
be managed, on average, was estimated. 
Based on a decision-analytic approach, the treatment strategy was noted and a summary 
probability of patients who would receive a particular investigation or treatment when 
suffering from a drug-induced side effect was generated. This was based on the 
estimated proportion of patients who would receive a particular treatment or 
investigation despite having the drug changed or stopped. For instance, out of 100 
cases of drug-induced constipation, one GP perceived that 80% of the patients would 
have their drugs changed while 20% would receive a laxative in addition to unchanged 
treatment. However, another GP would change drugs in 90% of the cases and co-
prescribe laxative to 10% of the patients. Therefore, the average estimated probability 
for the two GPs, of a patient having NSAID stopped would be 85% and the probability 
of receiving a laxative would be 15%. 
4.3.4 Cost Estimates 
Direct health service costs for the drugs and the treatment associated adverse effects 
were calculated. The acquisition drug costs, based on the defined daily dose, for a one-
month period, was calculated. The costs associated with managing adverse effects 
included costs of all GP visits, clinical investigations and additional medical treatment. 
The unit costs for the investigations and treatment procedures are multiplied by the 
number of units 'consumed' during the time period of interest. The number of units 
consumed is the calculated average of the GP treatment patterns, expressed as a 
probability. The cost for treating a particular side effect with respect to one patient is 
calculated for each drug. This cost - the 'shadow cost' - was determined by the 
incorporation of the expected cost for treating all the different side effects experienced 
for one particular drug, and is dependent on the estimated frequency of occurrence of 
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the side effect in question. Finally, the total cost of drug therapy, which incorporates 
the cost of managing associated side effects and the drug acquisition cost, was 
calculated. 
4.3.5 Sensitivity Analysis 
Extensive sensitivity analyses were undertaken to test the main assumptions in all the 
models. Input variables for the economic models including the incidence rates of the ADRs 
and the unit costs were varied to examine their influence on the model outcomes. 
The ADR rate is a major parameter that may significantly influence the outcome of the 
model. In addition to the sensitivity analysis of varying the ADR rate by 20% above and 
below that used by the basecase, a scenario-based analysis, based on the 95% confidence 
intervals was also performed. The 95% confidence intervals for the ADRs that are 
investigated in the models have been calculated. The upper and lower limit of the 
confidence interval represents the "best" (lower limit) and the "worse " (upper limit) case 
scenario associated with the use of individual drugs. It is expected that the ADR rates for 
some of the events would be extremely low due to their infrequent occurrence. In cases 
when the values of the counts are low, the quadratic approximation to the confidence 
intervals tends to have the lower bound below zero. Since in practice, it is impossible to 
obtain less than 0% for a particular ADR rate, all values in the interval below zero are 
rejected. All predicted rates of less than 0% (lower limit) for a particular event would be 
rounded to 0% and interpreted as near 0%. 
Scenario-based analysis was carried out by substituting the ADR incidence rates in the 
basecase with the lower limit and the upper limit of the confidence intervals, representing 
the "best" and the "worst" case scenarios, respectively. 
Unit cost data were also investigated by varying cost data by 20% above and below that 
used for the basecase. 
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4.4 THE IMPACT OF PHARMACOECONOIMC INFORMATION ON 
PRIMARY CARE PRESCIRBING 
In an attempt to investigate the potential impact of economic information, three strategies 
have been adopted: 
• Dissemination of the results of the meta-analysis based economic analyses, and 
examination of prescribing behaviour from routine data sources prior to and after 
the dissemination exercise. 
• A cross-sectional postal and email survey was conducted to gain insight into GPs' 
views on the usefulness of a variety of economic information and how it related to 
their everyday practice. 
• Qualitative interviews to explore, in depth, the views and current use of economic 
information among GPs. 
4.4.1 Dissemination Exercise 
Study Population 
Through earlier contacts with GPs while conducting interviews relating to ADRs, it was 
becoming apparent that the most difficult step in conducting research among GPs is 
recruitment. Therefore, the same LHCC in the Dumfries and Galloway Health Board area 
that participated in interviews regarding management of ADRs (as described in section 
4.3.3) was also selected for this dissemination exercise. It was hoped that, since this pool of 
GPs had already demonstrated a previous interest in the area of health economics and were 
familiar with the objectives of the research work and the author, it would encourage 
participation in the dissemination exercise. 
This LHCC serves nine practices, with 38 GPs. Similar to the previous recruitment, the 
author attended one of the monthly meetings and presented the aims and methodology of 
this part of study. During October 2001 to March 2002, those who consented to taking part 
were later contacted by telephone to arrange a convenient time for meeting. The GPs were 
visited individually at their practice. 
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Prescribing Data 
Prescribing reports are now regularly produced to enable both cost and quantities of 
prescribing to be analysed. Scottish Prescribing Analysis (SPA) data were originally 
designed and generated to aid community pharmacists with reimbursement of prescriptions, 
but have become an essential tool in prescribing support. Furthermore general practitioners 
are increasingly using audit to rationalise their prescribing 126• 
Scottish Prescribing Analysis (SPA) Level 1 data contain breakdowns of total costs and 
numbers of items prescribed for major therapeutic categories. Expensive items (those over 
£100) and drugs of abuse are also included. These data are specific to individual GPs, and 
comparisons can be made with the averages for the practice, the Health Board and Scotland. 
Scottish Prescribing Analysis Level 2 data contain a full catalogue of all dispensed items 
over a period of three months, available on request. Prescribing details include: separate 
listing of generic and proprietary preparations, dose and formulation of the drug, number of 
times prescribed, total quantity and cost, average quantity per prescription and cost. SPA 
Level 2 data was used to measure change in prescribing. 
The results of the pharmacoeconomic evaluations were compared against current 
prescribing data - overall Scottish data and practice-specific data - to assess the cost 
effectiveness of the prescribing trends. Key messages of the evaluations plus 
recommendations for change towards more cost-effective prescribing were devised. This 
was presented to the GPs during a 20-minute meeting with the author. Comparisons in their 
prescribing prior to and after visits were made using SPA data. In comparison, self-selected 
controls consisted of those within the LHCC who declined to participate in the study, and 
therefore received no intervention. Prescribing data from these practices were used as a 
baseline and compared to the intervention group. 
4.4.2 Survey - Quantitative and Qualitative 
Two questionnaires were designed and disseminated among GP members of the West of 
Scotland Primary Care Research and Development Network (WestNet) during the period 
of January to March 2001. The West of Scotland Primary Care Research and 
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Development Network is a consortium of 55 general practices, set up to develop and 
conduct non-commercial research of benefit to general practice. 
Questionnaire (I) consisted of five questions, designed to examine the type of economic 
information currently used by GPs in medical decision-making (Appendix V). 
Questionnaire (II) consisted of four questions, designed to explore what GPs identify as 
sources of economic information and their perception on the relevance of the data 
presented (Appendix V). 
A complete list of members and their contact details were obtained from WestNet. All the 
non-GP members were excluded from the study. Those included were randomised into 
two groups - questionnaire (I) and questionnaire (II), stratified by their accessibility by 
email. Each member was either sent the appropriate questionnaire with a personalised 
covering letter and a pre paid addressed envelope, or emailed the covering letter, with the 
appropriate questionnaire attached. 
4.4.3 Qualitative Interviews 
Following consultation with experienced qualitative researchers in the Department of Public 
Health, a methodology was developed to explore GPs' personal views and opinions about 
the role and impact of economic information. Due to the recent changes relating to research 
ethics, ethical approval was sought for carrying out this part of the research. Purposive 
sampling was used to include ten GPs based on their previous consultation with SIGN and 
through snowball sampling. It was felt that this group of GPs would have some level of 
interest and contact with health economic information. Participants were recruited by 
email, letter and/or telephone contact. During the period between March and June 2004, 
face to face qualitative interviews, which lasted approximately 45 minutes, were conducted. 
Although the interviews were semi-structured, an interview guide with a list of main points 
to be covered was used. Answers to pre-set questions were probed with further discussion 
and subsidiary questions. All interviews were conducted at the GPs' surgery and were tape-
recorded upon consent of the interviewee. Written consent was obtained. 
Main points covered included: 
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• The currently disseminated economic evidence; 
• The barriers and facilitators in implementing economic evidence; and 
• The role of economic issues in healthcare decision making. 
Interviewees were invited to discuss their views and opinions of the decision making 
process in relation to their own experience. In general, the interviewees were free to guide 
the interview according to what was felt to be important about decision making in relation 
to prescribing whilst drawing upon other aspects of healthcare decision making they have 
experienced. 
The method of sequential analysis was adopted 127, where data collected at early stages of 
the study helped shape ongoing data collection, allowing questions to be refined and 
negative cases identified. All the collected data was also preserved in text form and 
indexed to generate or develop analytical categories and theoretical explanations. 
The transcriptions of the meeting were compared to the notes taken during the meeting in 
order to try to fill any blanks in the notes and to obtain a different perspective on the 
meeting. Following word-for-word transcribing of the interviews, the data were coded to 
help identify themes and categories. All the data relevant to each category were identified 
and examined using the method of constant comparison, whereby each item was compared 
with the rest of the data to establish analytical categories. Multiple themes may emerge 
from the same section of data. Each theme was examined individually for different views, 
the frequency of the views that were expressed and how strongly the different views were 
expressed 127 . Codes were refined and reduced in number by grouping of the data. It was 
felt that the amount of data collected in this study did not warrant the need of employing 
traditional software packages designed specially to handle qualitative data (such as 
ATLAS/Ti) 128• Therefore, coding and organising of the data were conducted manually. 
The 'find' function in Microsoft Word was used to identify keywords that were related to 
the main themes of the study. 
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5 RESULTS 
5 RESULTS 
5.1 INTRODUCTION 
The results of the thesis are presented chronologically in this chapter. For ease of reading, 
all the tables and figures relating to the results are placed at the end of the thesis. 
In accordance to the first aim of the thesis, section 5.2 presents the results of the economic 
model based on population data. The clinical data recorded in the database is described 
(section 5.2.1 and 5.2.2), followed by the cost (section 5.2.3). Results of the sensitivity 
analysis are presented in section 5.3.4. Tables containing detailed breakdown of the data 
are presented in the Appendix VII. 
Section 5.3 presents the results of the three meta-analysis based economic analyses. The 
results of the literature review of randomised controlled trials for each of the three classes 
of drugs are presented in section 5.3.1. Relevant data on adverse drug reactions were 
aggregated and are presented in section 5.3.2. The clinical management pattern was 
determined (section 5.3.3). Finally, the calculation of costs and the sensitivity analysis are 
presented in section 5.3.4 and 5.3.5. 
In accordance with the second aim of the thesis, the results of the impact study are 
presented in section 5.4. The findings of the dissemination exercise are reported in 5.4.1. 
This is followed by results of the GP survey (section 5.4.2). The findings of the qualitative 
interviews are presented in 5.4.3. 
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5.2 POPULATION BASED PHARMACOECONOMIC ANALYSIS: AN 
EXAMPLE WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS 
(NSAIDs) 
5.2.1 Study Population - Demographics 
The study population comprised 98 887 people (42 648 male and 56 239 female), divided 
into four subgroups for effective modelling: 
• Comparator cohort (N = 47 350) 
• NSAID only sub-cohort (N = 49 212) 
• NSAID and misoprostol sub-cohort (N = 212) 
• NSAID and H2 blocker or omeprazole sub-cohort (N = 2113) 
Demographic details and clinical history of the patients from the MEMO population 
database are shown in Table 2. The age distributions of the patients in the four treatment 
groups are similar, predominantly between the age of 60 and 74 years. However, both the 
NSAID only and the misoprostol sub-cohorts have a higher percentage of elderly patients 
over 75 years (approximately 20% and 24% respectively) compared with the H2 sub-cohort 
(19%) and the comparator cohort (17% ). It is evident from the data that female patients 
have a higher probability of receiving NSAIDs compared to male patients. Therefore, 
economic analyses were conducted in sex and age specific groups. 
Overall, 4% (N = 3994) of the study population had a history of a GI diagnosis in the six 
months prior to the index date. These patients were almost as likely to be NSAID users 
(52%) as non-NSAID users (50%). The proportion of patients who had a previous history 
of GI diagnoses was similar in the NSAID only sub-cohort (3%) to the comparator cohort 
(4%). However, patients with a prior GI diagnosis were four times and six times more 
likely to be prescribed concomitant prescriptions of misoprostol (13%) and H2/omeprazole 
(18%) respectively. 
Twice as many GI endoscopies (N = 8052) as GI diagnoses (N = 3994) were recorded in the 
six months prior to the index date. Approximately 7% and 8% of the patients had previous 
endoscopies in the NSAID only sub-cohort and the comparator cohort respectively. 
75 
Patients with prior endoscopies were over four times more likely to receive concomitant 
H2/omeprazole (32%) and three times more likely to receive concomitant misoprostol 
(20%) than NSAIDs alone. 
Patients with a previous history of CV diagnosis were 39% more likely to be NSAID users 
than those without a prior CV diagnosis. Only a relatively small proportion of patients 
(6%) from the comparator group had a previous history of CV diagnoses, which is unlike 
the other treatment sub-cohorts (ranging from 12% observed in the NSAID only sub-cohort 
to 21% in the H2/omeprazole sub-cohort). A similar trend was noted for a prior history 
which included a diagnosis of RA/SLE, and OA. 
Based on the details of the inception NSAIDs, it is apparent that, irrespective of the 
different treatment groups, ibuprofen, diclofenac sodium and naproxen are the more 
commonly prescribed NSAIDs in Tayside (Table 2). The data also show a preference for 
ranitidine among all H2 blockers prescribed by GPs in Tayside, which was given to 81% of 
the patients in the H2/omeprazole sub-cohort. 
Mortality within a year after the study period has been recorded. The highest crude 
mortality rate has been observed among those who were on H2/omeprazole (16.4%). Lower 
but similar rates were found among NSAID takers (13.7%) and those who were given 
misoprostol (13.2%). The differences were reduced after adjusting for age and sex, as 
might be expected given the mean age of the cohorts, but the trends were unchanged. 
5.2.2 Clinical Events 
When comparing the three age groups, the highest endoscopy rate is observed in the 60 to 
74 years age group. Unsurprisingly, those aged above 75 years were substantially less 
likely to receive endoscopies than younger patients in both the comparator and the NSAID 
cohort. This pattern is consistent throughout the three study periods (Figure 7). 
Endoscopies were required more often in NSAID patients than in those who were non-users 
of NSAIDs. Patients deemed to require GI protection and given concomitant H2 blockers or 
omeprazole have a higher probability of receiving endoscopic investigations ( 6%) 
compared to those on NSAIDs alone (2%). Over the 12-month period, the relative risk was 
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3.67. The relative risk among patients deemed to need GI protection and prescribed 
misoprostol was only 1.21 relative to those on NSAIDs alone. 
There were no endoscopies recorded in the misoprostol sub-cohort during the first 45 days 
of the study period. The proportion of patients in the NSAID only sub-cohort who received 
endoscopies within the initial45 days (0.2%) is the same as that observed in the comparator 
cohort (Table 3). A substantial increase (up to four fold in the NSAID only sub-cohort) in 
endoscopies is observed in all groups at six months following the index date. The high 
rates observed in the Hz sub-cohort remained consistent throughout the follow-up period 
(5.7% compared with 1.9% in the misoprostol sub-cohort, 1.6% in NSAID only sub-cohort 
and 1.2% in the comparator cohort). In addition, female patients who are on NSAIDs, 
regardless of the sub-cohort (NSAID only, NSAID with concomitant misoprostol or NSAID 
with concomitant Hz blocker/omeprazole) have been shown to be more likely to have 
undergone endoscopic examinations. A larger number of endoscopic events were observed 
in females in these three sub-cohorts at all time periods (Table 3). This was most apparent 
among the Hz/omeprazole sub-cohort where an approximately four-fold difference was 
observed in the first 45 days. However, this may be by chance as few events were actually 
recorded. 
Records of dispensed prescriptions were high in the NSAID cohort, ranging from 35.3% in 
the NSAID only sub-cohort at 45 days, to as much as 93.4% in the NSAID and Hz sub-
cohort in 12 months. Over the period of 12 months, patients on NSAIDs alone received 3.3 
times more prescriptions than non-users. Those on Hz/omeprazole received 25% more 
prescriptions compared with those on NSAIDs alone, but those on misoprostol received 
only 9% more. Records of any dispensed prescriptions for only 8.7% (45 days) to 22.8% 
(12 months) of the comparator cohort were formed. Similar to that observed with the 
endoscopic examinations, there is a consistent trend among the population that, irrespective 
of drug therapy, patients in the 60 to 74 years age group and females have a higher 
probability of being prescribed drugs (Table 4). There was no age trend amongst the 
patients in the comparator cohort. However, a clear increase in prescriptions per patient 
with increasing age among NSAID users was observed. A similar trend was present, but 
less pronounced among the Hz/omeprazole sub-cohort. 
The highest proportion of patients receiving prescriptions was observed with the Hz sub-
cohort (ranging from 1.13 times greater than that of misoprostol to 6.7 times greater than 
77 
that of the comparator cohort at 45 days). A consistent increase in patients receiving 
prescriptions has also been noted over time, the amount of increase mirroring the above 
trends - an increment of 39.4% was observed in the NSAID only sub-cohort from 45 days 
to 12 months of follow-up compared to 34.4% increase in the H2/omepazole sub-cohort, 
29.2% in the misoprostol sub-cohort and 14.1% in the comparator cohort. 
All the patients who were admitted due to any diagnosis over the three observation periods 
are shown in Table 5. The H2/omeprazole sub-cohort has the highest hospital admission 
rate for almost all combinations of admission diagnosis and study periods. Hospitalisations 
of a CV-cause are the most common cause of admission in this population, followed by GI-
cause, OA-cause and RA-cause respectively. 
Admissions of a GI-cause have been observed in all groups. Patients on NSAIDs alone 
(1.1%) were 1.5 times more likely to be admitted for a GI event than non-users (0.7% ). 
Those on NSAIDs and H2/omeprazole were twice as likely to be admitted for GI events 
compared with those on NSAIDs alone. However, only one GI admission has been 
recorded from the misoprostol sub-cohort throughout the follow-up periods. This resulted 
in a GI admission rate lower than that of the comparator cohort at one year (0.5% compared 
with 0.7%). 
Cardiovascular events were the most common cause for hospital admissions irrespective of 
study groups and study periods. Over the 12-month period, there were 3.4 times as many 
patients admitted due to a CV event among all NSAID users (N = 2250) than non-users (N 
= 658). Cardiovascular admission rates ranged from 0.2% at 45 days to 1.4% at one year 
observed in the comparator cohort, and 1.7% at 45 days to 7.6% at one year observed in the 
H2 sub-cohort. 
Patients admitted due to a RA-cause were rare in non-NSAID users (0.03%). Rheumatoid 
arthritis admissions were more common among NSAID takers - 0.2% recorded in the 
NSAID only sub-cohort, 0.5% recorded in the NSAID and misoprostol sub-cohort, and 
0.6% recorded in the NSAID and H2/omeprazole sub-cohort. Similarly, the OA admission 
rate was low among non-NSAID users (0.2%) when compared with NSAID users (1.3%). 
Admissions for OA ranged from 0.2% observed in the comparator cohort to 2.4% observed 
in the misoprostol sub-cohort at one year. Females dominate both OA and RA admissions 
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across the comparator and the NSAID cohorts. (In the whole database 56.9% were female 
Table 2). 
Details for the longest hospital admission were recorded for each patient in the study 
population. The mean LOS for the longest admission and other admissions vary among 
treatment groups and different diagnoses (Table 6). For instance, the mean LOS due to the 
longest GI admission in the first 45 days of the study period range from 5.57 days in the 
comparator cohort to 34.00 days in the misoprostol sub-cohort. The number of hospital 
admissions can be deduced from table 6 by adding the number of cases of the longest 
hospital admission and the sum of counts for additional admissions. For instance, in the 
case of the misoprostol sub-cohort, only a few cases of hospital admissions were recorded 
over the 12-month period- four GI admissions (one recorded as the longest admission plus 
three additional admission counts), 23 CV admissions (13 recorded as the longest admission 
plus 10 additional admission counts), one RA admission (one longest admission and no 
additional admission counts) and eight OA admissions (five longest admissions recorded 
plus three additional admission counts). This may be, in part, due to the small sample size 
of this study group. Therefore, these results are difficult to interpret and may not reflect the 
true pattern in clinical practice. 
On average, patients with one admission are likely to have one to two additional 
admissions, irrespective of treatment groups and admission causes. However, no additional 
admissions of any causes were recorded among the misoprostol sub-cohort over the six-
month period. Over the first 45 days of the study, no additional RA and OA admissions 
were recorded in the comparator and Hz blocker sub-cohort respectively. 
The mean additional admission counts were calculated in a similar manner to that of the 
mean LOS as described above. For instance, the mean number of additional GI admissions 
during a 12-month period for the few patients in the NSAID only sub-cohort with any 
admission is 3.24 (total number of admissions divided by the number of individuals 
concerned; for example 327 admissions for 101 individuals). Similar GI mean additional 
admission counts were recorded in all the NSAID sub-cohorts. 
Over a period of 12 months, the longest mean LOS among NSAID users (ranged from 13.3 
days among the Hz/omeprazole users to 34 days among misoprostol users), were longer 
than non-NSAID users (12 days). Gastroprotective agents (Hz blockers, omeprazole and 
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misoprostol) appeared to have no effect on GI LOS. The mean LOS of the longest CV 
admission was shorter for patients in both the NSAID only (16 days) and NSAID and 
H2/omeprazole sub-cohort (15 days), relative to the comparator cohort (25 days). The 
misoprostol sub-cohort was associated with the longest mean LOS at 31 days. The longest 
mean LOS of both the comparator cohort (37 days) and NSAID only sub-cohort (25 days) 
was observed in RA admissions. Osteoarthritis admissions were also the cause of the 
longest mean LOS in the NSAID only (23 days) and H2/omeprazole sub-cohort (24 days). 
5.2.3 Cost Estimates 
Weighted average costs for inpatient admissions and outpatient visits were calculated by 
individual specialty (Appendix IV, Table 34 and 35). Separate data on admission costs to 
specialties such as nephrology, cardiology, anaesthetics and haematology were not 
available. These were costed as medical cases at £188.48 per case per day of stay. The 
average LOS and the cost per case per day vary significantly among the various specialities. 
Geriatric long stay has the longest average LOS at a cost of £96.25 per case per day. 
Although A&E has the shortest average LOS (0.8 days), it has incurred the highest cost 
amongst all the specialties at £1480 per case per day. The recorded hospital admissions in 
the dataset were dominated by medical cases. 
All the additional drugs and hospital interventions were costed and incorporated into the 
economic model to calculate the shadow cost of the drug therapies i.e. the cost of 
interventions for events associated with the drug therapy. This cost is added subsequently 
to the costs of the initial NSAID prescriptions to provide the total cost of the therapy. The 
individual costs which were incorporated in the three study-period models are shown in 
Appendix IV. The costs of the additional drugs (NSAIDs, ulcer-healing drugs and other 
drugs) dispensed to the patients, the GP consultation costs, the costs contributed by all the 
hospital events (longest admission and other admissions due to GI, CV, RA or OA-causes) 
and the cost of GI endoscopies, all contribute to the shadow cost. 
The composition of the total costs for the three separate study periods is shown in Figures 8 
to 10. The trends of individual cost composition are similar across the different groups and 
the different time periods. Endoscopies and GI admissions were not the most cost dominant 
variables, but admission due to CV related events was consistently the most dominant cost 
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variable. The individual total cost compositions for all the time periods and sub-cohorts are 
shown in Figure 11. Although it is a repetition of the data displayed in Figures 8 to 10, it 
allows comparisons across the time periods and study groups to be made readily. 
The estimated average cost per patient for each treatment group is shown in Table 7. The 
basic inception drug cost for the H2/omeprazole sub-cohort was substantially higher than 
the basic NSAID drug cost (3.4 times) and the basic misoprostol drug cost (1.7 times). At 
45 days, the shadow cost associated with the NSAID only sub-cohort was greater than that 
of the comparator cohort (£44.19 and £13.35 respectively). The H2/omeprazole sub-cohort 
was associated with the highest shadow cost (£104.06) indicating a relatively high level of 
clinical events subsequent to the initial prescription. There was a smaller increase in the 
misoprostol sub-cohort (£75.56). When the basic drug costs were incorporated, the ranking 
of the total costs of the treatment groups remained the same. The difference between the 
shadow and total costs represented the cost of all drugs dispensed per patient of each cohort 
averaged across all. 
However, when the study period was extended to six months, a substantial increase (four 
times) in associated shadow cost was observed for the NSAID group (£179.01 compared 
with £44.19). This is roughly in line with the four-fold increase in the time covered (six 
months compared with 45 days). A similar escalation in cost was also observed in the 
misoprostol group (shadow costs: £356.50 and £99.90 respectively). However, an even 
greater difference was noted when the study period is one year. H2 therapy remained the 
most expensive throughout the three observation periods (£144.79 at 45 days, £458.93 at six 
months and £937.76 at one year). 
Similar patterns are observed when males and females are analysed independently (Table 
8). The average shadow cost for females is greater than that of males in both the 
comparator and the misoprostol therapy groups. When misoprostol therapy is compared 
with NSAID only and H2 therapy, potential savings were observed among males- 3% at 45 
days to 7.4% at one year when compared with NSAID therapy and 55% at one year to 
77.2% at six months when compared with H2 blocker therapy. However, misoprostol 
therapy does not produce savings among females. 
Age specific total costs are shown in Table 9. Misoprostol therapy remained cheaper than 
H2/0meprazole therapy, with the exception of all time periods for those above 75 years old. 
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A savmg was also observed at six months when comparing misoprostol therapy with 
NSAID therapy among those aged 60 to 74. More detailed breakdown of sex and age-
specific costs are shown in Appendix VII (Tables 36 to 38). 
There is a consistent trend of substantial savings m total costs being achieved when 
comparing misoprostol prophylaxis to H2/omeprazole therapy at all ages and time periods 
(13.4% to 31 %), the only exception being females above the age of 75 years. These 
potential savings are shown in Tables 10 to 12. From a NHS perspective, potential savings 
of £34 400 to £266 513, according to time period, may be achieved if all the Tayside 
patients in the H2/omeprazole sub-cohort had their prescriptions replaced by misoprostol. 
However, the results also show that misoprostol therapy failed to provide a saving for 
female H2 blocker takers, especially those above the age of 75 years. For male NSAID 
takers, misoprostol therapy has shown to generate potential savings of 5.3% at 45 days and 
33.8% at six months. 
5.2.4 Sensitivity Analysis 
Extensive sensitivity analysis has been carried out to test the assumptions made when 
developing the economic model. The basic model has assumed that each episode of care 
recorded in the database is representative of an individual hospital admission. Therefore, 
the economic consequence of the alternative assumption was investigated (Appendix VIII, 
Tables 39 to 41) - that multiple episodes of care recorded for each patient, were from one 
single hospital admission. The resultant costs were marginally lower than those from the 
base case, but there were no effects on the results of the basic model (Table 13). 
The much lower history of CV diagnosis observed in the comparator cohort compared with 
the other treatment groups suggested a selection bias. It was initially suspected that this 
was due to patients who were prescribed aspirin in the treatment groups. Aspirin may be 
prescribed for prevention of CV disease, which would explain the high rates of previous 
history of CV diagnosis in the NSAID treatment cohorts. Therefore, as part of the 
sensitivity analysis, patients who were receiving aspirin were removed from the study. The 
results showed an expected reduction in the average shadow cost but no change was 
observed in the overall ranking of the treatment groups. 
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Other factors which may influence the final results were also examined (Appendix VIII, 
Tables 42 to 44). Patients who had a prior history of GI and CV diagnoses, patients who 
had prior GI endoscopic examinations, those who had received NSAID prescriptions, and 
those who died in the year after the study period- termed 'survivors' -were excluded from 
the analyses independently. Analysis was also carried out by eliminating the above risk 
factors simultaneously. Only patients with 'no risk factors' were included in the analysis. 
No consistent changes were observed in the overall ranking of the drugs (Table 14) . 
Sensitivity analysis was also carried out by varying the cost data. Other published GP 
consultation costs were also used to test the robustness of the results. The costs of £4.77 
and £8.38 have been selected for a low and high cost scenario respectively (Table 15). In 
addition, the endoscopy cost has also been investigated by increasing and reducing the cost 
of endoscopy by 50% independently. The results remained consistent when these 
alternative costs were used in the modelling, and the actual overall effect was small. The 
greatest change in cost was found when the cost of GP consultations was estimated at 
£4.77. This only resulted in a modest change in the total costs in all groups - 2% in the 
comparator cohort and the NSAID and misoprostol sub-cohort, and 3% in the NSAID only 
and the NSAID and H2/omeprazole sub-cohorts. 
The overall effects of varying individual clinical factors and costs on the shadow costs of 
the different therapies are shown in Figures 12 to 14. The absolute differences between the 
base case costs and each sensitivity analysis are shown. The left hand part of the graph 
shows costs in groups with various risk factors. These costs tend to be higher than the base 
case. The rankings of the four groups changed little, but the absolute differences in costs 
varied markedly - mostly because of small numbers of the affected individuals. Patients on 
misoprostol with a prior GI admission seemed particularly at risk and were expensive, but 
the numbers were small (N = 27). 
The right hand part of the graph shows similar findings for the groups with high risk factors 
excluded. The size of the groups are much larger, variation is much less. 
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5.3 MODEL-BASED PHARMACOECONOMIC ANALYSIS: EXAMPLES 
WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs), 
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRis) AND 
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS 
5.3.1 Data Collection 
Despite a large number of clinical trials being identified by the searches, only a small 
proportion of the resulting references fulfilled the inclusion criteria for the meta-analyses 
(Figure 15). The is particularly the case with NSAIDs as most of the clinical trials were 
conducted ten to 30 years ago (clinical trials dated as far back as 1972 were included in the 
analysis), before quality guidance for conducting good clinical trials was established. 
Although most well conducted clinical trials recorded and described drug-induced side 
effects, only a small proportion of the trials contained detailed reports of incidence rates of 
side effects of interest to the study. As a result, the final number of clinical trials included 
in the analyses was small. 
The search filters used in the literature search focused on sensitivity instead of specificity. 
Therefore, the number of references identified by the search differs significantly from the 
number of studies included in the analysis. In all, over 9000 trials were identified from the 
databases for NSAIDs, SSRis and ACE inhibitors. These included comparative trials of 
any of these drugs against a placebo or active control. The majority of the trials were small, 
phase III, double-blind, randomised controlled trials of short duration - four to six weeks. 
A total of only 69 trials met the selection criteria and contributed usable data to the three 
meta-analyses. 
Non-Steroidal Anti-Inflammatory Drugs 
Over 3000 studies were identified by the search through the databases. Studies that did not 
fulfil the inclusion criteria, including those evaluating biological inflammatory indicators 
for arthritis, the use of NSAIDs for indications other than RA or osteoarthritis, and absence 
of recorded frequencies of individual adverse events, were excluded. These studies 
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included clinical trials that did not compare individual NSAIDs, those that failed to provide 
detailed figures of individual adverse drugs reactions, trials that reported serious GI adverse 
events only as opposed to all adverse drug reactions. 
Fifteen studies evaluated RA patients, eight studied OA patients and one study included 
both RA and OA patients. In total, 24 studies were included in the meta-analyses of 
NSAIDs-induced adverse events 129-152 (Table 16). The mean study period was 10 weeks 
(range two to 51 weeks). Eight studies reported efficacy and tolerability of indomethacin, a 
further six on naproxen, assessment of ibuprofen and ketoprofen were all reported in four 
studies; there were three on piroxicam and tolmetin, two on sulindac, fenoprofen, and one 
on diclofenac. Although it was possible to extract numerical adverse drugs reactions 
(ADR) data from these trials, the methods used for recording these events are not always 
known (52.4%). Only two trials (9.5%) reported the use of checklists, while 11 trials 
(52.3%) depended on indirect questioning to obtain ADR data. No trials gave detailed 
definitions of each ADR. The qualities of the studies were generally poor, with a Jadad 
score of less than three. The median Jadad score for the NSAID trials was two. 
Selective Serotonin Reuptake Inhibitors 
Clinical studies on SSRis have been dominated by comparative studies between SSRis and 
TCAs as a class of drug. Generally, data were presented in aggregated format for the drug 
class instead of individual drugs, focusing on the differences in efficacy and safety between 
SSRis and TCAs. The search for studies on SSRis produced 21 randomised controlled 
trials with usable data on all SSRis 153-173 (Table 17). The mean duration of study was nine 
weeks (range four to 76 weeks). Nine studies reported data on fluoxetine, seven on 
fluvoxamine, four on paroxetine and a further four on sertraline. Although five studies 
were found to report detailed ADR rates associated with citalopram, they were excluded 
from the analysis due to insufficient sample sizes (N < 20). 
Clinical trials on SSRis were performed more recently (1983 onwards) and were of better 
quality than those on NSAIDs. Only one study had a Jadad score of less than three and the 
median Jadad score for all the studies was three. Various methods of ADR recording were 
used. Thirty-eight percent of the trials did not specify the method used to collect ADR data, 
while checklists were the most frequent method, used by 33.3% of the trials. 
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Angiotensin Converting Enzyme Inhibitors 
The meta-analysis on ACE inhibitors adverse events was based on data from 24 trials 174-197 
(Table 18). The mean duration of the studies was 11 weeks (range four to 51 weeks). Ten 
were trials on enalapril, six on linsinopril, three each on captopril and ramipril. Data on 
trandolapril, moexipril and perindapril were only based on one randomised controlled trial. 
Although one trial was identified with ADR rates for fosinopril, the sample size was too 
small to be included in the analysis. 
The clinical trials for ACE inhibitors were conducted more recently than those for NSAIDs 
and SSRis. The Jadad score for the clinical trials ranged from two to five (maximum 
score), with a median score of three. Methods of ADR recording included open (12.5%), 
direct and indirect questioning (8.3%), spontaneous reporting (33.3%) and the use of 
checklists (4%). However, 16.7% of the trials did not specify the method of ADR 
recording. 
5.3.2 Adverse Drugs Reactions Data 
The ADR profile for NSAIDs, SSRis and ACE inhibitors are presented in Tables 19, 20 and 
21 respectively. The total number of events reported, the weighted number of events and 
the weighted percentage of events (weighted according to the sample size of the group) 
associated with each individual symptom were calculated for each drug. 
Non-Steroidal Anti-Inflammatory Drugs 
A meta-analysis of 1987 patients on eight NSAIDs was conducted (Table 19). Large 
variations in event rates have been observed among individual NSAIDs. In particular, 
fenoprofen appeared to be the least well tolerated of all the NSAIDs in the analysis. It was 
shown to have the highest rate for abdominal pain, constipation, confusion, headache, 
tinnitus, visual disturbance, rash/pruritis and oedema. 
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Gastrointestinal symptoms such as abdominal pain, dyspepsia and nausea and vomiting 
have dominated the ADR profile irrespective of some variation in ADR rates among 
individual drugs. Most of the GI events reported are minor symptoms. The highest 
incidence of GI events has been observed with fenoprofen. Many of the GI events such as 
abdominal pain, constipation, diarrhoea, dyspepsia and nausea and vomiting have been 
reported consistently by all NSAIDS. Although less commonly reported, serious events 
such as peptic ulcer has been reported by 0.03% of patients in trials of ibuprofen. 
Many non-gastrointestinal ADRs have also been reported in the clinical studies. Dizziness 
and vertigo, and headache have been reported by patients on all the individual NSAIDs. In 
particular, headache has been reported by 15.2% of those on fenoprofen, 11.1% of those on 
diclofenac, 6.0% of those on sulindac, 2.8% of those on indomethacin, and less than 2% of 
those on the remaining NSAIDs. Patients have reported high incidences of rash or pruritis, 
up to 30.8% on fenoprofen. One case of anaemia has been reported by patients on 
indomethacin during the clinical trials. A serious complication, such as anaemia, was only 
recorded by one patient in the indomethacin group. 
Selective Serotonin Reuptake Inhibitors 
An aggregated total of 779 patients was included in the meta-analysis of SSRis-induced 
adverse events (Table 20). There were 194 patients in the fluoxetine group, 183 in the 
sertraline group, 132 in the fluvoxamine group, and 270 in the paroxetine group. The ADR 
profiles between individual SSRis vary considerably. Sertraline appeared to have the worst 
toxicity profile among all the SSRis evaluated. This is most apparent in drug-related 
decreased libido (14.2% compared with 0.1% among fluoxetine patients, 0.9% among 
fluvoxamine patients and 3.5% among paroxetine patients). The most common ADRs 
reported by patients on SSRis included nausea and vomiting, ranging from 10.4% among 
those on fluvoxamine to 25.8% among sertraline takers, dry mouth, ranging from 2.2% 
among those on fluoxetine to 21.6% of sertraline patients, and drowsiness, reported by 
1.5% of fluoxetine patients to 23.5% of paroxetine patients. 
Many side effects referable to the central nervous systems such as dizziness, constipation, 
fatigue and headache are also prominent with SSRis. Both fluoxetine and fluvoxamine 
87 
appeared to be better tolerated than paroxetine and sertraline. Adverse events incidence 
rates for fluoxetine and fluvoxamine are generally lower than those of sertraline and 
paroxetine. 
Angiotensin Converting Enzyme Inhibitors 
Data on 2211 patients on ACE inhibitors were used to calculate weighted average incidence 
rates for reported ADRs (Table 21). In general, with the exception of perindapril, ADR 
incidence rates for ACE inhibitors were low, thus they all appeared to be well tolerated. 
The ADR rates recorded in patients taking perindapril were much higher than all the other 
ACE inhibitors being assessed irrespective of individual symptoms. However, this was 
only based on one study. 
The most common ADR reported was headache- 0.7% among those on enalapril to 25.5% 
among those on perindapril. Cough, which is a well-documented adverse event induced by 
ACE inhibitors, was observed among 3.3% to 31.9% of patients who were on lisinopril and 
perindapril respectively. No serious adverse drug reactions have been reported by the 
published clinical trials. 
5.3.3 Management of Adverse Drugs Reactions 
The local LHCC that participated in our study consisted of 38 GPs in nine practices. 
Following recruitment via post and telephone follow-up, only nine GPs agreed to take part 
in the interview. Semi-structured, face-to-face interviews were conducted to determine the 
possible treatment strategies and outcomes associated with the adverse events reported in 
the clinical trials. When presented with the list of ADRs associated with NSAIDs, SSRis 
and ACE inhibitors, all GPs recognised the events as symptoms of possible drug-induced 
adverse events. However, symptoms such as "eyelid soreness", "malaise", "shoulder ache" 
and "taste impairment" would be unlikely to result in patients seeking consultations with 
their GPs, and were not included in the analysis. 
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Estimates of the following parameters were made by the GPs, based on their personal 
experience in dealing with patients who were on any of the three classes of drugs in general 
practice: 
• the proportion of patients who would have their drugs stopped or changed when 
experiencing side-effects, 
• those who would receive a particular investigation and/or treatment (dependent on the 
estimated rate of recovery), 
• those who would fail to improve and require hospitalisation, and 
• the total number of GP or outpatient visits involved. 
Analysis of the GP interviews has provided a summary of the average probability of a GP 
performing a particular investigation or allocating any specific treatment to counteract the 
adverse drug reactions induced by a course of drug therapy. The results are shown in 
Figure 16a- din the form of decision trees. When dealing with drug-induced events, it was 
believed that on average, two GP visits would be involved for the purpose of diagnosis, 
investigations and treatment. Often, patients would be recommended to stop the drug or 
switch to a therapeutically equivalent drug, possibly of the same class, in the expectation 
that the ADR would diminish without further management. This has been the preferred 
choice with all GPs when confronted with suspected drug-induced side effects. However, 
there are instances when further investigations and co-prescribing of additional drug 
treatment would be necessary, such as endoscopies and co-prescribing of ulcer-healing 
drugs in the case of peptic ulcers. This is most prominent among GI complications. 
5.3.4 Cost Estimates 
Drug costs vary considerably among drugs of the same class. The calculations for the cost 
of drugs were based on the assumption that where possible, the formulations of the lowest 
purchasing costs would be prescribed, and generic formulations would be preferred to 
proprietary formulations. It was also assumed that the defined daily dose (DDD) would be 
prescribed. Ranges of costs representing the lowest and the highest DDD are presented in 
Table 19. All the drug costs and defined daily doses were taken from the British National 
Formulary (BNF). The higher the DDD, the higher the drug acquisition costs, with the 
exception of ketoprofen. The maximum DDD of ketoprofen incurs lower costs than when 
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the minimum DDD is prescribed. This is due to potential savings from larger pack size of 
the drugs. The 100 mg formulation for ketoprofen has a lower cost than the 50 mg 
formulation. 
For consistency purposes, all three classes of drugs were modelled for the same duration of 
treatment. The average length of all the clinical trials (in all three classes of drugs) used in 
the meta-analysis was approximately 10 weeks; therefore, the costs of drugs were 
calculated for a duration of 10 weeks. 
Amongst NSAIDs, piroxicam and indomethacin have the lowest acquisition costs- £3.54 to 
£11.44 and £3.57 to £5.60 respectively, over a 10-week period, while ketoprofen is 
associated with the highest cost- £22.12 to £22.45 over 10 weeks. There is at least a six-
fold increase in cost when comparing the costs of piroxicam with ketoprofen. 
This is also observed among SSRis, where drug acquisition costs range from £18.01 to 
£54.04 for fluoxetine, to £41.44 to £125.81 for paroxetine, a three-fold increase in cost. 
This large difference in costs may be partially explained by the lack of generic versions 
available for paroxetine (Seroxat ®) and sertraline (Lustral ®), the two more expensive 
preparations. 
ACE inhibitors are relatively new drugs, only captopril and enalapril are available in 
generic forms. The drug acquisition costs in this class of drugs ranged between £5.75 to 
£10.51 for captopril and £24.06 to £69.49 for Perindopril, representing as much as a three-
fold increase in costs. 
Unit costs used to calculate the costs for managing individual adverse events are shown in 
Appendix IV. The direct medical costs related to the management of individual adverse 
events were calculated. The calculation of these costs has taken into account the resource 
utilisation and the costs of input variables such as GP consultations, prescriptions, clinical 
investigations (such as GI endoscopies for suspected ulcers and blood tests for anaemia), 
any outpatient hospital visits and possible hospitalisation in the more serious cases. 
The least costly adverse events were those associated with the central nervous system 
including symptoms such as headache, dizziness and tinnitus (Table 23). The results of the 
GP interviews suggested that only minor cases of these events have been seen and would 
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only require one GP visit and no co-prescription, at a cost of £8.50. However, more serious 
adverse events, such as peptic ulcers, incur much greater costs (£308.41) due to further 
investigations, referrals and co-prescriptions. These costs were applied to the weighted 
probabilities (Tables 19 to 21), calculated from the meta-analysis and are shown in Tables 
24 to 26. The sum of these costs is the estimated cost of managing all associated adverse 
drugs reactions - i.e. the shadow costs. The shadow costs for each individual drug per 
patient and per 1000 patients are presented in the tables. 
The results of the cost analyses are shown in Table 27. The drug acquisition costs, the 
shadow costs (costs of managing adverse drug reactions) and the total costs of therapies per 
1000 patients are presented. Irrespective of individual drugs, the total costs of drug 
therapies increased substantially when the shadow costs are taken into account. 
In the case of NSAIDs, the cost of drug therapy increased between 12.3% (ketoprofen) and 
59% (diclofenac sodium) when the cost of managing ADRs was taken into account. The 
most significant increase was observed in both fenoprofen (£19 860 to £43 204 per 1000 
patients) and diclofenac sodium (£5850 to £14 288 per 1000 patients), when the total cost of 
therapy rose by over two fold when the shadow costs were taken into account. 
The cost of SSRis therapy increased by approximately 25% (fluoxetine and fluvoxamine) to 
42% (sertraline) when shadow costs were included in the total cost of therapy. 
The cost of ACE inhibitors therapy increased by 4% (enalapril and lisinopril) to 54% 
(perindopril) folds when shadow costs were taken into account. The costs associated with 
managing enalapril and lisinopril associated ADRs were low - £357 and £626 per 1000 
patients over 10 weeks, respectively - and have little impact on the final cost of drug 
therapy. 
Table 27 also shows the relative ranking of the drugs according to their costs. The original 
ranking represented the ranking of drugs according to their acquisition costs alone. For 
NSAIDs, piroxicam is the cheapest to purchase, followed by indomethacin, ibuprofen, 
diclofenac, naproxen, sulindac, fenoprofen and ketoprofen. However, when the shadow 
costs for these drug therapies were taken into account, the final ranking of the drugs, 
according to the total costs of therapy, changed. Indomethacin became the therapy with the 
lowest cost, followed by piroxicam. Naproxen previously ranked fifth, became the third 
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cheapest drug to use. Fenoprofen became the most costly drug therapy, in place of 
ketoprofen. 
If NSAID prescribing decisions were based on the acquisition costs, piroxicam would be 
the preferred choice. However, when shadow costs were taken into account, indomethacin 
became less costly, a potential saving of £1131.85 (£6651.58 with piroxicam minus 
£5519.73 with indomethacin) in 1000 patients over 10 weeks may be achieved. 
A similar finding was observed with SSRis. Although the ranking of fluoxetine and 
fluvoxamine remained unchanged when the shadow costs were taken into account, the 
ranking of sertraline and paroxetine switches between placed third and fourth. If SSRI 
prescribing decisions were based on the acquisition costs, sertraline (£40 500 per 1000 
patients) would be a cheaper alternative to paroxetine (£41 440 per 1000 patients). 
However, when shadow costs were taken into account, paroxetine became more cost 
effective, a potential saving of £7063.14 in 1000 patients over 10 weeks may be achieved. 
In the case of the ACE inhibitors. Moexipril became more costly than trandolapril when the 
shadow costs were taken into account, and a potential saving of £320.34 (£27 155.43 with 
moexipril minus £26 835.09 with trandolapril) in 1000 patients over 10 weeks may be 
achieved. 
5.3.5 Sensitivity Analysis 
The input values on costs and probabilities of ADRs used in the model above were 
tested in the sensitivity analysis. Both the unit costs and the probabilities of developing 
an ADR were inflated and reduced by 20%, singly and combined. Scenario analysis 
based on the extremes of the 95% confidence intervals was also conducted. The 
resultant effect on the three models are shown in Figure 17, 18 and 19. Overall, the 
results are robust and the ranking of the drugs all the three models remained unchanged. 
Increasing and reducing the costs and probabilities resulted in corresponding increase 
and reduction in the total cost of drug therapies. 
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5.4 THE IMPACT OF PHARMACOECONOMIC INFORMATION ON 
PRESCRIBING IN PRIMARY CARE 
5.4.1 Dissemination Exercise 
Recruitment took place during one of the monthly LHCC meetings when seven GPs from 
five different practices were present. During the meeting, all seven GPs showed interest in 
the study and also agreed to encourage colleagues from the same practice to participate. 
However, only five GPs participated in the study. Two GPs were from the same practice, 
while others were from different practices. The main reason for non-participation was "lack 
of time". 
Prescribing Data 
The national prescribing trends for NSAIDs, SSRis and ACE inhibitors evaluated in the 
previous sections are shown in table 28. There is no indication of any particular pattern, in 
relation to purchasing cost and relative cost effectiveness, in prescribing of any of the three 
classes of drugs. 
Overall, there is a general decrease in NSAID prescribing. This may reflect the increase in 
the use of cyclo-oxygenase II (COX-II) inhibitors, replacing the traditional NSAIDs. The 
results from the economic analysis favoured the use of piroxicam and indomethacin. 
However, the national prescribing trend showed that these drugs were not particularly 
favoured by GPs. Diclofenac, ibuprofen and naproxen- ranked 3, 4 and 5 in the economic 
analysis -were the top three NSAIDs prescribed in Scotland. The drugs shown to be less 
cost effective - ketoprofen, sulindac and fenoprofen- were the least prescribed drugs. 
Selective serotonin re-uptake inhibitors prescribing appeared to be generally in agreement 
to the results of the economic analysis, with the exception of fluvoxamine. Although 
fluvoxamine was the second most costly drug to purchase and the second most cost-
effective drug to use in comparison to other three SSRis evaluated, it appeared to be the 
least preferred choice among GPs. While increase in prescribing was recorded for all other 
SSRis, an 11.71% reduction in fluvoxamine prescribing was observed. 
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The less favourable ACE inhibitors, ranked 5, 6 and 7 according to the results of the 
economic analysis, were prescribed in smaller volumes than those ranked 2, 3 and 4. 
However, the least costly and the most cost effective ACE inhibitor - captopril, was not the 
most commonly prescribed ACE inhibitor. 
The prescribing trend of the LHCC in the study was in agreement with national prescribing. 
The change in national prescribing over a 12-month period differed from those recorded in 
the LHCC in this study. This is not unexpected given the sample size for this study is 
small. Two drugs that were included in the economic analyses- fenoprofen and moexipril 
- were not used by the LHCC. 
Overall, there was a reduction in NSAID prescribing in both groups. The only exception 
was observed with diclofenac. A moderate increase (1.02%) was observed in the study 
group compared with a 5.27% reduction recorded in the control group over a six-month 
period (table 29). However, this difference was not statistically significant. The only 
difference in the change of prescribing was observed with ketoprofen. A larger reduction in 
prescribing was recorded in the control group (29.01 %) when compared with the study 
group (17.23%). 
Increases in fluoxetine, sertraline and paroxetine prescribing were observed in both groups 
over the six-month period. However, none of the differences were of sustainable 
significance. Similar to that observed with the national prescribing data, there was a 
reduction in fluvoxamine prescribing, but the differences between the study group were not 
statistically significant. 
The only statistically significant difference in the change in prescribing among the ACE 
inhibitors was observed with trandolapril. The prescribing of trandolapril was reduced by 
8.79% compared with 0.12% in the control group. 
This dissemination exercise appeared to have no obvious effect on prescribing. Neither a 
significant increase in the more cost effective drugs, nor a significant reduction in the less 
cost effective drugs was observed in the study group. The significantly large reduction of 
trandolapril prescribing when compared with the control group may be a positive result, 
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however, it is almost certain that this observation could be explained by the small number 
of prescriptions recorded. 
5.4.2 Survey - Quantitative and Qualitative 
A total of 53 members and 17 affiliated members were identified by the WestNet 
database. Four non-GP members (pharmacist, optometrist, clinical auditor and dentist) 
were excluded from the survey. All the eligible GPs (n = 66) were divided into two 
groups- email group, i.e. those with a contact email addresses (n = 33) and postal group, 
i.e. those without contact email addresses (n = 33). However, email was undeliverable to 
five members - three from questionnaire (I) group and two from questionnaire (II) group. 
Response Rates 
A total of 27 GPs returned the questionnaires, an overall response rate of 44%. Table 30 
gives a detailed breakdown of the response rate by each group. Higher response rates 
were observed with the postal group when compared with the email group and with 
questionnaire (I) when compared to (II). However, none of the differences between 
groups were significant. 
Questionnaire (I)- Economic Information Used in Medical Decision-Making 
All respondents indicated they believe that economic information comparing cost and 
effectiveness of treatments has influenced their medical decision-making. The majority of 
the respondents (n = 9; 69%) reported that such a decision was made as recently as one 
month previously or less, while 15% (n = 2) reported such decisions made one to six 
months ago and another 15% (n = 2), over six months ago. 
Both published and verbal economic information produced by local authorities (Health 
Boards, PCGs, Prescribing Medical Advisors [PP As] and Medical Prescribing Advisors 
[MPAs]) were the most commonly used by GPs, followed by information generated by the 
pharmaceutical industry (table 31). However, only 13% (n = 2) and 20% (n = 3) have 
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used conferences, semmars, and journal articles as economic information sources 
respectively. A slight preference to published information was noted. 
All respondents (n = 15) uniformly reported changes in prescribing as their recent 
economic-information-influenced medical decision. Change in proton pump inhibitors 
prescribing was described by 33% (n = 5), statin prescribing in 20% (n = 3), and 13% (n = 
2) described changes in the prescribing of non-steroidal anti-inflammatory drugs. 
Four respondents described circumstances when economic information had failed to 
influence their decision-making. 50% (n = 2) felt it was 'impossible to implement these 
findings into practice', while one respondent disagreed with the results of the information 
presented. One respondent described the reason to be due to the 'cost of time in 
implementing changes not being reimbursed'. 
Questionnaire (IT) - Sources and Relevance of Economic Information 
All respondents believed that economic information should be incorporated in healthcare 
decision-making. They were all, with the exception of one (n = 11; 92% ), able to describe 
the various sources of economic information they had used (table 32). The most common 
source was the Scottish Prescribing Analysis (SPA) data- used by 83% of the respondents 
(n = 10), 80% (n = 8) of whom found the material relevant to their everyday practice. 
This was followed by the literature produced by the pharmaceutical industry, which was 
used by 75% of the respondents (n = 9), but only 20% (n = 2) found the material relevant 
to practice. Fifty-eight percent (n = 7) recognised medical prescribing advisors and 
pharmaceutical prescribing advisors as a source of economic information, while 62% 
(n = 5) regarded the information as relevant. 
However, 80% (n = 8), 73% (n = 8) and 67% (n = 8) of the respondents did not regard the 
British Journal of General Practice, locally produced newsletters and prescribing 
formularies, and the General Practice Administration System for Scotland (GP ASS) 
feedback as an economic information source. 
Higher proportions of respondents preferred published material compared with verbally 
presented material (table 33). In particular, locally specific information and summarised 
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information in leaflet format were favoured by 54% (n = 6) respondents. 
5.4.3 Qualitative Interviews 
Fifty letters of invitation were sent to GPs by post and followed up by telephone, only four 
agreed to be interviewed. Another four GPs were recruited through snowball sampling. 
All of the eight GPs participated in the interviews were from different practices. None of 
the GPs interviewed had any previous training. One of the GPs interviewed was relatively 
non-communicative giving brief and often mono-syllabic answers and was excluded from 
the formal analysis. 
The Use of Current Evidence 
All the GPs interviewed were able to describe the most recent economic information they 
have encountered. However, at the onset, the majority of the interviewees described the 
reviewing of Scottish Prescribing Analysis data. 
"I had economic information coming from the prescribing centre in Edinburgh. They 
would send out regular analysis on prescribing costs, etc.; and it drew attention to 
your placing in terms of your individual practice, your locality and nationally." (GP 
2) 
"I look at level 2 reports, detail breakdown of the prescribing quarter and analysis of 
prescribing; and also look at the information the prescribing bureau send us on drugs 
and cost analysis." (GP 3) 
Subsequently during the interview, the term "economic information" was defined as 
"information relating to both costs and benefits" and the question was repeated. 
Although peer-reviewed medical journals, including the Lancet and the British Medical 
Journal, were the most commonly cited source of recent economic information, none of 
the interviewees were able to recall details of the information they had read. Some of the 
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GPs interviewed described economic information presented to them by pharmaceutical 
drug representatives, however, they showed much scepticism towards the quality and the 
validity of the information presented to them. One interviewee recalled economic 
information that was discussed in a regular newsletter disseminated by the British Heart 
Foundation. While all the interviewees described the information as of interest to varying 
degrees, none had made or changed decisions in practice based on this information. 
" ... but she was telling me about the additional benefit adding that into statin therapy. 
And if you double the statin dose, compare that to the cost of adding this additional 
drug, you get this benefit and that. What the cost benefit was, I can't remember ... 
That's probably the most often source I see it from. But that's the source I tend to 
ignore." (GP 5) 
"I think there was something recently in promotional literature concerning the use of 
statins... there were some explanation, rationale to statin in a much more broader 
population context and its effect on the reduction on ischaemic heart disease and 
stroke." (GP 7) 
Despite defining economic information as information relating to both costs and benefits, 
most GPs interviewed did not differentiate between economic evidence and cost data. All 
the GPs interviewed stressed that they bear cost issues in mind when prescribing; five 
interviewees described "paying attention" to the costs of drugs that are displayed with the 
GPASS system that they use. However, one GP described the use of a GPASS-integrated 
online formulary produced by the local medicines management team that takes into 
account the relative cost effectiveness of drugs. 
"If !felt it did not compromise the treatment in any way, then I would certainly use the 
generic brand of drug; if I felt there was an issue in relation to the efficacy of the 
medicine, and that's what the patient needed and that was important, then take 
precedence. But other than that, I would go for generic or the cheapest. " ( GP I) 
" ... the cost of the drugs comes on the screen with the GPASS and I do have a look at 
that" (GP 4) 
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"Recently, I had a look at CV drugs because my prescribing cost for CV drugs are 
above the national average. So, I looked at level 2 data and try to analysis why this 
was ... " (GP 2) 
"I suppose when you have two drugs and there is nothing to choose between them, 
previously you would have looked at the cost; now with the formulary, you get first 
choice and second choice... The formulary takes into account the cost of buying the 
drugs and the associated costs. " ( GP 7) 
Two interviewees indicated that they were satisfied with the way economic information is 
presented in the literature. However, all the GPs interviewed, including these two, said 
they were unfamiliar with most of the economic principals presented to them. All the 
interviewees recognised terms such as "direct and indirect costs", "cost effectiveness", 
"cost benefit" and "quality of life adjusted years"; however, only a small proportion 
recognised the terms "marginal cost" and "incremental cost effectiveness". 
In addition to the commonly used economic jargon, the concept of "shadow costs" -
taking into consideration the cost of managing adverse drug reactions was discussed. 
Overall, the interviewees described this to be "interesting" and "relevant". However, most 
believed that such information is purely academic and would not have significant impact 
on their prescribing decisions. 
"It would be (of interest) if you put it in a form that is clear, that will be good 
information to know." (GP 4) 
" ... it's probably more of academic interest than anything ... it is not going to influence 
prescribing unless it is a side effect that is very common. .. 
... So if you treat 100 patients and 2% get a side effect and they will be more expensive, 
forget it. If you can show that 90% will get the side effect, therefore, 90% of the time 
more expensive, so that's worth considering." (GP 5) 
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Some GPs felt that they are already taking into account such considerations when 
prescribing. 
"Perhaps subconsciously, this shows an influencing factor in your choice ... although 
you know this other product is slightly more expensive than another, if from your 
experience, patients seem to tolerate it better, come back less often, feel it's more 
efficacious... Therefore, you wouldn't necessarily be selecting based on the ways you 
have been suggesting, the product that was more expensive... But from your 
perspective is a better product for that individual patient for a combination of all the 
reasons that I have mentioned, so although, there was economics involved, they were 
indirect economics, of the kind you mentioned, but I don't particularly remember 
analysing it in the way you have presented ... 
. . . I do wonder a lot of GPs with experience possibly do the same thing, but not think in 
those terms. These products work well, patients takes them, like them. I know it's 
slightly more expensive that product B, but for these reasons, I think, it's worth the 
expense." (GP I) 
"That process you've described is exactly what (the formulary) has done to decide the 
first choice for (drug) use... It's not something that I do personally. It's been done for 
me." (GP 7) 
The Barriers and Facilitators in Implementing Economic Evidence 
All the interviewees uniformly stated lack of time to be the major barrier to implementing 
economic evidence. It is also clear that the recent introduction of the new GP contract has 
taken priority in the thoughts of most GPs. 
"We don't really have the time ... a lot of people come in and give you chapters and 
verse on the studies, where to find them and what they show and you tend to just accept 
that -well ok." (GP 4) 
"Time is the key barrier. We don't have time to do much more than what we're already 
doing." (GP 5) 
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" ... Again, it's .finding the time to read many of these articles ... " (GP 6) 
"Frankly, we have the new contract, where is there time to put it in? There is so much 
in general practice at the moment. " ( GP 7) 
" ... especially with the new contract coming into place, I don't think GPs will have time 
to think about much else" (GP I) 
Some GPs interviewed regard health economics as an academic discipline and lacks 
practical applications. 
"I suppose GPs traditionally, again in a non-critical way, don't see themselves as 
academics. Therefore, they're practical people getting on with their day-to-day job of 
"real" medicine." (GP 2) 
"They're (economic studies) often are involved in hospital trials rather than general 
practice trials and hospital trials are a different environment to general practice. And 
you feel the conditions and the controlling factors are quite different to the people 
coming into general practice in the daily surgery. Although it might recommend a 
particular product for hypertension or whatever, you did feel it didn't necessarily 
provide the information in the setting that you were familiar with. So, it wasn't 
necessarily, you couldn't extrapolate it directly." (GP 6) 
None of the GPs were able suggest facilitators that may help implement economic 
information in their practice. There were suggestions about improving the presentation of 
the findings in a more precise manner. However, it was also pointed out that although this 
may increase the likelihood that such information may be read, none of the GPs believe that 
the information will be absorbed and used in clinical practice. This may, in part be due to 
their perspective on the role of economic issues in health care decision making as a whole, 
which is presented below. 
The Role of Economic Issues in Healthcare Decision Making 
101 
Overall, the participants believed that it is important to have a general awareness of health 
economic issues, however, they don't believe that such information has a role at a practice 
level. All the GPs interviewed believed that the use of economic information should be 
carried out either nationally or at the least, by the local trusts. 
"I think these decisions should not be taken at a general practice level ... 
. . . these information should be filtered through either regional or national level ... you 
can't have decisions made at practice level. You'll then have undoubted result in one 
practice doing one thing and another practice doing another, and then you have an 
inequality." (GP 7) 
"And I think it is reasonable that GPs as gatekeepers to these services that cost money 
have responsibility and awareness ... I don't think there's a way round for GPs; I think 
they have to have information like that. Whether they use it or not it's up to them but I 
think they need to have the information of cost, because otherwise, you would loose 
sight within a few years absolutely of relative costs. " ( GP 1) 
"Well, I think... trusts or nationally. We're in the sharp end here- we have 10 minutes 
with the patients, and patients may come with 10 problems each, so there's really no 
time to think about economics in the wider sense. But if we have some sort of feedback 
from the trusts or nationally, in a simple form, it might be interesting." ( GP 3) 
" ... it would have to done at a national level, probably medicines committee of the NHS, 
centrally, that would have to do that. But some sort of body like that. " ( GP 5) 
Overall, all the GPs interviewed have regularly come across health economic information 
and feel that they should be kept informed. However, the difficulty they expressed in 
recalling the information has indicated the lack of impact the information has had. Time 
and applicability has been found to be the key barrier to implementing the findings of 
economic studies. However, the view that the implementation of economic information 
should be at a national or a trust level has represented an indirect barrier to their using of 
such information. 
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6 DISCUSSION 
6 DISCUSSION 
6.1 INTRODUCTION 
The discussion of this thesis follows the same order as the work described in previous 
chapters. The discussion on the results of the thesis starts with the findings of the 
population based economic analysis in section 6.2. This is followed by discussion on the 
findings from the meta-analysis based economic analyses of NSAIDs, SSRis and ACE 
inhibitors (section 6.3). The findings of the dissemination exercise, the survey and the 
qualitative interviews follow in section 6.4. 
6.2 POPULATION BASED ECONOMIC ANALYSIS 
The cost of drug therapy cannot be represented solely by its purchasing cost. The 
population based pharmacoeconomic evaluation of NSAID therapy (section 5.2), by 
calculating its complete cost, including that of unintended adverse events, is made from a 
NHS perspective. 
The strength of using population data in cost analyses has been demonstrated by this study. 
Detailed recording of epidemiological data, such as those recorded by MEMO, provide a 
clear view of drug use in real clinical practice. These data are particularly valuable when 
investigating unintended adverse effects and subsequently their costs for individual drugs. 
In contrast, clinical trials would not be able to provide accurate data for this type of costing 
exercise due to issues surrounding the transferability of appropriate prescribing decisions 
into real practice and the methods adopted to record adverse drug reactions. In addition, the 
number of subjects in clinical trials are several orders of magnitude smaller than those in 
the population-based study described here. However, this population dataset has one major 
limitation, in that the absence of indication for prescribing makes these studies particularly 
vulnerable to confounding by indication. 
Sensitivity analysis has shown that the results obtained from this study are robust. Taking a 
NHS perspective, misoprostol therapy concurrent with NSAID treatment has been shown to 
produce significant savings in a Tayside population compared with H2 blockers or 
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omeprazole therapy. In comparison to NSAID only therapy, modest savings may also be 
made on males who are over 75 years old, but not females in any age group. 
From a NHS perspective, a disproportionate increase in costs is observed in those who were 
prescribed any GI protective such as H2 blockers, omeprazole or misoprostol, concurrently 
with NSAIDs. This is likely to be due to confounding by indication in groups perceived by 
GPs to have higher risks who were co-prescribed ulcer-healing drugs. Patients with GI 
symptoms, or more ill are more likely to be given GI protective agents by their GPs. 
Therefore, there is an inherent bias against both the sub-cohorts receiving GI protectives. 
This study has attempted to remove all possible bias in the sensitivity analysis, by using 
very strict subject selection. All the patients that are potential confounders, those who may 
be 'more ill' were removed from the dataset for reanalysis. All the patients with prior GI 
events and endoscopies were excluded. These patients are perceived to be at high risk of GI 
events and may be prescribed different patterns of drugs from those who were at low risk. 
All the patients who were prescribed aspirin were also excluded from the sensitivity 
analysis. These patients may be receiving prophylactic aspirin in the prevention of 
peripheral CV disease. In addition, patients with prior history of CV events were also 
excluded. These patients may be at high risk of developing CV events, thus perceived to be 
'more ill' may be also prescribed different patterns of drugs. Finally, those who died within 
the 12 months post-study period were also excluded as they may also indicate increased 
severity of illness. These factors were excluded alone and in combination in the various 
analyses performed in the sensitivity analysis to replicate the principles of the 'restrictive 
cohort design' 123 •• 
Despite the attempts at removing all potential biases from the study, the findings of this 
study are most probably due to uncontrollable confounding factors that are unmeasured or 
cannot be measured. The baseline risk in the two groups given NSAID and GI protectives 
were high demonstrating that these patients were not comparable with regards to GI and CV 
risks. There are other recognised techniques to deal with confounding issues such as 
propensity scores 198. However, these analytical techniques are only useful for reducing 
confounding that has been measured and would add little value to the findings of this study. 
For each individual, the clinical and cost impact of the non-GI related events - shown in 
particular, by the additional prescriptions, GP consultations and CV admissions - was 
shown to be significantly elevated. The costs of these events accounted for the excess over 
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the comparator group of £166 in the NSAID only group, and £577 in the two groups 
prescribed NSAID and GI protective combined. It was found that 78% of the incremental 
cost (total cost of the two NSAID and GI protective groups compared with the comparator 
group) was attributable to CV admissions and prescriptions in the NSAID and GI protective 
(Hz blockers, omeprazole or misoprostol) patients. The unexpected finding was that GI 
admissions and endoscopies accounted for only 8% of incremental costs. The high 
incidence of CV events, seen in particular among those on GI protectives, is associated with 
a high background rate of prior CV admissions. This is not unusual in a Scottish 
population. An association between NSAIDs usage and increased CV events has been 
documented in some studies - prior history of CV disease has been shown to be one of the 
risk factors for serious upper GI complications 199. NSAIDs elevate blood pressure in 
h . d 1 . . d" "d 1 76 200-203 h" h 1 ypertensiVes, an to a esser extent, normotensive m 1v1 ua s ' , w 1c may a so 
have contributed to the increased CV events observed. There is additional evidence in the 
literature about the association between biochemical evidence of chronic inflammation and 
increased CV risks 204. However, it seems unlikely that these factors could explain the 
difference between the two NSAID groups. Removing pure aspirin takers from the 
analyses (suspected to have been prescribed for prophylaxis of CV events) had little effect 
on the results. 
From a cost perspective, the most striking feature of the study is the exceptionally high cost 
of individuals in the groups taking NSAIDs and any GI protective (such as Hz blockers or 
proton pump inhibitors) or misoprostol- these costs were 135% more than the NSAID only 
group. Further investigation into this sub-cohort of individuals who receive concomitant 
prescriptions of GI protective agents seems useful. Although the groups co-prescribed 
misoprostol and GI protectives have a higher mean age, a greater proportion of females, a 
higher mortality rate and a greater proportion of individuals with prior endoscopies and 
admissions, these findings do not explain the differences. Excluding all patients with 
evidence of prior co-morbidity would be expected to help to adjust for 'confounding by 
indication', i.e. the groups prescribed GI protective or misoprostol are more expensive 
merely because these patients are already at risk from co-morbidities (and already more 
expensive to the NHS) and were more likely to be prescribed GI protective drugs or 
misoprostol. The incremental cost of the groups prescribed GI protective drugs or 
misoprostol were unaffected by this analysis. Therefore, factors such as sex, age, prior 
admissions, and prior use of ulcer healing drugs, did not appear to be responsible for the 
additional cost observed among the GI protective and misoprostol takers. The residual 
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explanation may be that the profile of this group of individuals includes more illness -
additional to the restricted list of GI, CV, RA and OA events recorded in this study -
explaining their greater utilisation of healthcare resources. The use of GI protective drugs 
and misoprostol may possibly be related to other clinical factors, not measured here. 
There are several recently developed population databases which record reasons for 
prescribing (e.g. General Practice Research Database 31 , MediPlus 32 and Continuous 
Morbidity Recording 34). These databases record activities in GP practices and are able to 
provide indications for prescribing. However, it is uncertain whether data from these 
databases would be able to provide a clear explanation for the additional costs incurred in 
these patients. 
6.3 MODEL-BASED PHARMACOECONMIC ANALYSIS: EXAMPLES WITH 
NSAIDs, SSRis AND ACE INHIBITORS 
The literature review of the large amount of randomised controlled trials of the various drug 
therapies has resulted in only a few relevant studies suitable for inclusion in the meta-
analysis (24 on NSAIDs, 21 on SSRis and 24 on ACE inhibitors). This is not unusual in 
meta-analysis, when strict inclusion criteria have to be applied in order to aggregate data 
from similar studies to calculate a weighted average rate. Unlike most meta-analyses, 
where efficacy data are evaluated, this study is particularly problematic because of the focus 
on ADR data. Although the lack of good quality clinical trials (mostly due to time-factor, 
especially in the case of NSAIDs) were in part responsible for the resultant lack of data, the 
method of ADR reporting in many trials may have contributed to the problem. The initial 
result of the literature search has identified many randomised controlled trials with reports 
on associated ADRs. However, on reviewing the actual papers, it was apparent that ADRs 
are often secondary or tertiary outcome measures and data presented are often incomplete 
or unextractable. Graphical display of data or aggregated ADR data according to major 
organs or biological systems is common. Although these studies may have recorded 
reliable drug-induced ADR data, reviewers are unable to extract data for meta-analysis and 
are forced to exclude many studies from the analysis. 
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The pharmacoeconomic analyses of NSAIDs, SSRis and ACE inhibitors have successfully 
demonstrated that local economic analysis using local cost and resource data can be easily 
performed. The results of the studies have proved the importance of taking drug-induced 
ADRs into account when conducting pharmacoeconomic analyses. These adverse clinical 
events may add significantly to the total cost of therapy. In the case of NSAIDs, a 12% 
(ketoprofen) to 59% (diclofenac sodium) increase in cost was observed (table 31). In the 
more severe cases, inclusion of the shadow costs changed the ranking of the drugs. 
Although a change in ranking was not observed among SSRis, the incremental costs 
attributed by the shadow costs ranged from 24% with fluvoxamine to 42% with sertraline. 
Economic evaluations in drug therapies are generally used to calculate the incremental cost-
effectiveness ratio of two interventions. This ratio provides a standard comparison for the 
cost effectiveness of drugs, based on the difference in cost and clinical efficacy of the drugs 
being compared. However, in cases where the drug therapies being compared are of similar 
efficacy, as in the case of many drug treatments for chronic diseases such as RA, depression 
and hypertension, the measure of effectiveness is based on improved tolerability. This is 
often seen in economic evaluations of NSAIDs, where drug-induced GI toxicity is 
frequently used as a measure of clinical effectiveness. Similar methodology is used in 
comparing SSRis with TCAs, when reduced suicide rates have been used for the same 
purpose. In addition, these studies are predominantly based in hospital settings. 
Based on this methodology, pharmacoeconomic analyses were carried out to compare the 
real costs of NSAID, SSRI and ACE inhibitor drug therapies, taking into account their 
complete adverse drug reactions profile. This study attempted to widen this approach to 
incorporate all the drug-associated adverse events reported in the medical literature. In 
contrast to hospital-based publications, this study attempts to assess the real cost of drug 
therapies in a general practice setting. 
The study limitations associated with the economic analyses are inherent in any cost-
effectiveness analysis when definitive data do not exist on the probability of some or all of 
the outcomes examined. For instance, randomised controlled trials are designed to test the 
efficacy of drugs and may not provide an appropriate answer to effectiveness and safety. 
The objective of economic evaluation is to generate policy-relevant data to inform decision-
makers about the incremental costs and outcomes of the drugs that can be expected in 
routine clinical practice. It is often felt that clinical experiments, such as randomised 
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controlled trials, may not serve economic analysis well as they do not reflect practice in 
'real life'. In addition, there is concern regarding generalising trial results to clinical 
populations that are not studied in the trial but covered by a decision makers' drug plan (e.g. 
specific age groups), and to geographical settings and health care systems different from 
those studied. However, until such data are readily available, there is little alternative to the 
current methodologies. There is current encouragement and guidance to add economic data 
to trials 205 • 
The literature searches on randomised controlled trials were conducted systematically. 
Although they were not formal systematic reviews, the process was in line with the 
common guidance for carrying out a systematic review 206• An appropriate search strategy 
of the literature was developed, clinical trials inclusion and exclusion criteria were defined 
and followed, ADR data were extracted systematically and the quality of the clinical trials 
was assessed. In the case of a systematic review, the literature search would be more 
intense and at least two reviewers would be required to review the clinical trials and extract 
the data to eliminate personal bias 206 • However, this was not practicable for this study. 
Some heterogeneity may have existed between the trials selected for meta-analysis. For 
instance, the trials covered a range of drug dosages within the three classes of drugs. 
Adverse drug reactions are often dose-related effects and may potentially influence the 
findings of this study. However, it is believed that the dosages of the drugs covered in the 
clinical trials included in the meta-analysis were within the BNF recommended therapeutic 
range for their indication, therefore, it is unlikely that this would have significantly 
influenced the results. 
The results of the literature review have highlighted the need to improve adverse events 
data reporting in clinical trials. The method of gathering adverse drugs event data and 
number of adverse events reported are often unclear or not reported. The introduction of 
validation tools to assess clinical trial quality, such as the Jadad score, has helped to 
improve the quality of clinical trials substantially over the years. However, these quality 
assessments have focused on issues relating to randomisation, blinding and withdrawal. 
Given the importance of the potential toxicity profile, it is worth considering introducing 
the measure of adverse clinical events into the quality assessment of clinical trials. 
Although the adverse clinical data used to populate the economic models were based on 
randomised controlled trials, the pooled probabilities of individual adverse events are 
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robust, and generally agree with those reported in post-marketing surveillance reports. In 
addition to improving the quality of adverse events reporting in clinical trials, it is also 
important to report the complete range of adverse events. In the case of NSAIDs, many 
clinical trials have focused solely on the associated GI events. Other adverse events such as 
those related to the central nervous system (such as dizziness, headache, insomnia) may be 
of lower clinical risk, these events add substantially to the cost of the drug therapy and 
should not be ignored in pharmacoeconomic models. 
This study, unlike the population model described in the previous section, was based on 
data from randomised controlled trials. Although randomised controlled trials are the gold 
standard for examining the efficacy of drugs, they are not designed to measure the ADR 
profile of drugs. In addition, clinical trials are often limited by sample size and time. In 
order to fully appreciate drugs' toxicity profile, observations of a large sample over longer 
periods of time is required. The true ADR rates associated with these drugs may be 
underestimated by clinical trials. On the other hand, the proportion of patients who actually 
seek medical help as a result of experiencing these ADRs is unknown. This study is based 
on the assumption that all the patients who experience these ADRs would seek medical 
management. This may over-estimate the true costs associated with these drug therapies. 
However, this study is a comparative analysis and the drugs are ranked relative to each 
other; there is no evidence to suggest particular bias in any of the drugs studied. . 
The most difficult measurement in economic evaluations is the measuring of resource 
utilisation. Record linkage is a potential solution to this problem. Relevant measures 
include data on prescriptions, the number of GP consultations, referrals, outpatient visits, 
clinical procedures and diagnostic tests. Ideally, these data would be collected from 
patients' case notes. This is possible in situations in which resources used in a hospital 
setting are measured. Here one would expect definitive diagnoses and treatments to be 
recorded in a relatively standard manner, but often are not. This is even more rarely the 
case in the primary care setting. Many databases are beginning to record events and 
resource utilisation in primary care in a standardised format. However, to date, there is no 
readily available database to enable formal economic evaluations to be undertaken. 
The MEMO database that was used in the population study is a database with such 
potential. However, without linkage between prescriptions and indications, the value of the 
MEMO data in primary care research is limited. The great strength of the MEMO data lies 
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in the estimates it provides of the incidence of hospitalisation giving the ability to calculate 
the costs associated with them. Its weakness, in common with all observational data, is that 
it provides no reliable internal estimate of efficacy due to the inevitable, but unknown 
extent of confounding by pre-existing risk factors. 
Having explored the various available databases without success, a more traditional method 
of seeking expert opinions on resource utilisation was used in the economic analyses. The 
difficulty of recruiting GPs for research has been highlighted in all areas of primary care 
research. General practitioners are constantly under pressure from their trust and political 
issues which affect their daily practice, in particular working within their new contract; in 
addition, the 'researchability' of this group of healthcare professionals are reaching 
saturation point due to the large amount of academic and commercial research carried out in 
primary care. Therefore, it is unsurprising that only a small sample of GPs was successfully 
recruited for the economic study. 
A further problem with determining resource utilisation data from expert opinion is the 
method of surveying itself. General practitioners respond to questions posed at these 
interviews based on their own personal perspective and clinical experience. As a result, a 
subjective perspective of management strategies and resource used is obtained. A more 
effective method is to adopt the Delphi technique, an approach used for establishing and 
developing consensus 207 • It is usually based on experts being sent a self-completion 
questionnaire, analysing the responses, feeding back a summary of the group's view and 
asking respondents to re-evaluate their own views given the results. If a substantial amount 
of disagreement remains a further round of feedback may ensue. However, due to time and 
financial restraints, it was felt that revisiting andre-interviewing the participated GPs would 
not be feasible in this study. 
This thesis recruited GPs who have no special interest in the drugs being evaluated and the 
conditions they are indicated for. It is believed that a sample selected in this manner would 
represent average GP behaviour in primary care. Although the GPs in this study were not 
representative due to the small sample size, this could be the case if a large sample size can 
be achieved and if GPs were selected at random. An alternative approach is to create an 
expert panel with healthcare professionals who have special interest and knowledge in the 
area being investigated. This is the current approach adopted by the HTBS when 
conducting economic evaluations 208 . However, there is controversy surrounding this 
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approach. Creating an expert panel would overcome the problems related to recruitment 
and commitment, but such panels are unlikely to be representative of average clinical 
behaviour. 
The meta-analysis based economic analyses have attempted to measure and compare all the 
indirect costs associated with NSAIDs, SSRis and ACE inhibitors. Based on the measure 
of primary clinical outcomes such as pain reduction and mobility scores associated with 
arthritis, the Hamilton Rate Scale for Depression (HRSD) and the Clinical Global 
Impression (CGI) associated with major depression and the measure of blood pressure in 
hypertension, the literature has shown that there are no statistically significant differences in 
the efficacy of the individual preparations within these three classes of drugs. This was 
evident from the studies included in the meta-analysis. All the included studies that made 
comparisons between the drug being investigated and an active comparator reported no 
statistically significant difference in the measured outcomes. As a result, a therapeutic class 
effect may be speculated. In particular, the class effect of ACE inhibitors have been widely 
discussed in the literature 209. 
Therefore, the measure of secondary clinical outcomes associated with ADRs should be 
considered, but these are extremely difficult to measure. Adverse drug reactions are 
symptoms arising from drug therapy, and all the morbidity that may be associated with 
these events is limited and usually reversible on stopping or switching of drugs. Measures 
of health loss such as disability adjusted life years (DALYs) and quality of adjusted life 
years (QALYs) have been designed to measure health loss based on the assumption of 
permanent change and would not be applicable for morbidities associated with ADRs. 
One way of addressing non-permanent health loss associated with ADRs may be the 
measuring of utilities from the patients' perspective. Cost benefit analysis may be carried 
out to determine whether the benefits of preventing certain ADRs during drug treatment 
therapy outweigh costs from a societal perspective. The contingent valuation method 210•211 
may be used to measure willingness to pay for a reduction of certain ADR symptoms 
associated with individual drugs. This would potentially provide an estimate of the 'value' 
of preventing or reducing certain drug-associated ADRs from a societal perspective. 
However, this would require assessment at the level of individual patients which was 
beyond the scope of this thesis. 
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6.4 THE IMPACT OF PHARMACOECONOIMC INFORMATION ON 
PRIMARY CARE PRESCIRBING 
The impact study was an exploratory exercise to assess any change in prescribing pattern by 
GPs as a result of disseminating pharmacoeconomic information. 
Implementation of research findings has been recognised as a major hurdle in public health 
research. The implementation of the various strategies on improving clinical and cost 
effectiveness of primary care prescribing has been met with similar difficulties. A recent 
study 119 of the methods that have been adopted to promote the uptake of research findings 
suggested that it was possible to identify strategies that were more, or less effective. 
Strategies such as postal distribution of materials or didactic educational sessions were 
found to be largely ineffective. Local consensus conferences, the use of opinion leaders or 
audit and feedback were of variable effectiveness, and strategies such as interactive 
educational workshops, reminder systems, educational outreach and multifaceted 
interventions were suggested to be largely effective. In the case of influencing prescribing, 
the conclusions from implementation studies on different methods of changing prescribing 
behaviour in primary care are generally in agreement with those described in the review. 
The key to successful implementation of evidence in prescribing, and probably all other 
areas of healthcare is to conduct multifaceted, but tailored interventions. 
None of the strategies described in the literature, such as dissemination of printed material, 
educational outreach and feedback, are novel approaches to dissemination. These are all 
methods that have been adopted by the pharmaceutical industry in promoting the use of 
their products. Dissemination of printed material via simple advertising in journals and 
postal marketing literature and outreach visits by medical representatives are routine 
activities within the pharmaceutical industry. This is probably an indication of the potential 
benefit of these strategies. 
The impact study on pharmacoeconomic information on prescribing has failed to promote 
significant changes in prescribing patterns. There is no strong evidence in the literature to 
support or refute any particular interventions for changing prescribing in primary care. 
There is much diversity in the methodology and the quality of the implementation studies. 
Therefore, the transferability of the results from these studies is questionable, and it is 
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impossible to draw any firm conclusions about the effectiveness of the various 
interventions. The reported success of various interventions at influencing primary care 
prescribing, based on both clinical and economic material, is unclear. 
Generally studies that have shown positive results were those that involved GPs who hoped 
to implement change in their clinical practice irrespective of the type of intervention in the 
first place, thus willingness to participate. This has contributed to over-estimation of the 
impact of many interventions. In addition, confounding factors are extremely difficult to 
measure. Since it is impossible to create a controlled environment, factors that may play a 
role in influencing prescribing may not be identified or adjusted for. This is not always 
clear whether the observed effects are genuine effects as a result of the intervention. 
Due to the nature of this type of research, the majority of these studies are often focused on 
a small group and tend to have a limited follow-up period. Results of these studies are often 
interpreted as ineffective, however, size limitations meant that it is often difficult to 
demonstrate a positive effect, which does not equate to deducing there is no effect. Even in 
cases where positive effects were observed, there is no evidence to suggest such effects will 
be sustained over time. 
In a discussion paper on implementing evidence in general practice, Wensing M et al 
(1998) 212 summarised the challenge ahead. "Not all interventions to induce change achieve 
the intended results. Change is a stepwise process, in which several barriers have to be 
removed. For change to be successful it is necessary for the target group of clinicians to 
have the knowledge, skills and motivation needed to adopt a practice. In addition, it is that 
practical and organisational conditions make the new behaviour possible and that 
colleagues, patients and others accept it. Interventions to induce change should focus on 
the removal of these barriers, support the process of change, and consolidate the new 
practice." There is no "magic bullet" to achieve change. 
Salisbury C et al (1999) 213 conducted a study to attempt to understand the barriers and 
facilitators to implementation, and to study the characteristics of those who successfully 
implement evidence-based change, using prescribing as a model. Three key areas of 
change in prescribing were audited, and amalgamated to give an "implementation score" 
per practice. Wide variations were noted between practices' implementation scores. An 
innovative approach among GPs and fundholding status were the only factors shown to 
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have significant relationship with prescribing changes. Use of clinical protocols, disease 
registers, or computers was not associated with high implementation scores, nor was the 
GP' s age. It was also found that GPs feel that there is an information overload. It was felt 
that analysis at a practice level may be realistic, as patients' treatment may reflect decisions 
made by several different GPs as well as practice policy, but may mask the influence of 
characteristics such as the GP' s age. 
The most important factor in implementation is to recognise and understand the barriers that 
influence effectiveness. For instance, educational outreach as a strategy for changing 
prescribing behaviour has been the most extensively researched area in this field. Many 
American studies have suggested these interventions to be effective, and in some cases, 
even cost saving, but the UK studies have reported mixed findings. One uniform 
conclusion may be drawn from these studies - untargeted educational outreach 1s 
ineffective. However, how these interventions should be targeted, remains unclear. 
Another important factor in influencing behaviour and effectiveness is the acceptability of 
the intervention to the intended audience. The willingness to change and improve 
prescribing behaviour in both clinical and economic terms is crucial to the success of these 
studies. 
Finally, many small but important factors come into play during decision making. It is 
important to identify these factors and understand their interplay. For instance, the style of 
data presentation has significant influence of the acceptability of evidence. In one study, 
Elting LS et al showed that clinical investigators' decisions could be affected by factors 
unrelated to the actual data 214• The study showed that the accuracy of decisions was 
affected by the type of data display and by positive or negative framing of the data. Their 
principle conclusions were that the mean times to make decisions were similar for each 
display and professional group. The formats preferred by doctors were not the ones that led 
to optimal decision making. Pie charts and bar graphs were inferior to tables and icon 
displays. Icon displays and negatively framed data in tables led to superior decisions, but 
icons were not liked. 
The measure of effectiveness of interventions influencing prescribing is dependent on the 
available prescribing data. Prescribing data differ in quality and ease of data extraction. 
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There is growing pressure to make effective use of prescribing data in order to inform 
policy and to ensure equitable distribution of resources. 
Prescribing Analysis and Costs (PACT) data is the main source of prescribing data in 
England (from Prescribing Prescriptions Authority). These data are universal, 
comprehensive and accurate. Indicators based on PACT data could be used fairly easily for 
financial management of the drug bill. However, these data are not linked to patients or 
their diagnoses and it is difficult to use them to assess quality or cost-effectiveness. There 
are many limitations. The PACT data are based on costs. The cost included on data was 
the net ingredient cost (NIC) - i.e. the Drug Tariff price, not including dispensing fees, 
container costs and VAT. The number of items prescribed (indication of frequency of 
prescribing) is described, but not the item size, which is particularly important in repeat 
prescribing. There is no individual patient data although various prescribing measures 
weighted to registered populations are included in PP A reports. 
The advent of electronic PACT data has already had a considerable impact on prescribing 
analysis 215 • Further developments are taking place centring on electronic data interchange 
(EDI) which, unlike PACT, will be patient-based and comprise complete medication 
profiles with information on prescription quantities, frequencies, and duration. Various 
scenarios are being considered, involving transmission of electronic prescription records 
directly from GPs to pharmacies or indirectly via the PP A; the PP A would also receive 
electronic dispensing records from pharmacies. These records will contain a patient 
identifier code that will enable, for example, comparison of drugs prescribed and dispensed. 
A further step might involve using EDI to evaluate expert systems such as PRODIGY 
(Prescribing Rationally with Decision support In General practice studY) 216, which are 
currently being developed to provide on screen advice to GPs on treatment options. Other 
sources of prescribing data include EPACT, epact.net, community.net and the prescribing 
toolkit (a stand alone information system which currently contained information on 
potential savings from generic substitution, a specialist drugs catalogue and various 
prescribing indicators). 
The situation in Scotland is not that dissimilar. Basic prescribing statistics have been 
available to Health Boards and GPs in Scotland since 1954 based on prescriptions 
dispensed in a single month and supplied as an analysis three times each year. The 
Pharmacy Practice Division (PPD) was set up originally as the Prescription Pricing 
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Division to process GPs' prescriptions and pay community pharmacists and dispensing 
doctors. Following computerisation at PPD (commenced in 1987) a project was set up to 
develop a comprehensive database on GPs' prescribing which would enable speedy 
publications of more meaningful prescribing statistics to GPs and enable them to assess and 
develop their prescribing practice. The result of the project was the paper-based Scottish 
Prescribing Analysis (SPA). From April 1990 SPA level 1 has been sent quarterly to all 
GPs and health boards, containing basic information that gives feedback on prescribing 
frequency and cost compared with health board average. SPA level 2 is a very detailed 
catalogue of all prescribing over a three-month period supplied by PPD on request. 
It was recognised that paper-based information was of limited value to prescribing advisers 
and that access to computerised databases would be necessary. As a result, the Scottish 
Office funded PPD to develop, with input from prescribing advisers, a computer-based 
information system (Prescribing Information System for Scotland PRISMS), which holds 
detailed information on prescribing down to the root drugs (but not individual 
formulations), at GP, practice, health board and national level. It distinguishes between 
generic and proprietary prescribing on an 'intention to prescribe' basis. PRISMS has been 
available since 1993 and has proven to be an invaluable tool for analysing and monitoring 
trends in prescribing. A pilot project - the Computerised Prescribing Information for 
Practices (CPiP) has been set up to examine the feasibility of providing similar information 
on computer to interested practices and the preliminary feedback from GPs has been 
favourable. In addition, the PPD also provide regular reports on generic prescribing, 
monographs on new drugs and information tracking the prescribing of newly launched 
drugs. 
It has been argued that prescribing analysis should not focus solely on readily available 
measures (e.g. number of items prescribed or total costs). Other factors influencing 
prescribing such as volume, patient demographics and morbidity, are susceptible to should 
be taken into account to avoid misinterpretation of unadjusted 'raw' data 217•218 . More 
sophisticated measurements of prescribing - prescribing indicators have been developed. 
This study has not been able to adopt any prescribing indicators in the analysis of the 
prescribing data. 
The limited dissemination of economic information in this study has failed to show any 
impact on prescribing. However, this may be in part due to the limited design of the 
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dissemination exercise. Firstly, research in primary care, in particular among GPs are 
extremely difficult to conduct due to lack of time and research fatigue. This study had 
attempted to address this issue by targeting an LHCC that is familiar to the researcher has 
shown interest in the research area. The majority of the ground work such as meeting the 
group and introducing the concept of the research was conducted during their regular 
LHCC meetings in order to limit the taking up of the GPs' free time. However, recruitment 
remained relatively unsuccessful and ultimately, this study suffered from a lack of adequate 
sample size. 
Secondly, although the drugs evaluated were recommended by local prescribing advisers, 
these drugs may not be an individual GP's priority. Individual GPs within the same locality 
may have different patient mix, the drugs evaluated may not be commonly prescribed by 
all. 
Thirdly, there are many factors involved in prescribing decisions. The dissemination 
exercise has failed to adjust for external influences such as visits from pharmaceutical 
industry representatives and other sources of prescribing information. These may play a 
significant role in GPs' prescribing behaviour. 
Finally, the study duration may have been insufficient to measure any real change in 
prescribing. Promoting changes in any form of behaviour will take time to implement. The 
dissemination exercise was conducted over a period of six months which is not sufficient to 
examine prescribing trends. 
A GP perspective on economic information has not been explored previously. It is unclear 
what type of materials are being recognised and interpreted as economic information. The 
relevance and the extent of use of the wide variety of economic information being 
presented are also unknown. 
Despite the small sample size and low response rate, this survey has provided some 
preliminary indication about GPs' perceptions and their use of economic information in 
medical decision-making. 
Although questionnaire (I) was designed to record recent activities - using economic 
information in decision-making, while questionnaire (II) examined perceptions of 
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economic information, the results were comparable. Both questionnaires showed the SPA 
data being recognised and used by most respondents as a source of economic information. 
The SPA data (level 1) consist of a breakdown of total costs and the number of items 
dispensed for major therapeutic areas. These are sent automatically to GPs, comparing 
their own average values with those of other practices, the Health Board and Scotland as a 
whole. However, such data contain solely cost information on prescribing are not strictly 
an economic information source, they give no indication of the real quality of the 
prescribing taken place. Therefore, it is beneficial to consider including reliable 
economic information such as cost-effectiveness data, with the feedback information. 
The results have also showed that published materials are used in preference to 
information from verbal presentations. In particular, locally specific evaluations and 
summary leaflets of studies were favoured by 54%. However, 73% did not regard locally 
produced newsletters and prescribing formularies as economic sources. This may be an 
indication that locally produced newsletters and formularies lack adequate economic 
information that GPs find useful. The need for precise and summarised information, 
produced locally, has been highlighted. 
Since the launch of the Scottish Office's primary care communications initiative in April 
1997, 99% of the practices in Scotland were computer-connected by the year 2000 219 • 
However, a recent survey of internet connectivity and use in Lothian 220 reported that 43% 
of their respondents spend no time using email. Therefore, it is not surprising that our 
survey has shown that email communications from GPs are still scarce and often 
unreliable. 
It is clear that GPs recognise that economic information should be incorporated in medical 
decision-making. However, the task of incorporating economic into practice is a 
challenging one. Although all of our respondents in questionnaire (I) have indicated that 
economic information has previously influenced their medical decision-making, four 
described situations where such information had failed to influence their decision-making. 
This suggests that some economic information can only be applied in certain 
circumstances, and despite the effort and the cost spent on compiling and presenting such 
economic evidence, there is still wide variation in their usefulness and quality. 
The results of the survey have confirmed the difficulties of getting economics into 
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practice. This revelation may not be novel, but it is important as it suggests that the 
message, and the information, is not getting through to GPs. Despite the time and money 
spent on compiling and synthesising the evidence, and the prominent position GPs still 
occupy in the rationing process, especially after the creation of LHCCs, there is little 
evidence on effective use of economic information. Although these GPs are not 
representative of all GPs in the UK, the results of this study are likely to be an 
underestimation of the prevalence of poor understanding and implementation of economic 
information in primary care. 
The qualitative research had set out to interview a sample size of ten GPs, however, only 
eight could be interviewed during the given time of the study. Given the introduction of 
the new GP contract, the political turbulence and sense of "survey fatigue" known to 
characterise GPs, this is not surprising. There is also an inherent selection bias in this type 
of research. Several GPs added hostile comments to justify their non-participation, which 
may suggest that the non-participants may have been a more negative or hostile group. 
Therefore, the findings of this study may represent the overall GP perspective in economic 
matters in a less negative picture than actually obtains in practice. 
There is a "healthy" awareness relating to health economics among all the GPs 
interviewed. Often, despite the incomplete understanding about the economic information 
they were exposed to, there is still evidence of interest, which was reflected through their 
reading and partial recalling of relevant information. 
Similar to the findings in the current literature (reported in Section 3.3), the lack of time 
and the lack of practical applications have been described as the key barriers to 
implementing economic information. However, the barriers that have been identified are 
not unique to health economics. Similar findings have been reporting in implementing 
changes in other aspects of medical decision making and practice based on other sources 
of information. There is much similarity to the situation and responses at the time of 
introduction of evidence-based medicine in clinical practice. Many health professionals 
are still getting to terms with some of the evidence-based medicine principals such as 
"relative risk reduction" and "numbers needed to treat". Promoting changes in practice 
take time, as has been evident with the case of evidence-based medicine over the years. 
Overall, the GPs interviewed were unable to suggest a facilitating factor that may help 
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improve the use of economic information in practice. This may be explained by the 
feeling that economic issues should not be considered at a practice level. All the GPs 
interviewed believed that economic information should be considered at a higher level -
nationally through the NHS, or locally through the health board. This information should 
be "filtered" and incorporated in their guidance through guidelines and formularies. This 
should be viewed as a positive finding; although GPs do not feel they should personally 
digest and use economic information, they are demonstrating receptiveness and 
willingness to use guidance produced for them that has incorporated economic thinking. 
Finally, this qualitative study has helped to explain the findings of the dissemination 
exercise in Section 5.4.2. While GPs found such information of interest to their practice, 
they are reluctant to implement change. Overall, there is a strict adherence to prescribing 
formularies, although there is prescribing out with the recommendations of the 
formularies, it was felt that this has to be justified. Despite being purchasers themselves, 
it is becoming evident that GPs are implementers of other's decisions. 
Does health economics work? Does it not work? The answer is far from black and white. 
The lack of "use" described by GPs may be disappointing, however, in an indirect manner, 
GPs are taking into account of health economics in their decision making. In terms of 
prescribing, GPs are aware of the costs of the drugs and would always "choose the generic 
version or the cheaper alternative" if they feel that their patient care is not compromised. 
This reflects decisions based upon both the costs and the benefits; GPs might not use the 
terms that health economists' use, but they appear to be taking economics into account all 
the time. 
6.4 CONCLUSIONS 
Pharmacoeconomic information in healthcare is becoming an important component of the 
process of medical decision-making. This has been highlighted by the introduction of 
groups such as NICE and HTBS in the UK. Despite the volume of literature produced, 
there is still much confusion regarding the understanding, application and transferability of 
this information to clinical (patient) decision making. 
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This thesis has investigated the effect of incorporating ADRs in economic analyses of drug 
therapies including NSAIDs, for the management of rheumatoid arthritis, SSRis in the 
treatment of depression and ACE inhibitors in the management of hypertension. 
Adverse drug reactions add a considerable clinical and economic burden to the NHS. The 
economic studies included in this thesis have demonstrated the importance of adopting a 
wider perspective in considering cost effectiveness rather than costs alone. The population 
based economic analysis has demonstrated that the shadow costs associated with NSAID 
takers are substantial. Population databases such as the MEMO database are invaluable in 
reflecting 'real life' clinical practice. However, similar to all observational data, the 
interpretation of these data is limited by confounding issues. This study has attempted to 
address this by conducting sensitivity analyses based on the restrictive cohort technique, 
which did not alter the main conclusions. In the absence of prescribing indications, it is 
difficult to determine whether the recorded events and subsequently the costs are solely 
attributed to the drug therapy. Therefore, the MEMO database, at its current format may 
not be an appropriate data source for this type of economic analysis. Economic studies in 
other disease areas where the primary clinical outcomes of interest are focused primarily on 
the number of deaths prevented, number of hospital admissions prevented or the duration of 
hospital stay reduced may find the MEMO database an appropriate source of data. 
In the meta-analysis based economic analysis, the substantial costs due to management of 
drug-induced ADRs have been revealed. This was particularly prominent among NSAIDs, 
where as much as a 59% increase in costs associated with treatment of ADRs was observed 
with diclofenac sodium. In cases where clinical effectiveness is not compromised and costs 
may be one of the influencing factors, it is important not to be dependent on acquisition 
costs alone. A higher purchasing cost may result in cost savings in the long term if a 
broader perspective is adopted - as found for NSAIDs including naproxen, ketoprofen and 
trandolapril in this study, SSRis including sertraline and paroxetine and ACE inhibitors 
including lisinopril and moexipril. The meta-analysis based economic analyses allow 
comparisons to be drawn between the costing of three classes of drugs. When the shadow 
costs were incorporated, the impact on NSAID costs were more substantial than that 
observed with SSRis and ACE inhibitors. This may be explained by the more prevalent 
ADR profile associated with NSAID use. In particular, NSAID use is associated with GI 
events, some of which are extremely costly to manage. In contrast to NSAID therapy, 
SSRis and ACE inhibitors were associated with ADRs that are less costly to manage. 
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However, all three classes of drugs have demonstrated a change in ranking when taking into 
account shadow costs. This reflects the importance of adopting a wider perspective and 
taking the associated costs of managing ADRs when considering the cost effectiveness of 
drugs. 
This thesis demonstrated that producing pharmacoeconomic evaluations based on local 
ADR management data is possible. This study has pooled together ADR incidence data 
from the literature, disease management strategies and resource utilisation from expert 
opinions locally, and local costs and prescribing data. However, recent developments in 
population databases such as GP ASS and CMR could eventually lead to a much more 
effective means of carrying out such research. Currently, CMR produces and disseminates 
regular reports on GP workload, prescribing and disease prevalence. It provides a 
potentially ideal setting for inclusion of not solely cost, but also limited economic 
information. 
The course of researching this thesis has provided many opportunities for communicating 
with GPs. Within the small sample of GPs who were involved in this research, through 
face-to-face interviews for the purpose of extracting ADR management profile and the 
discussion of the pharmacoeconomic results during dissemination, a general consensus that 
echoes the research findings on GPs' perspective on economic matters was observed. Many 
of them were aware of the importance of pharmacoeconomic information and often recall 
studies published by major journals or information presented to them from industry medical 
representatives. However, there was a general feel of uncertainty on how these results 
should be understood or applied to their everyday practice. Their perspective on this 
research was generally positive and supportive. This is supported by the findings of the 
impact study and the qualitative interviews. 
The interpretation and implementation of economic information, with regards to prescribing 
are increasingly being conducted at a national or a local level by the health boards and 
PCTs. As a result, GP prescribing decisions have become limited and implementing 
economic information at a practice level is not feasible. 
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RECOMMENDATIONS 
Adverse Drug Reactions and Economic Evaluations 
It is clear that ADRs add considerable clinical and economic burden to the NHS. Although 
different drugs are associated with different ADR profile, and some drugs may only be 
associated with mild, symptomatic ADRs that may not result in hospitalisation or death, at 
the minimum, they may still cause inconvenience to the patients and incur an element of 
cost. Adverse events should be taken into account when conducting economic studies. 
When conducting such studies, clinical events, resource utilisation and cost are taken into 
account. Electronic record linkage has the potential to produce efficient and powerful 
economic evaluations based on real patient data. The lack of reliable data, especially about 
resource utilisation, has resulted in the reliance on expert opinions in economic modelling. 
This has often been criticised as one of the limitations of economic evaluations. The 
development of electronic record linkage such as MEMO and CMR may result in the 
possibility of conducting more powerful economic models for the NHS, based on local data. 
The scope of this should be explored. 
Incorporating Economic Information in Clinical Guidance Literature 
There is general acceptance among GPs that economic information is a factor when making 
decisions about prescribing. Despite having purchasing power, GPs are implementers of 
others' decision making. There is confidence among GPs that clinical guidance such as 
those produced by NICE and HTBS, clinical guidelines such as SIGN guidelines and local 
prescribing formularies provide the best evidence on clinical management and prescribing 
issues. Economic information should become and remain an integral part of these sources. 
There is much ongoing research in developing frameworks for incorporating cost 
effectiveness in evidence-based clinical guidelines 221 . Recently NICE has called for tender 
to develop methodology in incorporating economic evidence in guidelines. However, there 
is to date no formal framework for introducing the cost consequences of ADRs in economic 
analyses. 
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There is also a general agreement among GPs that they should not be sheltered from 
economic evidence themselves. Therefore, there is still a need to improve the current 
presentation of economic evidence to a more applicable form. 
Currently, econormc studies have focused on evaluation of new drugs and health care 
technologies. However, the bulk of the drugs prescribed on a daily basis are established 
drugs and economic information on these preparations are rare. Therefore, more research 
into the economic consequences of the more established therapies are needed. 
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Table 1 Studies exploring the role and impact of economic evidence in decision making in primary care. 
AUTHOR STUDY TYPE PARTICIPANTS METHODS 
Structured interviews containing a mixture of 
open and closed questions. Points covered: 
participants' characteristics, programme/policy 
characteristics, use of economic evaluation, if 
Decision makers - senior used how cost and benefits are measured, other 
KEY FINDINGS 
Ross J 
(1995) 117; 
Australia Survey managers in government (n = 34) factors and barriers. 
High level of awareness of economic evaluation among 
the group and that some (38%) had used it in decision 
making. However, there is not often time to consider 
economic evaluations when making decisions. Other 
limiting factors include availability of data and lack of 
expertise. Participants recommended that researchers 
should be more responsive to the needs of the decision 
makers using them. 
DrummondM 
et al ( 1997) 112; 
UK Survey 
Walley T et al 
(1997) 116; UK Survey 
Duthie T et al 
(1999) 114; UK Survey 
GinsburyME 
et al (2000) 122; 
US Survey 
A questionnaire was developed following a 
Prescribing advisors (n = 178), focus group meeting, covering four main The use of economic studies was limited. The major 
hospital directors (n = 202), themes: knowledge, importance, barriers and barriers were inflexibilities in healthcare budgets and 
directors of public health (n = 66)_ awarenes~-- concerns relating to methodological issues. 
Prescribing advisors in the UK 
(n= 178) 
Heterogeneous mix of decision 
makers (n = 34) 
Randomly selected physicians 
(n = 512) 
A questionnaire was developed following a 
focus group meeting, covering four main 
themes: knowledge, importance, barriers and 
awareness. 
Duo interviews (semi-structured) - participants 
were grouped in pairs to encourage quality 
discussion. 
Questionnaire containing 30 close-ended 
questions. 
Economic issues were rated to be less important than 
clinical issues, but were considered at most meetings 
between prescribing advisors and GPs. While they 
wish to consider true cost effectiveness, they often feel 
obliged to consider drug acquisition costs and risk of 
budgetary overspends. The perceived inflexibility of 
the system and the lack of credibility of evaluations 
were major barriers. 
A large proportion of statements relating to traditional 
health economics principals (e.g. incremental ratios, 
QAL Y s) were not understood or considered irrelevant. 
Most physicians regard cost effectiveness as important 
and appropriate in clinical practice. However, they 
varied considerably in terms of how such information 
should be implemented. 
-N 0\ 
Table 1 (cont) Studies exploring the role and impact of economic evidence in decision making in primary care. 
Motheral BR et 
al (2000) 123 ; 
US Survey 
Hoffmann C et 
al (2000) 113 ; 
Europe Survey 
Hoffmann C et 
al (2002) 115; 
UK Focus group 
Pharmacists and physicians 
(n = 409) 
Three questionnaires: (1) use and importance of Half the respondents reported to consider economic 
economic information, (2) sources of economic information for most or every decision, but 62% 
information used and (3) internal research indicated that only occasionally did this result in action 
activities and barriers to the use of economic or change. Peer-reviewed journals were identified as 
information. the key source of information. 
Survey by postal questionnaires, semi-structured Despite positive attitude, knowledge about formal 
interviews and focus group discussions. methodology is rather limited. Economic studies are 
Questions include issues about the extent of not widely used in decision making. Institutional 
knowledge on economic evaluations, the actual problems and credibility of the studies were viewed as 
Decision makers in nine European and potential use of study results as well as major barriers. Training and better explanations of the 
countries (n = 1041). barriers and incentives of the use of studies. practical relevance of economic studies is needed. 
Decision makers from two UK Focus group with convenience sampling. Four 
health authorities who had meetings (two at each HA) conducted: (1) 
demonstrated interest in health current knowledge and use of economic 
economics and willing to information, (2) usefulness of NHS EED 
participate (n = 12). abstracts. 
The value of economic studies was generally 
recognised, but methodological improvement was 
viewed to be necessary to increase the reliability of the 
studies. 
The study cohort described in Walley et al ( 1997) was a sub-cohort of those examined by Drummond Metal ( 1997). Walley et al reported detailed findings of the prescribing advisor sub-
cohort. QALYs- quality adjusted life years; HA- health authorities; NHS EED- National Health Service Economic Evaluation Database 
Table 2 Demographics and characteristics of the study population 
COMPARATOR % 
Total (N) 
Age (years) 
47350 100 
Sex 
50 to 59 
60 to 74 
75+ 
Mean Age (years) 
Male 
Female 
History of GI Diagnosis 
Yes 
No 
History of Endoscopy 
Yes 
No 
History of CV Diagnosis 
Yes 
No 
History of RA/SLE Diagnosis 
Yes 
No 
History of OA Diagnosis 
Yes 
No 
NSAID Prescriptions 
Acemetacin 
Azapropazone 
Diclofenac Sodium 
Diflunisal 
Etodolac 
Fenbufen 
Fenoprofen 
Flurbiprofen 
Ibuprofen 
Indomethacin 
Ketoprofen 
Mefenamic Acid 
Nabumetone 
Naproxen 
Naproxen Combination Pack 
Piroxicam 
Sulindac 
Tenoxicam 
Tiaprofenic Acid 
Tolectin 
Concomitant use of H2 
Cimetidine 
Ranitidine 
Nizatidine 
Famotidine 
18259 38.56 
20959 44.26 
8132 17.17 
64 years 
21918 46.29 
25432 53.71 
2012 4.25 
45338 
3458 7.30 
43892 
2835 5.99 
44515 
44 0.09 
47306 
531 1.12 
46819 
Concomitant use of Omeprazole - Losee 
Concomitant use of Misoprostol - Cytotec 
Concomitant use of Aspirin 
Death After Study Period to 1994 
crude rates (observed) 
adjusted for sex and age+ 
* Hz blockers/omeprazole 
5269 11.13 
11.13 
NSAID & NSAID & NSAID 
ONLY % MISOPROSTOL % Hz* % 
49212 100 
16509 33.55 
22913 46.56 
9790 19.89 
65 years 
19801 40.24 
29411 59.76 
1582 3.21 
47630 
3872 7.87 
45340 
6069 12.33 
43143 
187 0.38 
49025 
1483 3.01 
47729 
9 0.02 
1077 2.19 
6321 12.84 
437 0.89 
121 0.25 
876 1.78 
44 0.09 
785 1.60 
12512 25.42 
1814 3.69 
1074 2.18 
4026 8.18 
628 1.28 
7469 15 .18 
3079 6.26 
139 0.28 
384 0.78 
252 0.51 
5 0.01 
8160 16.58 
6767 13.75 
12.61 
212 100 2113 100 
57 26.89 594 28.11 
103 48.58 1115 52.77 
52 24.53 404 19.12 
67 years 66 years 
62 29.25 
150 70.75 
27 12.74 
185 
42 19.81 
170 
29 13.68 
183 
3 1.42 
209 
12 5.66 
200 
0 0.00 
9 4.25 
33 15 .57 
0 0.00 
2 0.94 
3 1.42 
0 0.00 
4 1.89 
34 16.04 
7 3.30 
8 3.77 
2 0.94 
4 1.89 
79 37.26 
30 14.15 
16 7.55 
0 0.00 
3 1.42 
0 0.00 
0 0.00 
182 85.85 
8 3.77 
28 13.21 
11 .25 
867 41.03 
1246 58.97 
373 17.65 
1740 
680 32.18 
1433 
448 21 .20 
1665 
30 1.42 
2083 
97 4.59 
2016 
0 0.00 
56 2.65 
341 16.14 
14 0.66 
7 0.33 
54 2.56 
3 0.14 
38 1.80 
334 15 .81 
59 2.79 
51 2.41 
146 6.91 
47 2.22 
275 13 .01 
165 7.81 
11 0.52 
26 1.23 
9 0.43 
2 0.09 
338 16.00 
1703 80.60 
14 0.66 
41 1.94 
17 0.80 
475 22.48 
346 16.37 
14.92 
+ Mortality rates were adjusted by the direct method to the comparator cohort distribution. 
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Table 3 Gastrointestinal endoscopies recorded in the three follow-up periods 
NSAID & 
Comuarator (n = 47 350} NSAID Onll: (n = 49 212} NSAID & Misourostol (n = 212} H2 blocker/Omeurazole (n = 2113} 
Male Female %(Both Sexes) Male Female % (Both Sexes) Male Female %(Both Sexes) Male Female %(Both Sexes) 
45 days 
50 to 59 years 14 19 0.07% 12 21 0.07% 0 0 0.00% 2 5 0.33% 
60 to 74 years 18 23 0.09% 15 21 0.07% 0 0 0.00% 1 7 0.38% 
75+ years 1 7 0.02% 4 7 0.02% 0 0 0.00% 0 2 0.09% 
sub-total 33 49 31 49 0 0 3 14 
%of each sex 0.15% 0.19% 0.16% 0.17% 0.00% 0.00% 0.35% 1.12% 
Total 82 0.17% 80 0.16% 0 0.00% 17 0.80% 
Six months 
50 to 59 years 57 49 0.22% 47 81 0.26% 0 0 0.00% 9 12 0.99% 
60 to 74 years 69 65 0.28% 74 110 0.37% 0 1 0.47% 9 19 1.33% 
75+ years 10 27 0.08% 22 51 0.15% 0 0 0.00% 3 5 0.38% 
sub-total 136 141 143 242 0 1 21 36 
%of each sex 0.62% 0.55% 0.72% 0.82% 0.00% 0.67% 2.42% 2.89% 
Total 277 0.59% 385 0.78% 1 0.47% 57 2.70% 
12 months 
50 to 59 years 110 102 0.45% 105 138 0.49% 1 0 0.47% 15 24 1.85% 
60 to 74 years 129 143 0.57% 153 234 0.79% 0 3 1.42% 27 42 3.27% 
75+ years 25 45 0.15% 40 100 0.28% 0 0 0.00% 6 7 0.62% 
sub-total 264 290 298 472 1 3 48 73 
%of each sex 1.20% 1.14% 1.50% 1.60% 1.61% 2.00% 5.54% 5.86% 
Total 554 1.17% 770 1.56% 4 1.89% 121 5.73% 
,__. 
N 
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Table 4 Prescription items recorded in the three follow-up periods 
NSAID& 
Coml!arator (n = 47 350} NSAID Onll: (n = 49 212} NSAID & Misol!rostol (n = 212} H2 blocker/Omel!razole (n = 2113} 
Male Female %(Both Sexes) Male Female %(Both Sexes) Male Female %(Both Sexes) Male Female %(Both Sexes) 
45 days 
50 to 59 years 594 801 2.95% 1967 2894 9.88% 10 16 12.26% 119 194 14.81% 
60 to 74 years 863 1051 4.04% 3439 4948 17.04% 14 39 25.00% 266 384 30.76% 
75+ years 268 561 1.75% 1188 2910 8.33% 5 27 15.09% 75 208 13.39% 
sub-total 1725 2413 6594 10752 29 82 460 786 
%of each sex 7.87 9.49% 33.30% 36.56% 46.77% 54.67% 53.06% 63.08% 
Total 4138 8.74% 17346 35.25% 111 52.36% 1246 58.97% 
Six months 
50 to 59 years 1200 1722 6.17% 3721 5558 18.86% 17 24 19.34% 210 302 24.23% 
60 to 74 years 1549 1869 7.22% 6264 8783 30.58% 21 54 35.38% 442 559 47.37% 
75+ years 414 950 2.88% 2182 4892 14.37% 6 33 18.40% 110 268 17.89% 
sub-total 3163 4541 12167 19233 44 111 762 1129 
%of each sex 14.43% 17.86% 61.45% 65.39% 70.97% 74.00% 87.89% 90.61% 
Total 7704 16.27% 31400 63.81% 155 73.11% 1891 89.49% 
12 111011ths 
50 to 59 years 1742 2395 8.74% 4652 6768 23.21% 20 25 21.23% 232 310 25.65% 
60 to 74 years 2157 2658 10.17% 7195 10211 35.37% 23 63 40.57% 459 583 49.31% 
75+ years 610 1248 3.92% 2420 5485 16.06% 6 36 19.81% 115 274 18.41% 
sub-total 4509 6301 14267 22464 49 124 806 1167 
%of each sex 20.57% 24.78% 72.05% 76.38% 79.03% 82.67% 92.96% 93.66% 
Total 10810 22.83% 36731 74.64% 173 81.60% 1973 93.37% 
....... 
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Table 5 Hospitalised patients recorded 
GI ADMISSIONS CV ADMISSIONS 
50 to 59 ~ears 60 to 74 ~ears 75+ ~ears 50 to 59 ~ears 60 to 74 ~ears 75+ ~ears 
N F M Total F M Total F M Total Incidence F M Total F M Total F M Total Incidence 
45 days 
Comparator 47350 7 7 14 13 13 26 5 2 7 0.10% I 22 23 9 16 25 35 8 43 0.19% 
NSAID 49212 7 9 16 25 18 43 23 10 33 0.19% 23 52 75 86 119 205 69 28 97 0.77% 
Misoprostol 212 0 0 0 0 0 0 I 0 1 0.47% 0 0 0 I 0 1 I 0 1 0.94% 
H2 blocker/Omeprazole 2113 3 I 4 0 4 4 I 0 1 0.43% 3 8 11 5 13 18 4 3 7 1.70% 
Six months 
Comparator 47350 21 26 47 45 37 82 19 12 31 0.34% 13 58 71 47 64 Ill 97 48 145 0.69% 
NSAID 49212 24 33 57 80 51 131 72 23 95 0.58% 73 171 244 240 334 574 226 105 331 2.33% 
Misoprostol 212 0 0 0 0 0 0 I 0 1 0.47% 0 0 0 I 0 I 3 0 3 1.89% 
H2 blocker/Omeprazole 2113 5 4 9 6 9 15 8 I 9 1.56% 6 16 22 21 32 53 14 5 19 4.45% 
12 months 
Comparator 47350 4 1 56 97 95 72 167 52 32 84 0.73% 36 114 150 98 135 233 176 99 275 1.39% 
NSAID 49212 58 62 120 153 98 251 142 44 186 1.13% 158 310 468 4 18 585 1003 401 205 606 4.22% 
Misoprostol 212 0 0 0 0 0 0 I 0 1 0.47% 0 I I 4 I 5 7 0 7 6.13% 
H2 blocker/Omeprazole 2113 12 6 18 II 15 26 II 2 13 2.70% II 25 36 36 50 86 28 10 38 7.57% 
RA ADMISSIONS OA ADMISSIONS 
50 to 59 ~ears 60 to 74 ~ears 75+ ~ears 50 to 59 ~ears 60 to 74 ~ears 75+ ~ears 
N F M Total F M Total F M Total Incidence F M Total F M Total F M Total Incidence 
45 days 
Comparator 47350 0 0 0 I I 2 0 0 0 0.00% 0 I I 4 2 6 9 I 10 0.04% 
NSAID 49212 2 3 5 7 0 7 2 0 2 0.03% 5 6 II 15 17 32 26 4 30 0.15% 
Misoprostol 212 0 0 0 0 0 0 0 0 0 0.00% 0 0 0 0 0 0 0 0 0 0.00% 
H2 blocker/Omeprazole 2113 I 0 I 0 I I 0 0 0 0.09% 2 0 2 2 I 3 2 0 2 0.33% 
Six months 
Comparator 47350 0 0 0 2 I 3 5 0 5 0.02% 3 6 9 8 9 17 24 4 28 0.11% 
NSAID 49212 8 7 15 25 2 27 13 I 14 0.11% 21 29 50 72 58 130 99 20 119 0.61% 
Misoprostol 212 0 0 0 0 0 0 0 0 0 0.00% 0 0 0 0 0 0 0 0 0 0.00% 
H2 blocker/Omeprazole 2113 I 0 I 4 2 6 I 0 I 0.38% 4 2 6 5 4 9 8 0 8 1.09% 
12 months 
Comparator 47350 I 0 I 3 2 5 6 0 6 0.03% 4 13 17 16 14 30 38 9 47 0.20% 
NSAID 49212 17 II 28 49 8 57 28 3 31 0.24% 53 52 105 172 124 296 192 47 239 1.30% 
,.... Misoprostol 212 0 0 0 I 0 I 0 0 0 0.47% 0 I I 2 0 2 2 0 2 2.36% 
v,) 
H2 blocker/Omeprazole 2113 3 0 3 6 2 8 2 0 2 0.62% 6 3 9 13 8 21 12 0 12 1.99% 0 
F =females; M =males 
-w 
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Table 6 Details of hospital events recorded in three follow-up periods 
longest admission 
mean los (days) 
GASTROINTESTINAL EVENTS 
comparator 
comparator 
comparator 
nsaid 
nsaid 
nsaid 
misoprostol 
misoprostol 
misoprostol 
h2 blocker/omeprazole 
h2 blocker/omeprazole 
h2 blocker/omeprazo\c 
CARDIOVASCULAR EVENTS 
comparator 
comparator 
comparator 
nsaid 
5.57 
7.20 
11.85 
I 1.05 
10. 15 
14.84 
34.00 
34.00 
34.00 
8.33 
12.73 
13.29 
16.48 
22 85 
24.96 
10.58 
nsaid 14.17 
nsaid 15.93 
misoprostol 20.50 
misopros10l 36 50 
misoprostol 30.92 
h2 blocker/omeprazole 9.36 
h2 blockcr/on1eprazole II 90 
h2 blocker/omeprazole 15.34 
RHEUMATOID ARTHRITIS EVENTS 
comparator 
comparator 
comparator 
nsaid 
nsaid 
nsaid 
misoprostol 
misoprostol 
misoprostol 
h2 blocker/omeprazole 
h2 blocker/omeprazole 
h2 blocker/omeprazole 
OSTEOARTHRITIS EVENTS 
comparator 
comparntor 
comparator 
nsa id 
nsaid 
13.50 
49.25 
37. 17 
13.64 
18.84 
24.76 
0.00 
0.00 
5.00 
5.00 
12.50 
14.85 
22.06 
30. JJ 
33 .52 
18.71 
23 .46 
nsaid 23.02 
misoprostol 0.00 
misoprostol 0.00 
misoprostol 25.20 
h2 blocker/omeprazole 23.57 
h2 blocker/omeprazole 23 .00 
h2 blockeriomeprazo le 23 .55 
EVENTS OBSERVED IN THE FIRST 45 DAYS. 
minimum 
los (days) 
13 
0 
15 
3 
maximum 
los (days) 
45 
77 
365 
45 
183 
365 
34 
34 
34 
26 
183 
183 
45 
183 
365 
45 
183 
365 
34 
88 
163 
45 
183 
365 
14 
183 
183 
27 
18J 
365 
46 
46 
45 
18J 
365 
45 
ISJ 
282 
0 
38 
42 
47 
58 
sum no. of cases 
los (days) N 
262 
11 52 
4704 
1017 
2872 
12257 
34 
34 
34 
75 
420 
1010 
1500 
7472 
1642 1 
3987 
16280 
33092 
41 
146 
402 
337 
1119 
2454 
27 
394 
446 
191 
1055 
2872 
0 
0 
10 
100 
193 
375 
1627 
3 184 
1366 
70 16 
14735 
0 
126 
165 
529 
989 
47 
160 
397 
92 
283 
826 
33 
57 
91 
327 
658 
377 
1149 
2077 
2 
4 
13 
36 
94 
160 
12 
14 
56 
11 6 
0 
0 
13 
17 
54 
95 
73 
299 
640 
0 
23 
42 
additional admissions 
mean los (days) 
2.80 
6. 11 
8.71 
6 .71 
10.37 
8.8 1 
0.00 
0.00 
15.00 
2.00 
4.75 
9.29 
6 . 14 
12 56 
19.77 
5.53 
12 56 
14.20 
0.00 
000 
11.67 
4.92 
9.87 
17.52 
0.00 
1600 
68.25 
4.00 
17 80 
51.79 
0.00 
000 
0.00 
0.00 
J 50 
20.25 
16.00 
32 00 
35.00 
8.00 
17.44 
35.58 
0.00 
0.00 
2.00 
0.00 
8.67 
27.00 
EVENTS OBSERVED SIX MONTHS FOLLOW ING THE INDEX DATE. 
minimum 
los (days) 
I 
0 
0 
I 
I 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
maximum 
los (days) 
18 
37 
15 
22 
95 
0 
15 
2 
I 
18 
21 
76 
259 
26 
87 
245 
0 
30 
3 1 
72 
29 
212 
4 
66 
249 
0 
0 
0 
48 
24 
53 
145 
12 
57 
236 
0 
0 
0 
sum 
los (days) 
14 
165 
592 
94 
425 
890 
15 
19 
65 
135 
1093 
3539 
531 
109J 
10322 
0 
35 
64 
375 
946 
0 
32 
273 
178 
725 
0 
0 
8 1 
32 
128 
21 0 
32 
47 1 
2206 
0 
additional admissions 
mean counts 
1.00 
2.4 1 
3 .59 
3.33 
2.27 
3.24 
0.00 
0.00 
3.00 
1.00 
2 25 
3. 14 
1.32 
2 31 
3.5 1 
1.39 
10 30 
3.62 
0.00 
000 
3.33 
1.54 
2 53 
4. 15 
~00 
200 
325 
1m 
2M 
D l 
~00 
~00 
~00 
~00 
~00 
~00 
1.00 
2 00 
3.00 
1.25 
2.07 
3. 13 
0.00 
0 00 
3.00 
0.00 
16 26 900 
II 43 108 3.25 
EVENTS OBSE RV ED 12 MONTH S FOLLOWING T HE INDEX DATE. 
minimum 
counts 
0 
maximum 
counts 
12 
17 
0 
0 
18 
6 
0 
sum 
counts 
65 
244 
20 
93 
327 
0 
9 
22 
29 
20 1 
628 
133 
896 
2635 
0 
0 
10 
20 
96 
224 
13 
22 
45 
0 
0 
0 
4 
16 
18 
56 
194 
0 
0 
0 
27 
13 
no. of cases 
N 
27 
68 
14 
41 
101 
22 
87 
179 
96 
87 
727 
0 
13 
J8 
54 
10 
14 
0 
0 
0 
0 
4 
6 
27 
62 
0 
average admissions 
per person 
1.11 
I 41 
1.6 1 
1.22 
I ~ 
I.W 
1m 
1 00 
~00 
I. II 
1n 
1 . ~ 
1.32 
1.6 1 
1.95 
1.35 
1.78 
2.27 
1.00 
1.00 
1 77 
1.56 
2 02 
2.40 
1.00 
1.50 
2.08 
1.07 
1.39 
1.39 
0.00 
0.00 
1.00 
1.00 
1. 50 
2.2J 
1.12 
1. 15 
1.1 9 
1.07 
1. 19 
1.30 
0.00 
0.00 
I 60 
1.00 
2. 17 
1.3 1 
Table 7 Calculated shadow and total costs (£) per individual 
Inception Period 1 Period 2 Period 3 
N Drug Costs (0 to 45 days) (0 to six months) (0 to12 months) 
Comparator 47350 £0.00 
shadow costs £13.35 £59.63 £141.51 
total costs £13.35 £59.63 £141.51 
95%CI (£11.44 to £15.27) (£53.82 to £65.45) (£126.58 to £156.43) 
NSAID Only 49212 £7.51 
shadow costs £44.19 £179.01 £386.93 
total costs £51.70 £186.52 £394.44 
95%CI (£47.38 to £56.03) (£176.71 to £196.32) (£374.79 to £414.09) 
NSAID & Misoprostol 212 £24.34 
shadow costs £75.56 £332.16 £787.29 
total costs £99.90 £356.50 £811.63 
95%CI (£22.75 to £177.05) (£40.26 to £672.73) (£403.93 to £1219.32) 
NSAID & H2 Blocker/Omeprazole 2113 £40.73 
shadow costs £104.06 £418.20 £897.03 
total costs £144.79 £458.93 £937.76 
95%CI (£119.71 to £169.87) (£403.64 to £514.22) (£805.01 to £1070.51) 
* F test probabilities: p = 0.00 (45 days) p = 0.00 (six months) p = 0.00 (12 months) 
-
(.)) 
N 
........ 
(j;) 
(j;) 
Table 8 
FEMALE 
Comparator 
NSAIDOnly 
NSAID & Misoprostol 
NSAID & Hz blocker/Omeprazole 
MALE 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID & Hz blocker/Omeprazole 
* F test probabilities 
Sex-specific total costs per individual (95% Cl) 
Total Costs (£) 
N 45 Days Six Months 12Months 
25432 £14.71 £64.71 £148.97 
(£11. 79 to £17.63) (£55.91 to £73.52) (£128.78 to £169.16) 
29411 £48.37 £184.20 £393.86 
( £43.97 to £52. 77) (£171.88 to £196.52) (£368.82 to £418.91) 
150 £119.02 £451.89 £971.56 
(£9.83 to £228.20) (£4.52 to £899.26) (£406.27 to £1536.86) 
1246 £135.30 £438.94 £934.25 
(£104.25 to £166.35) (£269.13 to £508.75) (£733.22 to £1135.29) 
21918 £11.78 £53.74 £132.85 
(£9.41 to £14.15) (£46.42 to £61.06) (£110.70 to £154.99) 
19801 £56.66 £189.96 £395.30 
(£48.12 to £65.19) (£173.87 to £206.05) (£363.65 to £426.44) 
62 £53.64 £125.70 £424.66 
(£43.70 to £63.58) (£95.19 to £156.22) (£150.50 to £698.84) 
867 £158.43 £487.65 £942.81 
(£116.60 to £200.26) (£397.57 to £577.73) ( £796. 72 to £1088.89) 
Comparator p = 0.13 (45 days) p = 0.06 (6 months) p = 0.29 (12 months) 
NSAID p = 0.06 (45 days) p = 0. 57 ( 6 months) p = 0.94 ( 12 months) 
Misoprostol p = 0.45 (45 days) p = 0.36 (6 months) p = 0.23 (12 months) 
H;/Omeprazole p = 0.37 (45 days) p = 0.40 (6 months) p = 0.95 (12 months) 
Table 9 
50 to 59 years 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID &Hz 
Blocker/Omeprazole 
60 to 74 years 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID &Hz 
Blocker/Omeprazole 
75+years 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID &Hz 
Blocker/Omeprazole 
* F test probabilities 
Age-specific total costs per individual (95% Cl) 
N 
18259 
16509 
57 
594 
20959 
22913 
Comparator 
NSAID 
Misoprostol 
103 
1115 
8132 
9790 
52 
404 
H z/Omeprazole 
45Days 
£7.45 
(£6.02 to £8.88) 
£35.30 
(£27.31 to £43.30) 
£50.32 
(£40.55 to £60.09) 
£133.38 
(£94.84 to £171.92) 
£11.42 
(£8.97 to £13.85) 
£55.10 
(£49.27 to £60.93) 
£67.32 
(£40.56 to £94.08) 
£149.96 
(£113.11 to£186.81) 
£31.60 
(£23.00 to £40.22) 
£71.41 
(£61.17 to £81.64) 
£218.77 
(£0 to £534.46) 
£147.31 
(£86.46 to £208.16) 
p = 0.00 (45 days) 
p = 0.00 (45 days) 
p = 0.22 (45 days) 
p = 0.85 (45 days) 
Total Costs (£) 
Six Months 
£32.08 
(£26.90 to £37.26) 
£108.77 
(£97.66 to £119.88) 
£122.60 
(£88.59 ti £156.61) 
£358.26 
(£293.44 to £423.09) 
£51.10 
(£44.42 to £57.77) 
£189.41 
(£175.48 to £203.33) 
£156.48 
(£118.95 to £194.01) 
£486.93 
(£399.02 to £574.83) 
£143.51 
(£116.83 to £170.19) 
£310.87 
(£279.14 to £342.58) 
£1,009.06 
(£0 to £2312.02) 
£529.67 
(£404.40 to £654.92) 
p = 0.00 (6 months) 
p = 0.00 (6 months) 
p = 0.07 (6 months) 
p = 0.07 (6 months) 
12Months 
£76.79 
(£60.60 to £92.98) 
£226.03 
(£207.98 to £244.07) 
£370.26 
(£97.70 to £642.82) 
£683.18 
(£578.87 to £787.50) 
£120.35 
(£102.59 to £138.10) 
£384.54 
(£361.64 to £407.43) 
£466.97 
(305.58 to £628.37) 
£942.35 
(£812.10 to £1072.59) 
£341.35 
(£277.22 to £405.48) 
£701.61 
(£624.77 to £778.46) 
£1,978.09 
(£375.18 to £3580.99) 
£1,299.41 
(£725.21 to £1873.61) 
p = 0.00 (12 months) 
p = 0.00 (12 months) 
p = 0.00 (12 months) 
p = 0.01 (12 months) 
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Table 10 Comparisons between the two NSAID and gastroprotectives sub-cohorts (45 Days) 
% Greater than %Less than Tayside 
N NSAID Only N H 2 blocker/Omeprazole Savings(£) 
Base Case 49212 93.23% 2113 31.00% £34,399.64 
Sex and Age-Specific 
Female 
50 to 59 years 9324 91.08% 339 60.68% £26,886.09 
60 to 74 years 13319 51.62% 623 42.98% £33,374.11 
75+ years 6768 218.76% 284 -57.00% -£26,576.72 
Total 29411 146.06% 1246 12.03% £20,284.88 
Male 
50 to 59 years 7185 5.67% 255 64.34% £22,465.50 
60 to 74 years 9594 -13.89% 492 68.54% £61,381.92 
75+ years 3022 9.53% 120 48.77% £6,286.80 
Total 19801 -5.33% 867 66.14% £90,852.93 
Sensitivity Analysis 
Non-aspirin Takers 41554 117.12% 1683 22.13% £48,285.61 
No Prior GI Admissions 47630 106.11% 1740 20.23% £45,830.03 
No Prior CV Admissions 43143 32.88% 1665 52.27% £105,439.79 
No Prior RA Admissions 49025 96.43% 2083 30.78% £92,919.09 
No Prior OA Admissions 47729 106.76% 2016 25.99% £71,128.71 
No Prior Endoscopies 45340 122.92% 1433 22.30% £45,224.62 
Survivors 42445 141.38% 1767 24.41% £60,063.69 
No Risk Factors * 30513 60.20% 764 35.45% £22,726.25 
* Excluded aspirin takers, those with prior Gf, CV, RA or OA admissions, prior endoscopies and those died 
during the study. 
% indicates the percentage of shadow costs greater than the NSAID Only and less than NSAID & H2 
blocker/Omeprazole sub-cohort. 
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Table 11 Comparisons between the two NSAID and gastroprotectives sub-cohorts (six months) 
% Greater than %Less than Tayside 
N NSAID Only N H2 blocker/Omeprazole Savings(£) 
Base Case 49212 91.13% 2113 22.32% £216,434.59 
Sex and Age-Specific 
Female 
50 to 59 years 9324 48.68% 339 59.00% £66,328.74 
60 to 7 4 years 13319 -4.03% 623 61.55% £158,983 .37 
75+ years 6768 251.71% 284 -131.20% -£170,956.64 
Total 29411 145.33% 1246 -2.95% £16,135.70 
Male 
50 to 59 years 7185 -20.59% 255 73 .53% £73,809.75 
60 to 7 4 years 9594 -33.00% 492 74.32% £211,520.64 
75+ years 3022 -52.85% 120 60.09% £22,713.60 
Total 19801 -33.83% 867 74.22% £313,810.65 
Sensitivity Analysis 
Non-aspirin Takers 41554 120.38% 1683 9.30% £62,341 .18 
No Prior GI Admissions 47630 16.36% 1740 49.47% £352,159.82 
No Prior CV Admissions 43143 96.54% 1665 18.00% £109,907.65 
No Prior RA Admissions 49025 94.53% 2083 21.74% £205,713.96 
No Prior OA Admissions 47729 112.18% 2016 18.12% £163,524.0 I 
No Prior Endoscopies 45340 129.97% 1433 6.54% £40,844.37 
Survivors 42445 157.79% 1767 4.68% £33,177.72 
No Risk Factors * 30513 0.85% 764 59.12% £112,097.82 
* Excluded aspirin takers. those with prior GI. CV. RA or OA admissions. prior endoscopies and those died during the study. 
%indicates the percentage of shadow costs greater than the NSAID Only and less than NSA ID & H2 blocker/Omeprazole sub-cohort. 
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Table 12 Comparisons between the two NSAID and gastroprotectives sub-cohorts (12 months) 
N 
Base Case 49212 
Sex and Age-Specific 
Female 
50 to 59 years 9324 
60 to 74 years 13319 
75+ years 6768 
Total 29411 
Male 
50 to 59 years 7185 
60 to 7 4 years 9594 
75+ years 3022 
Total 19801 
Sensitivity Analysis 
Non-aspirin Takers 41554 
No Prior GI Admissions 47630 
No Prior CV Admissions 43143 
No Prior RH Admissions 49025 
No Prior OS Admissions 47729 
No Prior Endoscopies 45340 
Survivors 42445 
No Risk Factors * 30513 
% Greater than 
NSAIDOnly N 
105.77% 2113 
44.16% 339 
35.79% 623 
219.25% 284 
146.68% 1246 
85.97% 255 
4.24% 492 
-48.73% 120 
6.96% 867 
135.80% 1683 
65.86% 1740 
87.33% 1665 
110.50% 2083 
126.20% 2016 
148.30% 1433 
139.38% 1767 
37.44% 764 
%Less than 
H2 blocker/omeprazole 
Tayside 
Savings(£) 
13.41% £266,512.69 
54.14% £115,632.90 
40.81% £202,524.84 
-50.12% -£227,631.68 
-3.99% -£46,488.26 
36.05% £69,298.80 
59.64% £330,673 .20 
65.63% £46,446.00 
54.96% £449,236.05 
1.31% £18,312.55 
27.80% £420,345 .55 
20.19% £255,151.26 
12.71% £246,639.49 
8.90% £165,073.51 
-5.29% -£66,884.42 
6.51% £86,662.34 
36.26% £123,475.77 
* Excluded aspirin takers, those with prior Gl, CV, RA or OA admissions, prior endoscopies and those died during the study. 
%indicates the percentage of shadow costs greater than the NSA ID Only and less than NSAID & H2 blockerlomeprazole sub-cohort. 
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Table 13 Sensitivity analysis - base case versus one admission (multiple episodes of care representing one individual admission) 
Cost of Cost of All CostofGP Cost of Cost of Cost of Cost of Cost of Shadow Total 
Inception Drugs EventRx * Consultations Endoscopy GI admissions CV admissions RA admissions OA admissions Costs Costs 
45Days 
Comparator 
base case £0.00 £3.18 £1.36 £0.40 £1.32 £5.28 £0.11 £1.70 £13.35 £13.35 
one admission £0.00 £3.18 £1.36 £0.40 £1.31 £5.24 £0.11 £1.69 £13.29 £13.29 
NSAID 
base case £7.51 £7.34 £5.61 £0.34 £4.39 £19.40 £0.84 £6.37 £44.29 £51.80 
one admission £7.51 £7.34 £5.51 £0.34 £4.35 £19.24 £0.84 £6.36 £43.98 £51.49 
Misoprostol 
base case £24.34 £18.74 £11.62 £0.00 £19.36 £25.84 £0.00 £0.00 £75.56 £99.90 
one admission £24.34 £18.74 £11.62 £0.00 £19.36 £25.84 £0.00 £0.00 £75.56 £99.90 
H2 blocker/omeprazole 
base case £40.73 £24.92 £12.27 £1.77 £7.26 £36.32 £0.95 £20.58 £104,07 £144.80 
one admission £40.73 £24.92 £12.27 £1.77 £7.23 £35.70 £0.95 £20.58 £103.42 £144.15 
Six Months 
Comparator 
base case £0.00 £14.59 £4.25 £1.46 £5.63 £26.63 £1.03 £6.04 £59.63 £59.63 
one admission £0.00 £14.59 £4.25 £1.46 £5.49 £26.41 £1.02 £6.02 £59.24 £59.24 
NSAID 
base case £7.51 £37.52 £18.91 £1.82 £11.92 £72.31 £4.11 £32.41 £179.00 £186.51 
one admission £7.51 £37.52 £18.91 £1.82 £11.71 £71.30 £4.09 £32.34 £177.69 £185.20 
Misoprostol 
base case £24.34 £78.94 £30.11 £1.97 £27.53 £193.61 £0.00 £0.00 £332.16 £356.50 
one admission £24.34 £78.94 £30.11 £1.97 £27.06 £192.97 £0.00 £0.00 £331.05 £355.39 
H2 blocker/omeprazole 
base case £40.73 £144.69 £41.74 £6.70 £31.70 £121.46 £9.05 £62.85 £418.19 £458.92 
one admission £40.73 £144.69 £41.74 £6.70 £31.26 £118.85 £8.95 £62.62 £414.81 £455.54 
12Months 
Comparator 
base case £0.00 £33.88 £8.10 £3.00 £17.33 £65.68 £1.35 £12.16 £141.50 £141.50 
one admission £0.00 £33.88 £8.10 £3.00 £18.89 £64.96 £1.34 £12.10 £142.27 £142.27 
NSAID 
base case £7.51 £83.47 £33.89 £3.83 £26.68 £156.08 £12.81 £70.17 £386.93 £394.44 
one admission £7.51 £83.47 £33.89 £3.83 £26.07 £153.31 £12.74 £69.84 £383.15 £390.66 
Misoprostol 
base case £24.34 £181.79 £49.11 £6.88 £45.01 £361.06 £4.71 £138.72 £787.28 £811.62 
one admission £24.34 £181.79 £49.11 £6.88 £43.95 £358.12 £4.71 £138.47 £783.03 £807.37 
H2 blocker/omeprazole 
-
base case £40.73 £312.61 £72.25 £14.99 £49.70 £309.49 £18.16 £119.83 £897.03 £937.76 
w one admission £40.73 £312.61 £72.25 £14.99 £48.33 £303.40 £17.73 £119.18 £888.49 £929.22 
00 
* Rx =prescription items. 
Table 14 Sensitivity analysis - excluding various clinical risk factors 
45 Days Six Months One Year 
Shadow Total Shadow Total Shadow Total 
N Costs Costs Costs Costs Costs Costs 
Base Case 
comparator 47350 £13.35 £13.35 £59.63 £59.63 £141.51 £141.51 
NSAID 49212 £44.19 £51.70 £179.01 £186.52 £386.93 £394.44 
misoprostol 212 £75.56 £99.90 £332.16 £356.50 £787.29 £911.63 
Hz blocker/omeprazole 2113 £104.06 £144.79 £418.20 £458.93 £897.03 £937.76 
Non-aspirin Takers 
comparator 47350 £16.03 £16.03 £59.63 £59.63 £141.51 £141.51 
NSAID 41554 £44.47 £52.95 £155.40 £163.88 £339.62 £348.10 
misoprostol 206 £93.12 £117.62 £336.65 £361.15 £796.31 £820.81 
Hz blocker/omeprazole 1683 £110.54 £152.35 £356.38 £398.20 £789.87 £831.69 
No Prior History of GI Diagnosis 
comparator 45338 £13.46 £13.46 £52.49 £52.49 £127.40 £127.40 
NSAID 47630 £48.99 £56.50 £170.15 £177.66 £370.79 £378.30 
misoprostol 185 £95.39 £119.45 £182.65 £206.71 £603.38 £627.44 
Hz blocker/omeprazole 1740 £112.61 £152.80 £369.29 £409.48 £828.83 £869.02 
No Prior History of CV Diagnosis 
comparator 44515 £12.99 £12.99 £47.81 £47.81 £111.14 £111.14 
NSAID 43143 £41.78 £49.59 £145.20 £153.02 £315.56 £323.38 
misoprostol 183 £49.04 £72.80 £276.97 £300.73 £582.01 £605.78 
Hz blocker/omeprazole 1665 £102.24 £143.34 £325.64 £366.74 £717.92 £759.02 
No Prior History of GI Endoscopy 
comparator 43892 £12.38 £12.38 £49.07 £49.07 £119.97 £119.97 
NSAID 45340 £47.58 £55.08 £169.58 £177.08 £366.35 £373.85 
misoprostol 170 £101.68 £125.92 £382.55 £406.79 £904.04 £928.29 
Hz blocker/omeprazole 1433 £124.44 £162.95 £397.23 £435.75 £843.10 £881.61 
No Prior NSAID Prescriptions 
comparator 47350 £16.03 £16.03 £59.63 £59.63 £141.51 £141.51 
NSAID 37871 £48.15 £55.14 £149.93 £156.92 £321.82 £328.82 
misoprostol 193 £95.47 £119.70 £350.13 £374.36 £811.03 £835.27 
Hz blocker/omeprazole 1452 £114.60 £154.70 £389.70 £429.81 £774.15 £814.26 
No Risk Factors * 
comparator 40612 £7.84 £7.84 £36.01 £36.01 £87.30 £87.30 
NSAID 27635 £29.05 £36.82 £99.72 £107.50 £216.67 £224.44 
misoprostol 116 £32.94 £56.02 £87.87 £110.95 £390.29 £413.37 
Hz blocker/omeprazole 610 £45.17 £83.32 £194.49 £232.64 £396.09 £434.24 
Survivors 
comparator 42081 £12.41 £12.41 £38.85 £38.85 £87.57 £87.57 
NSAID 42445 £42.23 £49.78 £140.70 £148.25 £286.92 £294.47 
misoprostol 184 £96.91 £121.38 £357.70 £382.18 £680.43 £704.90 
Hz blocker/omeprazole 1767 £121.11 £161.91 £360.15 £400.95 £713.14 £753.94 
Survivors with no risk factors 
comparator 36721 £6.33 £6.33 £25.57 £25.57 £59.14 £59.14 
NSAID 25332 £25.61 £33.35 £86.09 £93.83 £172.65 £180.39 
misoprostol 105 £32.41 £55.77 £76.36 £99.72 £219.93 £243.28 
Hz blocker/omeprazole 548 £43.95 £81.86 £160.09 £197.99 £350.75 £388.66 
* Excluded aspirin takers, those with prior Gl, CV, RA or OA admissios, prior endoscopies and those who died during 
the study. 
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Table 15 Sensitivity analysis - varying costs 
45 Days Six Months 12Months 
Shadow Total Shadow Total Shadow Total 
N Costs Costs Costs Costs Costs Costs 
Low GP Cost (£4.77) 
Comparator 47350 £12.83 £12.83 £57.98 £57.98 £138.33 £138.33 
NSAID Only 49212 £42.08 £49.59 £171.74 £179.25 £373.84 £381.35 
NSAID & Misoprostol 212 £71.19 £95.53 £320.86 £345.20 £768.37 £792.71 
NSAID & Hz hlocker/omeprazole 2113 £99.34 £140.07 £402.16 £442.89 £869.19 £909.91 
Low Endoscopy Cost (£208.33 x 0.5) 
Comparator 47350 £12.83 £12.83 £58.90 £58.90 £140.01 £140.01 
NSAID Only 49212 £45.24 £52.75 £178.10 £185.61 £385.01 £392.52 
NSAID & Misoprostol 212 £75.56 £99.90 £331.18 £355.51 £783.85 £808.19 
NSAID & Hz blocker/omeprazole 2113 £103.18 £143.91 £414.85 £455.58 £889.54 £930.27 
Base Case 
Comparator 47350 £13.35 £13.35 £59.63 £59.63 £141.51 £141.51 
NSAIDOnly 49212 £44.19 £51.70 £179.01 £186.52 £386.93 £394.44 
NSAID & Misoprostol 212 £75.56 £99.90 £332.16 £356.50 £787.29 £811.63 
NSAID & Hz blocker/omeprazole 2113 £104.06 £144.79 £418.20 £458.93 £897.03 £937.76 
High Endoscopy Cost (£208.33 x 1.5) 
Comparator 47350 £13.24 £13.24 £60.37 £60.37 £143.00 £143.00 
NSAID Only 49212 £45.58 £53.09 £179.92 £187.43 £388.84 £396.35 
NSAID & Misoprostol 212 £75.56 £99.90 £333.14 £357.48 £790.73 £815.07 
NSAID & Hz blocker/omeprazole 2113 £104.95 £145.68 £421.55 £462.28 £904.53 £945.26 
High GP Cost (£8.38) 
Comparator 47350 £13.51 £13.51 £60.12 £60.12 £142.44 £142.44 
NSAIDOnly 49212 £44.81 £52.32 £181.14 £188.65 £390.78 £398.29 
NSAID & Misoprostol 212 £76.85 £101.18 £335.48 £359.82 £792.85 £817.18 
NSAID & Hz blocker/omeprazole 2113 £105.45 £146.18 £422.91 £463.64 £905.22 £945.95 
...... 
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Table 16 NSAID trials included in the meta-analysis 
Year Author Indication Duration N Drugs Included in the Studl: Method of ADR Recording Jadad Score 
1982 AbeT RA 6 weeks 164 Piroxicam 10-20 mg; indomethacin 75 mg Unspecified 2 
1982 Abruzzo JL et al OA 12 weeks 114 Piroxicam 20 mg; aspirin 2.6-3.9 g Indirect questions 2 
1977 Aylward Metal RA 6 weeks 44 Tolmetin 1.6 g, alclofenac 4 g Spontaneous reporting 3 
1986 Bellamy N et al OA 6 weeks 57 Piroxicam 10-20 mg, isoxicam 100-200 mg Unspecified 3 
1983 BerryH et al OA 2 weeks 24 Naproxen 750 mg, antrafenine 450-900 mg, placebo Indirect questions 3 
1978 Bijlsma A RA 6 months 36 Diclofenac 75-125 mg, indomethacin 75-125 mg Unspecified 2 
1975 Blechman WJ et al RA 51 weeks 885 Ibuprofen 3-6 g, aspirin 800-1600 mg Indirect questions 4 
1975 Bowers DE et al RA 16 weeks 80 Naproxen 250-750 mg, aspirin 0.8-4.8 g Questionnaire 4 
1977 Brewis IDL RA 2 weeks 30 Indomethacin 100 mg, flurbiprofen 240 mg, placebo Indirect questions 2 
1976 BrookeJW OA 12 weeks 30 Fenoprofen 200-600 mg, aspirin 325-975 mg, placebo Daily checklist 2 
1986 Brown BL et al OA 6 weeks 148 Sulindac 300 mg, flurbiprofen 100 mg Unspecified 3 
1977 Cardoe N et al RA 4 weeks 24 Tolmetin 1600 mg, phenylbutazone 400 mg Spontaneous reporting 3 
1978 Castles JJ et al RA 20 weeks 132 Naproxen 500 mg, indomethacin 100 mg, aspirin 3.6 g, placebo Indirect questions 2 
1979 Daymond TJ et al RA 4 weeks 41 Ibuprofen 1200 mg, tiaprofenic acid 600 mg Unspecified 4 
1973 Fries JF et al RA 6 weeks 30 Fenoprofen 1.6-2.4 g, aspirin 4.0-6.0 g, placebo "Queried" 3 
1972 Gyory AN eta RA/OA 2 weeks 88 Ketoprofen 100 mg, indomethacin Indirect questions 4 
1976 Kirchheiner B et al RA 2 weeks 30 Ketoprofen, indomethacin Unspecified 1 
1977 KrugerHH RA 2 weeks 30 Indomethacin 150 mg, flurbiprofen 300 mg 'Enquired for' at each visit 2 
1981 Liyanage SP et al OA 4 weeks 30 Naproxen 750 mg, sulindac 400 mg Indirect questions 2 
1977 McMillen JI RA 12 weeks 104 Ibuprofen 1600 mg, tolmetin 1200 mg Unspecified 3 
1973 Mills SB et al RA 2 weeks 35 Ketoprofen 150 mg, ibuprofen 1200 mg Indirect questions 2 
1987 Vasey FB et al RA 6 months 367 Naproxen 500 mg, nabumetone 1500 mg Unspecified 4 
1987 Vetter G OA 4 weeks 36 Indomethacin 150 mg, SAMe 1200 mg Unspecified 2 
-
1978 Woolheim FA et al OA 4 weeks 30 Ketoprofen 200 mg, naproxen 750 mg Checklist 2 ~ 
-
Table 17 SSRI trials included in the meta-analysis 
Year Author Countr;r Duration N Drugs Included in the Stud;r Method of ADR Recording Jadad Score 
1994 Ansseau M et al Belgium 6 weeks 190 Milnacipran 100 mg, fluoxetine 20 mg Checklist and spontaneous reporting 3 
1995 Bennie EH et al UK 6 weeks 308 Sertraline 50-100 mg, fluoxetine 20-40 mg Spontaneous reporting 3 
1994 Bersani G et al Italy 8 weeks 68 Sertraline 50-100 mg, amitriptyline 50-150 mg Unspecified 3 
1988 Byerley WF et al us 6 weeks 103 Fluoxetine 20-80 mg, imipramine 75-300 mg Unspecified 4 
1996 Claghorn JL et al us 6 weeks 138 Fluvoxamine 50-150 mg, imipramine 80-240 mg, placebo Indirect questions 3 
1991 Dunbar GC et al us 6 weeks 717 Paroxetine 20-50 mg, imipramine 80-275 mg, placebo COST ART 3 
1991 Fabre LF et al us 5 weeks 205 Nortriptyline 43 mg, fluoxetine 17.4 mg Unspecified 3 
1985 Feighner JP us 5 weeks 44 Fluoxetine 55 mg, amitriptyline 159 mg Unspecified 3 
1995 Geretsegger C et al Australia 6 weeks 91 Paroxetine 20-30 mg, amitriptyline 50-150 mg Checklist 3 
1983 Guelfi JD et al France 4 weeks 158 Fluvoxamine 300 mg, imipramine 200 mg Checklist 3 
1983 Itil TM et al us 4 weeks 69 Fluvoxamine 101 mg, imipramine 127 mg DOTES/TWIS 2 
1998 Keller MB et al us 76 weeks 169 Sertraline 200 mg, placebo Unspecified 3 
1997 Kiev A et al us 7 weeks 60 Fluvoxamine 50-150 mg, paroxetine 20-50 mg Spontaneous reporting 4 
1987 Lapierre YD Canada 6 weeks 63 Fluvoxamine 50-300 mg, imipramine 50-300 mg, placebo DOTES/TWIS 3 
1988 Muijen M et al UK 6 weeks 81 Fluoxetine 20-80 mg, mianserin 20-80 mg, placebo Unspecified 3 
1991 Noguera R et al Spain 6 weeks 120 Fluoxetine 20-40 mg, chlorimipramine 100 mg Unspecified 3 
1984 Norton KRW et al UK 4 weeks 91 Fluvoxamine 132.8 mg, imipramine 153.3 mg, placebo DOTES/TWIS 3 
1989 Perry PJ et al us 6 weeks 40 Fluoxetine 21-50 mg, trazodone 241-357 mg Adverse events form 3 
1989 Rickels K et al us 6 weeks 111 Paroxetine 10 mg, placebo Recorded in open-ended fashion 3 
1990 Reimherr FW et al us 8 weeks 448 Sertraline 104 mg, amitriptyline 145 mg, placebo Unspecified 3 
1987 Young JPR et al UK 6 weeks 64 Fluoxegne 40-8Q mg~mitriptyline 50-150 mg Adverse events form 3 
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Table 18 ACE inhibitor trials included in the meta-analysis 
Year Author Countr~ Duration N Drugs Included in the Stud~ Method of ADR Recording Jadad Score 
1991 Beevers DG et al UK 8 weeks 144 Lisinopril10-40 mg, atenolol50-100 mg, placebo Open questioning 3 
1987 Bolzano K et al Austria 12 weeks 490 Lisinopril20-80 mg, atenolol50-200 mg Unspecified 3 
1994 Chrysant SG et al us 12 weeks 505 LisinoprillO mg, HCTZ 12.5 mg, lisinoprillO "Questioned" 2 
mg/HCTZ 12.5 mg, placebo 
1998 Cushman WC et al us 12 weeks 891 Enalapril5 mg, diltiazem ER 120-180 mg, enalapril5 Indirect questions 3 
mg/diltiazem ER 120-180 mg, placebo 
1984 EHSG UK 12 weeks 54 Enalapril5-20 mg, propranolol40-120 mg Open questioning 2 
1990 Ferme I et al France 4 weeks 96 Enalapril 20 mg, diltiazem SR 300 mg, enalapril 20 Unspecified 3 
mg/diltiazem SR 300 mg 
1994 Fernandez M et al Mexico 8 weeks 67 Fosinopril 20 mg, HCTZ 12.5 mg, fosinopril 20 Spontaneous reporting 3 
mg/HCTZ 12.5 mg, placebo 
1995 Gradman AH et al us 8 weeks 576 Enalapril20 mg, losartan 10-150 mg, placebo Observed and reported 3 
1997 Gradman AH et al us 8 weeks 707 Enalapril5-20 mg, felodipine 2.5-10 mg, enalapril5-20 Spontaneous reporting 2 
mg/felodipine 2.5-10 mg, placebo 
1990 Grunfeld J-P et al France 8 weeks 186 Enalapril20 mg, spironolactone 15 mg/altizid 25 mg Spontaneous reporting 3 
1993 Lacourcciere Y et al Canada 8 weeks 43 Captopril25-50 mg, amlodipine 5-10 mg Indirect questions 3 
1988 Mehta Jet al us 12 weeks 26 Lisinopril 20-80 mg, lisinoprill 20-80 mgHCTZ 12.5- "Interviewed" 3 
50mg 
1998 Meserli F et al us 6 weeks 631 Trandolapril 4 mg, verapamil SR 20 mg, trandolapril 4 Unspecified 3 
mg/verapamil SR 20 mg, placebo 
1992 Morgan Australia 12 weeks 190 Perindopril 2 mg, atenolol 25 mg Direct questioning and 2 
spontaneous reporting 
1987 Morlin C et al Sweden 12 weeks 136 Lisinopril 20-80 mg, nifedipine 40-80 mg Unspecified 3 
1991 Mroczek WJ et al us 4 weeks 159 Enalapril5-20 mg, ramipril2.5-10 mg "Questioned" 2 
1995 Nicaise J et al Belgium 8 weeks 100 Captopril12.5-25 mg, diltiazem SR 200-300 mg Observed and reported 3 
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Table 18 (cont) ACE inhibitor trials included in the meta-analysis 
--
Year Author Country Duration N Drugs Included in the Study _Method of ADR Recording 
1995 Prisant L et al US 12 weeks 218 Enalapril5-20 mg, amlodipine 2.5-10 mg, Spontaneous reporting 
bisoprolol2.5-10 mg/HCTZ 6.25 mg 
1996 Stimpel M et al Germany 12 weeks 159 Captopril25 mg, moexipril 7.5 mg Open questioning 
1995 Thijs Let al Belgium 4 weeks 611 Ramipril 5 mg, piretanide 6 mg, ramipril 5 Spontaneous reporting 
mg/piretanied 6 mg 
1991 TOMHS us 12 months 902 Enalapril 5 mg, acebutolol 400 mg, amlodipine 5 Checklist 
mg, chlorthalidone 15 mg, doxazosin 2 mg, placebo 
1991 Vasmant D et al France 8 weeks 205 Ramipril 2.5-5 mg, placebo Spontaneous reporting 
1991 V erkaaik R et al The Netherlands 8 weeks 44 Enalapril 20-40 mg, nitredipine 20-40 mg Open questioning and 
spontaneous reporting 
1987 Zachariah PK et al US 8 weeks 179 Lisinopril 40-80 mg, metoprolol 100-200 mg Unspecified 
....... 
t 
Jadad Score 
5 
2 
3 
4 
2 
4 
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Table 19 Adverse drug reactions data extracted from NSAID trials 
Ibuprofen Naproxen Piroxicam Sulindac 
(N= 560) (N= 548) (N= 138) (N= 85) 
Weighted Weighted Weighted Weighted 
N N % N N % N N % N N % 
Abdominal Pain 36 24.02 4.29% 32 6.41 1.17% 14 4.90 3.55% 4 3.29 3.88% 
Anorexia 7 4.07 0.73% 3 0.29 0.05% 2 0.81 0.59% 2 1.65 1.94% 
Constipation 6 3.97 0.71% 34 6.37 1.16% 3 1.22 0.88% 8 4.65 5.47% 
Diarrhoea 9 4.94 0.88% 14 3.65 0.67% 5 1.77 1.28% 5 4.12 4.84% 
Peptic Ulcer 2 0.19 0.03% 
Dyspepsia 28 14.98 2.67% 30 4.10 0.75% 2 0.77 0.56% 3 1.18 1.38% 
Flatulence 0.09 0.02% 4 0.66 0.12% 
GI Haemorrhage 
Nausea/Vomiting 44 26.71 4.77% 45 9.64 1.76% 3 1.00 0.72% 6 4.29 5.05% 
Oral Ulcers 9 2.73 0.50% 3 1.00 0.72% 1 0.18 0.21% 
Fatigue 3 0.28 0.05% 2 0.24 0.04% 8 2.96 2.15% 2 1.65 1.94% 
Confusion 
Depression 6 3.25 0.58% 10 2.08 0.38% 0.82 0.97% 
DizzinessN ertigo 16 11.14 1.99% 14 3.21 0.59% 4 1.21 0.88% 8 5.94 6.99% 
Drowsiness 0.06 O.Ql% 4 0.31 0.06% 2 0.42 0.30% 
Dry Mouth 0.21 0.15% 
Headache 28 10.69 1.91% 39 7.55 1.38% 0.41 0.29% 7 5.12 6.02% 
Nervousness 
!Irritability 5 3.22 0.58% 4 0.83 0.15% 
Sleep/Restlessness 0.06 0.01% 3 0.47 0.09% 
Nightmares 
Tinnitus 13 10.17 1.82% 17 3.01 0.55% 3 1.17 0.85% 2 1.65 1.94% 
Visual Disturbance -
Flu-Like Symptoms - 5 0.33 0.06% 2 0.62 0.45% 
Rash/Pruritis 30 19.23 3.43% 50 7.50 1.37% 8 2.99 2.16% 3 2.47 2.91% 
Oedema 2 0.19 0.03% 8 1.66 0.30% 10 3.04 2.20% 
Anaemia 
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Table 19 (cont) Adverse drug reactions data extracted from NSAID trials 
Fenoprofen Ketoprofen Indomethacin Diclofenac 
(N= 57) (N= 186) (N = 395) (N = 18) 
Weighted Weighted Weighted 
N N % N N % N N % N % 
Abdominal Pain 22 11.37 19.94%18 3.65 1.96%29 4.16 1.05% -
Anorexia - 2 0.31 0.17% 7 1.19 0.30% -
Constipation 6 3.16 5.54% 4 0.97 0.52% 7 1.25 0.32% -
Diarrhoea - 6 2.03 1.09%16 3.64 0.92% 1 5.56% 
Peptic Ulcer 
Dyspepsia -18 5.28 2.84%18 1.86 0.47% -
Flatulence 
GI Haemorrhage - - 1 0.05 0.01% -
Nausea/Vomiting 11 5.53 9.70%17 4.13 2.22%51 6.79 1.72%3 16.67% 
Oral Ulcers - 7 2.52 1.35% 5 0.93 0.24% -
Fatigue - 4 1.38 0.74%10 1.47 0.37% -
Confusion 6 3.16 5.54% -
Depression - 6 2.04 1.10% 4 0.84 0.21% -
DizzinessN ertigo 6 3.16 5.54% 3 0.81 0.43%31 5.18 1.31%2 11.11% 
Drowsiness 6 3.16 0.29% - - 3 0.17 0.04% -
Dry Mouth - 1 0.15 0.08% 1 0.08 0.02% -
Headache 17 8.68 15.24% 8 1.27 0.68%62 10.93 2.77%2 11.11% 
Nervousness/ 
Irritability 6 3.16 5.54% - - 1 0.29 0.07% -
Sleep/Restlessness - - 1 0.29 0.07% -
Nightmares - 1 0.05 0.01% -
Tinnitus 26 13.26 23.27% 2 0.30 0.16% 8 1.67 0.42% -
Visual 
Disturbance 12 6.32 11.08% 1 0.15 0.08% -
Flu-Like 
Symptoms - 3 0.35 0.09% -
Rash!Pruritis 35 17.53 30.75%15 3.70 1.99%18 3.81 0.96% -
Oedema 12 6.32 11.08% - - 3 0.72 0.18% -
Anaemia - 1 0.08 0.02% -
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Table 20 Adverse drug reactions data extracted from SSRI trials 
Fluoxetine (N = 194) Sertraline (N = 183) 
N WeightedN Weighted% N WeightedN Weighted% 
CNS Anxiety 27 8.60 4.43% 18 14.66 8.01% 
Blurred Vision 14 3.37 1.74% 16 13.03 7.12% 
Confusion 4 0.52 0.27% 
Depersonalized Syndrome 
Dizziness/Syncope 12 3.33 1.72% 26 18.66 10.19% 
Drowsiness 17 2.80 1.45% 29 23.61 12.90% 
Dry Mouth 16 4.31 2.22% 57 39.50 21.58% 
Dysmenorrhoea 
Fatigue 8 1.21 0.62% 13 10.58 5.78% 
Headache 23 4.98 2.57% 24 19.54 10.68% 
Insomnia 16 4.66 2.40% 26 21.17 11.57% 
Palpitation 
Paraesthesia 
Sweating 0.11 0.06% 11 8.96 4.89% 
Taste Perversion 4 3.26 1.78% 
Tinnitus 
Tremor 18 4.17 2.15% 24 19.54 10.68% 
GI 
Anorexia 6 4.89 2.67% 
Constipation 9 2.64 1.36% 21 14.58 7.97% 
Decreased Appetite 2 0.27 0.14% 
Diarrhoea 7 1.88 0.97% 35 28.50 15.57% 
Flatulence 0.11 0.06% 
Dyspepsia 0.11 0.06% 23 12.44 6.80% 
Nausea!V omiting 52 13.87 7.15% 58 47.22 25.81% 
Weight Gain, Excessive 3 1.44 0.74% 
Weight Loss, Excessive 8 3.47 1.79% 
cv 
Hypotension 3 1.44 0.74% 
Tachycardia-Palpitations 7 3.36 1.73% 7 5.70 3.11% 
Vasodilation 
Skin 
Dermatites/ Allergy 19 4.48 2.31% 18 14.66 8.01% 
Flu Symptoms 
Flu-Like Symptoms 5 0.54 0.28% 
Urinary Problems 
Urinary Problems 4 1.92 0.99% 2 1.63 0.89% 
Sexual Problems 
Abnormal Ejaculation 
Decreased Libido 0.11 0.06% 32 26.05 14.24% 
lml!otence 
147 
Table 20 (cont) Adverse drug reactions data extracted from SSRI trials 
Fluvoxamine {N = 132) Paroxetine (N- 270) 
N WeightedN Weighted% N WeightedN Weighted% 
CNS 
Anxiety 31 8.74 6.62% 6 0.67 0.25% 
Blurred Vision 12 10.67 3.95% 
Confusion 
Depersonalized 
Syndrome 2 0.45 0.34% 4 0.44 0.16% 
Drowsiness 39 10.64 8.06% 82 63.56 23.54% 
Dry Mouth 43 10.82 8.20% 64 48.33 17.90% 
Dysmenorrhoea 2 0.71 0.54% 3 0.33 0.12% 
Headache 32 9.20 6.97% 12 1.33 0.49% 
Insomnia 23 5.26 3.98% 9 1.00 0.37% 
Palpitation 0.23 0.17% 4 0.44 0.16% 
Paraesthesia 12 10.67 3.95% 
Sweating 20 5.09 3.86% 29 23.44 8.68% 
Taste Perversion 5 4.44 1.65% 
Tinnitus 2 1.78 0.66% 
Tremor 22 5.52 4.18% 27 21.67 8.02% 
GI 
Anorexia 28 7.32 5.54% 
Constipation 19 5.30 4.01% 40 34.00 12.59% 
Decreased Appetite 19 16.89 6.26% 
Diarrhoea 26 7.25 5.49% 14 1.56 0.58% 
Flatulence 1 0.23 0.17% 4 0.44 0.16% 
Dyspepsia 9 2.69 2.04% 7 0.78 0.29% 
Nausea!V omiting 54 13.77 10.43% 78 60.78 22.51% 
Weight Gain, Excessive 
Weight Loss, Excessive 
cv 
Hypotension 
Tachycardia-
Palpitations 9 8.00 2.96% 
Vasodilation 5 1.46 1.11% 5 4.44 1.65% 
Skin 
Dermatites/ Allergy 15 3.69 2.79% 2 0.22 0.08% 
Flu Symptoms 
Flu-Like Symptoms 20 7.12 5.39% 
Urinary Problems 
Urinary Problems 17 15.11 5.60% 
Sexual Problems 
Abnormal Ejaculation 5 1.39 1.06% 15 12.56 4.65% 
Decreased Libido 5 1.14 0.86% 14 9.33 3.46% 
lml!otence 3 0.68 0.52% 2 0.22 0.08% 
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Table 21 Adverse drug reactions data extracted from ACE inhibitor trials 
Lisino~ril (N = 653) Enala~ril (N = 699) Trandola~ril (N = 159) 
Weighted Weighted 
N N % N N % N % 
CNS 
Asthenia/Fatigue 25 6.37 0.98% 18 2.13 0.30% 5 3.14% 
Ataxia 2 0.27 0.04% 
Depression 0.10 O.Ql% 
Dizziness/ 
Vertigo/Syncope 28 7.85 1.20% 21 2.58 0.37% 4 2.52% 
Dryness Of Mouth 
Headache 39 11.03 1.69% 41 4.81 0.69% 17 10.69% 
Insomnia 2 0.13 0.02% 
Nervousness 
Paresthesia 3 0.34 0.05% 0.13 0.02% 
Somnolence 
/Tiredness 2 0.36 0.06% 3 0.18 0.03% 
Ageusia/Taste Impairment 0.13 0.02% 
Tinnitus 
Visual Disturbance 0.02 0.00% 
GI 
Abdominal Pain 5 3.14% 
Anorexia 0.13 0.02% 
Constipation 0.04 O.Ql% 0.63% 
Diarrhoea 6 0.91 0.14% 6 0.68 0.10% 5 3.14% 
Dyspepsia 2 0.20 0.03% 
Nausea & Vomiting 9 3.43 0.52% 8 0.79 0.11% 5 3.14% 
cv 
Oedema 0.14 0.02% 13 1.96 0.28% 4 2.52% 
Palpitations 
/Breathlessness 12 1.00 0.14% 
Postural Hypotension 8 0.98 0.14% 
Flu Symptom 36 36 4.84 0.69% 25 15.72% 
Skin Rash 9 2.67 0.41% 5 0.31 0.04% 5 3.14% 
Im,eotence 3 0.19 0.03% 
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Table 21 (cont) Adverse drug reactions data extracted from ACE inhibitor trials 
Ramipril Captopril Moexipril Perindapril 
(N=397) (N = 104) (N= 105) (N= 94) 
Weighted Weighted 
N N % N N % N % N % 
CNS 
Asthenia/Fatigue 5 1.15 0.29% 7 3.63 3.49% 11 10.48% 24 25.53% 
Ataxia 
Depression 4 2.11 0.53% 0.48 0.46% 
Dizziness/ 
Vertigo/Syncope 17 7.79 1.96% 8 4.12 3.96% 8 7.62% 25 26.60% 
Dryness Of 
Mouth 16 17.02% 
Headache 20 8.98 2.26% 10 5.12 4.92% 13 12.38% 24 25.53% 
Insomnia 6 3.16 0.80% 0.48 0.46% 27 28.72% 
Nervousness 3 1.56 1.50% 4 3.81% 
Paresthesia 
Somnolence 
/Tiredness 9 4.74 1.19% 3 1.56 1.50% 0.95% 
Ageusia/Taste 
ImpairmEnt 0.48 0.46% 
Tinnitus 1 0.48 0.46% 8 8.51% 
Visual 
Disturbance 
GI 
Abdominal Pain 2 0.54 0.14% 
Anorexia 
Constipation 
Diarrhoea 0.27 0.07% 6 5.71% 14 14.89% 
Dyspepsia 
Nausea & 
Vomiting 4 1.85 0.47% 20 21.28% 
cv 
Oedema 5 2.56 2.46% 12 11.43% 
Palpitations/ 
Breathlessness 4 2.11 0.53% 3 1.56 1.50% 2 1.90% 
Postural 
Hypotension 16 17.02% 
Flu Symptom 11 5.79 1.46% 17 8.75 8.41% 
Skin Rash 0.48 0.46% 14 14.89% 
lm}!otence 7 3.69 0.93% 3 3.19% 
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Table 22 Drug costs 
Defined Dail~ Dose (DDD) Cost 
Minimum Maximum MinimumDDD MaximumDDD 
NSAIDs 
Ibuprofen 1200 mg 2400mg £5.58 £11.17 
Naproxen 500mg 1000 mg £7.85 £15.10 
Piroxicam 10mg 30mg £3.54 £11.44 
Sulindac 200mg 400mg £18.63 £32.50 
Fenoprofen (Fenopron ®) 900mg 2400mg £19.85 £51.21 
Ketoprofen lOOmg 200mg £22.45 £22.12 
Indomethacin 50mg 200mg £3.57 £5.60 
Diclofenac Sodium 75mg 150mg £5.85 £9.28 
SSRis 
Fluoxetine 20mg 60mg £18.01 £54.04 
Sertraline (Lustral®) 50mg 200mg £40.50 £132.55 
Fluvoxamine 100mg 300mg £38.71 £116.13 
Paroxetine (Seroxat ®) 20mg 50mg £41.44 £125.81 
ACE Inhibitors 
Captopril 25mg 100mg £5.75 £10.51 
Cilazapril (Vascace ®) 1 mg 5mg £16.15 £35.70 
Enalapril Maleate 5mg 40mg £9.40 £30.60 
Fosinopril (Staril ®) 10mg 40mg £30.10 £65.00 
Imidapril Hydrochloride (Tanatril ®) 5mg 20mg £14.13 £19.18 
Lisinopril (Zestril ®) 2.5 mg 40mg £15.65 £54.85 
Moexipril (Perdix ®) 7.5mg 30mg £20.30 £70.20 
Perindopril (Coversyl ®) 2mg 8mg £24.06 £69.49 
Quinapril (Accupro ®) lOmg 80mg £17.93 £48.75 
Ramipril (Tritace ®) 1.25 mg lOmg £13.25 £32.50 
Trandolapril ®) 0.5mg 4mg £20.45 £61.40 
>--' 
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Table 23 Calculated cost of managing clinical adverse events 
Adverse Drug Events Cost(£) 
Dyspepsia £ 30.89 
Suspected peptic ulcer £ 33.02 
Abdominal pain £ 21.88 
Nausea and vomiting £ 33.55 
Constipation £ 22.22 
Diarrhoea £ 17.24 
Peptic ulcers £ 308.41 
Rash or Pruritis £ 20.24 
Insomnia £ 18.14 
Other CNS symptoms £ 8.50 
Oedema £ 23.74 
Anaemia £ 91.87 
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Table 24 
Abdominal Pain 
Anorexia 
Constipation 
Diarrhoea 
Peptic Ulcer 
Dyspepsia 
Flatulence 
NauseaN omiting 
Oral Ulcers 
Fatigue 
Confusion 
Depression 
Dizziness!V ertigo 
Drowsiness 
Dry Mouth 
Headache 
Nervousness/ 
Irritability 
lnsonmia 
Tinnitus 
Visual Disturbance 
Flu-Like Symptoms 
Rash!Pruritis 
Oedema 
Anaemia 
Cost 
£21.88 
£8.50 
£22.22 
£17.24 
£308.41 
£30.89 
£8.50 
£33.55 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£8.50 
£18.14 
£8.50 
£8.50 
£8.50 
£20.24 
£23.74 
£91.87 
The cost of managing adverse drug reactions in NSAID therapies 
Fenoprofen !N = 57) 
Weighted 
Diclofenac !N = 18) Sulindac !N - 85l Ibuprofen !N - 560) Ketoprofen !N - 186) Piroxicam !N = 138) Naproxen !N = 548) Indomethacin !N = 395l 
% Cost % Cost Weighted % Cost Weighted % Cost Weigllted % Cost Weighted % Cost Weighted % Cost Weighted % Cost 
19.94% 
5.54% 
9.70% 
5.54% 
5.54% 
0.29% 
15.24% 
5.54% 
23.27% 
11.08% 
30.75% 
11.08% 
£4.36 
£1.23 
£3.25 
£0.47 
£0.47 
£0.02 
£1.30 
£0.47 
£1.98 
£0.94 
£6.22 
£2.63 
5.56% £0.96 
16.67% £5.59 
11.11% £0.94 
11.11% £0.94 
3.88% 
1.94% 
5.47% 
4.84% 
1.38% 
5.05% 
0.21% 
1.94% 
0.97% 
6.99% 
6.02% 
1.94% 
2.91% 
£0.85 
£0.16 
£1.21 
£0.84 
£0.43 
£1.69 
£0.02 
£0.16 
£0.08 
£0.59 
£0.51 
£0.16 
£0.59 
4.29% 
0.73% 
0.71% 
0.88% 
0.03% 
2.67% 
0.02% 
4.77% 
0.05% 
0.58% 
1.99% 
0.01% 
1.91% 
0.58% 
0.01% 
1.82% 
3.43% 
0.03% 
£0.94 
£0.06 
£0.16 
£0.15 
£0.10 
£0.83 
£0.00 
£1.60 
£0.00 
£0.05 
£0.17 
£0.00 
£0.16 
£0.05 
£0.00 
£0.15 
£0.70 
£0.01 
1.96% 
0.17% 
0.52% 
1.09% 
2.84% 
2.22% 
1.35% 
0.74% 
1.10% 
0.43% 
0.08% 
0.68% 
0.16% 
0.08% 
1.99% 
£0.43 
£0.01 
£0.12 
£0.19 
£0.88 
£0.74 
£0.11 
£0.06 
£0.Q9 
£0.04 
£0.01 
£0.06 
£0.01 
£0.Ql 
£0.40 
3.55% 
0.59% 
0.88% 
1.28% 
0.56% 
0.72% 
0.72% 
2.15% 
0.88% 
0.30% 
0.15% 
0.29% 
0.85% 
0.45% 
2.16% 
2.20% 
£0.78 
£0.05 
£0.20 
£0.22 
£0.17 
£0.24 
£0.06 
£0.18 
£0.07 
£0.03 
£0.01 
£0.02 
£0.07 
£0.04 
£0.44 
£0.52 
1.17% 
0.05% 
1.16% 
0.67% 
0.75% 
0.12% 
1.76% 
0.50% 
O.Q4% 
0.38% 
0.59% 
0.06% 
1.38% 
0.15% 
O.Q9% 
0.55% 
0.06% 
1.37% 
0.30% 
£0.26 
£0.00 
£0.26 
£0.11 
£0.23 
£0.01 
£0.59 
£0.04 
£0.00 
£0.03 
£0.05 
£0.00 
£0.12 
£0.01 
£0.02 
£0.05 
£0.01 
£0.28 
£0.07 
1.05% 
0.30% 
0.32% 
0.92% 
0.47% 
1.72% 
0.24% 
0.37% 
0.21% 
1.31% 
0.04% 
0.02% 
2.77% 
0.07% 
0.08% 
0.42% 
0.09% 
0.96% 
0.18% 
0.02% 
£0.23 
£0.03 
£0.07 
£0.16 
£0.15 
£0.58 
£0.02 
£0.03 
£0.02 
£0.11 
£0.00 
£0.00 
£0.24 
£0.01 
£0.02 
£0.04 
£0.01 
£0.20 
£0.04 
£0.02 
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Table 25 
CNS 
GI 
cv 
Skiu 
Flu Symptoms 
Urinary Problems 
Sexual Problems 
The cost of managing adverse drug reactions in SSRI therapies 
Sertraline {N- 183 Paroxetine {N = 270) 
Unit Costs Weighted% Cost Weighted% 
Anxiety £8.50 8.01% £0.68 0.25% 
Blurred Vision £8.50 7.12% £0.61 3.95% 
Confusion £8.50 
Depersonalized Syndrome £8.50 0.16% 
Dizziness/Syncope £8.50 10.19% £0.87 14.40% 
Drowsiness £8.50 12.90% £1.10 23.54% 
Dry Mouth £8.50 21.58% £1.83 17.90% 
Dysmenorrhoea £8.50 0.12% 
Fatigue £8.50 5.78% £0.49 15.43% 
Headache £8.50 10.68% £0.91 0.49% 
Insomnia £18.14 11.57% £2.10 0.37% 
Palpitation £8.50 0.16% 
Paraesthesia £8.50 3.95% 
Sweating £8.50 4.89% £0.42 8.68% 
Taste Perversion £8.50 1.78% £0.15 1.65% 
Tinnitus £8.50 0.66% 
Tremor £8.50 10.68% £0.91 8.02% 
Anorexia £8.50 2.67% £0.23 6.26% 
Constipation £22.22 7.97% £1.77 12.59% 
Diarrltoea £17.24 15.57% £2.68 0.58% 
Flatulence £8.50 0.16% 
Dyspepsia £30.89 6.80% £2.10 0.29% 
Nausea/Vomiting £33.55 25.81% £8.66 22.51% 
'Veight Gain, Excessive £17.00 
'Veight Loss, Excessive £17.00 
Hypotension £8.50 
Tachycardia-Palpitations £8.50 3.11% £0.26 2.96% 
Vasodilation £8.50 1.65% 
Dennatites/ Allergy £20.24 8.01% £1.62 0.08% 
Flu-Like Symptoms £8.50 
Urinary Problems £8.50 0.89% £0.08 5.60% 
Abnonnal Ejaculation £17.00 4.65% 
Decreased Libido £17.00 14.24% £2.42 3.46% 
Impotence £17.00 0.08% 
Fluvoxamine {N -JJ2l Fluoxetine {N- 124l 
Cost Weighted% Cost Weighted% Cost 
£0.02 6.62% £0.56 4.43% £0.38 
£0.34 1.74% £0.15 
0.27% £0.02 
£0.Ql 0.34% £0.Q3 
£1.22 4.19% £0.36 1.72% £0.15 
£2.00 8.06% £0.69 1.45% £0.12 
£1.52 8.20% £0.70 2.22% £0.19 
£0.01 0.54% £0.05 
£1.31 1.50% £0.13 0.62% £0.05 
£0.04 6.97% £0.59 2.57% £0.22 
£0.Q7 3.98% £0.72 2.40% £0.44 
£0.Ql 0.17% £0.01 
£0.34 
£0.74 3.86% £0.33 0.06% £0.00 
£0.14 
£0.06 
£0.68 4.18% £0.36 2.15% £0.18 
£0.53 5.54% £0.47 0.14% £0.Ql 
£2.80 4.01% £0.89 1.36% £0.30 
£0.10 5.49% £0.95 0.97% £0.17 
£0.01 0.17% £0.Ql 0.06% £0.00 
£0.Q9 2.04% £0.63 0.06% £0.02 
£7.55 10.43% £3.50 7.15% £2.40 
0.74% £0.13 
1.79% £0.30 
0.74% £0.06 
£0.25 1.73% £0.15 
£0.14 1.11% £0.09 
£0.02 2.79% £0.57 2.31% £0.47 
5.39% £0.46 0.28% £0.02 
£0.48 0.99% £0.08 
£0.79 1.06% £0.18 
£0.59 0.86% £0.15 0.06% £0.01 
£0.Ql 0.52% £0.09 
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Table 26 
CNS 
Asthenia/Fatigue 
Ataxia 
Depression 
Dizziness/Vertigo/Syncope 
Dryness Of Mouth 
Headache 
Insomnia 
Nervousness 
Paresthesia 
Somnolence/Tiredness 
Ageusia/Taste Impairmnt 
Tinnitus 
Visual Disturbance 
GI 
Abdominal Pain 
Anorexia 
Constipation 
Diarrhoea 
Dyspepsia 
Nausea & Vomiting 
cv 
Oedema 
Palpitations/Breathlessness 
Postural Hypotension 
Flu Symptom 
Skin Rash 
Impotence 
Cost per Patient 
Cost per 1 000 Patients 
The cost of managing adverse drug reactions in ACE inhibitor therapies 
PerindaJlril (N = 94l Moexiuril (N - 105l Trando!auril ili = 159l Cautouril (N - 104l 
Unit Cost % Cost % Cost % Cost Weighted% Cost 
£8.50 25.53% £2.17 10.48% £0.89 3.14% £0.27 3.49% £0.30 
£8.50 
£8.50 0.46% £0.04 
£8.50 26.60% £2.26 7.62% £0.65 2.52% £0.21 3.96% £0.34 
£8.50 17.02% £1.45 
£8.50 25.53% £2.17 12.38% £1.05 10.69% £0.91 4.92% £0.42 
£18.14 28.72% £5.21 0.46% £0.08 
£8.50 3.81% £0.32 1.50% £0.13 
£8.50 
£8.50 0.95% £0.08 1.50% £0.13 
£8.50 0.46% £0.04 
£8.50 8.51% £0.72 0.46% £0.04 
£8.50 
£21.88 3.14% £0.69 
£8.50 
£22.22 0.63% £0.14 
£17.24 14.89% £2.57 5.71% £0.99 3.14% £0.54 
£30.89 
£33.55 21.28% £7.14 3.14% £1.06 
£23.74 11.43% £2.71 2.52% £0.60 2.46% £0.58 
£8.50 1.90% £0.16 1.50% £0.13 
£8.50 17.02% £1.45 
£8.50 15.72% £1.34 8.41% £0.72 
£20.24 14.89% £3.01 3.14% £0.64 0.46% £0.09 
£17.00 3.19% £0.54 
£28.69 £6.86 £6.39 £3.03 
£28,691.49 £6,855.43 £6,385.09 £3,027.72 
Ramiuril ili = ~97l Lisinouril (N - 653l Enalauril (N = 699l 
Weighted% Cost Weighted% Cost Weighted% Cost 
0.29% £0.02 0.98% £0.08 0.30% £0.03 
0.04% £0.00 
0.53% £0.05 0.01% £0.00 
1.96% £0.17 1.20% £0.10 0.37% £0.03 
2.26% £0.19 1.69% £0.14 0.69% £0.06 
0.80% £0.14 0.02% £0.00 
0.05% £0.00 0.02% £0.00 
1.19% £0.10 0.06% £0.00 0.03% £0.00 
0.02% £0.00 
0.00% £0.00 
0.14% £0.03 
0.02% £0.00 
0.01% £0.00 
0.07% £0.01 0.14% £0.02 0.10% £0.02 
0.03% £0,0) 
0.47% £0.16 0.52% £0.18 0.11% £0.04 
0.02% £0.00 0.28% £0,07 
0.53% £0.05 0.14% £0.01 
0.14% £0,0) 
1.46% £0.12 0.69% £0.06 
0.41% £0.08 0.04% £0.01 
0.93% £0.16 0.03% £0.00 
£1.20 £0.63 £0.36 
£1,199.17 £625.58 £357.35 
Table 27 Total costs of the three drug therapies 
Original Final 
MinimumDDD Drug Costs Shadow Costs Total Costs Ranking_ Ranking_ 
NSAIDs 
Ibuprofen £5.58 £5,580.00 £5,133.63 £10,713.63 3 4 
Naproxen £7.85 £7,850.00 £2,144.27 £9,994.27 5 3 
Piroxicam £3.54 £3,540.00 £3,111.58 £6,651.58 1 2 
Sulindac £18.63 £18,630.00 £7,308.74 £25,938.74 6 7 
Fenoprofen (Fenopron ®) £19.85 £19,850.00 £23,353.56 £43,203.56 7 8 
Ketoprofen £22.45 £22,450.00 £3,164.71 £25,614.71 8 6 
Indomethacin £3.57 £3,570.00 £1,949.73 £5,519.73 2 1 
Diclofenac Sodium £5.85 £5,850.00 £8,438.23 £14,288.23 4 5 
SSRis 
Fluoxetine £18.01 £18,010.00 £6,026.56 £24,036.56 1 1 
Sertraline (Lustral®) £40.50 £40,500.00 £29,878.45 £70,378.45 3 4 
Fluvoxamine £38.71 £38,710.00 £12,500.68 £51,210.68 2 2 
Paroxetine (Seroxat ®) £41.44 £41,440.00 £21,875.31 £63,315.31 4 3 
ACE Inhibitors 
Captopril £5.75 £5,750.00 £3,027.72 £8,777.72 1 1 
Enalapril Maleate £9.40 £9,400.00 £357.35 £9,757.35 2 2 
Lisinopril (Zestril ®) £15.65 £15,650.00 £625.58 £16,275.58 4 4 
Moexipril (Perdix ®) £20.30 £20,300.00 £6,855.43 £27,155.43 5 6 
Perindopril (Coversyl ®) £24.06 £24,060.00 £28,691.49 £52,751.49 7 7 
Ramipril (Tritace ®) £13.25 £13,250.00 £1,199.17 £14,449.17 3 3 
...... Trandolapril ®) £20.45 £20,450.00 £6,385.09 £26,835.09 6 5 Vl 
0'1 
Table 28 National prescribing trends (Scotland) 
No of Items Prescribed 
2001 2002 Difference in Prescribing 
NSAIDs 
Ibuprofen 603 438 576 681 -4.43% 
Naproxen 174 258 156 350 -10.28% 
Piroxicam 37 578 37 809 0.61% 
Sulindac 3743 3216 -14.08% 
Fenoprofen 1048 860 -17.94% 
Ketoprofen 18 593 9274 -50.12% 
Indomethacin 58 550 51 389 -12.23% 
Diclofenac 639 938 626 941 -2.03% 
SSRis 
Fluoxetine 463 076 500 390 8.06% 
Sertraline 195 388 210 468 7.72% 
Fluvoxamine 4073 3596 -11.71% 
Paroxetine 456 232 468 847 2.77% 
ACE Inhibitors 
Captopril 105 781 89 992 -15.78% 
Enalapril 387 311 388 295 0.25% 
Lisinopril 543 257 599 070 10.27% 
Moexipril 131 73 -44.27% 
Perindopril 113 748 135 479 19.12% 
Ramipril 219 472 369630 68.42% 
Trandolaeril 18 025 17 381 -3.57% 
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Table 29 Study prescribing trends over six months 
Study Group Prescribing Control Group Prescribing 
(n=5 GPs) (n=33 GPs) P values 
NSAIDs 
Ibuprofen -2.48% -3.96% 0.55 
Naproxen -3.51% -9.59% 0.08 
Piroxicam -2.90% -2.97% 0.98 
Sulindac -31.58% -27.78% 0.56 
Fenoprofen Not Prescribed Not Prescribed N/A 
Ketoprofen -17.23% -29.01% *0.05 
Indomethacin -2.63% -8.51% 0.07 
Diclofenac 1.02% -5.27% 0.08 
SSRis 
Fluoxetine 9.78% 9.62% 0.97 
Sertraline 10.85% 13.61% 0.96 
Fluvoxamine -20.31% -28.92% 0.92 
Paroxetine 5.48% 7.34% 0.59 
ACE Inhibitors 
Captopril -18.17% -29.4% 0.06 
Enalapril 4.65% 0.44% 0.06 
Lisinopril 8.58% 10.47% 0.65 
Moexipril Not Prescribed Not Prescribed N/A 
Perindopril 10.45% 17.00% 0.12% 
Ramipril 5.3% 2.25% 0.26 
Trandolapril -8.79% -0.12% *0.00 
*statistical significance 
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Table 30 Survey response rates (number returned/number sent) 
Email 
Postal 
Total 
Questionnaire(!) 
6/13 (46%) 
9/17 (53%) 
15/30 (50%) 
Questionnaire (II) 
4/15 (27%) 
8/16 (50%) 
12/31 (39%) 
Total 
10/28 (36%) 
17/33 (51%) 
Table 31 Economic information influencing decision-making 
Published Information 
Local Health Board/PCG/PP As/MP As 
Articles in Journals 
Industry Literature 
Others 
Verbally Presented Information 
Meetings with Representatives from Local Health Board/PCG/PP As/MP As 
Conferences and Seminars 
Pharmaceutical Industry Representatives 
Others 
Missing Data n=O 
'Yes' N (%) 
12 (80%) 
3 (20%) 
5 (33%) 
2 (13%) 
6 (40%) 
2 (13%) 
5 (33%) 
2 (13%) 
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Table 32 Sources of economic information used (numbers found the material 
relevant) 
Yes No (Sometimes) Don't Know Missing 
SPA Prescribing Feedback 10 (8) 2 (0) (2) 
Industry Literature 9 (2) 2 (2) (4) 
MP As and PPAs 7 (5) 3 (0) (2) 
British Medical Journal 6 (4) 5 (0) (2) 
Industry Representatives 6 (1) 5 (2) (2) 
GP ASS Feedback 4 (2) 8 (0) (2) 
Local Newsletter * 3 (3) 8 (1) (1) 
Other Journals ** 3 (2) 3 (0) (2) 
British Journal of General Practice 2 (1) 8 (0) (2) 
Local Prescribing Formulary 2 (1) 8 (0) (1) 
*Newsletters generated from the Local Healthcare Co-operatives, Glasgow Prescriber 
**Prescriber, Journal of Health Economics, Bandolier, Durgs & Therapeutics Bulletin 
Table 33 Preferred methods of presenting economic data 
Locally specific evaluations and studies 
Summary of evaluations and studies published in leaflet format 
Evaluations and studies published in literature 
Simple recommendations presented in leaflet format 
Summary of evaluations and studies presented verbally at a meeting 
Simple recommendations presented verbally at a meeting 
Missing Data n=l 
0 (0) 
1 (2) 
2 (1) 
0 (0) 
1 (2) 
0 (1) 
0 (1) 
0 (0) 
0 (0) 
1 (2) 
N(%) 
6 (54%) 
6 (54%) 
5 (45%) 
5 (45%) 
3 (27%) 
1 ( 9%) 
0 (2) 
0 (2) 
0 (4) 
1 (6) 
0 (5) 
0 (7) 
1 (6) 
6 (8) 
2 (9) 
1 (8) 
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Figure 1 The annual percentage increase in expenditure for NHS as a whole and community prescribing, compared with hospital and community 
health services pay and price inflation 
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Data on NHS expenditure and community prescribing were obtainedfi'om Information Statistics Division for Scotland. Inflation data were obtained from the Scottish Executive through 
personal communications. 
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Figure 2 The increase of prescribing volume and cost over time (1994 to 2000) 
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Figure 3 Study population from the Medicines Monitoring Unit (MEMO) database 
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Figure 4 The population study - study cohot1 (not drawn to scale) 
Tayside population 
N = 400 000 
Comparator Group 
N = 47350 
NSAID Only Group 
N = 49212 
NSAID & Ulcer 
Healing Drugs 
N = 2113 
Study population 
N = 98 887 
• All living individuals residing in the Tayside health board area during the period: 1 January 89 to 31 December 93. 
• Registered with a GP. 
• Individuals less than 50 years old on 1 Jan 89 were excluded . 
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Figure 5 Cost composition of the population study 
inception drugs 
dayO 
all GI endoscopies 
all hospital admissions (GI, CV, RA or OA related) 
I co~ts I 45 days Rx 1 I co~~ I 6 months Rx2 Rx1 
1 
I GP consultations I 
Rx 1 =first prescription Rx 2 =last prescription 
Rx counts =total number of additional prescriptions recorded 
switch represents a change in prescriptions 
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Figure 6a The contribution of drug prescriptions and GP consultation costs (example for 45 days and for six months) 
dayO 45 days 
Rxl EJ Rx2 Rx3 GP~v 
GP3 
0 
GP4 
Rx 1 = First prescription recorded at inception 
Rx 2 = Last prescription recorded during the 45-day period 
Rx 3 = First prescription recorded at the onset of the 45 days to 6 months period 
Rx 4 = Last prescription recorded at the 45 days to 6 months period 
COSTS OF DRUG PRESCRIPTIONS 
Cost of all prescriptions at 45 days: 
Rx 1 + Rx 2 + 112(Rx 1 + Rx 2) x N1 
Cost of all prescriptions at 6 months: 
Rx 1 + Rx 2 + 1/2(Rx 1 + Rx 2) x N1 + Rx 3 + Rx 4 + 1/2(Rx 3 + Rx 4) x N2 
COSTS OF GP CONSULTATIONS 
Based on the assumption that prescription switches have taken place: 
At 45 days, total cost of GP consultations = £7.56 x 2 
At 6 months, total cost of GP consultations = £7.56 x 4 
6 months 
Rx4 
N1 =number of additional prescriptions recorded from 0 to 45 days 
N2 = number of additional prescriptions recorded from 45 days to 6 months 
GP 1-4 =visits to GPs (for change in prescriptions) 
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Figure 6b The contribution of endoscopy and hospital admission costs and costs to total cost (example for 45 days and for six months) 
dayO 
El 
LOSt 
N (admit) 1 
45 days 
N (admit) 2 
E1 =number of endoscopies recorded at 45 days 
E2 
LOS2 
E2 = number of endoscopies recorded at 45 days to six months 
LOS 1 = length of stay of the longest admission at 45 days 
LOS 2 = length of stay of the longest admission from 45 days to six months 
COSTS OF GASTROINTESTINAL ENDOSCOPIES 
Cost of all endoscopies at 45 days: £208.33 x E1 
Cost of all endoscopies at six months: £208.33 x (E1 + E2) 
COSTS OF HOSPITAL ADMISSIONS 
Cost of hospital admissions at 45 days: 
6months 
N (admit) 1 =number of other admissions at 45 days 
N (admit) 2 =number of other admissions from 45 days to six months 
(LOS 1 x specialty cost+ 2 x GP visits+ 1 x outpatient visit)+ [1: length of stay of additional admissions x specialty cost+ 2 x N (admit) 1 x GP visits+ N (admit) 1 x outpatient visits] 
Cost of hospital admissions at six months: 
(LOS 1 x specialty cost+ 2 x GP visits+ 1 x outpatient visit)+ [1: length of stay of additional admissions x specialty cost+ 2 x N (admit) 1 x GP visits+ N (admit) 1 x outpatient visits] 
+ 
(LOS 2 x specialty cost+ 2 x GP visits+ 1 x outpatient visit)+ [1: length of stay of additional admissions x specialty cost+ 2 x N (admit) 2 x GP visits+ N (admit) 2 x outpatient visits] 
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Figure 7 Trend of gastrointestinal endoscopies recorded by the three study periods 
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Figure 8 Composition of total costs for the 45-day follow-up period 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID & H2/0meprazole 
£0 £20 £40 £60 £80 £100 
Total Cost per Patient 
ll OA admissions • RA admissions 0 CV admissions 0 Gl admissions • Endoscpies 
• Other Rx 0 H2/Losec Rx • NSAID Rx 0 Drug Rx 
£120 £140 £160 
0 GP Visits (Rx) 
Figure 9 Composition of total costs for the six-month follow-up period 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID & H2/0meprazole 
£0 £50 £100 £150 £200 £250 £300 £350 £400 £450 £500 
Total Cost per Patient 
OA admissions • RA admissions D CV admissions D Gl admissions • Endoscpies 0 GP Visits (Rx) 
• Other Rx 0 H2/Losec Rx • NSAID Rx D Drug Rx 
-
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Figure 10 Composition of total costs for the 12-month follow-up period 
Comparator 
NSAID Only 
NSAID & Misoprostol 
NSAID & H2/0meprazole 
£0.00 £100.00 £200.00 £300.00 £400.00 £500.00 £600.00 £700.00 £800.00 £900.00 £1,000.00 
Total Cost per Patient 
Ill OA admissions • RA admissions D CV admissions D Gl admissions • Endoscpies D GP Visits (Rx) 
• Other Rx D H2/Losec Rx • NSAID Rx • Drug Rx 
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Total costs composition showing increase in total costs over all study periods 
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Figure 15 Studies selected for meta-analysis 
Potentially relevant randomised 
controlled trials identified and 
screened for retrieval, excluding 
hand searches. 
• NSAIDs (n = 3132) 
• SSRis (n = 1660) 
• ACE inhibitors (n = 4508) 
Trials excluded: reviews, pilot 
studies, co-morbidities, drugs 
indicated for other reasons or 
generally did not fulfil inclusion 
criteria. 1----------1~~ • NSAIDs (n = 2861) • SSRis (n = 1270) 
Trials retrieved for more detailed • ACE inhibitors (n = 4273) 
evaluation 
• NSAIDs (n 271) 
• SSRis (n = 390) Trials excluded: either not 
• ACE inhibitors (n = 235) randomised clearly or did not fulfil 
inclusion criteria 
.. • NSAIDs (n = 66) 
r 
1lr 
• SSRis (n = 65) 
Potentially appropriate trials to be 
• ACE inhibitors (n = 115) 
included in meta-analysis 
• NSAIDs (n = 205) 
• SSRis (n = 325) 
• ACE inhibitors (n = 120) Trials not included in meta-
analysis: clinical heterogeneity, 
insufficient reporting of primary 
.. data r 
'lr 
Trials included in meta-analysis 
• NSAIDs (n = 181) 
• SSRis (n = 304) 
• NSAIDs (n = 24) 
• ACE inhibitors (n = 96) 
• SSRis (n = 21) 
• ACE inhibitors (n = 24) 
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Figure 16a The Management of Adverse Events 
DYSPEPSIA 
2 x GP visits 
SUSPECTED PEPTIC 
ULCERS 
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5o/c 0 
stop drug 
45% 
switch drug 
50% 
remain 
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stop drug 
50% 
switch drug 
40% 
remain 
5% 
stop drug 
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switch drug 
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remain 
A 
20% 
UHDs ) 
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2 x GP visits, OP 
75% A 
no further treatment 
A 
A 
75% A 
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2 x GP visits, OP, bloods 
15% A 
no further treatment 
A 
A 
20% 
UHDs 
5% 
2 x GP visits, OP, bloods 
75% A 
no further treatment 
UHDs - ulcer healing drugs; OP- outpatient visits, FOB - fecal occult blood 
4% 
endoscopy 
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no further treatment 
4% A 
endoscopy 
96% A 
no further treatment 
4% A 
endoscopy, FOB 
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no further treatment 
4% A 
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no further treatment 
177 
Figure 16b The Management of Adverse Events 
50% 
stop drug 
NAUSEA/VOMITING 50% A 
UHDs 
2 x GP visits 
50% 15% A 
remain endoscopy 
25% 
no further treatment 
50% A 
stop drug 
CONSTIPATION 
50% A 
UHDs 
2 x GP visits 
50% 4% A 
remain FOB, 2 x GP visits 
46% A 
no further treatment 
50% A 
stop drug 
DIARRHOEA 
40% 
_A 
switch drug 
2 x GP visits 
2% A 
2xOP 
10% 
remain 
75% A 
no further treatment 
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UHDs - ulcer healing drugs; OP- outpatient visits, FOB -fecal occult blood 
Figure 16c The Management of Adverse Events 
DEFINITE PEPTIC 
ULCERS 
2 x GP visits, OP, 
Endoscopy, FBC, UHDs 
RASH 
ORPRURITIS 
2 x GP visits 
INSOMNIA 
2 x GP visits 
OTHERCNS 
EVENTS 
1 x GP visit 
17% 
sigmoidoscopy, OP 
83% 
no further treatment 
50% 
antihistamine 
50% 
stop drug 
50% 
no co-prescription 
50% 
antihistamine 
50% ) 
remain 
50% 
no co-prescription 
50% 
change drug 
50% 
remain, Zopiclone 
95% 
change drug 
5% 
no further treatment 
UHDs - ulcer healing drugs; OP- outpatient visits, FOB - fecal occult blood 
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OP ~ 
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Figure 16d The Management of Adverse Events 
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endoscopy 
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change drug UHDs 
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ANAEMIA no further treatment 
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UHDs, OP, FOB, bloods T 
95% 1\ 
75% 
') no further treatment 
remain 
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Sensitivity Analysis- ACE Inhibitor Study 
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Cost Containment Strategies 
The need to control escalating NHS prescribing expenditure has long been recognised 
(Figure 20). Early evidence dated back to 1911, when prescribing policies included a 
national formulary, a list of prescribable products, the use of regional medical officers to 
visit high cost prescribers, and an incentive scheme designed to encourage GPs to control 
their prescribing costs. The latter scheme was called the "floating sixpence" which offered 
a financial reward to GPs who spent less than the allocated budget per patient. This scheme 
was abolished in 1920 because it was felt that patients were not getting the drugs they 
needed 222• 
Prescription charges were first imposed by the government in 1951 when they used the 
legislation to bring in a one-shilling (five pence) charge per prescription. The charges have 
remained (except between 1965 and 1968) and risen progressively since 1979, from £0.45 
to the present value of £6.20 per item. However, approximately five out of six prescriptions 
are exempt from charges under the exemption scheme. Of all the items prescribed, almost 
half were issued to those over 60 years old (one of the categories eligible for exemption). 
Between the years 1969 and 1992, there was a 3.2% fall in paid-for prescriptions following 
a 10% increase in the charge. The 1992 increase in the charge from £3.75 to £4.25 brought 
in £17.3 million of extra revenue and cut the 55 million prescriptions not exempt from 
charge by 2.3 million. Although, the increases in prescription charge seemed to have an 
impact on the consumption of prescribed drugs, there is concern about the adverse effect on 
compliance for some patients requiring chronic treatment. If those deterred from using 
prescription drugs ended up being treated for more serious conditions, the cost of that 
treatment could erode the savings 223 • Other strategies on unit cost reduction such as retail 
networks and manufacturer contracting were introduced in the 1970s. However, these 
schemes were designed solely to reduce drug acquisition costs. 
Over the years the government introduced several initiatives to improve prescribing. At a 
national level, strategies included educational publications, improving prescribing data and 
prescribing advice to GPs. Locally, Health Boards began to introduce measures to control 
the growth of local drug costs, in an attempt to promote rational prescribing. Prescribing 
advisers were employed to do this, this is discussed later. 
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Drug Formularies 
Drug formularies introduced in the 1980s formed the cornerstone of strategies aimed at 
influencing the range of pharmaceutical preparations available for prescription. They were 
originally designed to control the introduction of new therapies in hospitals. Subsequently, 
this concept has been developed in primary care by using practice-based formularies to 
promote rational and quality prescribing, and to limit costs. These vary from a simple list 
of pharmaceuticals with no prescribing information to a comprehensive prescribing guide 
which is usually agreed through the local Drugs and Therapeutics Committees. In 1985, the 
government introduced the 'selected list', which barred GPs from prescribing certain drugs 
in their proprietary state. However, this measure has had little impact on cost and, in some 
instances was counter-productive as relatively cheap proprietary products were replaced 
with more expensive alternatives 5• However, a recent review 224 concluded that acquisition 
cost was the prime influencer of formulary decisions, rather than overall benefits and costs 
in healthcare. By 1990 the Department of Health recommended development and 
ownership, and voluntary implementation of local practice formularies. 
Although it has been possible to demonstrate that formularies have an impact on prescribing 
habits, it is very difficult to extrapolate this into real savings because of the number of 
influencing variables, particularly the increase in numbers of patients treated. There is little 
evidence to show whether formularies reduced cost, improved care or both. A recent search 
to locate systematic reviews, reviews, or randomised trials looking at the effect of formulary 
restriction on benefits and costs, was rather fruitless 225 • One open-label, randomised trial 
of two formulary systems was found 226• Prescribers were randomised into either a 
restricted thyroxine dose (five doses) formulary or an unrestricted one where more dose 
strengths (ten doses) were available. Treatment efficacy was assessed by thyroid function 
tests, prescriptions were analysed and their cost calculated. The study concluded that 
simplifying the doses of thyroxine available to prescribers did not adversely affect patients 
or increase costs. In another study, Avery AJ et al demonstrated the effect of a formulary to 
produce positive changes in prescribing towards greater compliance over time 227• Ten 
practices in Lincolnshire developed a formulary for NSAIDs, to help GPs to prescribe from 
a narrower range of drugs. Prescribing analyses and cost (PACT) data from intervention 
practices and matched controls were analysed to determine whether changes had occurred. 
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The results showed significant differences in the reduction of mean number of different 
drugs used (focused on three main NSAIDs) and an increase in prescribing NSAIDs in their 
defined daily doses. 
In 1996, Hill-Smith conducted a controlled trial comparing prescribing by 50 GPs (from 11 
practices) who participated in creating a district drug formulary, with other GPs in south 
Bedfordshire 228• The proportion of prescription items listed in the formulary rose 
significantly in three therapeutic groups: cardiovascular (by 7-12% above control), 
musculoskeletal (by 1-11%) and obstetrics and gynaecology (by 6-9% ). The number of 
items prescribed per prescribing unit fell significantly in three therapeutic groups: 
musculoskeletal (by 1-7% below control), nervous (by 7-12%) and nutrition and blood (by 
15-21% ). It was suggested that estimated savings of up to £150 000 (£3 000 per doctor per 
year) were achieved, but this was not based on any formal calculations or economic 
analysis. One American study did provide empirical evidence about the influence of 
hospital formulary restrictions 229 • They found that across-the-board restrictions did not 
result in cost savings, although savings may be realised for particular drug categories. The 
observations from these studies could neither prove nor disprove the effect of formularies 
on overall benefit and cost savings to the NHS. 
The concept of outcomes or disease management, which originated in North America in the 
late 1990s, brought in the introduction of disease management guidelines and shared 
protocols between primary and secondary healthcare sectors. Unlike formularies, clinical 
guidelines contain guidance on how drugs should be used. Prescribers were given clinical 
scenarios and then taken through the treatment of the clinical situation step by step -
diagnosis, treatment, monitoring and discharge policy. The focus is the disease and its 
optimum cost effective management, rather than on the drug acquisition costs alone. It was 
believed that such programs would ensure higher and more consistent standards of care, and 
that treatment and support were received in the most appropriate setting. 
In Scotland, the Scottish Intercollegiate Guidelines Network (SIGN) was formed in 1993, to 
improve the quality of healthcare by reducing variation in practice and outcome by 
developing and disseminating national clinical guidelines based on current evidence. 
Improvements in the quality of care resulted by complying to SIGN guidelines have been 
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apparent 230, but there is still no evidence, to date, about their impact on costs. In recent 
years, guidelines produced by SIGN are beginning to introduce evidence on resource 
utilisation and cost effectiveness. 
Deregulation of Pharmaceuticals 
In the early 1980s, deregulation of pharmaceuticals was introduced in the hope of helping to 
strengthen the role of community pharmacists and to create savings in the NHS prescribing 
budget. The first radical deregulation occurred in 1983, when the legal classification of 
loperamide was changed from prescriptions-only-medicine (POM) to pharmacy medicine 
(P). This was followed by a wide range of drugs that were previously POMs, subsequently 
deregulated to be available for sale from community pharmacists. In 1994, cimetidine 
became the first H2 blocker to become available over-the-counter (OTC). By the beginning 
of 1997, the UK and Germany each had 67 switched products, which was the highest in 
Europe. This number continued to increase over the following years. 
Newly deregulated pharmaceuticals are widely purchased. However, it is unclear whether 
this increase in commercial sales translates into NHS savings. A clear reduction in 
prescriptions for aciclovir was observed since its deregulation. In addition, early economic 
analyses were able to demonstrate significant savings to the NHS through the deregulation 
of loperamide and hydrocortisone 231 • These reductions in prescriptions and costs were not 
apparent in all deregulated drugs, as demonstrated by the case with H2 blockers. Since 
deregulation, the number of prescriptions for H2 blockers and proton pump inhibitors 
continued to rise. This may be in part due to patients who previously self-medicated 
themselves for chronic dyspepsia with antacids, found H2 blockers to be effective but 
expensive, and subsequently seeking long-term supply through prescriptions. 
Prescribing Advisers 
In addition to organisational reforms, it was apparent that prescribing support at a local 
level is extremely important. At a local level, Health Boards were becoming increasingly 
188 
active in providing prescribing support, promoting high quality and cost-effective drug use, 
and in improving pharmaceutical care of patients. Practices, especially fundholders, have 
sought extra prescribing advice or pharmaceutical expertise and have employed staff from a 
variety of pharmaceutical backgrounds to assist. Initially Medical Prescribing Advisers 
(MP As) were introduced, and later Pharmaceutical Prescribing Advisers (PP As) were 
created to supplement the role of MP As. 
Subsequent to the 1990 White Paper 'Improving Prescribing', Prescribing Advisers were 
employed by local Health Boards in attempt to control prescribing costs in primary care. 
Their role included provision and interpretation of information on prescribing matters 
mainly to GPs, Health Boards, regional office and secondary care. Their methods of 
managing GP prescribing involved working with hospitals to ensure appropriate shared care 
and provide primary care oriented input into local Drugs and Therapeutics committees. 
They also introduced programmes to reduce patients' demand for prescriptions, and 
promoted cost-effective prescribing among GPs via education, feedback and possible 
manipulation of financial incentives. In addition, the Scottish Association of Medical 
Prescribing Advisers (SAMP A) - their professional group, met regularly to share ideas and 
offer mutual support and training. The group also meets Scottish Office personnel two to 
three times a year to discuss national prescribing issues. 
Prescribing advisers have been visiting GPs to offer prescribing support since the early 
1990s. During their visits, they presented GPs with prescribing data including feedback on 
practices' prescribing and making comparisons with their peers, offering suggestions for 
rationalisation. Prescribing Bulletins, containing therapeutic articles written from a local 
perspective, were disseminated on a regular basis. Later, they became increasingly 
involved in production and implementation of formularies and guidelines. Prescribing 
advisers have been successful in promoting good quality evidence based, cost-effective 
prescribing, while reducing the expenditure on drugs in general practice without depriving 
patients of essential medications. In Glasgow alone, the result was the transformation of a 
budget £3.4m overspend in 1992 to £1.3m below budget in 1998. GPs also recognise them 
as a useful source of independent information and advice about prescribing matters 232• 
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Many factors hampered prescribing advisers in their attempts to alter local prescribing 
patterns and behaviour. For instance, prescribing advisers work to counter generously 
financed and well organised marketing from pharmaceutical industry. However, the 
number of pharmaceutical company representatives still outnumber prescribing advisers 
(8000 vs. 200 in 1997), with a promotional expenditure of £250 million a year, while the 
Department of Health now spent £4 million a year on advising GPs on prescribing 233 . 
Industry representatives are extremely well trained in communication and presentation 
skills, but lack credibility among GPs. Although prescribing advisers have high credibility 
with GPs, they do not have the benefit of the extensive training in interviewing, influencing, 
and the persuasion skills that industry representatives receive. While fulfilling their other 
duties, the lack of time to make repeat visits to the same practice regularly reduces their 
effectiveness. Other factors include local hospitals' prescribing policies and patient 
demands, which significantly affect attempts made by advisers to change local prescribing 
behaviour. 
The majority of prescribing advisers now sit within Public Health Directorates and the 
remainder within Primary Care Directorates. Recent reforms in primary care, the 
introduction of PCTs, together with central and local policy directives (such as National 
Service Frameworks and Clinical Governance) have provided prescribing advisers with the 
opportunity to grow their activities beyond their more traditional boundaries. The focus of 
the work of prescribing advisers is changing. They are likely to become more involved in 
providing strategic direction, devising local policies and acting as PCT prescribing co-
ordinators. 
Until recently, medical and pharmaceutical advisers provided the mainstay of formal 
prescribing advice and support to GPs at a local level. However, there is still a need for 
greater local support of the prescribing process beyond that able to be provided by Health 
Boards. Therefore, many locally led initiatives have begun to look at additional models of 
providing prescribing support. These initiatives have considered the role of various 
healthcare professionals in the prescribing process. 
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Drugs and Therapeutics Committees (DTCs) 
In 1994, all Health Boards were instructed to establish joint prescribing committees- Area 
Drugs and Therapeutics Committees, Purchasing Prescribing Committees or Therapeutics 
Committees - for the development of local prescribing strategies. Prescribing advisers and 
other healthcare professionals worked together in attempts to resolve issues surrounding the 
responsibilities for prescribing high cost therapies and the need to plan for therapeutic 
development. They work closely with local Drugs and Therapeutics Committees, especially 
in the management of entry of new drugs, and to improve prescribing across the primary-
secondary care interface. 
Local Research Ethics Committees were instructed to standardise procedures used to review 
research applications, including local evaluations of new pharmaceutical products. At the 
Health Board level, introduction of new interventions would require review by Drugs and 
Therapeutics Committees. Evidence for efficacy and safety would be reviewed, often 
without taking into account cost effectiveness and the financial implications of the decision 
for the trust or the Health Board as a whole. However, even if a request was refused, 
consultants may ask GPs to prescribe the therapy, thereby circumventing the Drugs and 
Therapeutics Committees and shifting the cost to primary care. 
Indicative Prescribing Scheme (IPS) and GP Fundholding 
Prescribing in primary care had been viewed as too unpredictable to impose a cash limit 
system, and until the NHS reforms in 1991 no attempt had been made to impose a ceiling 
on the total primary care drugs bill. A range of measures has been adopted to encourage 
prescribers to take costs as well as effectiveness of drugs into account. These have ranged 
from exhortation of GPs not to waste resources, through provision of prescribing 
information (the PACT scheme) and the setting of indicative prescribing targets, to 
provision of financial incentives to achieve savings within GP fundholding. 
Indicative Prescribing Scheme (IPS) and GP fundholding made more subtle alterations to 
prescribing habits. The emphasis of IPS was on improving prescribing through enhanced 
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information, education and reasoned persuasion. General practitioners were given more 
discretion but a financial rigour, which was perceived to be absent previously. The scheme, 
in particular amongst fundholders, led to some cost containment of expenditure without any 
apparent disadvantage to patients. However, these effects seemed to be less for later waves 
and early gains made were not sustained over time. 
The Fundholding Scheme stemmed from a blueprint for the 'internal market' drawn up by 
Alain Enthoven, a health management specialist at Stanford University. In theory, under 
this scheme, health authorities would be able to buy and sell services from each other and 
the private sector instead of providing the full range of services themselves. In 1984, as 
part of the government's review, two health economists - Alan Maynard and Nick 
Bosanquet - suggested that GPs should be given control of their own budgets to buy 
hospital services. They believed that this would help in directing funds towards hospitals 
and specialists who did most to meet patients' needs, as interpreted by their GPs. However, 
at the time, the idea was dismissed on the grounds that GPs lacked the skills to administer 
such budgets. 
Following the publication of the White Paper "Working for Patients" in 1991, GP 
prescribing budgets were established as one of a number of measures to exert pressure on 
expenditure on drugs within the NHS - indicative prescribing or cash-limited budgets for 
fundholders. On 1 April 1991, as part of the NHS reform, GP fundholding was introduced. 
Each year, the Treasury approves the cash resources for the primary care bill in Scotland 
based on the estimated expenditure submitted by the Scottish Office. The money was held 
centrally by the Management Executive and a notional sum -representing the expected cost 
of prescribed drugs and appliances - is allocated to each Health Board. In tum, this is 
divided amongst practices as Target Budgets (initially termed Indicative Prescribing 
Amounts) set by each Health Board's prescribing advisers. Larger practices could choose 
to have an overall practice budget with which to buy treatment for their patients -
'fundholding practices'. However, a GP could still overspend his target budget in order to 
prescribe necessary interventions. 
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The original Target Budgets were based on previous patterns of prescribing expenditure. 
However, as prescribing advisers became more familiar with their practices, weighted 
capitation - based on the age/sex profile of practice lists, morbidity in the locality, and the 
degree of socio-economic deprivation - was introduced to set budgets which closely 
reflected the predicted health needs of the patients. Similarly, the Management Executive 
introduced a simple needs based element into their prescribing budget setting methodology 
for Health Boards. A working group, the Prescribing Allocation Review Group, has been 
commissioned by the Scottish Office to examine the current pattern of prescribing costs at 
Health Board level with a view to recommending a budget setting methodology which 
would more closely reflect the varying needs of the population in different Health Board 
areas. These figures were intended as benchmarks. Practices and Health Boards were 
expected to contain prescribing costs within their allocated amounts unless they had to 
exceed their amount for justifiable clinical need. The prescribing budget became part of the 
allocated sum for fundholding and the fundholder was expected to live within the 
prescribing budget. 
In addition, each GP and Health Board received a monthly budget schedule prepared by the 
Pharmacy Practice Division (PPD) to enable the performance against Target Budgets to be 
monitored. Similarly, each GP in England and Wales received a monthly expenditure 
statement, a monthly 'Merec Bulletin' (provides information on an area of therapeutics) and 
a three-monthly PACT standard report (summary of prescribing data for the practice over 
the past quarter). 
This had been the strongest move yet, to shift emphasis from secondary to primary care. 
Under the voluntary fundholding scheme, GPs were given responsibilities to buy non-
urgent treatments for their patients and placed budgetary responsibility firmly on GPs. Any 
savings achieved by a practice within its total budget could be reinvested at the practice's 
discretion. As purchasers, however, GPs increasingly recognise that they are responsible 
for the whole care of the patient and the optimal use of the drug budget. This has made 
some fundholders re-evaluate their role in accepting recommendations of hospital 
consultants. They began to question the appropriateness of some proposed treatment 
options when the health gain may be small. 
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Over the years, increasing numbers of practices joined the scheme, and by 1997/98,60% of 
the population was covered by fundholding GPs. 
Early studies showed positive effects of fundholding on prescribing costs. Baines et al 233 
found a clear consensus that fundholding practices achieved one-off reductions in their 
prescribing costs relative to non-fundholders, releasing savings for use elsewhere. 
Brandlow & Coulter (1993) 234 compared prescribing and cost information (prescribing 
costs, number of items prescribed, the proportion of generics) of 15 practices (fundholding 
vs non-fundholding, dispensing vs non-dispensing, use of formularies and protocols) over 
two six-month periods. They showed that fundholders seemed to curb increasing 
prescribing costs. Similar results were seen in a study by Wilson et al (1995) who analysed 
growth in prescribing costs as measured by the percentage increase in annual net ingredient 
cost per prescribing unit of virtually all practices (412 in total) in the former Mersey Region 
between April 1990 to March 1994. Their results suggested that in comparison growth in 
prescribing costs of fundholders tended to be substantially lower in the early period, but had 
subsequently returning to a growth rate similar to that of non-fundholders 235 • Thus the GP 
fundholding scheme appeared to have controlled costs in the short-term only. 
Later studies in England and Wales have concluded that fundholding did not contribute to 
any great extent to the observed variation in prescribing behaviour between practices but 
that fundholders have contained their prescribing costs more effectively than non-
fundholders 235•236 • This may be because GPs who become fundholders have different 
attributes to those who do not. It was suggested that financial incentives can bring about 
changes and motivate GPs in both fundholding and non-fundholding, but there is doubt 
about how long the effects persist. Initial savings can be from increased generics use and 
other strategies that are relatively easy to implement, but sustained improvement requires a 
more fundamental change in attitudes and a commitment to cost-effective prescribing. 
The Indicative Prescribing Scheme (IPS) stressed cost containment, and made little 
allowance for the consideration of the quality of appropriateness of prescribing. Overall, 
the IPS has generally failed to control the increasing drug expenditure due to unrealistic 
targets and the absence of an incentive or penalty to encourage compliance. Fundholding 
has been shown to reduce the rates of rising drug costs in participating practices. However, 
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the overall evidence of their success in restraining the rise in prescribing costs was 
inconclusive. Often many studies targeted selected practices and only looked at short-term 
outcomes. Prescribing budgets for fundholders and indicative prescribing amounts for non-
fundholding practices, especially in the early years, were often set arbitrarily. In some cases 
disproportionately large budgets were given to fundholders, which inevitably meant that 
they could more easily under-spend than others. Fundholding was eventually abolished in 
March 1999. However, GPs retained their role in buying treatment through 'locality 
purchasing', whereby groups of practices in an area make decisions about purchasing. 
Primary Care Trusts (PCTs) and Local Healthcare Co-operatives (LHCCs) 
In April 1999, cash-limited unified budgets were introduced and called Joint Investment 
Funds. These were expected to tackle costs at the primary-secondary care interface, by 
transferring resources to match changes in clinical practice. Under this new scheme, 
overspending in prescribing would be managed within the overall primary care budget, 
resulting in a reduction in resources available for hospital and community services. 
Conversely, more rational and effective prescribing of high cost drugs should allow 
resources to be "freed up" and redirected to areas of unmet clinical needs, or to areas seen 
as national or local priorities. 
Primary Care Trusts were introduced to offer new ways for GPs in the same area, regardless 
of whether previously fundholding or not, to work with each other and other health 
professionals to plan the way in which care should be provided. These trusts receive a 
budget to manage purchasing of hospital services, prescriptions and employ staff. The total 
number of trusts was reduced and most Health Boards now have one primary care trust and 
one acute trust. The responsibility for primary care was moved from being a Health Board 
function to become a PCT function, which include services for primary care and all other 
community-based healthcare. PCTs will typically include community hospitals and mental 
health services, as well as networks of local healthcare co-operatives (LHCCs). Local 
healthcare co-operatives are voluntary groupings of GPs and primary care professionals, 
accountable to PCTs, and members are accountable for their use of resources and quality of 
care. 
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Currently, there are 79 LHCCs across Scotland, covering 952 practices in all mainland 
areas, except West Lothian 237 • The size of the LHCCs vary widely, patient populations 
range from 4 000 to 172 000 patients, the number of practices covered by each LHCC 
ranges from two to 31, and the number of GPs ranges from eight to 115. 
Local healthcare co-operatives are positioned to have major impact on improving the 
quality and cost-effectiveness of prescribing, and significant work is being done. Eighty-
eight percent of the LHCCs in the survey have dedicated pharmacist input, varying from 
one session per week in 25% of the LHCCs to 30 sessions per week in one LHCC. 
Seventy-five percent (n=44) of LHCCs are involved in specific prescribing projects, while 
32% (n=19) use a formulary. The average prescribing budget, based on data from 26 
LHCCs, is 38% (ranging from 23% to 68%) of the total devolved budget. 
Primary Care Trusts (PCTs) and LHCCs were designed to encourage the development of 
joint working between GPs and pharmacists on prescribing, medicines management and 
direct patient care services. Often each locality has a small team of GPs with a full-time 
general manager, a core management team and a multi-disciplinary board, such as a 
pharmacist for prescribing advice, which determines policy and direction. 
Summary 
The continuing rise in the prescribing expenditure is an ongoing challenge for the NHS. 
Over the years, a confusion of policies including cost containment and reallocation of 
budgets have been introduced. Various approaches to cost containment have been 
introduced and adopted throughout the years, ranging from the "stick" approach (e.g. 
restricted list) to the "carrot" approach (e.g. incentives with a prescribing message on them). 
However, there is often a lack of rigorous evidence because interventions were 
implemented as part of a strategic decision rather than on a formally evaluated basis. In 
addition, most of these methods appear only to have short-term benefits. Cost containment 
strategies could only generate a finite amount of savings, which would reach a plateau in 
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the long term. In order to achieve cost effectiveness in healthcare, a wider perspective 
needs to be adopted. 
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APPENDIX II 
LITERATURE SEARCH STRATEGIES 
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LITERTURE REVIEW- THE IMPACT OF ECONOMIC INFORMATION OF 
PRIMARY CARE DECISION MAKING 
The following search strategy was used to search Medline, EMBASE and Cinahl for 
relevant studies. 
1. Economic$ in ti ab 
2. Cost$ in ti ab 
3. (Primary adj3 care) inti ab 
4. (General adj3 practice$) inti ab 
5. (General adj3 practitioner$) inti ab 
6. Impact$ in ti ab 
7. Influen$ inti ab 
8. Chang$ in ti ab 
9. Attitude$ inti ab 
10. Deci$ inti ab 
11. Or/1-10 
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LITERTURE REVIEW- META-ANALYSIS 
The search filters recommended by the SIGN guidelines were used to retrieve randomised 
controlled trials in Medline, EMBASE and Cinahl. Keywords for the individual drugs were 
combined with the appropriate filters to retrieve relevant studies. 
Medline 
12. Randomized controlled trials/ 
13. Randomized controlled trial. pt. 
14. Random allocation/ 
15. Double blind method/ 
16. Single blind method/ 
17. Clinical trial. pt. 
18. Exp clinical trials/ 
19. or/1-7 
20. (cline$ adj trial$).tw. 
21. ((sigl$ or doubl$ or treb$ or trip$) adj (blind$3 or mask$3)).tw. 
22. Placebos/ 
23. Placebo$.tw. 
24. Randomly allocated.tw. 
25. (allocated adj2 random).tw. 
26. or/9-14 
27. 8 or 15 
28. Case report.tw. 
29. Letter.pt. 
30. Historical article.pt. 
31. Review of reported cases.pt. 
32. Review, multicase.pt. 
33. or/17-21 
34. 16 not 22 
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EMBASE 
1. Clinical trial! 
2. Randomized controlled trial/ 
3. Randomization/ 
4. Single blind procedure/ 
5. Double blind procedure/ 
6. Crossover procedure/ 
7. Placeb/ 
8. Randomi?ed controlled trial$.tw. 
9. Rct.tw. 
10. Random allocation.tw. 
11. Randomly allocated.tw. 
12. Allocated randomly. 
13. (allocated adj2 random).tw. 
14. Single blind$.tw. 
15. Double blind.tw. 
16. ((treble or triple) adj (blind$)).tw. 
17. Placebo$.tw. 
18. Prospective study/ 
19. Or/1-18 
20. Case study/ 
21. Case report. tw. 
22. Abstract report/ 
23. Letter/ 
24. Or/20-23 
25. 19 not 24 
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Cinahl 
1. Exp clinical trials/ 
2. Clinical trial.pt. 
3. (cline$ adj trial$).tw. 
4. (singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$)).tw. 
5. Randomi?ed control$ trial$.tw. 
6. Random assignment/ 
7. Random$ allocat$.tw. 
8. Placebo$.tw. 
9. Placebos/ 
10. Quantitative studies/ 
11. Allocat$ random$.tw. 
12. Or/1-11 
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APPENDIX III 
DIAGNOSTIC (ICD-9) AND OPERATIONAL 
(OPCS) CODES OF CLINICAL EVENTS OF 
INTEREST 
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Gastrointestinal Events 
208 leukaemia of unspecified cell type 
530 disease of oesophagus 
531 gastric ulcer 
532 duodenal ulcer 
533 peptic ulcer, site unspecified 
534 gastrojeujunel ulcer 
535 gastritis and duodenitis 
536 disorder of function of stomach 
578 gastrointestinal haemorrhage 
787 symptoms involving digestive systems 
Cardiovascular Events 
401 to 405 Hypertensive Disease 
401 essential hypertension 
402 hypertensive heart disease 
403 hypertensive renal disease 
404 hypertensive heart and renal disease 
405 secondary hypertension 
410 acute myocardial infarction 
411 to 414 Ischaemic Heart Disease 
411 other acute and subacute form of ischaemic heart disease 
412 old myocardial infarction 
413 angina pectoris 
414 other forms of chronic ischaemic heart disease 
415 acute pulmonary heart disease 
416 chronic pulmonary heart disease 
425 cardiomyopathy 
426 conduction disorders 
427 cardiac dysrhythmias 
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428 heart failure 
429 ill-defined descriptions and complications of heart disease 
440 atherosclerosis 
441 aortic aneurysm 
Rheumatoid Arthritis 
710 diffuse diseases of connective tissue 
714 rheumatoid arthritis and other inflammatory polyarthropathies 
Osteoarthritis 
715 osteoarthrosis and allied disorders 
W37 total prosthetic replacement of hip joint using cement 
W38 total prosthetic replacement of hip joint not using cement 
W39 other total prosthetic replacement of hip joint 
W40 total prosthetic replacement of knee joint using cement 
W41 total prosthetic replacement of knee joint not using cement 
W42 other total prosthetic replacement of knee joint 
W43 total prosthetic replacement of other joint using cement 
W44 total prosthetic replacement of other joint not using cement 
W45 other total prosthetic replacement of other joint 
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APPENDIX IV 
UNIT COSTS USED IN THE ANALYSIS 
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The following unit costs were used in the non-population model. 
Resources 1993 Values 1995 Values 2000 Values 
GP Visit £ 6.90 £ 8.50 
Investigations 
ESR £ 3.00 £ 4.02 
FBC £ 3.00 £ 4.02 
WBC £ 5.00 £ 6.70 
WBC diff £ 7.00 £ 9.38 
Ferritin £ 12.00 £ 16.08 
Marrow £ 70.00 £ 93.81 
Bloods £ 23.00 £ 30.82 
LFT £ 11.00 £ 14.74 
U&E £ 7.00 £ 9.38 
Glucose £ 3.00 £ 4.02 
Amylase £ 3.00 £ 4.02 
Renal Biopsy £ 60.00 £ 80.41 
Gastric Biopsy £ 58.00 £ 77.73 
Creatinine £ 4.00 £ 5.36 
Immunoglobin £ 15.00 £ 20.10 
XR abdo £ 21.00 £ 28.14 
XR chest £ 12.00 £ 16.08 
IVP £ 80.00 £ 107.21 
Barium meal £ 34.00 £ 45.56 
Barium enema £ 41.00 £ 54.94 
Upper endoscopy £ 119.00 £ 159.47 
Sigmoidoscopy £ 50.00 £ 67.01 
ECG £ 6.00 £ 8.04 
Faeces OB £ 11.00 £ 14.74 
Faeces Culture £ 10.00 £ 13.40 
GP consultation cost was taken from the following study and inflated to present value. 
Graham B & McGregor K. What does a GP consultation cost? BJGP 1997; 47:170-172 
All investigative costs were taken from a previous study and inflated to present value. 
Knill-Janes RP. An economic evaluation of Arthrotec in the treatment of arthritis. 
Br J Med Econ 1992;5:51-58 
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Table 34 Tayside Weighted Average Inpatient Costs by Specialty 
Inpatients 
Acute Specialties 
General Surgery 
Weighted Values 
Orthopaedics 
Weighted Values 
ENT 
Ophthalmology 
Urology 
Weighted Values 
Neurosurgery 
Cardiothoracic Surgery 
Plastic Surgery & Burns 
Weighted Values 
Oral Surgery & Medicine 
Weighted Values 
Medical 
Weighted Values 
Neurology 
Dermatology 
Rehab Medicine 
Respiratory Med 
Communicable Disease 
Radiotherapy 
Spinal Paralysis 
Surgical Paediatrics 
Medical Paediatrics 
Weighted Values 
Gynaeco1ogy 
Weighted Values 
LOS• 
Code (days) 
2 
4 
5 
6 
7 
12 
16 
19 
23 
26 
28 
31 
34 
38 
39 
40 
42 
5.7 
3.7 
4.6 
4.39 
7.1 
8.1 
8.2 
30.5 
8.19 
29 
2.9 
4.1 
4.1 
4.10 
7.6 
4.8 
2.4 
4.78 
1.8 
1.1 
1.55 
5.2 
6.9 
5.5 
5.4 
5.38 
8.3 
13.2 
8.8 
7.7 
10.8 
1.9 
2.9 
2.8 
2.87 
3.6 
3.1 
1.8 
3.41 
Baby Special/Intensive 46 16 
9.4 
13.60 Weighted Values 
• LOS = length of stay in hospital 
Cost/Case Number of Cost/Case Inpatients LOS • Cost/Case Number of Cost/Case 
Discharges per Day (£) (£) Discharges per Day(£) Acute Specialties Code (days) (£) 
1451 
926 
1049 
1080.52 
1794 
2336 
1951 
12038 
2234.63 
907 
892 
1222 
1198 
1218.32 
2787 
1405 
938 
1400.77 
1008 
681 
892.44 
1085 
1219 
813 
955 
1013.14 
2468 
2050 
1136 
2768 
1586 
683 
1024 
822 
966.67 
870 
994 
250 
916.68 
7279 
3677 
5968.57 
1725 
3770 
1793 
7288 
3116 
1843 
1279 
158 
6396 
2803 
1909 
2112 
383 
2495 
842 
1751 
16 
1767 
666 
364 
1030 
12014 
972 
4422 
3067 
20475 
474 
562 
2895 
1361 
1006 
397 
2728 
1081 
3809 
1725 
1076 
4 
2805 
341 
195 
536 
Intensive Therapy Unit 
Weighted Values 
245.86 
A&E 
48 
49 
6.6 
1.5 
2.57 
0.8 
Geriatric Assess 50 15.3 
272.98 
312.76 Weighted Values 
21.5 
28 
44.5 
25.3 
25.41 
307.59 General Practice 73 21.2 
297.15 
366.71 
Weighted Values 
18.9 
10.6 
14.4 
24.1 
17.7 
13.1 
16.3 
17.7 
16.18 
Acute Other 98 14.4 
293.15 
574.79 
188.48 
297.35 
155.30 
129.09 
359.48 
146.85 
359.47 
Weighted Values 
Geriatric Long Stay 51 
Weighted Values 
Young Chronic Sick 
336.63 
52 
269.17 Casted as Medical Cases: 
Nephrology 24 
Cardiology 17 
Anaesthetics 41 
438.90 Haematology 62 
14.4 
14.4 
14.40 
10611 
1221 
3194.00 
1184 
1945 
2331 
3276 
4745 
3438 
3010.97 
2363 
2038 
1223 
1390 
2527 
1927 
1434 
1623 
2674 
1759.12 
2738 
3345 
2633 
2815.07 
270 
1015 
1285 
766 
494 
930 
652 
368 
815 
3259 
281 
104 
422 
326 
148 
289 
175 
265 
86 
2096 
409 
200 
409 
1018 
Cost per iopatient week 
466 21 
589 
736 
820 
579 
19 
389 
110 
203 
666 52 
580 
517 
547 
535 
678 
850 
689 
673.75 
1243 
61 
40 
20 
11 
7 
6 
18 
957 
130 
209 
1242.03 
1480.00 
118.50 
108.74 
195.49 
96.25 
177.57 
188.48 
188.48 
188.48 
188.48 
Table 35 Tayside Weighted Average Outpatient Costs by Specialty 
Outpatients Total Cost Outpatients Total Cost 
Se,ecialties Code Attendance e,er Attendance (£1 Se,ecialties Code Attendance e,er Attendance (£) 
General Surgery 18400 175 Neurology 19 5031 41 
2308 37 249 36 
736 20 976 49 
673 43 Weighted Cost 6256 42.05 
8446 23 Dermatology 23 28962 33 
386 93 1319 31 
1003 46 632 28 
589 42 4408 32 
580 29 520 50 
170 47 707 44 
183 77 Weighted Cost 36548 33.18 
173 110 Rehab Medicine 26 As Medical Outpatients 
Weighted Values 33647 110.20 
Orthopaedics 2 26200 35 Respiratory Medicine 28 441 39 
2171 31 297 54 
73 27 1230 45 
681 37 645 42 
11019 35 7415 53 
5438 55 Weighted Values 10028 50.73 
1280 42 Communicable Disease 31 1521 93 
378 42 
46 65 Radiotherapy 34 6724 52 
37 27 1333 26 
39 51 Weighted Values 8057 47.70 
43 116 Spinal Paralysis 38 As Medical Outpatients 
Weighted Values 47405 37.48 Surgical Paedicatrics 39 1137 206 
ENT 3 15660 47 Medical Paediatrics 40 6676 78 
1496 40 438 39 
246 37 161 43 
625 42 3247 120 
4116 27 146 55 
1053 45 1742 46 
566 51 Weighted Values 12410 82.40 
268 30 Gynaecology 42 12782 41 
246 28 793 32 
138 36 192 31 
Weighted Values 24414 115.52 417 41 
Ophthalmology 4 24935 34 3346 71 
1790 32 482 60 
1132 42 311 51 
9894 22 93 43 
369 65 109 28 
489 31 38 79 
Weighted Values 38609 31.32 Weighted Values 18563 46.59 
Urology 5 5379 112 Baby Care Intensive 46 896 35 
18 278 A&E 49 4844 57 
274 47 46801 34 
499 80 3041 20 
Weighted Values 6170 107.01 2497 24 
Neurosurgery 6 3472 43 25687 37 
Ill 117 5446 61 
Weighted Values 3583 45.29 4475 21 
Plastic Surgery & Burns 8 11646 20 1372 24 
529 30 1576 34 
Weighted Values 12175 20.43 1441 37 
Oral Surgery & Medicine 12 650 108 696 45 
4435 45 2165 26 
309 178 8 125 
Weighted Values 5394 274.38 Weighted Values 100049 35.91 
Medical 16 53933 35 Geriatric Assessment 50 535 82 
6459 53 687 95 
3111 47 1409 45 
621 19 489 27 
597 65 Weighted Values 3120 59.53 
15029 49 
1391 92 General Practice 73 As Medical Outpatients 
810 60 
378 79 Acute Other 98 974 49 
252 44 1106 45 
253 40 389 98 
128 63 6742 128 
138 36 Weighted Values 9211 108.41 
3 333 
Wei hted Values 83103 40.97 
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From: Olivia Wu 
Direct line: 0141 330 3296 
Dr R P Knill-Jones 
Direct line: 0141 330 5010 
[Date] 
Dear 
UNIVERSITY 
of 
GLASGOW 
Pharmacoeconomic Evaluations of Adverse Drug Reactions 
We are conducting research on the impact of pharmacoeconomic information on GP 
prescribing. Part of our research involves conducting economic evaluations on three classes 
of drugs - NSAIDs, ACE inhibitors and SSRis. This involves modelling the additional costs to 
the NHS of treating most side effects, onto the basic drug dispensing cost. This calculation of 
the total costs of prescriptions leads to a more accurate comparative evaluation of the 'real' 
costs of prescribing different NSAIDs. 
In order to calculate the costs of treating side effects, we need to establish a general 
treatment model from GPs. This activity involves a half-hour interview asking about the 
actions GPs would take, and investigations/follow-up initiated, given a series of complications 
which could arise in a patient on one of the three classes of drugs mentioned above. No 
special interest or expertise in the particular drugs or economic evaluations is needed. We 
have had experience in doing this successfully on several occasions in the past. 
This study is independent of any pharmaceutical sponsorship for good academic reasons. We 
would be most grateful if you could help. 
Yours sincerely 
Olivia Wu 
Research Student 
Dr Robin Kniii-Jones 
Senior Lecturer in Epidemiology 
Honorary Consultant in Public Health 
Department of Public Health, University of Glasgow 
1 Lilybank Gardens, Glasgow G12 SRZ 
Tel: +44 141 330 4039 Fax: +44 141 330 5018 
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From: Olivia Wu and Dr Robin Kniii-Jones 
Direct line: 0141 330 3296/5010 
[Date] 
Dear 
Dr Philip Wilson 
WestNet 
4 Lancaster Cresent 
Glasgow G12 ORR 
UNIVERSITY 
of 
GLASGOW 
Exploratory Survey among WestNet Members 
We have noted the large increase in economic data about health care. These range from 
simple recommendations on cost issues to purposefully designed economic evaluations. Many 
GPs are concerned about the increasing dominance of economic issues in major decisions 
about clinical care, and feel their opinions on economic matters have not been heard. However, 
it is unclear whether this information has any impact on everyday clinical practice in a primary 
care setting. 
We are conducting a short exploratory survey among WestNet members to look into this. This 
survey would allow us to gain valuable insight into your views on the usefulness of a variety of 
economic information in relation to your everyday practice. We believe the results of this survey 
would provide a sense of direction to future research in this area. 
From personal experience, we know that there is very little spare time in a GP's day. We have 
restricted this survey to a very short questionnaire which is enclosed. We would be most 
grateful if you could take some time to complete this and return it in the reply-paid envelope 
provided. 
Yours sincerely 
OliviaWu 
Research Student 
pp Dr Philip Wilson 
Enc 
Dr Robin Kniii-Jones 
Senior Lecturer in Epidemiology 
Honorary Consultant in Public Health 
Section of Public Health and Health Policy 
Division of Community Based Sciences, University of Glasgow 
1 Li1ybank Gardens, Glasgow G12 8RZ 
Tel: +44 141 330 4039 Fax: +44 141 330 5018 
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Please mark 'x' or type, where appropriate, within the brackets provided. 
1. Has economic information comparing cost and effectiveness of treatments ever influenced 
your decision-making? 
Yes (please proceed to fill in questions 2 to 4) 
No (please go straight to question 5) 
Don't Know (thank you for your time, your questionnaire ends here) 
2. If yes, when was the last time economic information has influenced your decision-making? 
3. What was the source of this information (pick all relevant options)? 
Published information: 
] from local Health Board/PCG/PPAs/MPAs 
] articles in journals 
] from pharmaceutical industry 
] others, please specify 
Verbally presented information: 
] from individual meetings with representatives from local Health 
Board/PCG/PPAs/M PAs 
] from conferences and seminars 
] from pharmaceutical industry representatives 
] others, please specify 
4. What was the decision made? 
5. Why has economic information failed to influence your decision-making (pick all relevant 
options)? 
I never receive any economic information. 
I do not receive economic information relevant to my decision-making. 
It is not possible to implement the economic information into my everyday practice. 
I do not agree with the results of the information presented. 
Other reasons, please specify. 
Please return the completed questionnaire in the reply-paid envelope provided. 
Thank you very much for your time. If you have any questions regarding this survey, please contact: 
Olivia Wu or Dr Robin Knill-Janes 
Department of Public Health 
University of Glasgow 
Tel: 0141 330 3296/5010Fax: 0141 330 5018 
Email: 9406070w@clinmed.gla.ac.uk or 
R.P.Knill-Jones@udcf.gla.ac.uk 
Dr Philip Wilson 
WestNet, 4 Lancaster Crescent 
Glasgow G12 ORR 
Tel: 0141 2111690 Fax: 0141 2111667 
Email: p.wilson@clinmed.gla.ac.uk 
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Please mark 'x' or type, where appropriate, within the brackets provided. 
Have you ever used this as a source of 
economic information? By economic 
information, we mean information If yes, do you find this information of 
comparing the costs and benefits of relevance to your everyday practice? 
different kinds of health care. (Y = yes N = no S = sometimes 
(Y =yes N = no DK = don't know) DK = don't know) 
MPAs and/or PPAs Y[ N[ ]DK[ Y[ N[ S[ OK[ 
Prescribing Feedback (SPA) Y[ N [ ]OK[ Y[ N [ S[ DK[ 
Prescribing Feedback (GPASS) Y[ N [ ]OK[ Y[ N [ S[ DK[ 
Locally Produced Newsletters, please 
specify [ ] Y[ N [ ]OK[ Y[ N [ S[ DK[ 
Local Prescribing Formulary Y[ N [ ]OK[ Y[ N [ S[ DK[ 
Pharmaceutical Industry Literature Y[ N [ ]OK[ Y[ N[ S[ DK[ 
Pharmaceutical Industry Representatives Y[ N [ ]DK[ Y[ N [ S[ DK[ 
British Medical Journal Y[ N [ ]OK[ Y[ N[ S[ DK[ 
British Journal of General Practice Y[ N [ ]DK[ Y[ N [ S[ DK[ 
Other Journals, please specify 
] Y[ N [ ]DK[ Y[ l N [ l S[ l DK[ 
2 If there are sources of economic information that you find relevant and are not on the list above, please specify. 
3 How do you think economic information should be presented to you (pick all relevant options)? 
evaluations and studies published in literature 
summary of evaluations and studies presented in a leaflet format 
summary of evaluations and studies presented verbally at a meeting 
simple recommendations presented in a leaflet format 
simple recommendations presented verbally at a meeting 
] locally specific evaluations and studies 
4 Do you think economic information should be used in health care decision-making? 
Yes 
No 
Please return the completed questionnaire in the reply-paid envelope provided. 
Thank you very much for your time. If you have any questions regarding this survey, please contact: 
Olivia Wu or Dr Robin Kniii-Jones 
Department of Public Health, University of Glasgow. 
Tel: 0141 330 3296/5010 Fax: 0141 330 5018 
Email: 9406070w@clinmed.gla.ac.uk or 
R.P.Knill-Jones@udcf.gla.ac.uk 
Dr Philip Wilson 
WestNet, 4 Lancaster Crescent 
Tel: 0141 2111690 Fax: 0141 2111667 
Email: p.wilson@clinmed.gla.ac.uk 
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From: Olivia Wu and Dr Robin Kniii-Jones 
Direct line: 0141 330 3296/5010 
[Date] 
Dear 
UNIVERSITY 
of 
GLASGOW 
The Use of Economic Evidence in Primary Care 
We have noted the large increase in economic data about health care. These range from 
simple recommendations on cost issues to purposefully designed economic evaluations. Many 
GPs are concerned about the increasing dominance of economic issues in major decisions 
about clinical care, and feel their opinions on economic matters have not been heard. 
We are conducting an exploratory survey to look into this. This survey would allow us to gain 
valuable insight into your views on the role of economic information in relation to your everyday 
practice. We believe the results of this survey would provide information that will help the 
design of useful and comprehensible economic evidence for GPs and tackle 'information 
overload'. 
Your participation in this would be voluntary and should you agree to be involved, you may 
withdraw at any point without prejudice. If you consent to take part, then we will need to 
undertake one semi-structured interview with you. This will last no longer than 45 minutes and, 
with your permission, will be audio-recorded. These interviews will be transcribed and your 
replies will be treated as confidential. We will also ensure that none of your responses can be 
directly attributed to you. 
As a general guide, the interview will cover your views on the use of economic evidence in 
clinical decision making. However, no special knowledge on economics is required. If you 
require further information or wish to discuss this in more detail, please do not hesitate to 
contact us. 
Yours sincerely 
Olivia Wu 
Research Assistant 
Dr Robin Kniii-Jones 
Reader in Epidemiology 
Honorary Consultant in Public Health 
Section of Public Health and Health Policy 216 
Division of Co=unity Based Sciences, University of Glasgow 
1 Lilybank Gardens, Glasgow G12 8RZ 
Tel: +44 141 330 4039 Fax: +44 141 330 5018 
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N 
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Table 36 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total Comparator Cohort 
NSAID ONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
N 
8640 
11360 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
50 to 59yrs 7 t 85 
60 to 74yrs 9594 
75+yrs 3022 
sub-total of all male 19601 
Total NSAID Only Sub-Cohort 49212 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
33 
75 
42 
150 
24 
28 
10 
62 
Total NSAID & Misoproslol Sub-Cohort 212 
Female 
Male 
NSAID & H2/0MEPRAZOLE 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
339 
623 
284 
1246 
255 
492 
120 
867 
Total NSAID & H210meprazole Sub-Cohort 2113 
All the Costs(£) Incorporated In the Economic Modelling of the Tayside Population Based on 45 Days Observations (from the Index date) 
Base Cost Additional Additional Addlllonal Event Cost GP Visit (Rx) Cost of Cost of Cost of Cost of Cost of Cost or Hidden Shadow 
Drug Rx NSIAD RX Ulcer Rx Other Rx All Rx Costs Endoscopies Gl admissions CV admissions RH admissions OS admissions all admissions Costs Costs 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6 .69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41 .08 
41.32 
40.28 
40.37 
37.00 
39.88 
40.73 
2.47 
2.92 
3.30 
2.87 
2.04 
2.49 
2.80 
2.37 
2.67 
5.01 
3.07 
8 .58 
5.04 
4.05 
2.33 
3.09 
3.12 
4.48 
3.87 
3.64 
5.40 
4 .10 
2 .68 
3.14 
2.98 
2.98 
3.64 
1.39 
1.88 
2.17 
1.77 
1.48 
2.36 
2 .20 
1.96 
1.88 
1.49 
1.85 
1.75 
1.71 
1.42 
1.75 
1.42 
1.58 
1.66 
9.68 
8.79 
11 .07 
9.62 
8.30 
11.95 
9.83 
10.20 
9.79 
14.88 
16.30 
18.15 
16.33 
13.22 
13.48 
14.44 
13.54 
15.18 
1.50 
1.26 
2.02 
1.50 
0.85 
1.30 
1.39 
1.12 
1.32 
2.83 
3.16 
3.67 
3.17 
1.97 
3.21 
3.29 
2.77 
3.01 
3.31 
4.82 
5.05 
4.55 
2.13 
5.85 
5.05 
4.28 
4.47 
5.16 
6.76 
6.34 
6.23 
4.17 
6.56 
6.89 
5.90 
6.10 
2.89 
3.14 
4 19 
3 28 
2.33 
3.67 
359 
3.07 
3. 18 
6.79 
7 93 
8 72 
775 
5 43 
7 45 
7 51 
6 73 
7 34 
17 .98 
1668 
24 .70 
1921 
14.48 
20.14 
17 96 
17 60 
\8 74 
2390 
26 70 
29.89 
26 67 
20.05 
23 17 
24.31 
22.41 
24.92 
I 28 
151 
I 86 
1.50 
086 
I 42 
I 56 
I 19 
1 36 
4 46 
6 .01 
7 44 
585 
3 76 
551 
6 31 
500 
551 
10 05 
10 92 
15 47 
12 01 
818 
12.09 
12.86 
10.70 
11.62 
11.02 
12 71 
17 38 
13 32 
9 32 
11 .01 
1281 
10.76 
12 27 
0 51 
0 44 
0 27 
0 43 
0 .37 
0 48 
008 
0 38 
0 40 
0 49 
0 33 
0 22 
0 35 
0 35 
0 33 
028 
0 33 
0 34 
000 
000 
0 .00 
000 
000 
0 .00 
000 
000 
000 
3.07 
2 34 
I 47 
2.34 
I 63 
0.85 
000 
0.96 
1.77 
0.70 
1.21 
2.04 
1.21 
0.79 
2.18 
1.13 
1.44 
1.32 
0.94 
4.87 
9.19 
4.62 
2.62 
3.60 
8.96 
4.06 
4.39 
0.00 
0.00 
97.71 
27.36 
0.00 
0.00 
0.00 
0.00 
19.36 
5.68 
0.00 
4.44 
2.56 
4.65 
22.28 
0.00 
14.01 
7.26 
0.64 
1.99 
23.34 
6.07 
3.93 
3.89 
7.59 
4 .37 
5.28 
4.07 
13.57 
30.39 
14.43 
23.97 
31 .97 
17.03 
26.78 
19.40 
0.00 
18.34 
97.71 
36.53 
0.00 
0.00 
0.00 
0.00 
25.84 
12.34 
24.74 
24.51 
21 .32 
60.99 
62.27 
33.30 
57.88 
36.32 
0.00 
0.22 
0.00 
0.10 
0.00 
0.28 
0.00 
0.12 
0.11 
0.30 
1.89 
0.96 
1.17 
0.99 
0.00 
0.00 
0.36 
0.84 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
0.00 
0 .00 
1.26 
0.00 
0.88 
0.00 
0.50 
0.95 
0.00 
0.96 
7.93 
2.12 
0.46 
1.81 
1.72 
1.21 
1.70 
1.81 
4.57 
16.39 
6.42 
1.64 
10.67 
3.46 
6.29 
6.37 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
27.76 
17.26 
45.41 
26.53 
0.00 
21.19 
0.00 
12.03 
20.58 
I 34 
4 38 
33.31 
9.50 
5 .18 
817 
\0 44 
7 14 
8 41 
7 II 
24 90 
56 93 
26 63 
29 21 
46 24 
29 45 
37 50 
3100 
0.00 
18 34 
195 41 
63 89 
000 
000 
0.00 
000 
45.20 
50.39 
42.00 
74 36 
51.66 
6565 
106.62 
33.30 
84 42 
85.10 
6 .02 
9.47 
39.62 
14.71 
8.74 
13.73 
15.67 
11.78 
13.35 
18.85 
39.17 
73.30 
40.58 
38.75 
59.53 
43.55 
49.55 
44 .19 
28.03 
45.94 
235.58 
95. 10 
22.66 
32.22 
30.82 
28.30 
75.56 
88.39 
83.76 
123.09 
93.98 
96.65 
141.65 
70.42 
118.55 
104.06 
6.02 
9.47 
39.62 
14.7 1 
8.74 
13.73 
15.67 
11.78 
13.35 
26.90 
46.88 
80.86 
48.37 
46.2 \ 
86.50 
50.24 
56.66 
51.70 
51.40 
71.08 
257.75 
11 9.02 
48.83 
57 .26 
55.03 
53.64 
99.90 
130.71 
124 .65 
164 .17 
135.30 
136.93 
182.02 
107.42 
158.43 
144.79 
N ,.... 
\0 
Table 37 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to59yrs 
60 to 74yrs 
75+yrs 
sul>-lolal of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of afl male 
Total Comparator Coh0/1 
NSAID ONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
N 
8640 
11360 
5410 
25432 
9617 
9579 
2722 
219t8 
47350 
9324 
13319 
6768 
29411 
50 to 59yrs 7185 
60 to 74yrs 9594 
75+yrs 3022 
sub-total of all male 19801 
Total NSAID Only Sui>-Cohort 492t 2 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
33 
75 
42 
150 
24 
28 
10 
62 
Total NSAID & Misoproslol Sui>-Coh0/1 212 
NSAID & H2/0MEPRAZOLE 
Female 
50 to 59yrs 339 
60 to 74yrs 623 
75+yrs 284 
sul>-lolal of all female 1246 
Male 
50 to 59yrs 255 
60 to 74yrs 492 
75+yrs t20 
sub-total of all male 867 
Tolal NSAID & H2/0meprazole Sui>-Coh0/1 2t t3 
All the Costs(£) Incorporated In the Economic Modelling of the Tayside Population Based on Six Months Observations (from the Index date) 
Base Cost Event Costs Event Costs Event Costs Event Costs Costs of Cost of Cost of all Cost of all Cost of all Cost of all Cost of all Hidden Shadow 
Drug R)( NSAID Rx H21Losec Rx Other Rx All Rx GP VIsits (Rx) Endoscopies Gl admissions CV admissions RH admissions OS admissions admissions Costs Costs 
8.05 
7.71 
7.55 
7.78 
7.46 
6 .98 
6 .69 
7.11 
7.51 
23.37 
25.14 
22.t 7 
23.92 
26.17 
25.04 
24.20 
25.34 
24 .34 
42.32 
40.89 
41 .08 
41 .32 
40.28 
40.37 
37.00 
39.88 
40.73 
11 .16 
13.92 
16.32 
13.59 
8 .57 
11.88 
14 .27 
11.04 
12.57 
12.64 
14.82 
21.17 
16.t2 
15.34 
12.14 
16.62 
14.10 
15.53 
20.09 
18.96 
25.49 
20.75 
13.25 
15.25 
16.11 
14.78 
18.30 
6.49 
8.18 
9.27 
7.83 
6.72 
9.54 
8.14 
8.13 
7.97 
6. t8 
8.44 
8.47 
7.73 
6.31 
8 .20 
7.32 
7.38 
7.59 
27.76 
41 .06 
36.73 
36.92 
28.05 
47.78 
34.93 
38.07 
37.26 
90.27 
94.00 
104.11 
95.29 
75.54 
90.20 
87.48 
85.51 
91.28 
7.90 
6.69 
8.77 
7.55 
4.12 
6.67 
6.85 
5.55 
6.62 
16.22 
17.73 
20.59 
17.91 
12.50 
18.28 
20.77 
16.56 
17.36 
43.48 
23.56 
24.30 
28.15 
12.66 
31.44 
13.83 
21.33 
26.15 
28.25 
36.05 
38.46 
34.48 
25.34 
40.85 
39.73 
36.02 
35.11 
14.39 
14.87 
18.04 
15 38 
10.84 
16 21 
14 79 
13 68 
14.59 
33.56 
4008 
45 37 
39 23 
27 37 
3835 
42 36 
34 98 
37.52 
83.88 
79 44 
82 20 
81 19 
56 04 
91 .36 
85.38 
73 50 
78 94 
138 61 
149 01 
168.06 
150 52 
I 14 .13 
146.10 
143.33 
136.31 
144.69 
4 40 
4 59 
549 
4.72 
2.85 
4 37 
4.42 
3 7 1 
4 25 
15 52 
20 38 
24 88 
19 87 
12 76 
19.36 
22 81 
17 49 
18.91 
28 72 
30 96 
34.49 
31 .46 
2200 
32. 16 
23.70 
2686 
30 II 
3890 
42.63 
52 01 
43.76 
33.05 
40.43 
44.68 
38.85 
41 .74 
1 30 
I 52 
I 16 
1 37 
1.45 
I 81 
I 15 
1.57 
I 46 
2.08 
I 91 
1 79 
I 93 
I 51 
1 74 
1 65 
164 
1 82 
0.00 
5.56 
0.00 
2 78 
0.00 
000 
000 
000 
1 97 
7 37 
7 02 
660 
7.02 
7 35 
5.93 
5 21 
6 25 
6.70 
1.78 
8 .45 
7.08 
5.89 
3.05 
6.46 
9.42 
5 .33 
5 .63 
2.73 
11 .92 
30.03 
13.17 
6.53 
9.60 
19.88 
t0.05 
11 .92 
0.00 
0.00 
138.98 
38.92 
0.00 
0.00 
0.00 
0.00 
27.53 
18.62 
11.17 
33.04 
18.18 
13.36 
81 .54 
6.75 
51 .14 
31 .70 
3.27 
16.83 
92.33 
28.28 
t6.20 
t7.94 
78.72 
24.73 
26.63 
15.45 
49.15 
141.98 
59.82 
60.12 
114.45 
89.08 
90.87 
72.3t 
0.00 
18.34 
944.50 
273.63 
0.00 
0.00 
0.00 
0.00 
193.61 
28.25 
97.35 
134.07 
86.92 
151 .89 
203.74 
78.01 
171.09 
121.46 
0.00 
0.45 
7.53 
1.80 
0.00 
0.28 
0.00 
0.12 
1.03 
2.78 
9 .08 
5.38 
6.23 
1.65 
0.54 
0.61 
0.96 
4.11 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
12.68 
14.80 
10.97 
0.00 
11.11 
0.00 
6.30 
9.05 
1.85 
3.00 
24.94 
7.28 
2.28 
5.67 
9.05 
4.60 
6.04 
11.28 
25.90 
90.56 
36.15 
13.84 
30.71 
45.64 
26.87 
32.41 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
52.94 
53.88 
170.72 
80.26 
33.60 
49.25 
0.00 
37.83 
62.85 
689 
28 73 
131 88 
43 25 
21 53 
3036 
97 20 
34 79 
39 33 
32 25 
9604 
267 96 
I 15 38 
82 15 
155 30 
155 21 
128 74 
120.76 
26.98 
49.71 
156.57 
64 .7 1 
36.67 
52.75 
I 17.55 
53.74 
59.63 
83.40 
158.41 
339.99 
176.42 
123.79 
214.75 
222.D3 
182.86 
179.01 
0.00 I 12.6 1 
18.34 134 .30 
1083 48 1200.17 
312.54 427.97 
0.00 
000 
000 
000 
221 14 
104 43 
175 07 
352.63 
196.32 
198.85 
345.85 
84 .76 
266 36 
225.06 
78.05 
123.52 
89.08 
100.36 
332. 16 
289.31 
373.74 
579.30 
397.62 
353.39 
538. 10 
277.98 
447.77 
418.20 
26.98 
49.7 1 
156.57 
64 .71 
36.67 
52.75 
117.55 
53.74 
59.63 
9 1.45 
166. 13 
347.54 
184 20 
131 .25 
221 72 
228.73 
189.96 
186.52 
135.97 
159.44 
1222.34 
451.89 
104 .22 
148.56 
11 3.28 
125.70 
356.50 
33 1.63 
4 14.63 
620.38 
438.94 
393.67 
578.48 
314.98 
487.65 
458.93 
N 
~ 
Table 38 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 lo 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total Comparator Cohort 
NSAIDONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total NSAIO Only Sub-Cohort 
NSAID & MISOPROSTOL 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
1otal NSAIO & Misoprostol Sub-Cohort 
NSAID & H210MEPRAZOLE 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
. NSAIO & H2/0meprazole Sub-Cohort 
N 
8640 
11380 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
7185 
9594 
3022 
19801 
49212 
33 
75 
42 
150 
24 
28 
10 
62 
212 
339 
623 
284 
1246 
255 
492 
120 
867 
2113 
All the Costs (E) Incorporated In the Economic Modelling of the Tayside Population Based on 12 Months (from the Index date) 
Base Cost Event Costs Event Costs Event Costs Event Costs Costs of Costs of all Costs of all Costs of all Costs of all Costs of all Costs of all 
Drug Rx NSAID Rx H21Losec Rx Other Rx All Rx GP Visits (Rx) Endoscpies Gl admlsslonsCV admlsslonsRH admisslo"'OS admlsslo"' admissions 
8.05 
7.71 
7.55 
7.78 
7.46 
6 .98 
6 .69 
7.11 
7.51 
23.37 
25.14 
22 .17 
23.92 
26.17 
25.04 
24 .20 
25.34 
24 .34 
42 .32 
40 .89 
41.08 
41.32 
40 .28 
40 .37 
37.00 
39.88 
40.73 
0.00 
0 .00 
0 .00 
0 .00 
0.00 
0.00 
0.00 
0.00 
0.00 
21 .72 
27.18 
31.91 
26.54 
16.50 
23.45 
28.02 
21.63 
24.56 
24 .75 
30.80 
31 .20 
29.58 
28.29 
23.34 
31.27 
26.53 
28.69 
39.29 
37.32 
46.42 
39.93 
29.30 
30.00 
31 .33 
29.98 
35.85 
13.23 
17.48 
18.99 
16.35 
13.89 
19.89 
16.91 
16.89 
16.60 
14.02 
18.90 
18.76 
17.32 
14.16 
18.23 
15.78 
16.38 
16.94 
52.68 
91.23 
84.28 
75.21 
57.45 
96.12 
75.05 
77 .75 
75.95 
184.48 
194.05 
211 .11 
195.33 
165.42 
192.37 
188.51 
183.91 
190.65 
19.74 
17.36 
22.75 
19.31 
10.39 
17 .72 
21 .11 
14.93 
17.28 
39.35 
42 .14 
45.63 
42 .06 
31.87 
46.53 
50.53 
41.82 
41 .96 
143.66 
68.93 
49.58 
79.95 
42.38 
107.54 
33.55 
70.38 
77 .15 
74.80 
89.85 
84.65 
84 .57 
67.39 
100.22 
84 .10 
88.33 
86.11 
32 .97 
34 .83 
41.74 
35.67 
24 .29 
37 .61 
38.01 
31 .81 
33.88 
75.10 
88.22 
96.29 
85.92 
62.53 
88.20 
94 .33 
79.82 
83.47 
221.10 
190.96 
145.07 
184 .74 
128.11 
227 .00 
139.87 
174 .67 
181.79 
298.57 
321 .22 
342.18 
319.83 
262.1 I 
322.60 
303.94 
302.22 
312.61 
8.58 
8 .8 1 
9 .95 
8 .97 
5.52 
8.29 
8.34 
7.08 
8. 10 
28.30 
36.46 
43.33 
35.46 
23.21 
34 .91 
40.77 
31 .56 
33.89 
44 .52 
52 .54 
52 .06 
50 .64 
39.49 
52 .95 
38.59 
45.42 
49 .11 
67 .80 
73.38 
86.60 
74 .88 
59.36 
70 .93 
77 .80 
68.48 
72 .25 
2.75 
3.33 
2.12 
2.88 
2.82 
3.57 
2.76 
3.14 
3.00 
3.66 
4.19 
3.76 
3.92 
3 .65 
3 .84 
3.24 
3.68 
3.83 
0 .00 
16.67 
0.00 
8.33 
8.68 
0 .00 
0 .00 
3.36 
6.88 
15.36 
17.05 
9.54 
14.88 
15.52 
16.09 
10.42 
15.14 
14 .99 
5.98 
17.48 
25.42 
15.26 
19.60 
16.26 
32.38 
19.73 
17.33 
7.04 
21 .55 
82.26 
30.92 
14.44 
16.71 
46.22 
20.39 
26.68 
0.00 
0.00 
227.18 
63.61 
0.00 
0.00 
0.00 
0.00 
45.01 
35.87 
21 .06 
44.63 
30.46 
31 .27 
116.04 
16.59 
77.34 
49.70 
8.75 
46.41 
212.36 
68.92 
31 .22 
45.98 
226.51 
61.92 
65.68 
41.29 
106.38 
313.35 
133.37 
120.43 
224 .22 
245.56 
189.82 
156.08 
0.00 
56.57 
1607.34 
478.34 
24.94 
149.82 
0.00 
77.31 
361.06 
52.17 
195.32 
766.53 
286.57 
280.17 
423.11 
143.96 
342.43 
309.49 
0 .57 
1.13 
7.66 
2.33 
0.00 
0.52 
0 .00 
0.23 
1.35 
10.71 
14.70 
17.19 
14.01 
2.72 
1.44 
61 .25 
11.03 
12.81 
0.00 
13.31 
0.00 
6.66 
0 .00 
0 .00 
0.00 
0 .00 
4.71 
14.01 
23.92 
31.75 
23.01 
0 .00 
19.72 
0 .00 
11 .19 
18.16 
1.95 
8.28 
49.74 
14.95 
7 .04 
8.21 
18.17 
8.94 
12.16 
26.32 
68.03 
188.30 
82.48 
24.75 
59.99 
90.66 
51 .89 
70.17 
0.00 
116.33 
346.98 
155.32 
254.62 
0.00 
0.00 
98.56 
138.72 
103.98 
103.75 
276.98 
143.30 
65.06 
118.03 
0.00 
86.11 
119.83 
17.25 
73.30 
295. 18 
10 1.45 
57 .86 
70.97 
277.06 
90.81 
96.53 
85.36 
210.67 
601.09 
260.78 
162.34 
302.36 
443.68 
273 .12 
265 .75 
0.00 
186.22 
2181 .50 
703.93 
279.56 
149.82 
0.00 
175.87 
549.50 
206.04 
344.06 
I I 19.89 
483.34 
376.49 
676.91 
160.55 
517 .08 
497 .19 
Hidden 
Costs 
61.55 
120.28 
348.99 
148.97 
90.49 
120.43 
326.17 
132.85 
141.5 1 
I 92.42 
339.54 
744.47 
386.08 
251.73 
429.32 
582 .03 
388.19 
386.93 
265.62 
446.38 
2378.64 
947 .64 
455.84 
429.76 
178.46 
399.32 
787 .29 
587.77 
755.71 
1558.2 1 
892 .93 
713.49 
1086.53 
552.71 
902 .93 
897 .03 
Shadow 
Costs 
61 .55 
120.28 
348.99 
148.97 
90.49 
120.43 
326.17 
132.85 
141 .51 
200.47 
347.25 
752.02 
393.86 
259.19 
436.30 
588.72 
395.30 
394.44 
288.99 
471.52 
2400.8 1 
97 1.56 
482.0 1 
454.80 
202.66 
424 .66 
811 .63 
630 .09 
796.60 
1599.29 
934 .25 
753.77 
1126.90 
589.7 1 
942 .81 
937 .76 
APPENDIX VII 
SENSITIVITY ANALYSIS -POPULATION MODEL 
221 
N 
N 
N 
Table 39 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total Comparator Cohort 
NSAID ONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total NSAID Only Su!>-Cohort 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
N 
8640 
11380 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
7185 
9594 
3022 
19801 
49212 
33 
75 
42 
150 
24 
28 
10 
62 
Tofal NSAID & Misoprostol Su!>-Cohort 212 
Female 
Mafe 
NSAID & H2/0MEPRAZOLE 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
339 
623 
264 
1246 
50 to 59yrs 255 
60 to 74yrs 492 
75+yrs 120 
sub-total of all mafe 867 
Total NSAID & H2/0meprazo/e Su!>-Cohort 2113 
Costs (£} Incorporated In the Sensitivity Analysis -when multiple episodes of care represent one single admission - Based on 45 Days Observations 
Base Cost Additional Additional Additional Event Cost GP Visit (Rx) Cost of Cost of Cost of Cost of Cost of Cost of Hidden Shadow 
Drug Rx NSAID RX Ulcer Rx Other Rx All Rx Costs Endoscopies Gl admissions CV admissions RH admissions OS admissions all admissions Costs Costs 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7.11 
7.51 
23.37 
25.14 
22.17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41.08 
41.32 
40.28 
40.37 
37.00 
39.88 
40.73 
2.47 
2.92 
3.30 
2.87 
2.04 
2.49 
2.80 
2.37 
2.67 
5.01 
3.07 
8.58 
5.04 
4.05 
2.33 
3.09 
3.12 
4.48 
3.87 
3.64 
5.40 
4.10 
2.66 
3.14 
2.98 
2.98 
3.64 
1.39 
1.68 
2.17 
1.77 
1.48 
2.36 
2.20 
1.96 
1.86 
1.49 
1.85 
1.75 
1.71 
1.42 
1.75 
1.42 
1.58 
1.68 
9.68 
8.79 
11.07 
9.62 
8.30 
11.95 
9.83 
10.20 
9.79 
14.68 
16.30 
18.15 
16.33 
13.22 
13.48 
14.44 
13.54 
15.18 
1.50 
1.26 
2.02 
1.50 
0.85 
1.30 
1.39 
1.12 
1.32 
2.83 
3.16 
3.67 
3.17 
1.97 
3.21 
3.29 
2.77 
3.01 
3.31 
4.82 
5 .05 
4.55 
2.13 
5.85 
5.05 
4.28 
4.47 
5 .16 
6.76 
6.34 
6.23 
4.17 
6.56 
6.89 
5.90 
6.10 
2.89 
3.14 
4.19 
328 
2.33 
3.67 
3 59 
3.07 
3.18 
679 
7 93 
8 72 
775 
5 43 
7 45 
7 51 
6 73 
7 34 
17.98 
16.68 
24 .70 
19.21 
14.48 
20. 14 
17.96 
17.60 
18.74 
23.90 
26.70 
29.89 
26.67 
20.05 
23. 17 
24.31 
22.41 
24.92 
I 28 
1.5 1 
186 
150 
086 
I 42 
1.56 
1.19 
1 36 
4 46 
6 .01 
7 44 
5 85 
3 76 
5 51 
6 31 
500 
5 51 
10 05 
10 92 
15 47 
12.01 
818 
1209 
12.68 
10.70 
11.62 
t1 02 
12 71 
17 .38 
13.32 
9.32 
11 01 
12.81 
10.76 
12 27 
051 
0 44 
0.27 
0 43 
0 37 
0.48 
0.08 
0 38 
0 40 
0 49 
0 33 
0 22 
0 35 
0 35 
0 33 
028 
0 33 
0.34 
0.00 
0.00 
0.00 
000 
000 
000 
000 
000 
0.00 
3 07 
2 34 
1.47 
2 34 
1 63 
0.85 
000 
096 
1.77 
0.70 
1.19 
2.03 
1.20 
0.78 
2.18 
1.13 
1.44 
1.31 
0.92 
4.86 
9.06 
4.58 
2.58 
3.56 
8.92 
4.03 
4.35 
0.00 
0.00 
97.71 
27.36 
0.00 
0.00 
0.00 
0.00 
19.36 
5.68 
0.00 
4.44 
2.56 
4.85 
22.16 
0.00 
13.95 
7.23 
0.64 
1.97 
23.25 
6.05 
3.86 
3.85 
7.54 
4.31 
5.24 
4.02 
13.45 
30.19 
14.31 
23.78 
31 .68 
16.93 
26.56 
19.24 
0.00 
18.34 
97.71 
36.53 
0.00 
0.00 
0.00 
0.00 
25.64 
12.01 
24.85 
23.72 
21.00 
59.35 
61.24 
33.30 
56.82 
35.70 
0.00 
0.22 
0.00 
0.10 
0.00 
0.28 
0.00 
0.12 
0.11 
0.30 
1.89 
0.96 
1.17 
0.98 
0.00 
0.00 
0.35 
0.64 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
0.00 
0.00 
1.26 
0.00 
0.68 
0.00 
0.50 
0.95 
0.00 
0.96 
7.91 
2.11 
0.46 
1.81 
1.72 
1.21 
1.69 
1.81 
4.57 
16.36 
6.41 
1.64 
10.66 
3.46 
6.29 
6.36 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
27.76 
17.26 
45.41 
26.53 
0.00 
21.19 
0.00 
12.03 
20.58 
I 34 
4 34 
33 20 
9 46 
509 
8 13 
10.39 
7 08 
8.36 
7 04 
2476 
56.57 
26 46 
2898 
4590 
29 31 
37 23 
3060 
000 
18 34 
195.41 
63.89 
000 
0.00 
0.00 
000 
45 20 
5006 
41 91 
73 57 
51 34 
6400 
105 48 
3330 
83 29 
64.45 
6.02 
9.42 
39.5 1 
14.67 
8.65 
13.69 
15.63 
11 .72 
13.30 
18.79 
39.03 
72.94 
40.42 
38.52 
59.20 
43.41 
49.29 
43.99 
28.03 
45.94 
235.58 
95.10 
22.66 
32.22 
30.82 
28.30 
75.56 
88.06 
83.67 
122.30 
93.67 
95.00 
140.51 
70.42 
117.42 
103.41 
6.02 
9.42 
39.5 1 
14.67 
8 .65 
13.69 
15.63 
1 1.72 
13.30 
26.84 
4674 
80.50 
48.20 
45.98 
66. 17 
50. 10 
56 39 
51 50 
5 1.40 
71.08 
257.75 
11 9.02 
48.83 
57.26 
55.03 
53 64 
99.90 
130.38 
124 .56 
163.38 
134 .99 
135.28 
180.88 
107.42 
157.30 
144 . 14 
N 
N 
w 
Table 40 
Female 
Male 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sulrtotaf of alf female 
N 
8640 
11380 
5410 
25432 
50 to 59yrs 9617 
60 to 74yrs 9579 
75+yrs 2122 
sub-total of aff mate 2t9t8 
Total Comparator Cohort 47350 
NSAID ONLY 
50 to 59yrs 9324 
60 to 74yrs 13319 
75+yrs 6768 
sulrtotal of all female 294 11 
50 to 59yrs 7185 
60 to 74yrs 9594 
75+yrs 3022 
sub-total of all male t9801 
Total NSAID Only Sui>-Cohort 49212 
NSAID & MISOPROSTOL 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sulrtotal of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sutrtotal of all male 
33 
75 
42 
150 
24 
28 
10 
62 
Total NSAID & Misoprostol Sub-Cohort 212 
Female 
Male 
NSAID & H210MEPRAZOLE 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sutrtotal of all female 
339 
623 
284 
1246 
50 to 59yrs 255 
60 to 74yrs 492 
75+yrs 120 
sub-total of all male 867 
Total NSAID & H210meprazole SulrCohort 2113 
Costs(£) Incorporated In the Sensitivity Analysis· when multiple episodes of care represents one single admission· Based on Six Months Observations 
Base Cost Event Costs Event Costs Event Costs Event Costs 
Drug Rx 
8.05 
7.71 
7.55 
7.78 
7.46 
6.98 
6.69 
7. 11 
7.51 
23.37 
25. 14 
22. 17 
23.92 
26.17 
25.04 
24.20 
25.34 
24.34 
42.32 
40.89 
41.08 
41.32 
40.26 
40.37 
37.00 
39.66 
40.73 
NSAID Rx H2/losec Rx Other Rx 
11.16 
13.92 
16.32 
13.59 
8.57 
11.66 
14.27 
11 .04 
12.57 
12.84 
14.82 
21.17 
16.12 
15.34 
12.14 
16.62 
14.10 
15.53 
20.09 
16.96 
25.49 
20.75 
13.25 
15.25 
16.11 
14.76 
18.30 
6.49 
8.18 
9.27 
7.83 
6.72 
9.54 
8.14 
8.13 
7.97 
6.18 
8.44 
8.47 
7.73 
6.31 
8.20 
7.32 
7.38 
7.59 
27.76 
41.06 
36.73 
36.92 
26.05 
47.76 
34.93 
36.07 
37.26 
90.27 
94.00 
104. II 
95.29 
75.54 
90.20 
87.48 
85.51 
91.28 
7.90 
6.69 
8.77 
7.55 
4.12 
6.67 
6.85 
5.55 
6.62 
16.22 
17.73 
20.59 
17.91 
12.50 
18.28 
20.77 
16.56 
17.36 
43.48 
23.56 
24.30 
26.15 
12.66 
31.44 
13.83 
21 .33 
26.15 
26.25 
36.05 
38.46 
34.46 
25.34 
40.65 
39.73 
36.02 
35. II 
AIIRx 
14 .39 
14 .87 
18.04 
15.38 
10.84 
16 21 
14 79 
1366 
14 59 
33.56 
40 08 
45.37 
39 23 
27 .37 
38.35 
42.36 
34 98 
37 52 
83.88 
79 44 
8220 
8 1 19 
56 04 
9 1 36 
65 38 
7350 
78.94 
138.6 1 
14901 
16606 
15052 
114. 13 
146.10 
143.33 
136 3 1 
144 69 
Costs of Cost of Cost of all Cost of all Cost of all Cost of all Cost of all 
GP Visits (Rx) Endoscopies Gl admissions CV admissions RH admissions OS admissions admissions 
Shadow 
Costs 
4.40 
4 59 
5 49 
4 72 
285 
4 37 
4.42 
3 71 
4 25 
15.52 
20 36 
24.88 
19 87 
12.76 
19.36 
22.8 1 
17 49 
18 91 
26.72 
30.96 
34.49 
31.46 
22.00 
32.16 
23 70 
2686 
30 11 
38 90 
42.63 
52.01 
43.76 
3305 
40.43 
44 .68 
38.85 
41. 74 
I 30 
152 
I 16 
137 
145 
1.8 1 
I 15 
I 57 
I 46 
2.06 
1.91 
I 79 
I 93 
I 51 
1.74 
165 
I 64 
I 62 
0 00 
5 56 
0.00 
2 78 
0 00 
000 
000 
0.00 
I 97 
7 37 
7.02 
660 
7 02 
7 35 
5 93 
5 21 
6 25 
6.70 
1.77 
8.35 
7.03 
5.83 
2.99 
6.41 
9.25 
5.26 
5.57 
2.66 
11 .86 
29.81 
13.08 
6.42 
9.53 
19.73 
9.96 
11 .82 
0.00 
0.00 
136.62 
36.81 
0.00 
0.00 
0.00 
0.00 
27.46 
18.62 
10.77 
32.51 
17.86 
13.36 
81.40 
6.75 
51.06 
31.46 
3.24 
16.72 
91.92 
26.14 
16.06 
17.77 
76.40 
24.55 
26.46 
15.25 
48.61 
141.00 
59.30 
59.36 
113.26 
66.37 
89.90 
71.61 
0.00 
18.34 
944.14 
273.53 
0.00 
0.00 
0.00 
0.00 
193.53 
27.83 
96.64 
130.86 
85.72 
147.99 
201.00 
76.95 
166.24 
119.58 
0.00 
0.45 
7.51 
1.60 
0.00 
0.28 
0.00 
0.12 
1.02 
2.77 
9.06 
5.35 
6.21 
1.65 
0.54 
0.61 
0.95 
4.10 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
4.61 
12.56 
14.60 
10.91 
0.00 
10.96 
0.00 
6.22 
8.98 
1.65 
3.00 
24.92 
7.27 
2.28 
5.67 
9.03 
4.60 
6.03 
11.27 
25.87 
90.40 
36.09 
13.62 
30.70 
45.83 
26.85 
32.38 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
0.00 
52.94 
53.66 
169.66 
60.02 
33.60 
49.25 
0.00 
41 .29 
62.71 
6.66 
26 52 
131.37 
43.04 
21 33 
30 13 
9669 
34 53 
39 10 
31 97 
95 40 
266 56 
11 4 .68 
81 25 
154 03 
154 34 
127 67 
119 9 1 
26.94 
49.50 
156.06 
64 .50 
36.47 
52.5 1 
I 17.04 
53.49 
59.40 
83.12 
157 .77 
338.59 
175.72 
122.89 
2 13.48 
22 1. 17 
18 1.78 
178. 16 
000 112.61 
18 34 134.30 
1082.76 11 99.45 
312 34 427 .77 
0.00 
000 
0.00 
000 
221 .00 
104.01 
173.84 
347.65 
194.50 
194.96 
342.6 1 
63.70 
266.8 1 
222.75 
78.05 
123.52 
69.08 
100.36 
332.D2 
266.69 
372.50 
574.53 
395.60 
349.50 
535.07 
276.92 
446.22 
415 .89 
Total 
Costs 
26.94 
49.50 
156.06 
64.50 
36.47 
525 1 
11 7.04 
53.49 
59.40 
9 1. 17 
165 .49 
346.14 
183 50 
130.35 
220.45 
227.86 
166 89 
185.67 
135.97 
159.44 
122 1 62 
45 1.69 
104 .22 
148.56 
11 3.28 
125 70 
356.35 
33 1 2 1 
41 3.39 
6 15.60 
437 . 12 
389.78 
575.44 
313.92 
488.10 
456.62 
N 
N 
+::-. 
Table 41 
Female 
Male 
Female 
Male 
COMPARATOR 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 lo 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total Comparator Cohort 
NSAIDONLY 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
Total NSAID Only Sub-Cohort 
NSAID & MISOPROSTOL 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
7otal NSAID & Misoprostol Sub-Cohort 
NSAID & H210MEPRAZOLE 
Female 
Male 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all female 
50 to 59yrs 
60 to 74yrs 
75+yrs 
sub-total of all male 
. NSAID & H2/0meprazole Sub-Cohort 
N 
8640 
11380 
5410 
25432 
9617 
9579 
2722 
21918 
47350 
9324 
13319 
6768 
29411 
7185 
9594 
3022 
19801 
49212 
33 
75 
42 
150 
24 
28 
10 
62 
212 
339 
623 
284 
1246 
255 
492 
120 
867 
2113 
Costs (£)Incorporated In the Sensitivity Analysis ·when multiple episodes of care represent one single admission ·Based on 12 Months 
Base Cost Event Costs Event Costs Event Costs Event Costs Costs of Costs of all Costs of all Costs of all Costs of all Costs of all Costs of all Shadow 
Drug Rx 
8 .05 
7.71 
7.55 
7.78 
7.46 
6 .98 
6 .69 
7.11 
7.51 
23.37 
25.14 
22 .17 
23.92 
26. 17 
25.04 
24 .20 
25.34 
24 .34 
42 .32 
40.89 
41.08 
41.32 
40.28 
40 .37 
37.00 
39.88 
40.73 
NSAID Rx H21Losec Rx Other Rx 
0.00 
0.00 
0.00 
0.00 
0 .00 
0 .00 
0.00 
0.00 
0.00 
21.72 
27 .18 
31 .91 
26.54 
16.50 
23.45 
28.02 
21 .63 
24 .56 
24 .75 
30.80 
31 .20 
29.58 
28.29 
23.34 
31.27 
26.53 
28.69 
39.29 
37 .32 
46.42 
39.93 
29.30 
30.00 
31.33 
29.98 
35.85 
13.23 
17.48 
18.99 
16.35 
13.89 
19.89 
16.91 
16.89 
16.60 
14.02 
18.90 
18.76 
17.32 
14.16 
18.23 
15.78 
16.38 
16.94 
52.68 
91 .23 
64 .28 
75.21 
57.45 
96.12 
75.05 
77.75 
75.95 
184.48 
194.05 
211 .11 
195.33 
165.42 
192.37 
188.51 
183.91 
190.65 
19.74 
17 .36 
22.75 
19.31 
10.39 
17.72 
21 .11 
14 .93 
17 .28 
39.35 
42.14 
45.63 
42 .06 
31 .87 
46.53 
50.53 
41 .82 
41.96 
143.66 
68.93 
49.58 
79.95 
42.38 
107.54 
33.55 
70.38 
77 .15 
74 .80 
89.85 
84 .65 
84 .57 
67 .39 
100.22 
84.10 
88.33 
86.11 
All Rx 
32.97 
34 .83 
41.74 
35 .67 
24.29 
37 .6 1 
38 .01 
31 .81 
33 .88 
75.10 
88.22 
96.29 
85.92 
62 .53 
88.20 
94 .33 
79.82 
83.47 
221 . 10 
190.96 
145.07 
184 .74 
128.11 
227.00 
139.87 
174 .67 
181.79 
298.57 
321 .22 
342.18 
319.83 
262 .11 
322.60 
303.94 
302.22 
3 12.61 
GP Vis its (Rx ) Endoscpies Gl admlsslonsCV admlssionsRH admlsslonsOS admissions admiss ions 
8.58 
8.81 
9.95 
8 .97 
5.52 
8 29 
8 .34 
7 08 
8.10 
28.30 
36.46 
43.33 
35.46 
23.21 
34.9 1 
40 .77 
31.56 
33 .89 
44 .52 
52.54 
52.06 
50 .64 
39 .49 
52 .95 
38.59 
45.42 
49.11 
67.80 
73.38 
86.60 
74.88 
59.36 
70 .93 
77 .80 
68.48 
72.25 
2 .75 
3.33 
2.12 
2.88 
2 .82 
3.57 
2.76 
3. 14 
3 .00 
3.66 
4.19 
3.76 
3.92 
3.65 
3.84 
3.24 
3.68 
3 .83 
0.00 
16 .67 
0.00 
8.33 
8.68 
0.00 
0.00 
3.36 
6.88 
15.36 
17.05 
9.54 
14.88 
15.52 
16.09 
10.42 
15. 14 
14 .99 
5.95 
17.20 
25.06 
15.05 
19.49 
16.12 
31.90 
19.56 
17.14 
6 .94 
21.40 
81.68 
30.69 
14.15 
16.54 
45.78 
20.13 
26.44 
0 .00 
0 .00 
224.68 
62.91 
0.00 
0.00 
0.00 
0.00 
44 .51 
35.87 
20.63 
43.91 
30 .08 
31 .21 
115.46 
16.47 
76 .98 
49.33 
8.67 
46.18 
211.47 
68.59 
30.90 
45.57 
225.40 
61.47 
65.29 
40.69 
105.23 
311 .23 
132.17 
118.72 
221.41 
244 .10 
187.61 
154.48 
0 .00 
55.57 
1601 .73 
476.27 
24.94 
149.82 
0.00 
77 .31 
359.60 
51.75 
192.46 
761.78 
283.94 
275.11 
416.52 
142.90 
337.06 
305.74 
0.57 
1.11 
7.62 
2.32 
0.00 
0.52 
0.00 
0.23 
1.35 
10.69 
14.67 
17.12 
13.97 
2.71 
1.44 
61 .25 
11 .03 
12.79 
0 .00 
13.31 
0.00 
6.66 
0.00 
0.00 
0.00 
0 .00 
4 .71 
13.90 
23.68 
31.75 
22.86 
0.00 
19.09 
0.00 
10.83 
17.92 
1.95 
8.28 
49.70 
14.94 
7.03 
8 .21 
18.14 
8 .92 
12.15 
26.30 
67.92 
187.97 
82.35 
24 .72 
59.95 
90.59 
51 .84 
70 .08 
0 .00 
116.33 
346.98 
155.32 
252.42 
0.00 
0 .00 
97.71 
138.47 
103.98 
103.75 
275.94 
143.06 
65.00 
117.93 
0 .00 
86.04 
119.66 
17.15 
72.77 
293.85 
100 .90 
57 .41 
70.42 
275.45 
90 .18 
95 .93 
84 .63 
209.23 
597.99 
259. 19 
160.30 
299.33 
441.70 
270.61 
263.79 
0.00 
185.22 
2 173.40 
701 .16 
277 .36 
149.82 
0.00 
175.03 
547 .29 
205.51 
340.51 
111 3.38 
479.94 
371 .32 
669.01 
159.37 
5 10.91 
492 .65 
Costs 
61.44 
11 9.74 
347.66 
148.4 1 
90.04 
119.88 
324 .56 
132.21 
140.9 1 
191 .69 
338.10 
741 .38 
384.49 
249.70 
426.29 
580.05 
385.68 
384 .96 
265.62 
445.38 
2370 .53 
944 .88 
453.65 
429.76 
178.46 
398.48 
785.08 
587.24 
752 .17 
1551 .70 
889.53 
708.32 
1078.63 
551.52 
896 .76 
892.50 
Total 
Costs 
6 1.44 
119. 74 
347 .66 
148.4 1 
90 .04 
119.88 
324.56 
132.21 
140.91 
199.74 
345.81 
748.93 
392.27 
257 .16 
433.27 
586.74 
392.79 
392.47 
288.99 
470.52 
2392 .70 
968.80 
479.82 
454.80 
202.66 
423.82 
809.42 
629.56 
793.06 
1592 .78 
930.85 
748.60 
1119.00 
588.52 
936.64 
933.23 
Table42 
base CO·Rx 
N drugs nsaid 
non-aspirin takers 
comparator 47350 0.00 0.00 
NSAID 41554 8.48 5.86 
misoprostol 206 24.50 9.07 
h2 1683 41.82 8.38 
aspirin takers 
comparator 
NSAID 
misoprostol 
h2 
no prior gi 
0 
7658 
6 
430 
comparator 45338 
NSAID 47630 
misoprostol 185 
h2 1740 
had prior gi 
comparator 2012 
NSAID 1582 
misoprostol 27 
h2 373 
no prior cv 
comparator 44515 
NSAID 43143 
misoprostol 183 
h2 1665 
had prior cv 
comparator 2835 
NSAID 6069 
misoprostol 29 
h2 448 
no prior endoscopy 
comparator 43892 
NSAID 45340 
misoprostol 170 
h2 1433 
had prior endoscopy 
comparator 3458 
NSAID 3872 
misoprostol 42 
h2 680 
no prior nsaid 
comparator 4 7350 
NSAID 37871 
misoprostol 193 
h2 1452 
had prior nsaid 
comparator 0 
NSAID 11341 
misoprostol 19 
h2 661 
no risk factors 
comparator 40612 
NSAID 27635 
misoprostol 116 
h2 610 
no mortality (survivors) 
comparator 42081 
NSAID 42445 
misoprostol 184 
h2 1767 
mortality 
0.00 
2.25 
18.73 
36.47 
0.00 
7.51 
24.06 
40.18 
0.00 
7.47 
26.23 
43.27 
0.00 
7.81 
23.76 
41.10 
0.00 
5.36 
27.95 
39.34 
0.00 
7.50 
24.25 
38.52 
0.00 
7.59 
24.70 
45.39 
0.00 
7.00 
24.23 
40.11 
0.00 
9.23 
25.40 
42.10 
0.00 
7.77 
23.08 
38.15 
0.00 
7.55 
24.47 
40.81 
comparator 5269 0.00 
NSAID 6767 7.24 
misoprostol 24 23.43 
h2 346 40.33 
survivors with no risk factors 
comparator 36721 0.00 
NSAID 25332 7.74 
misoprostol 105 23.36 
h2 548 37.91 
0.00 
2.21 
3.15 
2.68 
0.00 
5.27 
7.91 
7.11 
0.00 
5.90 
15.68 
7.76 
0.00 
5.42 
8.44 
7.77 
0.00 
4.37 
11.78 
5.19 
0.00 
5.33 
8.81 
7.29 
0.00 
4.88 
9.25 
7.09 
0.00 
4.19 
8.35 
4.85 
0.00 
8.99 
14.48 
12.44 
0.00 
2.29 
3.28 
3.03 
0.00 
5.08 
8.61 
6.99 
0.00 
6.65 
10.84 
8.41 
0.00 
2.22 
3.15 
3.12 
Sensitivity Analysis of Risk Factors • 45 Days Follow-up Period 
CO•Rx co·Rx gp visit 
ulcer other 
3.70 2.16 
3.27 4.57 
18.86 7.24 
29.23 9.33 
0.00 
3.42 
35.53 
34.40 
2.68 
2.75 
18.04 
29.74 
26.69 
19.77 
28.20 
32.81 
3.32 
2.95 
17.23 
28.74 
9.74 
5.74 
32.61 
36.03 
2.08 
2.15 
17.71 
28.01 
24.34 
16.76 
25.91 
35.07 
3.70 
3.52 
18.95 
28.90 
0.00 
2.55 
23.26 
33.32 
0.76 
0.91 
6.40 
11.68 
3.50 
3.23 
18.05 
29.68 
5.32 
3.70 
27.77 
33.38 
0.73 
0.87 
5.72 
11.41 
0.00 
8.53 
12.45 
15.33 
1.95 
5.06 
6.88 
10.04 
6.87 
9.09 
10.84 
12.94 
1.91 
4.49 
5.71 
9.03 
6.06 
10.16 
17.94 
16.23 
1.74 
4.81 
7.20 
8.98 
7.58 
9.64 
8.16 
13.87 
2.16 
4.91 
7.40 
10.53 
0.00 
6.13 
7.24 
10.62 
0.88 
2.02 
3.12 
3.71 
2.11 
4.84 
7.51 
10.12 
2.58 
7.35 
6.60 
12.74 
0.84 
1.95 
3.09 
3.72 
cost endoscop' 
1.36 0.40 
5.07 0.31 
11.44 0.00 
11.63 1.49 
0.00 
7.87 
18.05 
14.75 
1.14 
5.36 
10.76 
11.96 
6.21 
9.84 
17.55 
13.72 
1.23 
5.05 
10.14 
11.25 
3.34 
8.77 
21.01 
16.03 
1.00 
5.21 
11.59 
11.71 
5.96 
8.94 
11.77 
13.44 
1.36 
4.74 
11.12 
10.69 
0.00 
8.06 
16.75 
15.74 
0.84 
3.80 
8.29 
8.45 
1.31 
5.15 
10.67 
11.77 
1.77 
7.74 
17.89 
14.81 
0.82 
3.65 
7.35 
8.28 
0.00 
0.52 
0.00 
2.91 
0.28 
0.31 
0.00 
1.80 
3.11 
1.19 
0.00 
1.68 
0.39 
0.26 
0.00 
1.50 
0.66 
0.93 
0.00 
2.79 
0.20 
0.25 
0.00 
0.73 
2.95 
1.40 
0.00 
3.98 
0.40 
0.34 
0.00 
1.87 
0.00 
0.35 
0.00 
1.58 
0.19 
0.17 
0.00 
0.68 
0.38 
0.35 
0.00 
2.12 
0.59 
0.31 
0.00 
0.00 
0.19 
0.16 
0.00 
0.76 
hospital hospital hospital hospital shadow total 
gi 
1.32 
4.27 
19.92 
7.81 
0.00 
5.09 
0.00 
5.09 
0.89 
4.06 
22.18 
2.40 
11.09 
14.61 
0.00 
29.91 
1.32 
3.70 
0.00 
7.89 
1.34 
9.32 
141.51 
4.89 
0.98 
3.76 
24.14 
7.84 
5.63 
11.80 
0.00 
6.04 
1.32 
5.14 
21.26 
3.22 
0.00 
1.90 
0.00 
16.11 
0.83 
4.29 
0.00 
0.00 
1.11 
3.35 
22.30 
2.78 
2.98 
10.92 
0.00 
30.09 
0.66 
3.11 
0.00 
0.00 
cv 
5.28 
13.05 
26.60 
22.09 
0.00 
53.85 
0.00 
92.02 
4.86 
18.95 
29.62 
34.48 
14.77 
33.02 
0.00 
44.91 
3.21 
12.48 
7.52 
15.11 
37.89 
68.62 
141.51 
115.16 
4.62 
19.03 
32.23 
41.63 
13.66 
23.69 
0.00 
25.14 
5.28 
20.58 
28.39 
37.22 
0.00 
15.45 
0.00 
34.35 
2.77 
10.22 
11.86 
17.62 
2.31 
14.00 
29.78 
32.14 
28.98 
53.26 
0.00 
57.66 
1.57 
8.76 
13.10 
16.67 
ra 
0.11 
0.87 
0.00 
0.93 
0.00 
0.70 
0.00 
1.01 
0.06 
0.75 
0.00 
1.15 
1.25 
3.77 
0.00 
0.00 
0.06 
0.93 
0.00 
0.94 
0.88 
0.20 
0.00 
0.97 
0.12 
0.63 
0.00 
0.00 
0.00 
3.28 
0.00 
2.94 
0.11 
0.45 
0.00 
0.30 
0.00 
2.14 
0.00 
2.37 
0.07 
0.24 
0.00 
0.00 
0.06 
0.66 
0.00 
0.89 
0.51 
1.99 
0.00 
1.25 
0.00 
0.26 
0.00 
0.00 
oa 
1.70 
7.19 
0.00 
19.84 
0.00 
1.88 
0.00 
24.25 
cost 
16.03 
44.47 
93.12 
110.54 
0.00 
84.07 
69.18 
192.44 
cost 
16.03 
52.95 
117.62 
152.35 
0.00 
86.32 
87.91 
228.90 
1.60 13.46 13.46 
6.48 48.99 56.50 
0.00 95.39 119.45 
13.94 112.61 152.80 
3.96 
2.96 
0.00 
51.55 
1.56 
6.49 
0.00 
20.01 
3.87 
5.47 
0.00 
22.69 
1.65 
6.40 
0.00 
18.26 
2.30 
5.98 
0.00 
25.47 
1.70 
4.27 
0.00 
17.03 
0.00 
13.35 
0.00 
28.38 
1.51 
5.11 
0.00 
0.00 
1.63 
5.56 
0.00 
24.61 
2.26 
11.42 
0.00 
0.00 
1.53 
4.62 
0.00 
0.00 
73.94 73.94 
100.15 107.63 
72.27 98.50 
195.27 238.54 
12.99 
41.78 
49.04 
102.24 
63.79 
113.56 
366.35 
219.98 
12.38 
47.58 
101.68 
124.44 
62.42 
86.38 
55.09 
133.03 
16.03 
48.15 
95.47 
114.60 
0.00 
58.92 
61.72 
154.90 
7.84 
29.05 
32.94 
45.17 
12.41 
42.23 
96.91 
121.11 
45.00 
103.33 
63.10 
158.35 
6.33 
25.61 
32.41 
43.95 
12.99 
49.59 
72.80 
143.34 
63.79 
118.92 
394.30 
259.32 
12.38 
55.08 
125.92 
162.95 
62.42 
93.97 
79.78 
178.42 
16.03 
55.14 
119.70 
154.70 
0.00 
68.15 
87.12 
196.99 
7.84 
36.82 
56.02 
83.32 
12.41 
49.78 
121.38 
161.91 
45.00 
110.57 
86.53 
198.68 
6.33 
33.35 
55.77 
81.86 
225 
Table43 
N 
non-aspirin takers 
comparator 4 7350 
NSAID 41554 
misoprostol 206 
h2 1683 
aspirin takers 
comparator 0 
NSAID 7658 
misoprostol 6 
h2 430 
no priorgi 
comparator 45338 
NSAID 47630 
misoprostol 185 
h2 1740 
had prior gi 
comparator 2012 
NSAID 1582 
misoprostol 27 
h2 373 
no prior cv 
comparator 44515 
NSAID 43143 
misoprostol 183 
h2 1665 
had priorcv 
comparator 2835 
NSAID 6069 
misoprostol 29 
h2 448 
no prior endoscopy 
comparator 43892 
NSAID 45340 
misoprostol 170 
h2 1433 
had prior endoscopy 
comparator 3458 
NSAID 3872 
misoprostol 42 
h2 680 
no prior nsaid 
comparator 47350 
NSAID 37871 
misoprostol 193 
h2 1452 
had prior nsaid 
comparator 0 
NSAID 11341 
misoprostol 19 
h2 661 
no risk factors 
comparator 40612 
NSAID 27635 
misoprostol 116 
h2 610 
no mortality (survivors) 
comparator 42081 
NSAID 42445 
misoprostol 184 
h2 1767 
mortality 
comparator 5269 
NSAID 6767 
misoprostol 24 
h2 346 
base 
drugs 
0.00 
8.48 
24.50 
41.82 
0.00 
2.25 
18.73 
36.47 
0.00 
7.51 
24.06 
40.18 
0.00 
7.47 
26.23 
43.27 
0.00 
7.81 
23.76 
41.10 
0.00 
5.36 
27.95 
39.34 
0.00 
7.50 
24.25 
38.52 
0.00 
7.59 
24.70 
45.39 
0.00 
7.00 
24.23 
40.11 
0.00 
9.23 
25.40 
42.09 
0.00 
7.77 
23.08 
38.15 
0.00 
7.55 
24.47 
40.81 
0.00 
7.24 
23.43 
40.33 
survivors with no risk factors 
comparator 36721 0.00 
NSAID 25332 7.74 
misoprostol 105 23.36 
h2 548 37.91 
co-Rx 
nsaid 
0.00 
13.50 
15.24 
21.02 
0.00 
7.51 
25.51 
7.69 
0.00 
12.55 
14.68 
18.18 
0.00 
13.00 
21.33 
18.89 
0.00 
12.74 
14.69 
19.48 
0.00 
11.30 
20.84 
13.94 
0.00 
12.64 
16.25 
18.24 
0.00 
11.69 
12.61 
18.44 
0.00 
7.83 
13.52 
9.43 
0.00 
28.37 
35.94 
37.79 
0.00 
8.15 
12.91 
10.28 
0.00 
11.88 
13.92 
17.56 
0.00 
16.86 
26.07 
22.10 
0.00 
7.85 
11.96 
10.50 
Sensitivity Analysisof Risk Factors - Six Months Follow-up Period 
co-Rx 
ulcer 
7.97 
7.40 
36.23 
86.65 
0.00 
8.59 
72.45 
109.40 
5.89 
6.40 
34.68 
87.67 
54.84 
43.42 
54.95 
108.11 
7.18 
6.80 
30.68 
86.21 
20.37 
13.22 
78.76 
110.11 
4.53 
5.10 
35.16 
80.02 
51.64 
36.69 
43.92 
115.00 
7.97 
7.78 
36.63 
83.28 
0.00 
6.94 
43.66 
108.84 
3.38 
4.11 
22.54 
56.80 
7.59 
7.33 
34.95 
89.35 
11.02 
9.23 
52.40 
101.14 
3.25 
3.90 
19.72 
55.87 
co-Rx gp visit 
other 
6.62 
14.43 
26.13 
29.77 
0.00 
33.29 
26.84 
56.03 
6.09 
16.97 
23.43 
33.48 
18.52 
29.34 
44.81 
42.70 
5.77 
14.61 
21.61 
27.86 
19.96 
36.95 
54.86 
62.06 
5.46 
16.26 
22.88 
30.38 
21.31 
30.34 
39.40 
45.09 
6.62 
15.81 
26.54 
33.57 
0.00 
22.56 
22.27 
38.46 
4.67 
10.83 
18.79 
18.59 
6.41 
15.95 
23.84 
31.12 
8.30 
26.23 
41.34 
55.47 
4.44 
10.48 
12.11 
18.88 
cost EndOSCOpJ 
4.25 
16.85 
29.45 
39.57 
0.00 
30.10 
53.03 
50.22 
3.65 
18.54 
28.03 
40.74 
17.83 
30.13 
44.38 
46.43 
3.93 
17.40 
26.75 
39.06 
9.33 
29.69 
51.36 
51.70 
3.24 
18.17 
30.03 
39.69 
17.05 
27.64 
30.47 
46.06 
4.25 
15.20 
28.38 
35.97 
0.00 
31.31 
47.75 
54.53 
2.82 
11.87 
21.77 
27.41 
4.15 
17.74 
27.93 
40.36 
5.02 
26.31 
44.49 
48.78 
2.78 
11.48 
19.47 
26.94 
1.46 
1.64 
2.02 
5.94 
0.00 
2.75 
0.00 
9.69 
1.12 
1.64 
0.00 
6.23 
9.22 
7.24 
15.43 
8.94 
1.36 
1.68 
2.28 
6.01 
3.09 
2.82 
0.00 
9.30 
0.72 
1.27 
2.45 
2.62 
10.84 
8.18 
0.00 
15.32 
1.46 
1.77 
2.16 
6.31 
0.00 
1.97 
0.00 
7.56 
0.65 
1.03 
0.00 
2.39 
1.36 
1.76 
2.26 
7.43 
2.29 
2.19 
0.00 
3.01 
0.62 
0.99 
0.00 
2.28 
hospital hospital hospital hospital shadow total 
gi 
5.63 
10.71 
28.34 
23.87 
0.00 
18.45 
0.00 
62.34 
3.59 
9.55 
31.55 
12.53 
51.73 
83.22 
0.00 
122.90 
5.18 
9.96 
0.00 
24.55 
12.72 
25.83 
201.29 
58.30 
3.63 
9.98 
34.34 
29.73 
31.07 
34.62 
0.00 
35.86 
5.63 
12.27 
30.25 
27.64 
0.00 
10.73 
0.00 
40.62 
2.79 
8.41 
0.00 
2.42 
4.38 
9.40 
31.72 
11.45 
15.64 
27.74 
0.00 
135.12 
2.52 
6.61 
0.00 
1.12 
cv 
26.63 
50.64 
199.24 
76.43 
0.00 
189.91 
0.00 
297.68 
25.32 
68.62 
50.28 
114.24 
56.33 
183.64 
1175.64 
155.11 
18.11 
45.78 
180.97 
46.55 
160.53 
260.94 
273.33 
399.86 
25.34 
69.97 
241.44 
121.09 
43.09 
99.73 
0.00 
122.24 
26.63 
68.18 
212.66 
135.77 
0.00 
86.12 
0.00 
90.02 
16.30 
32.62 
11.86 
37.76 
10.60 
49.45 
223.07 
95.94 
154.69 
215.73 
0.00 
251.79 
7.88 
25.01 
13.10 
17.80 
ra 
1.03 
4.28 
0.00 
10.26 
0.00 
3.20 
0.00 
4.34 
0.96 
3.65 
0.00 
5.57 
2.58 
17.87 
0.00 
25.30 
1.03 
3.66 
0.00 
6.86 
0.88 
7.32 
0.00 
17.19 
0.88 
3.19 
0.00 
10.29 
2.91 
14.94 
0.00 
6.44 
1.03 
1.80 
0.00 
5.30 
0.00 
11.84 
0.00 
17.29 
0.89 
0.93 
0.00 
0.00 
0.22 
2.72 
0.00 
7.73 
7.47 
12.85 
0.00 
15.80 
0.18 
0.99 
0.00 
0.00 
oa 
6.04 
35.94 
0.00 
62.86 
0.00 
13.31 
0.00 
62.79 
5.88 
32.23 
0.00 
50.66 
9.68 
37.94 
0.00 
119.70 
5.26 
32.58 
0.00 
69.07 
18.36 
31.26 
0.00 
39.73 
5.27 
33.00 
0.00 
65.17 
15.82 
25.56 
0.00 
57.95 
6.04 
19.28 
0.00 
52.41 
0.00 
76.27 
0.00 
85.77 
4.52 
21.76 
0.00 
38.83 
4.14 
24.48 
0.00 
59.20 
21.19 
82.17 
0.00 
81.47 
3.89 
18.79 
0.00 
26.69 
cost 
59.63 
155.40 
336.65 
356.38 
0.00 
307.11 
177.84 
660.17 
52.49 
170.15 
182.65 
369.29 
220.72 
445.80 
1356.55 
648.09 
47.81 
145.20 
276.97 
325.64 
245.24 
419.32 
680.43 
762.19 
49.07 
169.58 
382.55 
397.23 
193.74 
289.39 
126.39 
462.39 
59.63 
149.93 
350.13 
389.70 
0.00 
276.11 
149.62 
480.88 
36.01 
99.72 
87.87 
194.49 
38.85 
140.70 
357.70 
360.15 
225.61 
419.31 
164.30 
714.68 
25.57 
86.09 
76.36 
160.09 
226 
cost 
59.63 
163.88 
361.15 
398.20 
0.00 
309.37 
196.57 
696.63 
52.49 
177.66 
206.71 
409.48 
220.72 
453.27 
1382.78 
691.35 
47.81 
153.02 
300.73 
366.74 
245.24 
424.68 
708.38 
801.54 
49.07 
177.08 
406.79 
435.75 
193.74 
296.97 
151.09 
507.78 
59.63 
156.92 
374.36 
429.81 
0.00 
285.34 
175.01 
522.97 
36.01 
107.50 
110.95 
232.64 
38.85 
148.25 
382.18 
400.95 
225.61 
426.55 
187.73 
755.00 
25.57 
93.83 
99.72 
197.99 
Table44 
N 
non-aspirin takers 
comparator 4 7350 
NSAID 41554 
misoprostol 206 
h2 1683 
aspirin takers 
comparator 0 
NSAID 7658 
misoprostol 6 
h2 430 
no priorgi 
comparator 45338 
NSAID 47630 
misoprostol 185 
h2 1740 
had prior gi 
comparator 2012 
NSAID 1582 
misoprostol 27 
h2 373 
no prior cv 
comparator 44515 
NSAID 43143 
misoprostol 183 
h2 1665 
had prior cv 
comparator 2835 
NSAID 6069 
misoprostol 29 
h2 448 
no prior endoscopy 
comparator 43892 
NSAID 45340 
misoprostol 170 
h2 1433 
had prior endoscopy 
comparator 3458 
NSAID 3872 
misoprostol 42 
h2 680 
no prior nsaid 
comparator 4 7350 
NSAID 37871 
misoprostol 193 
h2 1452 
had prior nsaid 
comparator 0 
NSAID 11341 
misoprostol 19 
h2 661 
no risk factors 
comparator 40612 
NSAID 27635 
misoprostol 116 
h2 610 
no mortality (survivors) 
comparator 42081 
NSAID 42445 
misoprostol 184 
h2 1767 
mortality 
comparator 5269 
NSAID 6767 
misoprostol 24 
h2 346 
base 
drugs 
0.00 
8.48 
24.50 
41.82 
0.00 
2.25 
18.73 
36.47 
0.00 
7.51 
24.06 
40.18 
0.00 
7.47 
26.23 
43.27 
0.00 
7.81 
23.76 
41.10 
0.00 
5.36 
27.95 
39.34 
0.00 
7.50 
24.25 
38.52 
0.00 
7.59 
24.70 
45.39 
0.00 
7.00 
24.23 
40.11 
0.00 
9.23 
25.40 
42.09 
0.00 
7.77 
23.08 
38.15 
0.00 
7.55 
24.47 
40.81 
0.00 
7.24 
23.43 
40.33 
survivors with no risk factors 
comparator 36721 0.00 
NSAID 25332 7.74 
misoprostol 105 23.36 
h2 548 37.91 
Sensitivity Analysis of Risk Factors- One Year Follow-up Period 
co-Rx 
nsaid 
0.00 
26.07 
28.45 
40.82 
0.00 
16.39 
37.11 
16.40 
0.00 
24.54 
27.68 
35.72 
0.00 
25.09 
35.60 
36.45 
co-Rx 
ulcer 
16.60 
16.38 
73.84 
181.22 
0.00 
19.96 
148.42 
227.54 
12.46 
14.45 
69.36 
181.23 
109.82 
91.96 
121.14 
234.56 
0.00 15.02 
24.81 15.18 
27.93 66.46 
37.82 179.94 
0.00 
22.77 
33.49 
28.51 
0.00 
24.73 
30.17 
35.44 
0.00 
22.65 
22.69 
36.70 
0.00 
14.49 
25.41 
17.77 
0.00 
58.18 
62.03 
75.55 
0.00 
14.74 
24.75 
18.25 
0.00 
23.19 
26.22 
34.81 
0.00 
33.15 
44.93 
41.17 
0.00 
14.20 
22.97 
18.49 
41.36 
29.43 
135.82 
230.44 
9.69 
11.82 
71.21 
163.63 
104.38 
76.92 
95.14 
247.58 
16.60 
17.09 
75.81 
173.62 
0.00 
16.44 
77.43 
228.05 
7.37 
9.49 
49.92 
114.10 
15.74 
16.31 
72.38 
186.98 
23.45 
20.89 
99.43 
209.36 
7.02 
9.02 
45.45 
112.62 
co-Rx gp visit 
other 
17.28 
35.25 
73.40 
73.74 
0.00 
78.40 
206.12 
134.53 
16.00 
40.97 
72.37 
80.27 
46.31 
71.82 
109.93 
113.39 
15.35 
35.56 
59.32 
65.75 
47.69 
87.48 
189.68 
161.78 
14.76 
39.34 
69.80 
76.42 
49.34 
72.74 
106.92 
106.52 
17.28 
40.03 
78.96 
86.71 
0.00 
48.43 
58.79 
84.81 
12.84 
28.23 
55.70 
41.75 
16.72 
38.33 
63.49 
76.07 
21.81 
64.76 
166.97 
137.43 
12.24 
26.15 
28.88 
38.85 
cost 
8.10 
30.13 
48.05 
68.61 
0.00 
54.28 
85.75 
86.53 
7.09 
33.27 
45.52 
70.52 
30.91 
52.35 
73.72 
80.31 
7.56 
31.28 
44.21 
67.83 
16.58 
52.39 
80.07 
88.67 
6.39 
32.66 
48.27 
68.23 
29.78 
48.26 
52.55 
80.73 
8.10 
27.37 
46.37 
62.53 
0.00 
55.67 
76.96 
93.60 
5.66 
21.46 
35.83 
47.18 
7.97 
31.93 
46.21 
70.19 
9.11 
46.16 
68.18 
82.81 
5.62 
20.84 
32.95 
46.66 
endoscop) 
3.00 
3.54 
7.08 
14.48 
0.00 
5.36 
0.00 
16.76 
2.34 
3.49 
4.50 
13.05 
17.81 
14.09 
23.15 
24.02 
2.86 
3.56 
7.97 
14.51 
5.14 
5.73 
0.00 
16.74 
1.66 
2.82 
8.58 
6.69 
20.00 
15.60 
0.00 
32.48 
3.00 
3.70 
7.56 
14.20 
0.00 
4.26 
0.00 
16.70 
1.52 
2.39 
7.18 
6.83 
2.65 
3.61 
7.93 
15.33 
5.77 
5.20 
0.00 
13.25 
1.36 
2.15 
7.94 
6.84 
hospital hospital hospital hospital shadow hidden 
gi 
17.33 
25.43 
46.32 
39.72 
0.00 
33.48 
0.00 
88.76 
13.40 
22.77 
51.58 
20.69 
105.79 
144.61 
0.00 
185.03 
cv 
65.68 
113.59 
371.58 
220.49 
0.00 
386.65 
0.00 
657.83 
63.31 
149.63 
225.78 
303.52 
118.99 
350.39 
1287.97 
337.36 
13.24 46.33 
23.99 97.59 
0.00 287.47 
42.93 185.71 
81.57 
45.83 
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